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Zusammenfassung 
Seit der Entdeckung der zentralen Rolle von Kinasen in der intrazellulären Signaltransduktion und 
der Entdeckung von Naturstoffen wie Staurosporin, die als unselektive Inhibitoren für Kinasen 
fungieren können, hat sich die Entwicklung von potenten Kinaseinhibitoren zu einem elementaren 
Teil der biologischen und medizinischen Forschung entwickelt. Während der letzten zwei 
Jahrzehnte hat die MEGGERS-Gruppe eine große Auswahl an selektiven und hoch-spezifischen 
ATP-kompetitiven Kinaseinhibitoren entwickelt, die auf inerten Koordinationskomplexen mit 
Metallzentren basieren, welche als strukturelles Templat zur Nachahmung des zuvor erwähnten 
Staurosporins dienen. Die generelle Struktur dieser Metallo-Pyridocarbazole ist in Abbildung 1 
dargestellt. Es konnte gezeigt werden, dass diese Verbindungen sehr potent sind und oft selektiv 
Kinasen in Enzymassays, in Krebszelllinien in vitro und einfachen eukaryotischen Systemen in vivo 
inhibieren können. Dabei hat die Gruppe neue und innovative Chemotypen entwickelt, welche 
einen weitgehend unerforschten Bereich des chemischen Raums einnehmen, und kann damit die 
stark besiedelten urheberrechtlich geschützten Gebiete umgehen. Basierenden auf dieser 
Grundlage werden diese Verbindungen als potentielle Krebstherapeutika angesehen.  
 
 
Abbildung 1: Strukturelles Templat  der ATP-kompetitiven Kinaseinhibitoren, welche in der Meggers-Gruppe entwickelt wurden. 
Zusätzlich sind die zwei entwickelten Beispielkomplexe np829 und RR97a dargestellt. 
 
Weiterführende Untersuchungen ihrer Eignung als potentielle Therapeutika, basierenden auf u.a. 
ihren pharmakokinetischen und pharmakodynamischen Eigenschaften, wurden dabei in der 
Vergangenheit nicht verwirklicht. Daher beschäftigt sich diese Arbeit mit der Eignung dieser 
Verbindungsklasse als potentielle Krebstherapeutika. Dabei sollte die beste Verbindung 
identifiziert und als Leitstruktur zur Optimierung der benötigten Eigenschaften verwendet werden.  
 
 
Im ersten Ansatz wurden dabei, basierend auf der bereits bekannten Funktion als Kinase- bzw. 
ATPase-Inhibitoren und der damit inhärenten Eigenschaft als zielgerichtete molekulare Agenzien, 
die Verbindungen in einer Substanzbibliothek von 441 Verbindungen zusammengefasst und in 
einem klassischen empirischen Screening bezüglich ihrer Wirkung gegen Krebszellen in einem 
MTT-basierten Zytotoxizitätsassay in HT-29 Zellen getestet. Die dabei erfolgversprechendste 
Verbindung np829 (Abbildung 1), sowie attraktive synthetisierte Derivate, zeigten aber Toxizität, 
die vermutlich nicht alleine durch die Inhibition von Kinasen zu begründen ist. Daher wurden in 
einem zweiten Ansatz selektierte Verbindungen auf ihre Wirkstoffartigkeit in Bezug auf 
Löslichkeit, Permeabilität und metabolische Stabilität in Kollaboration mit den Novartis Institutes 
of BioMedical Research in vitro getestet. Zwei interessante stereoisomere Verbindungen wurden 
dabei selektiert und nach Bestätigung ihrer allgemeinen Stabilität, ihr pharmakokinetisches 
Verhalten über 7 bzw. 24 h in vivo in rodentia untersucht. Für den attraktivsten Kinaseinhibitor 
(RR97a (Abbildung 1) u.a. Inhibition der Kinase Pim1 im niedrigen nanomolaren Bereich) wurde 
zusätzlich die Organverteilung 7 h und 24 h nach intravenöser Gabe untersucht, und die Lunge als 
primäres Ziel der Verbindung identifiziert. Eine Ausscheidung des Zentralmetalls, vermutlich in 
Form des ursprünglichen Komplexes, über Urin und Kot wurde ebenfalls gezeigt, wobei diese über 
die betrachteten 24 h unvollständig war. Weiterhin wurden die Verbindungen in verschiedenen 
Krebszelllinien in vitro und in einem Hepatotoxizitätsassay ex vivo untersucht. Um diese Tests 
durchführen zu können, wurde zusätzlich der synthetische Zugang, sowie die Möglichkeit einer 
Hochskalierung des Syntheseansatzes untersucht. Abschließend wurden Derivate der 
interessanteren Verbindung dargestellt, um die Wirkstoffartigkeit weiter zu verbessern. Dabei 
konnte insbesondere die Löslichkeit erhöht werden, teilweise unter Erhalt oder Verbesserung der 
ursprünglichen Eigenschaften als Pim1 Kinaseinhibitor. Die Kombination der gewonnenen 
Erkenntnisse könnte dabei zukünftig genutzt werden, um die ADME-Eigenschaften der 
Leitstruktur oder anderer Pyridocarbazol-basierter Komplexe weiter zu optimieren. ADME ist 
dabei der Überbegriff für die Parameter Absorption, Distribution, Metabolismus und Eliminierung 
welche den Wirkstoff-Spiegel und die pharmakologische Aktivität einer Verbindung im Körper 
beeinflussen. 
  
 
 
Als Nebenprojekt dieser Arbeit wurden in Prof. Angela Casinis Labor an der Rijksuniversiteit 
Groningen bekannte dinukleare Gold(III)-Komplexe als potentielle Histondeacetylaseinhibitoren 
untersucht. Histondeacetylasen (HDACs) sind dabei ein weiteres potentielles Ziel für die 
Behandlung von Krebs. Ein spezifischer Gold-Komplex (Abbildung 2), dessen antiproliferative 
Wirkung bereits zuvor gezeigt werden konnte, ist dabei der zytotoxischste Komplex aus einer Serie 
von Verbindungen in verschiedenen Krebszelllinien und zeigte dabei geringe Toxizität in einem 
Hepatotoxizitätsassay.  
 
 
Abbildung 2: Struktur des zytotoxischsten Gold-Komplexes aus einer Serie von potentiellen Histondeacetylase-Inhibitoren. 
 
In der Arbeit konnte in einem enzymbasierten Assay gezeigt werden, dass die Inhibition von 
Histondeacetylasen ein möglicher Grund der gezeigten Toxizität gegenüber Krebszellen ist. Der 
Effekt konnte dabei in Zellextrakt aus vorbehandelten Zellen nicht bestätigt werden, vermutlich 
aufgrund unterschiedlicher Zellzahlen der Kontrolle im Vergleich zu den behandelten Proben und 
damit verbundener unterschiedlicher Ausprägung der HDAC Expression basierenden auf 
Differenzen in der Zellzyklus-Verteilung. Weitere Untersuchungen sind dabei nötig um die Assay-
Bedingungen besser zu verstehen und zu optimieren, um anschließende Experimente zur 
Untersuchung des zugrundeliegenden Mechanismus der Verbindung durchführen zu können. 
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1. Introduction 
1.1. A brief history of cancer and its treatment strategies 
Today the second leading cause of disease related death in the world just after cardiovascular 
conditions is still cancer. In all its infinite variety, there is one common aspect in all cancer forms: 
It is always based on certain DNA-mutations that trigger cells to behave out of control in a way 
that they continue to grow and divide instead of dying. Some cancer cells are thereby able to travel 
to other parts of the body through blood circulation or lymph vessels, where they settle and form 
metastases.[1] It is important to acknowledge that tumours in vivo are not just a collection of cancer 
cells with one defined genome, but organ-like structures, that consist of different cancer as well as 
host stromal cells embedded in an extracellular matrix and nourished by a vascular network.[2] 
Tumours thereby have a high diversity of blood supply in individual areas, and even worse, inherit 
a certain genetic instability.[2,3] This makes “cancer” an umbrella term for very heterogeneous 
conditions, which, under the selective pressure of drug treatment, might develop resistance to 
certain drugs, if it was not already inherited in their original genome. In many cases, drug treatment 
of cancer, especially based on single agent therapy, therefore leads to a remission rather than a 
cure.[4]  
A brief glance into the history of cancer and treatment strategies shows us that the disease was 
already acknowledged in written form 5000 years ago by Egyptian physicians. Treatment options 
for cancer and other conditions during that time were based on a very elementary form of 
“chemotherapy”, using drugs derived from minerals, plant material or animal sources. The Greek 
physician Hippocrates (ca. 460–370 BC) later coined the term cancer, after noting crab leg like 
extensions emanating from certain tumours and calling them carcinos (Greek for crab), which was 
later translated to the Latin word cancer. From these early times on, through the medieval period 
and the Dark and Middle Ages, the practice of medicine and the understanding of cancer changed 
very little. The use of surgery, cautery, herbal medications, caustic pastes, and blood-letting 
persisted with little to no innovation, and represented almost 2000 years of relative medical 
stagnation, which was only supplemented around 1900 by the use of radiation therapy after the 
discovery of its beneficial effect against cancer.[5] 
The first development of new chemotherapeutic treatment methods in the 20th century was based 
on empirical, clinical observations, starting with nitrogen mustard. This substance was investigated 
after it was noted that upon exposure to mustard gas, which was used in WWI as a chemical 
weapon, severe lymphoid depletion, bone marrow aplasia, and neutropenia takes place in the 
human body. In 1935 it was discovered that nitrogen mustard however also had antitumor activity 
against murine lymphoma. This was followed by first trials of therapeutic use, in which several 
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lymphoma patients showed marked, but temporary, regression after treatment with nitrogen 
mustard.[5] Parallel developments during WWII led to the discovery or creation of various other 
compounds with clinical value. Thus, by the end of the “empirical” phase, drugs like nitrogen 
mustards, mechlorethamine, cyclophosphamide and the folic acid antagonists amethopterin and 
aminopterin were all used successfully to treat certain types of cancer.[2] All these drugs could 
produce impressive cancer remissions, however often being short or incomplete,[5] so that surgery 
and radiotherapy still dominated the field of cancer treatment.[6] 
Based on those remarkable first results, the research towards more and better drugs continued 
during the post-war years.[5] Different research centres started to use easily transplantable mouse 
models to screen compounds for their antitumor activity, narrowing down the universe of potential 
drugs.[5,6] These studies led to the discovery of various agents like the cytostatic (inhibition of cell 
growth and multiplication) taxanes and the cytotoxic (toxic towards cells) vinca alkaloids. In the 
late 1960s the first combinational therapies followed those single agent treatments, increasing the 
remission rates to such an extent, that people started to think about the possibility to one day be 
able to cure cancer. Overall, the higher confidence in chemotherapy led to a more routine use of it 
in earlier stages of the disease and in combination with surgery, radiation therapy, or both.[5]  
Starting in 1984, the signalling pathways that regulate normal cellular activities, such as proliferation 
and survival, were subsequently uncovered and many of these were found to be radically altered in 
cancer cells.[5] With the consecutive discovery of different oncogenes, tumour suppressor genes, 
and signalling pathways that are related to the carcinogenic process and angiogenesis, the idea of 
identifying new drug targets and matching drugs encouraged research activities even further.[2]  
Finally, in 1990, the mortality of cancer began to decline. As random screening was replaced by 
screening against specific critical molecular targets, the era of targeted therapy had begun.[6] 
Targeted therapy might include both small molecules (SM) and monoclonal antibodies (mAb)[5] as 
signal transduction inhibitors, gene expression modulators, apoptosis inducers or angiogenesis 
inhibitors, but also hormone- and immunotherapy. The first achievement in this area was the 
discovery of tamoxifen as an inhibitor for the estrogen receptor, which is an important target in 
certain breast cancer types. Subsequently, a number of drugs have been approved that e.g. block 
oncogene induced signal transduction such as imatinib (1, Chapter 1.2.2, Fig. 4) and others that 
affect proteins that regulate gene function, exemplified by vorinostat (32, Chapter 1.3.2, Fig. 9). 
Clearly, drugs designed to inhibit precise molecular targets or specific signalling pathways represent 
a valid approach for cancer therapeutics.[7] Two established target families, kinases and histone 
deacetylases, together with their FDA approved treatment options, will be discussed in more depth 
in the following chapters. 
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1.2. Kinases 
Kinases are proteins which belong to the transferase enzyme class and catalyse the transfer of the 
γ-phosphate group of ATP onto a specific side chain of their substrate, mainly serine, threonine 
and tyrosine, but also histidine.[8] In doing so, they mediate most signal transductions[9] and regulate 
various critical cellular activities, including proliferation, survival, apoptosis, metabolism, 
transcription, differentiation, and a wide array of other cellular processes.[10] Phosphorylation, and 
thereby regulation of signal transduction, is a reversible process which is not only governed by 
kinases but also counteracting phosphatases.[8] 
Protein kinases represent one of the largest gene families in eukaryotic genomes, which accounts 
for a percentage of 2-4% of all genes. In humans, at least 538 different members of the protein 
kinase family have been identified.[11] As every kinase thereby mediates a similar phosphoryl transfer 
process, it is unsurprising that a degree of sequence and structural homology exists, particularly in 
the active site regions, across all family members. This is further exaggerated within subclasses, 
where the catalytic activity is identical to a certain degree.[12] Human kinases can be divided into 9 
defined families, plus one catch-all category (“Other-Orphan”),[11] which are summarised in Table 
1. However, around 50% of the identified kinases are thought to be still largely uncharacterised, so 
that their function and structure is still unknown or speculated at the most.[13] 
 
Table 1: Kinase group classification based on phylogeny. [11,14] 
Kinase group Details 
AGC Protein kinases A, G and C-like 
CaMK Calcium-calmodulin-regulated kinases 
CMGC Cyclin-dependant, mitogen-activated, glycogen synthase, and DDK-
like kinases 
TK Tyrosine kinases (including both receptor and non-receptor kinases) 
STE Homologues of the yeast sterile kinases 
CK1 Casein kinase 1 group 
TKL Tyrosine kinase like (similar but distant to TK) 
RGC Receptor guanylate cyclase related 
Atypical Diverse group with no structural similarity to eukaryotic protein 
kinases 
Others/Orphan Kinases that are not members of a larger family 
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An example for the highly conserved overall structure of kinases is given in Fig. 1. Generally, the 
N-terminal domain consists of 5 β-sheets and some α-helices, including the so-called c-helix. The 
C-terminal domain on the other hand consist mainly of α-helices and contains the so-called 
activation loop, which is activated by phosphorylation, leading to structural reorganisation. Both 
domains are connected via a hinge-region, where, upon activation, the catalytically active centre is 
located.[3] 
 
Fig. 1: ATP bound to the cAMP-dependant protein kinase A (catalytic alpha subunit, pdb 4WB5)[15] as an example for the general 
structure of kinases. The N-terminal domain (residues 5-120, upper part) consists of 5 β-sheets (red) and some α-helices (cyan) 
including the C-helix (residues 85-97, yellow), the C-terminal domain (residues 128-350, lower part) consist mainly of α-helices 
(cyan). This domain interacts with a bound phosphoracceptor substrate and contains the so called activation loop (residues 184-
208), which is activated by phosphorylation at Thr197 in PKA, following structural reorganisation. Both domains are connected via 
a hinge-region (residues 121-127 please refer to Fig. 2) which is the active site of the kinase. [3] 
 
A closer look into the active site upon binding of ATP is given in Fig. 2. The recognition of ATP 
takes place in the hinge region, where typically two parallel H-bonds are formed between the co-
substrate and the enzyme. The adenine part is thereby located in the adenine pocket, ribose in the 
sugar pocket and the triphosphate group in the phosphate pocket.[14] The α- and β- phosphates of 
ATP interact with the ammonium group of a conserved K-residue, and are covered by the 
N-terminal domain 
C-terminal 
domain 
C-helix 
Introduction 
 
5 
 
phosphate binding loop (P-loop), which is a glycine rich loop in the N-terminal domain that is not 
involved in the phosphate transfer.[16] All three phosphates are further chelated to two Mg2+ ions.[14] 
An additional back pocket (selectivity pocket) might be accessible based on the size of the so called 
gatekeeper residue, and the outer lipophilic pocket or front pocket is generally solvent exposed.[14] 
An additional pocket might be formed by the so called DFG-motif, which is a highly conserved 
region on the activation loop. 
 
Fig. 2: ATP bound to the cAMP-dependant protein kinase A (catalytic alpha subunit; pdb 4WB5).[15] Schematic illustration of key 
interactions and pockets in the ATP-binding region, which might be used to modulate potency, selectivity and inhibitor properties. 
Adenine is recognised by two parallel H-bonds from the hinge regions (residues 121-127) protein backbone. The α- and β- 
phosphates of ATP interact with the ammonium group of the conserved K-residue, and all phosphates are further chelated to two 
Mg2+ ions (grey spheres). The outer lipophilic pocket or front pocket is solvent exposed. The entrance to the allosteric back pocket 
or selectivity pocket is limited by the gatekeeper residue. 
 
As indicated by the term activation loop, kinases normally exist in an activated and an inactivated 
state, which differ in the structural organisation of the enzymes shape. The active state of kinases 
is characterised by the presence of the conserved lysine – glutamate salt bridge (e.g. K67 and G89 
in the kinase Pim1), a closed lobe conformation and a well-structured activation segment, which is 
often unorganised in kinases that require phosphorylation for catalytic activity. Upon 
phosphorylation, the activation segment folds onto the lower lobe and structures the peptide-
binding site leading to enzymatic activation.[17] Thereby both the affinity for ATP and 
phosphoracceptor substrates, as well as the catalytic activity are increased.[3] 
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In a subset of kinases, the equilibrium between the active and inactive conformation is based on 
the orientation of the highly conserved DFG-motif. Phosphorylation of the activation loop thereby 
triggers activation by shifting the equilibrium to the active form (DFG-in, meaning the aspartate 
of the sequence faces into the ATP binding pocket Fig. 3 B).  
 
 
 
 
Fig. 3: A) DFG-out conformation of the protein kinase BCR-Abl (pdb 3KFA) with the bound inhibitor AP24283. B) AP24163 
bound to the DFG-in conformation of BCR-Abl (3KF4).[18] The DFG motif is shown in pink, the respective inhibitor in yellow 
and the hinge binding is depicted as dotted lines. 
 
The c-helix-in form is the active form of a further subset of kinases including EGFR, where 
activation and formation of the c-helix-in form is often driven by dimerisation. Based on the 
rotation of the DFG motif or c-helix, specific allosteric pockets become accessible in regions 
adjacent as well as remote to the ATP-binding site.[12,19] In inactive conformations on the other 
hand, special regions like the so called switch pocket (a pocket which is created when a kinase 
converts between its active and inactive form), or special hydrophobic motifs (e.g. in the 
autoinhibited inactive form of cMET) can be found.[20] 
  
A) 
B) 
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1.2.1. Kinases and their medical relevance 
Given the importance of phosphoryl transfer processes in cellular signalling, it is no surprise that 
the kinome has been extensively investigated as a family of potential drug targets.[12] After the 
identification of the first kinase oncogene in 1978,[21] the continuing development has led  to a 
point where kinases are the second most pursued drug target family after G-protein coupled 
receptors,[12] mainly because of the presence of an ATP binding pocket, which makes them easily 
amenable to medicinal chemistry efforts.[7] Their signalling cascades regulate diverse cellular 
activities related to various diseases and indications including inflammation, pain, CNS disorders, 
autoimmune disorders, respiratory conditions, ophthalmology, cardiovascular disease and 
diabetes.[19,22] The most important indication for kinase inhibition however is cancer, which is based 
on the deregulation of kinase function as one of the major mechanisms by which cancer cells avoid 
normal constraints on growth and proliferation.[7] There is a vast amount of dysregulated kinase 
signalling known which influences the formation, growth and metastasis of cancer, however a 
summary of this data is beyond the scope of this introduction. One example, the kinase Pim1, will 
be covered at a later point.  
 
1.2.2. Inhibition of kinases 
A large number of small molecule kinase inhibitors (SMKIs) have been studied in the context of 
human diseases including cardiovascular diseases,[23] autoimmune disorders such as rheumatoid 
arthritis,[24] neurodegenerative conditions like Alzheimer’s disease, diabetes or liver disorders.[25] An 
overwhelming focus however lies, as previously mentioned, in the oncology field, where several 
protein kinase inhibitors have progressed through development and onto the market as approved 
therapeutic agents.[12] Imatinib (1) was thereby the first small molecule, which has been FDA 
approved against cancer in 2001.[21,26] This approval was a breakthrough, not only because kinases 
were considered an undruggable class of targets by some in the early days of kinase drug discovery, 
mainly because of the challenge to achieve selectivity and to avoid side effects related to their close 
structural similarities,[12] but more importantly because it represented additional years of life span 
and a progress to cure for patients with several types of leukemia.[27]  
This milestone was thus followed by a slow yet steady approval of kinase inhibitors in the first 
10 years of this century (see Fig. 4 for structures and binding modes). Concurrently, our 
understanding of kinase signalling networks and disease pathology steadily grew, culminating in the 
approval of yet another set of new small-molecule kinase inhibitors until 2016 (Fig. 5),[19] giving a 
total of 28 SMKIs by the middle of 2016,[26] along with a large number of other compounds 
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currently being evaluated in clinical and preclinical trials.[19] All inhibitors, apart from nintedanib 
(24, indication: idiopathic pulmonary fibrosis) and tofacitinib (16, indication: arthritis), are thereby 
approved for different cancer indications.[26] A regularly updated list of all FDA approved SMKIs 
and indications can be found on the internet.[28]  
In addition to the ever growing field of SMKIs, three macrolides including sirolimus (29, also 
known as rapamycin), temsirolimus (30), and everolimus (31), which are mammalian target of 
rapamycin (mTOR) inhibitors, have been approved by the FDA as immunosuppressants and 
anticancer agents.[26] To cap it all, yet another significant amount of other pharmacological agents, 
which show their therapeutic effect by interacting with targets related to protein kinase signalling, 
have been FDA approved over the last 20 years or so, some even prior to imatinib (1). These 
include monoclonal antibodies like trastuzumab, cetuximab, bevacizumab and panitumumab, 
antibody fragments like ranibizumab, antibody-drug conjugates like trastuzumab emtansine, fusion 
proteins like aflibercept, recombinante growth factors like becaplermin, palifermin and 
mecasermin, aptamers like pegaptanib, as well as recombinant insulin.[29] However, when discussing 
kinase inhibitors in this work, macrolides and biologically designed pharmacological agents will not 
be further analysed, since their development and interaction modes differ highly from that of small 
molecules. 
 
Fig. 4: First nine approved small molecule kinase inhibitors (2001-2009). Structural features are marked according to their binding 
sites to the kinases BCR-Abl (1, 5, 7), EGFR (2, 3, 8), VEGFR2 (4, 6, 9) which might not be their major targets: blue = adenine 
pocket, yellow = hydrophobic pocket, red = allosteric pocket, grey = solvent exposed region.[19] 
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SMKIs are categorised according to their binding modes, and are grouped into the two classes 
reversible and irreversible. The former tend to covalently bind with a reactive nucleophilic cysteine 
residue proximal to the ATP-binding site, resulting in the irreversible blockage of the ATP site.[19] 
The most prominent examples are the only two FDA approved irreversible kinase inhibitors 
ibrutinib (20) and afatinib (21), which use a chemically-active Michael acceptor electrophile that 
reacts with a cysteine nucleophile adjacent to the hinge region of the ATP-binding pocket to form 
a covalent adduct.[19,26] Reversible inhibitors on the other hand, can be further classified into four 
main types based on the conformation of the binding pocket and the DFG motif.[19] Many of them 
are ATP-competitive, typically displaying a H-bond donor-acceptor motif which interacts with key 
amino acid residues in the adenine binding pocket. The majority thereby binds in the active DFG-
in state (type I inhibitors), mimicking the interaction of the adenine ring in ATP with the hinge 
region, thus often inhibiting multiple kinases.[12] These type I inhibitors include gefitinib (2), 
erlotinib (3), dasatinib (5), sunitinib (6) and vandetanib (13).[12] The selectivity of these inhibitors is 
thought to be triggered by interactions with the hydrophobic back cavity (selectivity pocket) based 
on structural differences between kinases found in this region. The size of that pocket, as well as 
the access to it, is controlled by the first residue of the hinge region (gatekeeper residue, Fig. 2). 
Targeting this pocket offers the potential of achieving good levels of selectivity, if the gatekeeper 
residue is appropriately small.[12] Thereby, if mutations occur in the gatekeeper region, resistance 
may develop, meaning that inhibitors which do not use this allosteric pocket might be less sensitive 
to resistance mutations.[3]  
Type II inhibitors on the other hand, interact with the kinase in its inactive state e.g. DFG-out or 
c-helix out state, where an additional allosteric hydrophobic pocket is formed adjacent to the ATP-
binding site, which the inhibitors might exploit. By binding to that state in a non ATP-competitive 
manner, they stabilise the inactive conformation.[19,26] Leading examples include imatinib (1), 
sorafenib (4), nilotinib (7) and lapatinib (8). It was originally thought that these inhibitors are more 
selective by binding to these unique allosteric sites,[12] however recent analysis showed, that this 
lead is unreliable.[26] Still they often benefit from slower enzyme off-rates compared to type I 
inhibitors.[20]  
Both type III and IV inhibitors achieve certain levels of selectivity by using unique structural 
features of allosteric pockets of the targeted kinase. In the type III binding mode, inhibitors like 
trametinib (23)[26] bind exclusively in an allosteric pocket adjacent to ATP without assuming any 
interaction with the ATP-binding pocket.[19] Type IV inhibitors bind to an allosteric site remote 
from the ATP-binding pocket, but no inhibitor of this type has been FDA approved yet. Some 
kinase inhibitors, such as bisubstrate and bivalent inhibitors (type V), exhibit more than one of 
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these binding modes.[19] The leading example is lenvatinib (27), which shows binding features of 
both type I and type II inhibition.[26] 
 
Fig. 5: FDA approved small molecule (2011-2016) and macrocyclic (1999-2007) kinase inhibitors. Structural features are marked 
according to their binding sites to JAK 2/3 (10*, 16), ALK (11, 26), B-Raf (12, 22*), RET (13), BCR-Abl (14, 18), MET (15*), 
VEGFR2 (17* ,19, 24, 27), BTK (20*), EGFR (21), PI3Kδ (25) and CDK (28) (*based on homology to other inhibitors available 
in co-crystal structures[19]): blue = adenine pocket, yellow = hydrophobic pocket, red = allosteric pocket, grey = solvent exposed 
region, cyan = P-loop cleft, pink = ribose pocket, purple = specificity pocket, green = RAS pocket, brown = MEK selective 
hydrophobic pocket, an arrow indicates the reactive group of irreversible inhibitors.[19] 
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As can be taken from the amount of FDA approved inhibitors, pharmaceutical companies have 
committed a major focus on kinase drug discovery over the last 20 years or so, producing a vast 
amount of compound collections well populated with agents able to provide hits within certain 
areas of this target class.[20] In the development of SMKIs, as with most other drug targets, 
screening strategies frequently served as a starting point to find hits against a certain indication or 
target. Afterwards, medicinal chemistry approaches were used for further development, including 
additional screenings, computational chemistry methods and x-ray crystallography.[14] This fact, in 
addition to the complexity of cancer signalling,[13] is surely the reason that in the beginning of kinase 
inhibitor development, only a small subset of the human kinome has been studied, and that most 
kinase inhibition efforts are still limited to a select group of kinases.[19] Among the 28 clinically 
approved kinase inhibitors, most are tyrosine kinase inhibitors, a few are serine/threonine kinase 
inhibitors, and only one, idelalisib (25), is a lipid kinase inhibitor that was approved in 2014.[19]  
That being said, it is also important to mention, that various SMKIs are generally less selective, 
than originally suggested, ranging from highly selective inhibitors like lapatinib (8) which targets 
EGFR and ErbB2, to fairly promiscuous ones like sunitinib (6), which binds to multiple kinases.[30] 
This demonstrates that probably more kinases are targeted than initially anticipated, probably as a 
result of their closely related binding sites. These non-selective kinase inhibitors (also called 
pankinase or multikinase inhibitors), which include approved drugs like dasatinib (5) and 
sorafenib (4), can be clinically useful, because simultaneous suppression of multiple kinases and 
thereby biological processes of the disease often seem to be required for a beneficial therapeutic 
effect.[3,7] This is probably based on the possibility of homeostasis of kinase signalling networks. By 
recruitment of alternative kinases, signalling may be restored, which leads to an offset of inhibition. 
It is therefore also possible that inhibition of multiple kinases not severely comprise clinically 
tolerability.[3] Therefore, although many of the initial SMKIs were not deliberately created for their 
multitargeting profile, a more rational design of molecules with multiple predefined targets has 
emerged, also embracing the concept of traditional combination chemotherapy and converting it 
to single molecules with multiple functions.[7] Still the extent of selectivity required in order to 
deliver clinical efficacy against the intended disease together with imparting a favourable 
therapeutic window is a well debated subject.[22] Though it is possible that homeostasis compensates 
for some unwanted effects, SMKIs are generally known to suffer from on-target, as well as 
unexpected off-target side effects (including inhibition of other enzymes binding ATP or adenine 
containing biomolecules) and cross-activity,[3,14] still leaving a broad field concerning kinase 
signalling and inhibition for research to exploit. 
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1.2.3. The kinase Pim1 and its family members as cancer target 
The proto-oncogene Pim1 (provirus integration site for Moloney murine leukemia virus)[17] is a 
serine-threonine kinase belonging to the calcium/calmodulin-regulated kinases (CAMK) group,[31] 
and the eponymous enzyme of the three members in the Pim family.[32] It was originally identified 
from mouse lymphoma samples as a frequently activated gene resulting from the preferential 
integration of Moloney leukemia virus into the 3’-untranslated region of the Pim1 gene.[33] This 
integration created a premature stop codon in front of the AUUU(A) sequence at the 3’ region in 
the Pim1 transcript. The consequence is an unusually long-lived transcript (Pim1 mRNA has 
generally a short half-life), which allows an increased level of translation and hence higher levels of 
Pim1 in the affected cells.[34,35] 
Rather than having to be activated by phosphorylation, the level of Pim enzymatic activity is 
dependent on the absolute amount of protein present,[36] making the stability of the transcript the 
key regulator of Pim activity.[37] This permanent catalytic activity is based on the large number of 
polar interactions from the activation segment with the lower kinase lobe, leading to a certain 
structural organisation. Generally Pim1 is an enzyme with a short half-life,[32] which is protected 
from proteasomal degradation by HSP90 (heat shock protein 90), but marked by HSP70 for 
ubiquitylation and proteasomal degradation.[38] 
The Pim1 gene encodes for two isoforms of 34 kD (Pim1S) and 44 kD (Pim1L) through the use of 
alternative initiation sites. Both isoforms contain the kinase domain and exhibit comparable in vitro 
kinase activity,[32] but show distinct cellular functions, with Pim1S predominately localising to the 
nucleus and Pim1L localising to plasma membrane.[39] Pim1 expression thereby is not only regulated 
at the transcriptional, but also at the posttranscriptional, translational and posttranslational levels[32] 
Transcription of Pim1 can be activated by several cytokines, such as IL‑2 (interleukin-2), IL‑3 and 
IL-6,[39] followed by signalling transduction to the nucleus through two families of proteins, Janus 
kinase (JAK) or signal transducers and activators of transcription (STAT) (Fig. 6). Pim1 may 
thereby form a feedback loop with the JAK/STAT pathway via SOCS1 or 3 for tight regulation of 
its own expression and function.[39]  
Pim1 is a critical enzyme which is involved in multiple cellular functions such as cell cycle, cell 
growth, cell survival, differentiation, apoptosis, senescence and drug resistance.[32,39] It is 
ubiquitously expressed throughout the body,[32] and shows a high and specific expression in liver, 
spleen and bone marrow in typical hematopoietic progenitors during embryonic development.[40,41] 
In the adult stage it is only slightly expressed in circulating granulocytes[40] and shows nearly 
undetectable expression in healthy tissue in general.[17,36] The expression of Pim1 during 
development and its subsequent shut off in adult tissues suggests that its untimely overexpression 
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may contribute to malignant transformation.[41] And indeed, its activity and especially 
overexpression supports in vitro and in vivo tumour cell growth and survival through modification 
of a number of common as well as isoform-specific substrates, including several cell cycle 
regulators and apoptosis mediators.[17,36,39] In hematopoietic malignancies and in a variety of solid 
tumours it is known to be overexpressed, with a higher expression level in hematologic than solid 
organ malignancies. The degree of expression has been shown to correlate with the stage of disease 
and a poor prognosis.[17,36]  
Pim1 overexpression appears to contribute to cancer development and survival in three major 
ways; by inhibiting apoptosis, by promoting cell proliferation and by promoting genomic 
instability,[17,36] thereby making the cells prone to multiple drug resistance.[42] However there are 
numerous mechanisms which involve Pims leading to oncogenic effects, too many to be covered 
here, which have recently been reviewed in literature.[37] A brief overview over selected interaction 
partners is given in Fig. 6. 
 
 
Fig. 6: Proviral integration site for Moloney murine leukemia virus-1 (Pim1) is regulated through the Janus kinase (JAK)/signal 
transducers and activators of transcription (STAT) pathway and regulates multiple signalling pathways, such as cell survival, cell 
cycle and cell growth.[39]  
 
One of the features, making Pim1 an attractive drug target, is that the knockout of Pim1 in mice is 
not lethal nor does its absence induce any immediately obvious phenotype.[36,43] Yet, elimination of 
Pim1 activity is lethal to overexpressing cancer cells, leading to the conclusion that targeting Pim1 
would avoid detrimental side effects that occur with most conventional treatments.[36] 
Inhibition of Pim1 has shown to lead to effects like induction of apoptotic cancer cell death or 
sensitisation to chemotherapy.[36] E.g. inhibition of Pim1 in the cytosol, nucleus and surface of 
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cancer cells by a monoclonal antibody was able to disrupt Pim1/Hsp90 complexes, inhibit the 
phosphorylation of BAD and induce the mitochondrial apoptotic pathway in cancer cells, while 
overcoming the Pim1 related drug resistance.[17,41,44] That, in combination with its interaction with 
different proteins and association with various signalling pathways, some of them presented in Fig. 
6, makes it an important therapeutic antitumor target.[39] In fact several recent studies demonstrated 
that functional interference with Pim kinases impaired growth and survival of cancer cells.[17] 
Studies with murine models of AML have demonstrated however, that a high tumour burden 
persists despite of improved survival with Pim inhibition,[45] suggesting that disease control, rather 
than significant tumour killing, is the realistic effect of Pims as single target.[37] By itself, Pim1 seems 
not to be a strong oncoprotein, but when expressed with other proteins such as Myc, it exerts a 
potent synergistic transforming effect on cells, particularly when the functions of those proteins 
are involved in proliferation and cell survival.[46]  
Pim1 features a classic protein kinase domain architecture with all conserved structural elements, 
except from a unique beta hairpin insert located N-terminal to helix αC. The ATP-binding in this 
kinase however differs from usual kinases insofar, that a proline residue in the hinge region (P123 
Fig. 7) prevents the formation of the second hydrogen bond from the hinge backbone to the 
adenine (c.f. Fig. 2). The hinge region additionally differs from other kinases, due to an additional 
residue in this region, resulting in the hinge sequence ERPXPX.[17]  
 
 
Fig. 7: Adenine (orange) bound to the active site of the kinase Pim1 (pdb 1YI4).[47] Adenine binds to Pim1 via a hydrogen bond to 
E121 (yellow).  The unique P123, which prevents adenine from forming a second hydrogen bond is shown in pink. K67, which is 
known to interact with many Pim1 inhibitors is indicated in stick format and the glycine rich loop is shown in green. 
 
Based on this unique hinge architecture very selective inhibitors for the Pim kinases can be 
identified, and various inhibitors have been reported.[17] A considerable amount of these inhibitors 
display different classes of highly potent Pim1 inhibitors, including ruthenium-containing 
P123 
E121 
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organometallic complexes,[48,49] bisindolylmaleimides,[50] imidazo[1,2-b]pyridazines,[51] pyridones,[52] 
flavonoids,[53,54] benzoisoxazoles,[55] isoxazoloquinoline-3,4(1H,9H)-diones,[56] 5-arylidene-2,4-
thiazolidinediones,[57] cinnamic acids,[58] 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones,[59] but also P9 
monoclonal antibodies.[39]  Most Pim1 SM inhibitors work either as ATP competitors or ATP 
mimetic compounds.[17,36] These compounds interact via polar interactions with the active site K67 
and a conserved water molecule, anchoring the inhibitors to the back of the ATP binding pocket. 
The binding is additionally stabilised by a number of hydrophobic interactions,[17] and several 
inhibitors use halogen atoms to interact with the hinge region.[36] 
A drawback in Pim1 inhibition can however be found in the fact that there exists a certain potential 
compensatory mechanism between the Pim family members, which suggests that inhibitors should 
block all Pim kinases for efficient cancer therapy, even if only Pim1 is thought to have a significant 
impact on tumour formation.[7,17] Despite the high homology (>60% in amino acids) in the ATP 
binding pocket, several proposed small molecule Pim inhibitors preferentially inhibit the activity 
of Pim1 and Pim3 rather than Pim2,[17] which might be related to the fact that the KM (MICHAELIS-
MENTEN constant, the concentration of substrate that leads to half maximal velocity) of Pim2 for 
ATP is up to 100-fold lower than that of Pim1 and Pim3.[60] This fact makes the design of a pan-
inhibitor more challenging in comparison to the development of specific inhibitors.[37,60,61] 
The development of pan-Pim inhibitors is still very successful. The first SM pan-inhibitor to enter 
the clinic was SGI-1776,[7,31] which induces apoptosis in Pim1 overexpressing cells. In a preceding 
study using K562 and HEL92.1.7 cells with either an Hsp90 inhibitor or with the pan-histone 
deacetylase inhibitor panobinostat (36), it was shown that the Pim1–Hsp90 association was 
disrupted and, at the same time, Pim1 binding to Hsp70 was increased, which led to proteasomal 
degradation of Pim1.[36] The clinical trials for this compound however were terminated early 
because of cardiac toxicity.[31] A second generation inhibitor AZD1208 followed,[39] but was 
discontinued due to lacking evidence of anti-tumour activity from monotherapy treatment.[62] There 
are still two pan Pim inhibitors in clinical trials, one of them LGH447 (respectively PIM447) a 
specific pan-Pim kinase inhibitor, which is tested as single agent (e.g. NCT02078609) and in 
combination with midazolam (NCT01456689), a PIK3α inhibitor (NCT02144038) and a 
JAK1/JAK2 or CDK4/6 inhibitor (NCT02370706). The second one is INCB053914, a novel 
ATP-competitive SM pan-inhibitor of Pim kinases[63,64] which is recruiting as of September 2016 
(NCT02587598).[65] All these efforts, not only basic research but also development for the clinic, 
suggest that the Pim family is a master drug target in numerous types of cancer.[39] 
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1.3. Histone deacetylases 
Due to their key role in the epigenetic gene expression by controlling the grade of acetylation of 
positively charged lysine residues located at the N-terminus of histones, which are the main protein 
component of chromatin, around which DNA coils, histone deacetylases (HDACs) are another 
oncologically interesting group of enzymes. If these N-terminal lysines are positively charged, they 
may interact with the negatively charged DNA phosphate backbone, leading to a very condensed 
chromatin structure, allowing little access for transcription proteins.[66,67] Hyperacetylation of these 
N-termini on the other hand, by inducing a loss of positive charges, has the opposite effect and 
leads to an open chromatin structure and an increase in the expression of particular genes.[66,68] The 
acetylation status thereby is not only governed by HDACs but also the counteracting histone 
acetyltransferases (HATs).[66,69]  
Apart from histone deacetylation, a function that the name “histone deacetylases” implies, HDACs 
also act as general lysine deacetylases, being responsible for the removal of acetyl groups on a vast 
array of nuclear and cytoplasmic proteins.[70,71] A high-resolution mass spectrometry study for 
example identified 3600 lysine acetylation sites on 1750 mammalian proteins.[69,72] However, 
research is just starting to grasp the role of acetylation of non-histone target proteins. [71]  
Overall 18 distinct human HDACs have been identified to date, which can be categorised into four 
classes based on the sequence homology to their Saccharomyces cerevisiae analogues. Class I (HDAC1, 
2, 3 and 8), class IIa (HDAC4, 5, 7 and 9), class IIb (HDAC6 and 10), and class IV (HDAC11) are 
zinc(II)-dependant metalloproteins, while the class III proteins (also known as sirtuins (Sirt1–
Sirt7)) are structurally distinct and characterised by their nicotinamide adenine dinucleotide 
(NAD+) dependency.[69,71,73,74] In this thesis, when talking about HDACs, only the zinc-dependant 
isoforms are considered, hence the term HDAC is always used with respect to class I, II and IV. 
Class I HDACs are homologous to yeast RPD3, share a compact structure (350-500 amino acids), 
and are ubiquitously expressed proteins, which are located almost exclusively in the cell 
nucleus.[71,75,76] They show the strongest enzymatic activity amongst the HDAC classes and their 
function, with the exception of HDAC8, is dependent on the formation of large multiprotein 
complexes, which often involve more than one HDAC subunit and are frequently in association 
with corepressor proteins.[68,69,75,77] HDAC8 is an atypical HDAC family member, which is 
expressed tissue specific and shows deacetylase activity as a single polypeptide.[69] The main 
structural difference to the other class I HDACs is an abbreviated C-terminal domain.[78]  
Class II HDACs are homologous to yeast HDA1 protein and can be further subdivided into two 
subclasses, IIa (HDAC4, 5, 7 and 9) and IIb (HDAC6 and HDAC10), based on their protein 
sequence homology and domain organisation. Class IIa HDACs have one catalytic domain and a 
Introduction 
 
17 
 
long N-terminal adaptor domain, while class IIb HDACs 6 and 10 contain a duplicated catalytic 
domain, although this duplication is partial and catalytically inactive, in the case of HDAC10.[69,71,79] 
Compared to class I, class II HDAC expression pattern is more restricted and their function is 
more tissue specific. Class IIa HDACs seem to have weak deacetylase activity and they may 
therefore more likely function as histone readers or as scaffold proteins, incorporating 
enzymatically active HDACs into multiprotein complexes.[80,81] They can shuttle between the 
nucleus and the cytosol in response to different stimuli, whereas HDAC6 and HDAC10 mainly 
localize in the cytoplasm.[69,75,79] 
HDAC11 is the only known member of class IV HDACs, but very little information is available 
about its expression and function.[75] Size, cellular locations, expression patterns and physiological 
functions of the Zn-dependant HDAC-isoforms vary widely and were summarised in various 
publications.[70,75,76,82] 
 
The active site of the zinc-dependant HDAC isoforms is structurally highly conserved[69] and 
comprises an 11 Å deep hydrophobic pocket which allows access to the catalytic centre in which 
the Zn(II)-ion can be found (Fig. 8). The residue composition of this tubular access is almost 
conserved in all HDACs and an alanine residue scan mutagenesis revealed the importance of all 
the residues found in the channel.[76] The zinc ion in the active site of HDAC class I/II is 
coordinated to two aspartic acids and one histidine, and the environment around it is generally 
considered common to all zinc dependant HDACs, with some possible residue changes (Fig. 8 
B).[76] A systematic comparison of the crystal structures of HDAC1, 2, 3, 4, 7, and 8 however 
revealed the differences between the enzymes, which can be found at the surface close to the 
entrance of the active site, at the enzymatic site as well as at the acetate release channel placed at 
the bottom of the active site channel (foot pocket). One example is found in HDAC8, which, when 
co-crystallised with different inhibitors, may or may not possesses a deep hydrophobic pocket 
adjacent to the active site channel, indicating a highly dynamic region next to the opening of the 
active site.[69]  Another example is the replacement of a tyrosine residue by a histidine in class IIa 
HDACs, leading to the afore mentioned decreased catalytic activity towards acetyl-lysine substrates, 
as well as an enlarged cavity.[69,81] 
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Fig. 8: The active site of human HDAC7 (grey) with the natural product trichostatin A (32 TSA, cyan) bound to it (pdb entry 
3C10).[83] A) The hydroxamate of TSA lies deep in the hydrophobic pocket coordinating to the catalytically important zinc-ion 
(magenta), while the dimethylaminophenyl-group is pointing outwards. B) Key interactions of zinc-coordination: While the zinc-
ion is directly coordinated by H709, D707 and D801, the two residues H669 and H670 form hydrogen bonds with the hydroxamate 
moiety of TSA, which itself forms a monodentate complex with the catalytic zinc ion. This is an atypical behaviour, which is 
triggered by a somewhat different topology of the active site related to the lack of a tyrosine residue in class IIa HDACs. This leads 
to a different orientation of the hydroxamate and a coordination of the carbonyl oxygen to a water molecule in the HDAC7 active 
site. Normally hydroxamates form a bidentate complex with the zinc-ion.[69,83] 
 
1.3.1. HDACs and their medical relevance 
HDACs have shown to be involved in different pathologies such as diseases of the central nervous 
system, inflammation, infection[69,70] and cardiac disease.[71] The main focus on HDACs in a medical 
context is drawn towards their involvement in cancer. HDACs are known to be often over- or 
under-expressed in cancer cells and their inhibition may lead to variable cellular responses. 
According to different reviews these include, but are not limited to, cell cycle arrest, suppression 
of cell proliferation, inhibition of angiogenesis, reversal of differentiation, enhanced 
immunogenicity and antigen-presenting capacity, enhanced reactive oxygen species (ROS) 
production and decreased free radical scavenger production, accumulation of DNA damage 
through transcriptional downregulated and impaired DNA repair proteins, inhibition of DNA 
replication, immunogenic cell death, senescence, intrinsic and extrinsic apoptotic mechanisms, 
induction of differentiation and mitotic or autophagic cell death.[66,70,73,75,80] The molecular 
mechanisms underlying these effects of inhibition however remain to be fully elucidated[75] and it 
 
 
H670 D707 
D801 
A) B) 
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is assumed that more than one mechanism of action is responsible for the antitumour effects across 
different tumour types mediated by inhibitors with diverse specificity profiles.[75,80] The 
predominant mode of action is thought to be the induction of apoptosis,[84] which occurs through 
altered expression of genes encoding proteins in both intrinsic and extrinsic apoptotic pathways; 
through effects on the proteasome/aggresome systems; through the production of reactive oxygen 
species and through alterations in the tumour microenvironment.[85] Generally spoken, it is assumed 
that the overall modulation in gene expression is not solely based on an altered histone acetylation 
degree.[71] This assumption is supported by diverse studies, one of them showing that, although 
inhibition of HDACs induces global protein acetylation, probably only 2–10% of genes' expression 
is significantly changed, with almost similar numbers of genes upregulated and downregulated.[86] 
Additionally, analysis of two promoter regions from genes differently affected by HDAC inhibition 
showed that promoters of both, downregulated and upregulated genes, displayed increased 
acetylation.[87]   
 
1.3.2. Inhibitors of the zinc-dependant HDAC isoforms 
HDAC inhibitors (HDIs) as potential anticancer agents, like various other drugs, were originally 
discovered through empirical screening for substances that induced tumour cell differentiation, 
without the initial knowledge of their molecular targets.[70] Nowadays HDACs are attractive targets 
for drug discovery programs, with a significant number of inhibitors identified and over 400 PCT 
(Patent Cooperation Treaty) patent applications submitted over the last two decades.[88] More than 
350 clinical trials have been completed or are underway using HDAC inhibitors for the treatment 
of various human malignancies with a focus on haematological tumours, both as single agents and 
in combination with chemotherapies and other targeted therapeutics.[70,75,80,82] To date, the FDA has 
approved three HDAC inhibitors for cutaneous or peripheral T-cell lymphoma (CTCL/PTCL): 
The suberanilohydroxamic acid SAHA 33 (vorinostat, approval for CTCL 2006), the cyclic peptide 
FK228 34 isolated from Chromobacterium violaceum (romidepsin, approval for CTCL 2009, PTCL 
2011) and the hydroxamic acid belinostat 35 (approval for PTCL 2014) (Fig. 9).[69,80,82,89] Currently 
all three drugs are being further studied for other diseases as well as other haematological 
malignancies and solid tumours, either as a single agent or in combination with other drugs.[82] More 
recently, in addition to that, the hydroxamic acid panobinostat 36 (approval 2015) (Fig. 9) has been 
FDA-approved as combination therapy with bortezomib (proteasome inhibitor) and 
dexamethasone (steroid medication) in patients with recurrent multiple myeloma, who have 
received at least two prior treatment regimens, including bortezomib and an immunomodulatory 
agent.[90] 
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In general, HDIs are classified into distinct structural groups, including the previously mentioned 
hydroxamic acids and cyclic peptides, as well as carboxylic acids (valproate, butyrate), 
aminobenzamides (entinostat, mocetinostat), epoxyketones (trapoxins), and hybrid molecules.[80] 
The most widely explored class of HDAC inhibitors, as evident from the FDA approvals, are 
hydroxamic acid-derived compounds.[82] Based on the highly conserved active site of zinc-
dependant HDACs, the pharmacophore for these inhibitors mostly includes three regions: a zinc-
binding group, such as a hydroxamic acid, carboxylic acid or benzamide, which chelates the zinc-
ion inside the active site, a solvent exposed cap-region which interacts with the protein-residues at 
the entrance of the active site pocket, and a linker which connects the other two regions and 
accommodates the hydrophobic tubular access of the active site (Fig. 9).[70,76,82]   
 
 
Fig. 9: The FDA approved HDAC inhibitors SAHA (33), FK228 (34), belinostat (35) and panobinostat (36). The regions which 
are thought to be the pharmacophore are highlighted: the zinc-binding groups are marked in blue, while for SAHA, belinostat and 
panobinostat the capping group (see below) is marked in yellow. In the three hydroxamic acid structures these two regions are 
connected by an organic linker which fills the hydrophobic pocket. For FK228 most of the peptide is seen as the capping group. 
 
The first generation of HDIs, including the approved compounds SAHA 33 and panobinostat 36, 
as well as the reference natural product TSA (32 Fig. 8), did not show any particular selectivity 
towards specific isozymes, and are classified as pan-HDAC inhibitors.[75,80] Other HDI derivatives 
are class I selective (e.g. the carboxylic acids like valproic acid (VPA) or sodium butyrate) or prefer 
class I over class II, like the depsipeptide FK228 34.[69,75] The development of such class- or 
isoform-specific inhibitors for the treatment of different cancer forms seems highly desirable to 
avoid off-target effects, since for example knockdown of HDAC1 or 2 is sufficient to reduce 
tumour growth in vivo and knockdown of class IIb HDACs induced the growth arrest of a variety 
of human solid tumour cell lines.[80] For achieving selectivity and specificity, variations in the zinc-
binding groups have shown to be promising, including chelating groups like benzamide derivatives, 
thiols, sulphamides, ketones and trithiocarbonates.[91] Additionally, variations in the cap region, 
which is considered predominantly responsible for selectivity, are being used to design inhibitors 
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that target different HDAC isoforms by using the variation in amino acids at the entrance to the 
active site.[67] Besides, HDACs involved in specific complexes may be targeted, as the cap region 
cannot only bind to the HDAC itself but also to other complex components near the active site.[76,92] 
Finally, linker modifications may also serve to direct specificity, such as the addition of an aromatic 
ring that can fit into the enlarged catalytic pocket of HDAC7 that is not present in class I or class 
IIb HDACs.[70,93] The target specificity of HDIs and the requirement for specific and selective 
inhibition of HDACs to achieve therapeutic efficacy still remain topics of debate.[80] One reason 
for that might be, that no major differences concerning the toxicity profile were observed between 
pan-HDAC inhibitors, class I selective inhibitors or FK228.[69]  
Despite positive responses in patients with hematologic malignancies, existing HDIs have only 
proven effective for the treatment of a relatively small population of patients and their effect on 
most other tumours is marginal at best.[80] Therefore, it has been speculated that HDIs, despite of 
the potency and reasonable toxicity profile of newer agents (second generation inhibitors), are 
unlikely to make a substantial impact in the clinic when used alone, and that the future of this very 
promising class of agents lies in rational combination therapy,[80,84] where a growing number of 
preclinical and clinical studies have demonstrated synergistic effects and more efficient and tumour 
specific anticancer activities.[75,82] A large number of rational HDI-based combinations is indeed 
possible, and new ones continue to emerge.[94] For a deeper insight into this topic, diverse reviews 
are recommended.[95–98] Briefly, combinations including cytotoxic chemotherapy, hypomethylating 
agents and proteasome inhibitors have advanced the farthest,[94] but also UV rays,[82] ionising 
radiation[75,82,98,99] and dual inhibitors combining HDAC inhibition e.g. with targeted therapy against 
PI3K, tyrosine kinases, topoisomerase II or nuclear receptors,[100] may be of interest for distinct 
cancer subtypes.[80]  
One particular example for the combination of HDIs and cytotoxic chemotherapy includes well 
established platinum drugs as promising treatment strategy. HDIs thereby act as chemosensitizers, 
since the chromatin relaxation, which is accompanied by histone hyperacetylation, allows easier 
access to the DNA and therefore more platinum-DNA adduct formation occurs. This concept has 
been proven successful in vitro and in vivo in various studies for many cancer types and stages and 
has also been reviewed recently.[95]  
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1.4. Metals in medicine 
Having mentioned platinum drugs in the previous chapter, it becomes clear that metal-based 
compounds might serve as promising drugs. Metal-based therapeutic or diagnostic agents have 
various applications today, with structurally most simple and probably best known examples being 
lithium carbonate (Li2CO3) for the treatment of bipolar disorder, or barium sulphate (BaSO4) as 
X-ray contrast agent in the gastrointestinal tract.[101] Interestingly the first accounts of pure 
inorganic compounds are as old as 3500 years, where a suspension of rust was administered as a 
cure of impotence, and iron compounds have often been used since for the treatment of 
anaemia.[102] In addition to that, the earliest reports on therapeutic use of metals or metal based 
compounds in cancer and leukaemia date from the sixteenth century.[103] 
The first metal containing compound which was used in the clinic against cancer worldwide, and 
which is still probably one of the most successful anticancer drugs, is one of the afore mentioned 
platinum drugs, cisplatin [Pt(NH3)2Cl2], which has been discovered by serendipity in the 1960s, and 
was FDA approved in 1978.  Cisplatin is a prodrug, which, after entering a cell, undergoes aquation 
in a way that one chlorido ligand of the active metal centre is displaced by an aqua ligand due to 
the lower chloride concentration inside the cell. The new complex might then enter the cell nucleus 
and react with the DNA, by forming intrastrand, interstrand or DNA-protein cross-links. If the 
resulting lesions are not repaired, the cell undergoes apoptosis. The side effects associated with 
cisplatin treatment can be severe and may include renal and nervous toxicity, hearing difficulties, 
nausea, vomiting, and several others.[104] Still, the clinical success of this anticancer compound has 
inspired extensive investigation into the utility of transition-metal complexes as diagnostic or 
therapeutic agents. Based on their wide spectrum of coordination numbers and geometries as well 
as kinetic properties, metal compounds offer mechanisms of drug action, that cannot be realised 
by organic agents, which still represent almost all drugs placed on the market nowadays.[105,106] 
Various newer generations of platinum-based drugs like carboplatin and oxaliplatin are available 
today,[104] as well as other FDA approved metal-based compounds like auranofin for the treatment 
of rheumatoid arthritis or arsenic trioxide against acute promyelocytic leukemia, to just give some 
examples.[102] In fact, to date practically all transition and main group metals have been tested for 
antitumour properties and other indications, with diverse outcomes.[107] The platinum based 
compounds however remain the only approved precious metal-based anticancer drugs.[108] 
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1.4.1. Metal templates as structural feature for enzyme inhibitors 
Most metal-based compounds like cisplatin use active metal centres as source of bioactivity and, in 
one way or another, interact with DNA as the primary target. However, metals can also be used as 
inert anchors to shape the overall structure of a compound and to synthesise small and medium-
sized globular molecules in a very economical fashion.[109] Taking into account Emil Fischer’s “Lock 
and Key Model” from 1894, where the lock is the specific structure of the enzyme in the active site 
and the key is the inhibitor,[8]  using a metal as the centre of the molecule, the key can be designed 
in a much tighter-fitting way due to the expanded structural complexity possible (Fig. 10, e.g. 
octahedral complexes may form up to 30 stereoisomers when using six different monodentate 
ligands). This enzyme-inhibitor concept was expanded in the 1950s by Daniel E. Koshland’s 
“Induced Fit” theory, which gives a more accurate picture of the interactions, since an enzyme is 
not a static but flexible structure, which might undergo structural rearrangement when the substrate 
or inhibitor binds.[8]  
 
 
Fig. 10: Extension of coordination geometry from linear, trigonal planar and tetrahedral as it is formed by carbon, to square planar, 
square pyramidal, octahedral, trigonal and pentagonal bipyramidal possible around a metal centre (M). A-H are residues or ligands 
around the respective central atom. 
 
Over the last decades, various groups have demonstrated the high versatility of inert metal 
complexes as powerful structural templates for the creation of such “key” structures for targeting 
proteins, with a large variety of reactive and inert protein-binding metal-containing compounds 
being available today as tools for chemical biology or as drug candidates.[110–120] The unique 
possibility of fine tuning the shape of inert sophisticated structures, by projecting the coordinated 
ligands into three-dimensional space, which fit tightly into an enzymes active site, thereby 
improving affinity and selectivity, may be one reason for the increasing use of this type of 
compounds. While Dwyer pioneered the field, using polypyridyl complexes as biologically active 
compounds with inhibitory properties against acetylcholinesterase over 60 years ago,[112,114] there is 
of course a much broader range of inert metal complexes as well as applications available today, 
still leaving polypyridyl complexes as one of the most important areas of research with their DNA-
binding, cytotoxic and enzyme inhibiting properties.[111,113,115–118]  
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A broad and important field of metal-based compounds are sandwich and half-sandwich 
complexes as scaffolds for metal complexes, which target biomolecules. Whereas octahedral 
coordination geometries offer a large structural complexity,[120] half-sandwich complexes offer the 
advantage that they are typically much easier to synthesise.[48,49,121,122] There are three main reasons 
to use sandwich complexes shown in the literature: The use as isosteres for purely organic groups, 
the improved uptake of cells and the occupation of unexplored chemical space.  
Some recent studies confirm the efficiency of replacing organic moieties by ferrocene in different 
types of bioactive compounds, structural examples can be found in 1.4.2 and 1.4.3.[118] Beyond 
ferrocene (37), ruthenocene (38) and ruthenium(II) pentamethylcyclopentadienyl benzene 
sandwich complexes have been reported as potent carbonic anhydrase inhibitors (Fig. 11),[123–125] 
revealing that not only the structure, but also the metal itself has an impact on the inhibition 
potency. Complex 38 is thereby almost an order of magnitude more potent (Ki = 9.7 nM) than the 
analogous ferrocene derivative 37 (Ki = 80 nM) for human carbonic anhydrase II (hCA II).[126] 
 
Fig. 11: Selected examples for metal-based compounds with enzyme inhibition properties, based on metallocenes, Ru half-
sandwich complexes and Ir and Rh polypyridyl complexes. 
 
Though, not every incorporation of a metal-containing moiety leads to an improvement in affinity 
or activity. This might be related to an increased space demand.[127,128] An example for modulated 
cellular uptake was given using a ferrocene-containing bioorganometallic inspired by the antibiotic 
platensimycin, which, according to modelling, fits nicely into the targets (FabF) active site, but 
shows no antibacterial activity up to 200 mg/mL.[129] Besides sandwich-compounds, half-sandwich 
complexes are popular metal-containing scaffolds for the design of protein binders, including 
recent reports of arene-Cr(CO)3-containing analogues of the antibiotic platensimycin,
[130] Cr(CO)3 
coordination to anti-inflammatory diterpenes,[131] Re(CO)3- and 
99mTc(CO)3-cyclopentadienyl 
complexes for targeting of human carbonic anhydrase IX[132] or  amino acid transporters.[133] In 
recent reports, η6-arene ruthenium half-sandwich complexes were used as templates for a broad 
Introduction 
 
25 
 
range of metal-based bioactive compounds, such as piano-stool complexes inhibiting carbonic 
anhydrase II,[134] selective organoruthenium inhibitors of protein tyrosine phosphates 1B (39),[135] 
as well as for the development of organoruthenium antagonists of human A3 adenosine 
receptor.[136] A 5-cyclopentadienyl ruthenium half-sandwich complex (40) was recently reported 
as a single digit nanomolar inhibitor for the human repair enzyme 8-oxo-dGTPase.[137] Octahedral 
complexes often cover the afore mentioned polypyridyl complexes, and recent examples are given 
with cyclometalated iridium(III) and rhodium(III) complexes 41 and 42 as tumour necrosis factor-
α (TNF-α) and NEDD8-activating enzyme (NAE) inhibitors.[138] For more examples of metal-
based compounds as inhibitors for kinases and HDACs please refer to the following two chapters. 
 
1.4.2. Metal-based kinase inhibitors and their in vitro and in vivo properties 
The use of metals to design kinase inhibitors is an ever-growing field, still being in its infancy. 
However, a range of structures and purposes for the choice of using a metal can be found in 
literature. Apparently, these include hybrid molecules which incorporate platinum to enhance 
structural complexity and/or functionality such as drugs with dual mechanism of action. 
Structurally simple planar Pt(II) complexes, like the 1,10-phenanthroline derived 43 (Fig. 12) serve 
as micromolar MAPK and CDK2 inhibitor, with much higher potency of the complex compared 
for the ligand.[139] Other examples for Pt-hybrids include Pt coordination compounds to organic 
TK like imatinib (1) or CDK inhibitors.[140,141] An oxaliplatin based imatinib analogue was thereby 
shown to circumvent TKI resistance, predominately mediated by the emergence of secondary 
mutations on oncogenic kinases, probably based on their dual mechanism of acting both as KI for 
the same oncogenic kinases and as DNA damaging agents, as well as a slightly different binding to 
the ATP binding pocket of BCR-Abl E255K.[140] CDK inhibitor-cisplatin hybrids like the 6-
benzylamino-9-isopropylpurine derived dimer 45 have shown anticancer activity in the micromolar 
region in different human cancer cell lines, including K-562, MCF7, G-361 and HOS in vitro, being 
up to five times more effective compared for the free ligand and roughly as effective as cisplatin.[141]  
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Fig. 12: Examples for metal-based kinase inhibitors based on platinum drug-conjugates (43-45), the universal linker system (46), 
ferrocenes (47-48) and inert rhodium complexes (49-50). 
 
The feature of platinum and other metals to be coordinated by ligands, as exemplified by the 
previous represented compounds, or in biological systems as DNA strand or protein cross-links, 
can also be used to create compounds in which the coordination chemistry is applied for the 
development of metal-based linkers to connect inhibitors with bioconjugates, which might facilitate 
transport or cellular uptake and cell selectivity. This so called universal linker system (ULS) has for 
example been applied to create linker of oxindole-based multikinase inhibitors with bioconjugates 
such as lysozyme. The obtained conjugates showed enhanced cell specificity and intracellular 
retention, thereby prolonging its pharmacological activity while avoiding uptake in healthy tissue 
and unwanted side effects. Inside cells, the platinum ligands are dissociated by competitive 
displacement with endogenous thiols such as glutathione (GSH), leaving a metal-based kinase 
inhibitor binding to the active site.[142] Another example is the conjugation of the approved kinase 
inhibitor gefitinib (2) with the approved mAb trastuzumab, which functions as anticancer drug by 
binding to HER2. The platinum centre is thereby coordinated by the gefitinib quinazoline nitrogen 
N1 and a methionine residue in trastuzumab (46). The linker is very stable in various media like 
PBS or serum but again cleaved by intracellular sulphur donors, probably by competing for the 
platinum binding.[143] 
Another example for metal-based kinase inhibitors are the previously mentioned ferrocene 
compounds. These include oxindole containing ferrocenes (e.g. 47), which inhibit DYRK3-4 and 
VEGFR2 at submicromolar to low micromolar levels, associated with antiangiogenic properties in 
Xenopus embryos[144] Other examples confirm the efficiency of replacing organic moieties by 
ferrocene in different types of bioactive compounds, such as derivatives of the anticancer drugs 
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erlotinib (3) and gefitinib (2), the ferrocenyl quinazoline compound 48 thereby inhibits the 
epidermal growth factor receptor (EGFR) kinase with low micromolar IC50 values.
 [145] 
Metal-based kinase inhibitors of course also include classical inert polypyridine complexes like the 
Rh-based mTOR inhibitor 49 or JAK2 inhibitor 50.[106,146] In molecules like this, the coordinative 
bonds are designed to be kinetically inert and thus stable in biological environments. Hence, such 
metal complexes should behave like purely organic compounds without displaying any metal 
related cytotoxicities.[48] Complex 49 shows a similar mechanism of action to rapamycin (29), by 
first binding to FKBP12 to create a protein–protein interface that is subsequently recognised by 
the mTOR FKBP12-rapamycin-binding domain, thereby presumably functioning as protein-
protein interaction stabiliser and antagonist of mTOR activity with an IC50 of 0.01 μM in a cell-free 
system.[106] The structurally related rhodium complex 50 on the other hand is a JAK2 inhibitor 
(IC50 = 3.5 µM), which has been shown to inhibit JAK2 autophosphorylation and cancer cell 
growth in human erythroleukemia (HEL) cells.
[146] The field of inert metal-based inhibitors was 
pioneered by the MEGGERS group,[109,119] who used inert metal complexes as structural scaffolds for 
the design of highly potent and selective inhibitors of various protein and some lipid 
kinases.[48,49,109,120–122,147–161] The original template for these kinase inhibitors was the natural product 
and non-selective ATP-competitive kinase inhibitor staurosporine (51), which was structurally 
modified by using inert metal centres as “hypervalent carbon” with extended structural 
opportunities (Fig. 13).[48]  
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Fig. 13: The natural product staurosporine served as structural template for the development of various inert metal-based kinase 
inhibitors. The indolo[2,3-α]carbazole of 51 is thereby displaced by pyrido[2,3-α]carbazole which serves as bidentate ligand for easy 
metal-coordination, and both groups occupy the hydrophobic adenine-binding cleft with their lactam or maleimide functional group 
respectively, mimicking the hydrogen-bonding pattern of the adenine base in ATP (52), indicated by the dotted lines shown. The 
globular shape of the perpendicular orientated carbohydrate moiety (blue) on the other hand is mimicked and structurally enhanced 
using different inert metal centres and various mono- or polydentate ligands, both groups forming hydrophobic contacts and 
hydrogen bonds within the globular ribose-binding site. [48,109,119,120] 
 
The close resemblance in globular shape and binding modes to kinases for staurosporine and the 
metallo-pyridocarbazole-based complexes has been confirmed in various crystal structures 
including PAK1,[153] BRAF,[156] Pim1,[48,122,152] Pim2,[155] GSK3β[120,154,157] and DAPK1.[120] One 
example for the alignment of Pim1 crystal structures of staurosporine (pdb 1YHS) and the pseudo-
octahedral cyclopentadienyl complex (S)-53 (pdb 2BZI) is given in Fig. 14.  
The type of pseudo-octahedral or rather pseudo-tetrahedral complexes, such as ruthenium half-
sandwich complex 53, have been in the early research focus of the MEGGERS 
group,[48,147,148,155,157,159,161] probably because of only 2 stereoisomers possible and their typically easy 
synthesis. It has repeatedly been proven that these complexes, containing modified or unmodified 
cyclopentadienyl-ligands, are promising scaffolds for ATP competitive protein kinase inhibitors, 
which can possess biological activities, such as anticancer properties, in vitro and in vivo,[48,121,149,162–
166] as discussed for certain highlights below. 
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This approach of using unique structural templates to populate previously inaccessible regions of 
chemical space with metal complexes has been proven to be very successful in regard to potency 
and affinity of the resulting complexes towards certain kinases, and the concept was soon expanded 
to true octahedral coordination geometries, which provide novel interactions with the glycine-rich 
loop, thus contributing significantly to binding potencies and selectivities.[120] Some of these so 
called octasporines, in combination with their IC50 values towards certain kinases are highlighted 
in Fig. 15.[120,150,158]  
In the years after the initial kinase inhibitor development, rapid acces to compound libraries was 
explored using ligand scanning approaches e.g. based on a common precursor complexes[150] or 
side chain active half-sandwich complexes.[49,163] These and other structural modifications, driven 
by structure based design, combinatorial chemistry, library screening and other medicinal chemistry 
methods, finally lead to inhibitors which display nanomolar, and in some cases picomolar, kinase 
inhibitory properties with high selectivities, which is considered a core competency in kinase 
inhibitor design due to the highly conserved ATP binding sites.[115,150] It could be shown that even 
slight modifications in the ligand sphere, like replacing a single monodentate ligand, lead to 
substantial differences in selectivity and potency towards different members of the kinase family. 
These changes are based on the interactions of the ligand spheres with different parts of the ATP-
binding site other than the hinge-region.[149] In addtion to that, inhibition profiles and selectivity 
shifts were also envisioned by structural modifications of the indole and pyridine heterocycles of 
the pyridocarbazole ligand,[122] as well as the use or design of single isomers, since stereochemistry 
obviously influences the interaction and binding affinities with biological targets. This has not only 
been shown by different kinase inhibition properties of single isomers, [48,49,121,151,153,154,157] but also 
much earlier for example in case of induced fit DNA recognition with ruthenium η6-arene 
complexes by the Sadler group, in which the metal is described as dynamic stereogenic centre since 
it is prone to epimerisation allowing DNA-recognition by an induced fit mechanism .[167] 
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Fig. 14: Example for the close similarity in binding of a metallo-pyridocarbazole and staurosporine (51) to kinase active site. In this 
example, S-53 (cyan) and 51 (orange) are bound to the kinase Pim1 (PDB 1YHS and 2BZI aligned to each other using PyMOL 
1.5.0.4). The lactam and maleimide moieties are pointing towards the hinge region, where they bind according to Fig. 13, the 
cyclopentadienyl ring and monodentate CO ligand mimic the carbohydrate moiety and the CO points towards the glycine rich loop. 
 
A vast amount of ligands, as well as various metals, have been used to sysnthesis a broad amount 
of metal-based kinase and ATPase inhibitors, often with a strong focus on pyridocarbazol 
compounds like 53-60 in Fig. 15. Apart from the ligand systems as discussed above, the choice of 
the metal centre plays a crucial role, since the complexes have to be easily designed and be inert in 
biological environment. Most of the developed complexes inherit ruthenium as the central metal 
(Fig. 15). This choice is based on some simple facts like its inexpensiveness. Ruthenium shows a 
preference for octahedral and pseudo-octahedral coordination spheres, in contrast to e.g. platinum, 
which preferes a square-planar coordination, with a predictable synthetic chemistry. Second, in its 
relevant oxidation states II and III it inherits a low toxicity, albeit due to the formation of inert 
bonds, the metall is by any means not considered free in biological systems.[109] Classic complexes 
like S-53 have been shown to be air- and water-stable, and can even withstand millimolar 
concentrations of thiols.[109]  
Rhodium, a d9 nobel metal, is also able to form very kinetically stable octahedral complexes. Its 
advantage over Ru(II) is that it can be coordinated to hard ligands like amines, with which Ru(II) 
would become prone to oxidation to the paramagnetic Ru(III). It has been shown that certain 
complexes like the highly selective picomolar Pim1 inhibitor 59 can also withstand millimolar 
concentrations of thiols. The downsides of using rhodium are its extremely high price and the not 
too well understood coordination chemistry, which is often reflected by overall modest yields.[168]  
 
 
Hinge region 
Glycine rich loop 
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Fig. 15: Various kinase inhibitors based on the metallo-pyridocarbazole with their respective IC50 values towards their targeted 
kinases and the ATP concentration used in the assay. If not otherwise indicated, the compounds are mixtures of their respective 
enantiomers. [120,150,168,169] 
 
Iridium, the heavier d9 homolgue metal scaffold used e.g. for the design of 56, on the other hand 
is also fairly inert and octahedral complexes are easily accessible from square-planar complexes by 
stereoselective oxidative addition.[164] Ir(III) has the great advantage to not only serve as a structural 
scaffold for kinase inhibitors, which show kinase inhibition related effects like antiangiogenetic 
properties based on FLT4 inhibiton like 56 does in 2D and 3D cell-based models, but might also 
be activiated by visible-light to enhance cytotoxicity. With the given complex upon irradiation with 
visible light (λ > 450 nm for 60 min) the cellular survival in HeLa cells droped by a factor of 34. 
This photoinduced cytotoxicity is thought to be the result of apoptotic cell death based on elevated 
activity of the executioner caspases 3 and 7. The effect is thereby known to be unrelated to the 
kinase inhibitory properties, since an inactive form, containing methylated maleimide, shows a 
similar cytotoxicity effect upon irradiation which might be related to ligand exchange reactions, 
since the selenocyanate tends to be replaced by chloride in the presence of these ions under 
irradiation.[165] 
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Another metal used in these scaffolds to combine kinase inhibitory properties and photoinduced 
cytotoxicity is rhenium. It was suggested that kinase inhibitors like the nanomolar Pim1 inhibitor 
60 might serve as templates for photodynamic therapy, based on their singlet oxygen generation 
upon irridiation with red light and resulting photoinduced up to three fold increased 
antiproliferative activity.[169] 
Besides these more heavily studied metals, also proof of concept scaffolds like osmium have been 
tested for their ability to form inert kinase inhibitors. For example osmium has been used to 
synthesise a lighter homologue of 53 that remarkably displayed almost indistinguishable biological 
activities to the original ruthenium complex, which can be explained by their nearly identical three-
dimensional structures and their identical mode of action as protein kinase inhibitors.[152] A less 
obvious choice for inert metal-based compounds is platinum, which also has served as anchor for 
pyridocarbazole-based nanomolar inhibitors of the kinase GSK3α. Although a good potency has 
been achieved, it has been suggested that this type of complexes is most likely not suitable for 
cellular application because of their respective charge and lower robustness in comparison to 
ruthenium complexes. Still the metal centre allows a differing coordination geometry and therefore 
might cover different parts of chemical space, suitable for exploring the kinase active sites.[170] 
As previously mentioned the first steps towards in vivo investigations concerning the suitability of 
these potent complexes as molecular probes in chemical biology or potential drugs have been done. 
The most interesting results will be briefly covered here. The previously introduced 53 for example 
was used to explore its GSK3 inhibitory properties in Xenopus laevis development. It is well 
understood that GSK3 is a negative regulator of the wnt signal transduction pathway that 
phosphorylates beta catenin, which itself is required for the dorsal axis formation in Xenopus 
embryos. Ectopic activation of the wnt pathway (e.g. with lithium), induces an ectopic dorsal axis. 
In the study, Xenopus embryos were exposed to 5-10 µM 53 from the 32-cell stage until the 
midblastula stage, and all embryos demonstrated a hyperdorsalised phenotype, with expansion of 
dorsal and anterior structures and loss of posterior tissues (Fig. 16 1.) similar to embryos exposed 
to lithium or other GSK3 inhibitors, showing the applicability of 53 and its GSK3 inhibitory 
properties, linked to activation of wnt signalling, in simple in vivo systems.[149] A similarly positive 
outcome was concluded for the second generation picomolar GSK3 inhibitor R-61 in Danio rerio. 
Again, the wnt signal transduction pathway is correlated with proper development of the species, 
here especially in the development of the metazoan. By inhibiting GSK3 e.g. with lithium, a 
perturbed development of the head structure with a no-eye phenotype, among others, is promoted. 
When the zebrafish embryos were treated with 1 µM of R-61 at 4 h post fertilisation (hpf), at 25 h 
hpf a decrease of head structure without eyes and a stunted and crooked tail were observed (Fig. 
16 2.), again showing the effect of successful GSK3 treatment in vivo.[121] 
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Fig. 16: Most successful in vivo results with metallo-pyridocarbazoles. A) Effect of GSK3 inhibition in Xenopus laevis embryos with 
(S)-53. Left: control. Right: after treatment with 10 µM of the complex Xenopus embryos show a hyperdorsalised phenotype.[149] 
B) Effect of GSK3 inhibition in Danio rerio embryos. Left: control. Right: after treatment with 1 µM of (R)-61 show a phenotype 
with a decreased head structure without eyes and a stunted and crooked tail.[121] C) FLT4-based antiangiogenic effect of 62 in a 
xenotransplanted proangiogenic human cancer cell model in GFP-labelled Danio rerio. Left: control, right: after treatment with 5 µM 
of 62 the vascular growth to the cancer cells is fully suppressed.[164] All figures are reproduced from the indicated publications under 
permission from John Wiley and Sons. 
 
The third important example includes the nanomolar FLT4 (VEFFR3) inhibitor 62. FLT4 is 
known to play an important role in angiogenesis, therefore its inhibition should reduce vascular 
growth. And indeed, using a transgenic Danio rerio model, where the vascular system inherits a GFP-
based green fluorescence, after treatment with 5 μm 62 all embryos showed significant damage in 
the development of their vascular system 72 hpf. Not only does this confirm the complex as a 
potential chemical probe for FLT4 and angiogenesis, but additional experiments using a 
xenotransplanted proangiogenic human cancer cell model in zebrafish embryos, in which full 
suppression of blood vessel development was observed after treatment with 5 µM of 62, confirm 
the compound as potential anticancer drug.[164,171] 
 
A) 
B) 
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1.4.3. Metal-based HDAC inhibitors 
Different HDIs which incorporate a metal are known in literature, amongst others modifications 
of the FDA approved HDI SAHA. Some of them, especially platinum-based drugs, try to combine 
the previously mentioned approach behind combinational therapy of platinum drugs and HDIs 
into one drug molecule.[172] These conjugates act by two independent mechanisms and are thought 
to have a greater capacity to circumvent resistance as compared to cisplatin.[173] One example 
includes the addition of a malonate substituent to the phenyl ring of SAHA, allowing Pt to bind in 
an O,O’-bidentate mode on the coordination functionality,  yielding in the associated cisplatin 
adduct cis-[Pt(NH3)2(malSAHA)] (63 Fig. 17).
[174] This compound shows a dual mechanism of 
action by binding to DNA and inhibiting HDACs,[172] e.g. HDAC1 in the single digit micromolar 
region.[174] However 63 was also shown to increase HDAC activity in CH1 cells after 24 h treatment, 
indicating no inhibition, while showing lower cytotoxicity as compared to cisplatin or SAHA if 
applied alone or in a 1:1 mixture.[172] Another HDI which is used heavily in conjugation with 
platinum is valproic acid. Early compounds like the Pt(II) complexes (trans-[Pt(VPA)2(NH3)(py)]) 
(64) and trans-[Pt(VPA)2(py)2] show IC50 values in the range of 100 µM.
[175] A conjugate of the acid 
to a Pt(IV) prodrug, [cisPt(NH3)2(Cl)2(VPA)2] (65), has been shown to induce cell cycle arrest and 
cell apoptosis in a time dependant manner after reductive activation to Pt(II) in the cytosol and 
release of VPA with a cytotoxicity in the sub-micromolar range. It showed a much better effect, 
when compared with the combination of VPA and the platinum prodrug. The compound also 
showed an inhibitory effect on tumour growth on A549-xenograft model with low systemic 
toxicity.[176]  Following the first publication, questions were raised whether the amount of VPA 
released is indeed sufficient to show HDAC inhibitory activity and whether a synergism is 
possible.[177] However newer studies showed that treatment of cells resulted in enhanced histone 
H3 acetylation and more effective decondensation of heterochromatin than free VPA, and that a 
considerably higher fraction of Pt is bound to DNA compared to conjugates with biologically 
inactive ligands. Most recent studies with acetyl ligands instead of VPA showed that the HDAC 
inhibition effect is not based on the direct inhibition of catalytic activity of HDACs, but is rather 
associated with additional mechanisms involving downregulation of HDACs, resulting in a marked 
reduction of the level of HDACs in cells.[178] 
Another ligand used for platinum-based HDIs is derived from a malonate derivate of the HDI 
belinostat giving cis-[Pt(NH3)2(mal-p-Bel)] (66), which shows an enhanced cytotoxicity over the 
malSAHA conjugate, as well as better cytoselectivity than cisplatin and belinostat.[173] 
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Fig. 17: Examples for metal-containing HDIs including SAHA-analogues and conjugates (63, 67 a/b, 68 a/b, 69 a/b, 70, 
71 a/b/c, 72), VPA-conjugates (64 ,65) belinostat-malonate-conjugate (66), a gold-porphyrin (73).  
 
As previously mentioned the HDI SAHA has been the inspiration for different metal containing 
compounds. These not only include platinum but also other metals like iron in ferrocene-based 
compounds called JAHAs (Jay Amin hydroxamic acid), where a ferrocenyl group serves as 
bioisostere of the SAHA-phenyl (e.g. 67a/b). Their IC50 values against single isoforms of class I 
HDACs are in the nano-, their cytotoxicity in the micromolar region.[179] This concept has been 
expanded to triazole-based analogues, namely click JAHAs (e.g. 68a/b) which showed IC50 values 
for individual HDAC isoforms of down to single digit nanomolar values. However, these 
compounds tend to show poor cellular penetration.[180] Another bioisostere of the SAHA-phenyl, 
which has been shown to have comparable antiproliferative activity (low micromolar IC50 values) 
as the original organic inhibitor and other organic congeners in five different cancer cell lines, is a 
rhenium tricarbonyl cyclopentadiene half-sandwich complex (e.g. 69a/b). The shown slight 
decrease of antiproliferative capacity c.f. SAHA indicates that the bulkier [Re(CO)3(Cp)] moiety is 
disfavoured over a simple planar phenyl ring and might be the cause of a reduced ability of cellular 
penetration.[132] A second rhenium compound, which contains a SAHA analogue is ReLMito 
([Re(DIP)(CO)3(L)](PF6) (70) with L=(N
1-hydroxy-N8-(pyridine-4-ylmethyl)octanediamide and 
DIP=4,7-diphenyl-1,10-phenanthroline). The multifunctional Re(I)–HDI conjugate showed 
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similar cytotoxic properties to SAHA in five cancer cell lines and HDAC activity that is only slightly 
less potent than that of SAHA. In addition to that, the phosphorescent compound locates in 
mitochondria and induces caspase-independent paraptosis, which may provide a strategy to 
overcome acquired and innate chemotherapy resistance.[181] Other metal-containing SAHA 
derivative complexes use ruthenium as central metal-ion. [Ru(NᴖN)2L](PF6)2 (71a/b/c) with L: 
N1-hydroxy-N8-(1,10-phenanthrolin-5-yl)octanediamide, and NᴖN = 2,2’-bipyridine (bpy), 1,10-
phenanthroline (phen) or DIP might function as dual imaging and therapeutic agents. These 
complexes show inhibitory effects in the micromolar region on HDACs in vitro. In addition to that, 
the DIP compound shows a cytotoxic potency that is higher than those of cisplatin and SAHA 
against five cancer cell lines examined and has been shown to significantly increase the acetylation 
of histone H3 in a dose- and time-dependant manner similar to that of SAHA.[182] Recent literature 
also describes Ir(III) complexes of the type [Ir(NᴖC)2L](PF6), where L is a phenanthroline 
derivative modelled after SAHA and NᴖC is phenylpyridine (ppy) (72), 3-(2-pyridinyl)-coumarin, 
2-(2-thienyl)pyridine (thpy) or 2-(2,4-difluorophenyl)pyridine (dfppy), which may combine HDAC 
inhibition and photodynamic therapy and serve as a starting point for novel tumour-oriented 
multifunctional metallo-anticancer therapeutics. The compounds show nanomolar inhibition of 
HDACs in HeLa nuclear extract and micromolar cytotoxicity in HeLa cells with a phototoxicity 
index of 3-19, meaning 3-19 times more cytotoxic if irradiated with 365 nm or 425 nm when 
compared with a non-irradiated sample.[183] 
In addition to these Pt, Fe, Ru, Ir an and Re containing HDIs, also Au compounds with HDAC 
inhibitory activity have been described previously in literature. One example is the 
gold(III)porphyrin compound [5-hydroxyphenyl-10,15,20-triphenylporphyrinato Au(III) chloride] 
which showed a 100-fold to 3,000-fold higher cytotoxicity compared to cisplatin and IC50 values in 
the nanomolar range in a panel of human breast cancer cell lines. The compound has been shown 
to selectively inhibit Wnt/β-catenin signalling through modulating histone deacetylase activities. 
Treatment with the complex resulted in a rapid decrease of the HDAC activities in MDA-MB-231 
cells, cell extracts and immunoprecipitated class I HDACs, with HDAC 1,2,3 and 8 inhibited in 
the nanomolar region.[184] The compound and derivatives have been patented amongst others in 
the USA.[185] Recently, gold nanoparticles precipitated with quercetin, and loaded into poly(DL-
lactide-co-glycolide) nanoparticles have been shown to reduce HDAC activity and the expression 
levels of HDAC1 and 2 in hepatocarcinoma cells.[186] Other gold (III) compounds like 
bis(thiosemicarbazonate) gold(III), which has been studied for in vitro reactivation of latent HIV-1, 
showed no inhibition of HDACs at 0.5 or 0.2 µM,[187] indicating that gold-ions do not unselectively 
inhibit HDAC enzymes and showing the great potential for this type of HDIs. 
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2. Concrete task 
Since the discovery of the pivotal role of kinases in intracellular signal transduction and their natural 
product inhibitors such as staurosporine (51), the development of potent kinase inhibitors has 
evolved to be an elemental part of biological and medical research. During the last two decades, 
the MEGGERS group has established a broad variety of selective and highly specific ATP-mimetic 
kinase inhibitors using metal centres for inert coordination compounds based on the afore 
mentioned multiple kinase inhibitor staurosporine.  Thereby, they created new and innovative 
chemotypes which occupy a rather unexplored part of the chemical space, avoiding the crowded 
intellectual property landscape in that field.[12,19] As indicated in the introductory section these 
compounds have been shown to be very potent and often selective with purified kinases as well as 
in cancer cell lines in vitro, and to show positive results in basic eukaryotic organisms in vivo. 
However, their suitability towards a therapeutic use e.g. in cancer treatment, which is also based on 
their pharmacokinetic (PK) and pharmacodynamic (PD) properties, has not been explored to a 
further extent. 
Therefore, the task of this work was the development of a lead compound based on these kinase 
inhibitors for a possible future metal-based anticancer drug by identifying the most suitable 
compounds and to further improve their properties, as well as to determine and enhance their 
overall synthetic access. This includes the evaluation and improvement of preclinical parameters 
like their overall anticancer and ADMET (absorption distribution metabolism excretion and 
toxicity) properties and determination of the possibility of upscaling of the compounds.  
The quest for new drug molecules in oncology is most often based on two different main 
approaches, namely the more classical empiric screening for cytotoxic agents against cancer cell 
and tumour models and the more up-to-date investigation of molecularly targeted agents along 
with the appreciation of their pharmacokinetic (PK) and pharmacodynamic (PD) properties.[188] 
Pharmacokinetics thereby studies the fate of a compound after administration, pharmacodynamics 
the effect of the drug on the body. Since these compounds comprise proven kinase inhibitory 
activity thereby being molecularly targeting agents, this knowledge was to be combined with a 
classical cytotoxicity screening against cancer cell lines, since toxicity and tumour regression most 
often are based on similar mechanisms and correlate to the dose.[189] The identification of their 
distinct target, if it was not identified already, was not the focus of this work. As a first step, all 
compounds previously synthesised and still available, were to be collected in a compound library 
and tested as single dose in a simple cancer cell model to identify suitable anticancer compounds 
(Fig. 18).  
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Fig. 18: Overview over the scope of this project. The goal was to find a lead structure for a potential clinical development of a 
metal-based anticancer drug. Starting with the composition of a compound library of available kinase and ATPase inhibitors 
developed in the MEGGERS group, a first high-throughput (HT) cytotoxicity screening in a cancer cell line was supposed to combine 
the molecularly targeting inhibitors with a basic screening for anticancer drugs. Selected molecules and structure derivatives were 
used to study possible upscaling to perform in vitro absorption, distribution, metabolism, excretion and toxicology (ADMET) studies 
for further selections. Finally, in vivo pharmacokinetic (PK) studies were to be performed parallel to further structural optimisation 
to improve relevant parameters, to give a final lead for a possible preclinical or clinical candidate. 
 
In a second step, their synthesis was supposed to be evaluated and improved and upscaling studies 
were pursued to obtain compound quantities to be able to investigate their ADMET properties 
and PK parameters in vivo (Fig. 18). In the final step the compounds were to be evaluated as lead 
structures for the development of compounds with improved properties concerning ADMET and 
PK, while maintaining their original kinase or ATPase activities. Structure activity relationships of 
new derivatives concerning both kinase inhibitions as well as ADME properties were to be 
performed, to learn more about the relationship of optimising these parameters in metal-based 
compounds in comparison to pure organic compounds. 
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3. Results and discussion 
3.1. Classical cytotoxicity-based approach 
Cytotoxicity and structure-activity relationships of metal-containing compounds have been studied 
and reviewed extensively in recent years,[117,190–198] revealing that many anticancer compounds under 
evaluation were either discovered through cytotoxicity screening or showed cytotoxicity against 
cancer cells in later stages of their investigation. In the MEGGERS group, numerous metal-based 
compounds, which possess demonstrated kinase inhibitory activities to different extents, were 
developed and synthesised over the last two decades as explained in more detail in the introductory 
section. Based on these inhibitory profiles, which are either very selective, or very broad (possible 
multi-kinase inhibitors), the question emerged, whether potential anticancer drugs based on these 
inhibitors might be identified by a classical in vitro cell-culture-based cytotoxicity pre-screening. 
Their properties should be investigated further as indicated in the concrete task section, after 
selecting the most promising candidates in this cell-based assay. These cell-culture screens are not 
only cost-effective for a first pre-selection, they might also be done in a relatively short time and 
avoid the use of animal models.[189] In addition to that, a drop-off in potency, compared to assays 
with isolated enzymes, based on high intracellular ATP-concentrations, low membrane 
permeability, interactions with other enzymes like phosphatases, or the relative concentration of 
the target kinase and their substrates, can be discovered in this more native situation.[12] On the 
other hand one must be aware, that testing in one cell line as the first instance means that the 
compounds are screened against only one single cancer type. In addition to that, cancer cell lines 
in general include inherent biases towards specific cell signalling and growth pathways that favour 
growth in cell culture, and therefore some pathway mutations are not well represented and drug 
molecules that target these pathways cannot be identified in such a simplified model.[4] For that 
reason, and because such models often solely lead to successes in the field of rapidly growing 
malignancies like lymphomas, childhood leukaemia and germline tumours, while relatively fewer 
success is seen for slow-growing solid-tumours of adults like lung, breast and colorectal 
cancer,[188,189]  usually a variety of cell lines and tumour types are used in the pre-screening stage.[189] 
Due to cost and time reason, further tests and other cell lines in this study were only done at a later 
stage for compounds which showed good results in the initial screening. 
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3.1.1. Database development 
For the matter of screening compounds for their cytotoxicity, at first a database containing all 
previously synthesised eligible compounds in the group had to be developed, which in the best 
case also allows a structure and substructure search, to be able to compare the compounds 
structure-activity relationship. In this database, not only kinase inhibitors, but also potential 
inhibitors of other purine-based nucleoside or nucleotide using enzymes like ATPase inhibitors 
were included, since their discovery was another focus in the group in the last couple of years. 
The LICCS system[199] (Excel-CDK) is a freeware Microsoft (MS) Excel application which 
combines all the afore mentioned properties by using the open-source CDK (Chemistry 
Development Kit), which is a Java-based library for bio- and cheminformatics. Using SMILES 
(Simplified Molecular Input Line Entry Specification) strings, LICCS features structure display 
(using JChemPaint), substructure and similarity searching, R group table creation, clustering, 
diverse compound picking, sammon projections, molecular property calculations, name to 
SMILES conversion and so on, which makes it easy to link compound property with activity data. 
Considering the application is MS Excel-based, the developed database can be shared by different 
users, since once the worksheet is enabled, it is usable with all its features by anybody with a running 
installation of MS Excel. However, SMILES strings are limited as they do not support multi-centre 
coordinations like the η5-coordination of cyclopentadienyls. Therefore, for compounds falling in 
this category, the database includes chemaxon extended SMILES, which do include this additional 
information, but are not searchable via the CDK-tools. In addition to the LICCs features, the 
structures of all compounds are displayable using JChem for Excel, which allows a more accurate 
view on the coordination and structure of the complexes, which get lost to a certain degree using 
SMILES strings, and includes additional features like structure and substructure searches, 
compound profiling etc. including multi-centre coordination compounds. JChem for Excel 
however needs to be installed to use its features and is a commercial software for which free 
academic licenses can be obtained[200] (valid as of December 2016). SMILES and extended SMILES 
were created using Marvin Sketch 15.2.16 from the same software package. 
The database was prepared using inhibitors of former group members including LI FENG, 
NICHOLAS PAGANO, SEBASTIAN BLANCK, STEFAN MOLLIN, SANDRA DIECKMANN, ALEXANDER 
WILBUER, KATHRIN WÄHLER and MANUEL STREIB, and includes 270 initial compounds tested in 
the later described setting. Additionally, 33 compounds which were previously tested in HeLa cells 
by ANJA LUDEWIG were included. Most of these 33 compounds showed no major limitation in cell 
viability in HeLa cells at 1 µM compound concentration and 24 h incubation time and were 
therefore defined as unattractive for this study. All compounds (3) with cell survival below 80% 
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were tested again in HT-29 cells in this study. In the database, also compounds including negative 
controls (like methyl, ethyl or benzyl-protected maleimids, where the protection group prevents 
binding in the hinge region), potentially metabolic labile compounds (e.g. including free hydroxyl 
groups at the 5-indole position of the pyridocarbazole or reactive functional groups) and 
compounds which potentially do not cross cell membranes (e.g. cationic complexes) were included, 
to get a full picture of the cytotoxic properties of all compounds. In addition to that, compounds 
were sometimes included twice intentionally (e.g. due to different batches or owners), since the 
integrity and purity of the stock solutions was not examined in advance, which might lead to 
inaccurate results due to improper concentrations or toxicity of degradation products, making it 
able to compare the results of different batches. 
The final updated library, as it can be found in the digital supplementary attachment, is based on 
MS Excel 2016 using LICSS V3.2., and includes a total of 440 compounds (some of them added 
at a later point, please refer to the digital supplementary information for the full list), of which 33 
were solely tested in HeLa cells by ANJA LUDEWIG and 407 compounds were tested in HT-29 cells 
for this study at least as single determination in quadruplicates. 
 
3.1.2. Library-based cytotoxicity screening 
After getting an overview over the available compounds and establishing the library-database, all 
compounds were screened for their cytotoxic properties, and therefore potential anticancer activity, 
which was expected to be based on their kinase and ATPase inhibitory properties. For this 
screening the human colon adenocarcinoma cell line HT-29 was used, which is a cancer cell line 
derived from a primary tumour in 1964, and which showed generally lower sensitivity towards 
cytotoxicity against our compounds compared to the classical human cervical cancer cell line HeLa, 
which was established through practical experience by ANJA LUDEWIG in our group. The 
cytotoxicity in this assay was based on the cell viability compared to an untreated standard, as 
determined by the MTT-method,[201] where light yellow water-soluble MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is reacted to insoluble purple formazan 
precipitate by healthy cells as direct function of redox potential (NADH and NADPH based). The 
amount of formazan formed is directly correlated to the vitality of the cells, which can further be 
correlated to the cytotoxic or cytostatic properties of the compound. The formazan is further 
dissolved in DMSO and its concentration measured via absorption spectroscopy. To keep the 
number of hits down to a manageable level, the compounds were screened using standard method 
I (see experimental section) at a single low concentration of 1 µM (using 1-1.5% DMSO) for 24 h, 
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and the limit for hits was set at a cell survival rate of <80%, which respects the fact, that the MTT-
method has quite high deviations due to different problems like inexact cell number per well, 
inaccurate pipetting of compound (variation of concentrations) or removal of formazan during 
aspiration of cell medium. Additional problems might include incomplete dissolution of formazan 
precipitate, possible interference of the assay mechanism with compounds (e.g. interference in the 
redox reaction), additional absorption or light scattering from compound or protein precipitates, 
higher toxicity of MTT in wells with lower cell numbers or damaged cells due to cytotoxic or 
cytostatic effects of the compound tested and higher MTT dose per cell. The cell survival rates of 
these 303 initial compounds under the given assay conditions are summarised in Fig. 19. 
 
Fig. 19: Overview of cell survival rates of human colon adenocarcinoma cells HT-29 after 24 h incubation with 1 µM of the 
according compound, as determined by the MTT method. Missing values stand for compounds which were not tested due to 
insufficient toxicity, as determined by ANJA LUDEWIG in HeLa cells. All hits (in total 13), namely compounds inducing a cell survival 
rate below 80% under the given concentration are marked in red and will be discussed below. 
 
Taken from Fig. 19 from the initial 303 compounds, of which 270 were tested in HT-29 cells, 13 
compounds showed a cell survival rate of <80% under the given assay conditions. The 
corresponding structures are summarised in Fig. 20. Additionally, two compounds (87 and 88) are 
listed, which had cell survival rates in HeLa cells <80% as determined by ANJA LUDEWIG under 
the same assay conditions. However, both compounds showed higher values in HT-29, therefore 
not being hits under the set limits. In addition to that, the more attractive compound 88, based on 
the MTT result in HT-29, is a reactive precursor molecule and does not fulfil the requirements for 
further studies of being an inert metal-based kinase inhibitor. 
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Fig. 20: Structures of the initial hits from Fig. 19 sorted by common structural features and their respective cell survival rates under 
the given concentrations. If not indicated otherwise, the compounds are racemic mixtures. Some compounds were tested in 
duplicate or triplicate, given numbers are the average rates. Compounds 87 and 88 were hits from the initial screenings in HeLa 
cells by ANJA LUDEWIG and were not confirmed in the HT-29 cell-based screening. 
 
Fig. 20 shows that the hits found cover a quite broad selection of compounds with a strong focus 
on classical pyridocarbazole-based ruthenium CpCO complexes (74-78), one non ATP-mimetic 
phenanthroline-based CpCO kinase inhibitor (81), octahedral pyridocarbazole-based ruthenium 
complexes with an additional bidentate ligand (82 and 83), octahedral isoquinolinocarbazole-based 
complexes (79-80, 84-85) and one pyridylnaphthalimide-based octahedral rhodium complex (86). 
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After analysing the structures of these compounds, some of them were excluded directly from the 
study due to a very complicated synthesis with low yields (74 and 86) or too labile or even reactive 
groups (e.g. trimethylphosphane ligand in 79). Others did not show the expected results in follow 
up concentration dependant MTT-tests (75, 78, 81, 82 and 85 Fig. 21) where the IC50, the 
compound concentration which results in 50% cell survival rate, was either not within the tested 
concentration limits (82 and 85), was just reached at the highest concentration of 30 µM (75 and 
81) or was reached at about 3 µM but the toxicity would not further increase with rising compound 
concentration, indicating a complicated mechanism or compound precipitation (78). Complex 84 
was excluded, since it did not confirm in a second test under the same conditions. 
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Fig. 21: Results of concentration dependant MTT assays in HT-29 cells of some of the hits from Fig. 20. Compounds were tested 
at a concentration of 30-0.1 µM in HT-29 as indicated in the experimental section. On the right side, results for the melanoma cell 
line WM1366 for compounds 78 and 80 are displayed. 
 
What emerges from Fig. 21 is that the two compounds np229 (78) np829 (80) are very promising 
concerning their cytotoxicities for both HT-29 cells (IC50 of 1.0 + 0.2 µM and 2.9 + 0.5 µM 
respectively using a sigmoidal fit in Origin Pro 8) and the NRAS mutated melanoma cell line 
WM1366 (IC50 of 0.3 µM and 0.8 + 0.3 µM respectively). However, 78 has previously been studied 
in a xenotransplanted tumour model in nude mice for its GSK3 inhibitory based anticancer activity 
and all mice either died or had to be sacrificed before the tumours in the control group went into 
an exponential growth phase (unpublished data). This acute toxicity meant an exclusion of this 
compound for our studies. It was also previously suggested, based on unpublished data, that this 
toxicity might be related to the 5-hydroxy group in the indole of the pyridocarbazole, which also 
poses a potential risk of enzymatic or chemical oxidation.[122] Therefore, compounds 77 and 83 
were also excluded from follow up studies for now. After these considerations np829 (80) was the 
obvious choice for pursing in this project, which was supported by the fact that it was the 
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compound with the lowest cell survival rate in the initial screening and showed good results in the 
first concentration dependant assays. 
It originally developed by NICHOLAS PAGANO together with a series of derivatives, which contain 
31 different cyclopentadienyl side chains (Fig. 23), to determine their TrkA activity and selectivity 
over Pim1,[202] using a rapid derivatisation methodology developed by HOWARD BREGMAN,[49] in 
which the Cp side chains can be easily introduced using a reactive N-hydroxy succinimide (NHS) 
ester. 
Based on the pseudo-tetrahedral ruthenium centre, in addition to two possibilities of the 
asymmetrical cyclopentadienyl moiety, a total of 4 stereoisomers are possible for this compound 
class, as indicated in Fig. 22.[203] Therefore, the library contained a total of 62 compounds, since the 
diastereomers, as their racemic mixtures, were separated from each other, as explained later in 
chapter 3.1.3. 
 
Fig. 22: Complex np829 ((R)- and (S)-88b) is actually a mixture of enantiomers, while 88a are their diastereomeric counterparts. 
For the validation of stereochemistry in this compound class see chapter 3.1.4. 
 
The complete library synthesised by NICHOLAS PAGANO is shown in Fig. 23. The side chain 
selection was thereby based on an observation by HOWARD BREGMAN, which concluded, that with 
an  unmethylated Cp moiety, a gain in selectivity towards GSK3 is achieved using amino acid side 
chains, but derivatives with an additional amine (which becomes an ammonium salt in assay buffer) 
and hydroxy functionalities display potency towards Pim1.[204] In addition to that, based on previous 
observations, all derivatives (alcohol and ester amino acid derivative derived side chains) were 
supposed to provide potency towards the kinases TrkA and Pim1 for both derivatives. Complexes 
including the structurally simpler ethyl ester derivative of the ethyl 2,4-dimethylcyclopenta-1,3-
diene for example, have been shown to have binding affinity towards Pim1 and TrkA but much 
less for GSK-3.  
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Both libraries were tested for their inhibitory potency towards Pim1 and TrkA at an ATP 
concentration of 100 µM by NICHOLAS PAGANO, with the b-series measured at a concentration of 
30 nM, and the a-series at 100 nM. As a trend the Pim1 rest activity was most often lower compared 
for the TrkA activity. With restactivities towards TrkA and Pim1 under the given ATP 
concentrations of 80b (<5% and <5%) and 80a (6% and ~25%), these two compounds are by far 
not the most potent or selective compounds in the series. The diastereomers however follow the 
established design strategy towards metal-based protein kinase inhibitors,[109] and might inhibit 
other kinases as well. It is therefore possible that their different cytotoxicities are due, at least in 
part, to distinct protein kinase inhibition properties. 
 
Fig. 23: Full list of compounds of the asymmetric library synthesised by NICHOLAS PAGANO, originally to identify TrkA 
inhibitors. For 112-115 the amine is part of the five membered pyrrolidine ring.  
 
In order to evaluate the differences in cytotoxicity of the half-sandwich complex library, including 
different diastereomers based on the opposite planar chirality, all compounds were screened for 
their cytotoxicity against HT-29 cells at a single concentration of 1 µM. The results are summarised 
in Fig. 24 and were included into the initial database. 
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Fig. 24: MTT results of NICHOLAS PAGANOS library, which includes the initial screening hit np829 (80b). Compounds 1-31 
represent the compounds 89b, 80b and 90-118b, compounds 32-62 the analogue compounds of the a series. All compounds with 
cell survival rates below 80% at 1 µM compound concentration for 24 h are indicated in red. 
 
Based on the results four compounds from the b series (80b, 93b, 115b, 117b) and one compound 
from the a series (98a) were identified as hits based on the previously set limits, while their 
diastereomers displayed no cytotoxicity under the same conditions. The results also confirmed 80b 
again as a very potent compound. Based on the kinase inhibitory assay against Pim1 and TrkA, 
these kinases however are not the primary reason for its cytotoxicity, since other compounds 
showed much better values in the original assay but lower cytotoxicity in the MTT screening.  
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3.1.2.1. Development of a simplified structural derivative of the hit 80b 
The synthesis of the ethyl 2,4-dimethylcyclopenta-1,3-dienyl-based complexes as 80b is quite time 
and resource extensive as shown in detail in chapter 3.1.3. Therefore, a simplified structural 
analogue was considered to avoid this problem. The easy access to varied side chain modifications 
using an active NHS ester functionality at an otherwise unmodified cyclopentadienyl ring has been 
described by the MEGGERS group.[49,163] Since the elimination of the two Cp-methyl groups are 
thought to have an effect on both the biological and physical properties of the complex, based 
primarily on possible nonpolar interactions, it was hoped to be able to compensate that by 
modifying the free terminal hydroxy group of the coupled amide to a methyl ether (Fig. 25).  
 
Fig. 25: Simplified structural analogue of 80b in which the terminal hydroxy group is modified towards a methyl ether to compensate 
for the missing methyl effect of the elimination of two Cp-based methyl-groups. 
 
The complex was easily prepared based on the literature known isoquinolinocarbazole[148] and some 
variations of the previously described NHS-ester approach (Scheme 1).[49] Starting with sandwich 
complex 120 the hexafluorophosphate salt of (η6-benzene)(η5-N-(2-methoxyethyl)cyclopentadienyl 
carboxamide) ruthenium (121) was prepared by amine coupling using  N-(3-dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride (EDCl) to form the according activated NHS-ester, which was 
further reacted with 2-methoxyethan-1-amine in situ. Following photochemical replacement of the 
benzene by three acetonitrile ligands and CO conversion (quantitative over 2 steps) led to the 
desired precursor complex 123.  
 
Scheme 1: Synthesis of metal precursor 123 based on a modified literature known synthesis.[49,163] The carboxylic acid is reacted to 
the carboxamide by EDCI coupling of NHS and subsequent reaction of the active ester with the amine. This is followed by 
photochemical replacement of the benzene and CO conversion. 
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The reaction of 123 with TBS-protected isoquinolinocarbazole 124[148] at 45 °C in the presence of 
K2CO3 provided the half-sandwich complex 125 in 69% yield, which was subsequently deprotected 
using TBAF to yield in 119 as racemic mixture in 94% yield. 
 
Scheme 2: Reaction condition towards the desired complex 119. The pharmacophore ligand and metal precursor are reacted in 
the presence of K2CO3 to yield in 125 which is subsequently deprotected using TBAF to yield in 119. 
 
The complex was further tested in the MTT setting in HT-29 cells in a concentration dependant 
assay and showed only marginal cytotoxicity up to 30 µM, indicating that either the methyl groups 
at the Cp ring are mandatory or the free terminal hydroxy group. 
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3.1.2.2. Further structural analogues of 119 
Based on the previously mentioned NHS active ester approach NICHOLAS has not only created a 
library of structural analogues of 80b but also of 119, using 44 different amide side chains,[202] to 
screen for a lead structure of improved MST-1 inhibitors. The respective structures are shown in 
Fig. 26. 
 
Fig. 26: Full list of structural analogues of 119 synthesised by NICHOLAS PAGANO for the identification of MST1 inhibitors. 
 
Some of the compounds in this library respectively showed remaining MST-1 kinase activity of 
down to <10% under the screening conditions (615 nM inhibitor, 100 µM ATP) in a kinase assay.[163] 
However, no compound showed significant cytotoxicity properties (<80%) in the subsequent cell-
based MTT assay (Fig. 27), thereby indicating the importance of the methyl groups on the 
cyclopentadienyl moiety, especially when comparing the structurally very similar compounds 80b 
to 134 (however 98b represents no hit), 93b to 169 and 117b to 158, where the first given structure 
each represents a hit in the 2,4-dimethylcyclopenta-1,3-diene-based library. 
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Fig. 27: MTT results of NICHOLAS PAGANOs second library (derivatives of 119), which contains no hits for the set limits. This 
highlights the importance of the dimethylation of the Cp-ring in the former library. Please refer to Fig. 26 for the full list of 
structures, compound 1-44 equals 126-169. 
 
Based on all accumulated results it was decided to take the two most promising compounds 
concerning cytotoxicity in HT-29 cells ahead for further investigations, namely 80b and 93b, which 
showed the lowest cell survival rates in the initial screening. 
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3.1.3. Synthesis and upscaling of the hits 80b and 93b 
As previously mentioned, the synthesis of ethyl 2,4-dimethylcyclopenta-1,3-dieyl-based complexes 
is quite complex. First, the ligand ethyl-2,4-dimethylcyclopenta-1,2-diencarboxylate had to be 
synthesised. Starting with ethyl-3-methylbut-2-enoate (170) E/Z-ethyl 4-bromo-3-methylbut-2-
enoate (171) can be easily synthesised using a literature known method.[205–207] All three publications 
however use carbon tetrachloride (CCl4) as solvent for the classical WOHL-ZIEGLER bromination 
using N-bromosuccinimide (NBS) and a radical starter like dibenzoyl peroxide (DBPO)[205,207] or  
azobis(isobutyronitrile) (AIBN)[206] at reflux conditions. To avoid the use of CCl4, the reaction 
conditions were optimised for the use of dichloromethane (CH2Cl2) using DBPO as radical starter 
and an increased reaction time, related to the reduced reaction temperature based on the lower 
boiling temperature of CH2Cl2. Please refer to the experimental section for reaction details of the 
most successful reaction conditions. Purified enoate 171 (Scheme 3) was further converted to its 
according phosphonium salt (172) using SN2 conditions following a literature procedure.
[208] The 
phosphoniumbromide was directly converted further to the cyclopentadiene according to a 
modified literature procedure,[209,210] using NaHCO3 aq. as base and chloroacetone as reaction 
partner. In this reaction 172 is deprotonated in the allylic position, forming a Wittig ylide, which 
attacks the chloroacetone in an SN2 reaction. After a second deprotonation, the cyclopentadiene is 
formed via a [2+2] cycloaddition (intramolecular WITTIG reaction) where triphenylphosphine 
oxide is eliminated. For obvious reasons of hindered rotation around the double bond, only the 
(Z)-isomer 172 can undergo the cyclisation to the five membered ring in 174, which also explains 
the low yield in the reaction.  
 
Scheme 3: Reaction conditions for the synthesise of ethyl-2,4-dimethylcyclopenta-1,2-diencarboxylate (174) based on variations of 
literature known methods. The enoate 170 was first brominated under WOHL-ZIEGLER bromination reaction conditions and further 
converted in an SN2 reaction to the according triphenylphosphoniumbromide which was reacted with chloroacetone (173) to yield 
the final ligand. The final reaction step includes the formation of a WITTIG ylide and intramolecular WITTIG reaction. 
 
Following the synthesis of the ligand 174, a metal precursor for the complex synthesis had to be 
prepared. Literature describes the preparation of 177 using sodium hydride to form intermediate 
175 from 174 and further conversion using thallium(I) (Tl2SO4) to form a cyclopentadienylation 
reagent before conversion to 177 using a metal source like 176,[203] which can be easily prepared 
Results and discussion 
 
53 
 
using a well-established literature method.[211] This reaction however also works, although in slightly 
lower yields, without the preparation of the Tl species, avoiding the use of the extremely toxic 
metal. While literature reports 67% yield over all steps,[203] the avoidance of Tl(I) still gives 44% 
yield (Scheme 4) using 175 as Cp transfer reagent. 
 
Scheme 4: Synthesis of metal precursor 177. The cyclopentadiene 174 is reacted with NaH and further converted with μ-chloro 
ruthenium dimer 176 to yield in the racemic sandwich complex 177. Only one isomer for 177 is shown for clarity. 
 
Starting with sandwich complex 177[209,210] the racemic metal precursor 180 can be obtained over 
four additional steps (Scheme 5), based on a procedure that is analogous to a recent report from 
our group.[49] Accordingly, the ethyl ester 177 was hydrolysed with K2CO3 to the analogous 
carboxylic acid 178 (90%) and subsequently protected with 2-(trimethylsilyl)ethanol by EDCl 
coupling (69%) to yield the ester 179. Following photochemical replacement of the benzene by 
three acetonitrile ligands[212] and CO conversion (quantitative over 2 steps) led to the desired metal 
precursor 180 in good yields.  
 
Scheme 5: Synthesis of racemic metal complex precursor 180. Only one enantiomer each is shown. After the ester 
hydrolysation, the resulting carboxylic acid is protected using 2-TMS-EtOH in an EDCl coupling. Photochemical 
replacement of the benzene and subsequent CO conversion yields the final metal precursor 180. 
 
The reaction of 180 with TBS-protected isoquinolinocarbazole 181[148] in the presence of K2CO3 
and 2-(trimethylsilyl)ethanol provided the two diastereomeric half-sandwich complexes 182a and 
182b in 69% yield as nearly equal mixtures of diastereomers (Scheme 6), which were separated via 
preparative HPLC on a silica gel stationary phase using hexane/ethyl acetate (93:7) as eluting 
solvent. It has been previously shown, that the separation of diastereoisomers or enantiomers at 
this point is much more successful compared to the final complexes, as it is true for the analogue 
complexes using an unmethylated cyclopentadiene derivative.[202] In smaller scales (0.39 mmol 
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based on the ligand) the separation can easily be done with standard silica flash chromatography 
using toluene as eluting solvent,[202] however using larger scales (1.00 mmol) the insolubility of the 
compound leads to a strong smearing of the diastereomers based on low solubility and therefore a 
more complicated separation process. A dry load of the compound, which is stable enough to be 
heated on silica at 40 °C to remove the solvent, using CH2Cl2/acetone for loading improves the 
situation, but still leads to an unclear separation using either toluene or hexane/ethyl acetate in 
comparison to the HPLC approach using hexane/ethyl acetate (93:7) as confirmed by both TLC 
and NMR analysis. The same holds true using toluene as eluting solvent for HPLC or adding acids 
like acetic acid in the flash column chromatography approach, which seems to improve the overall 
solubility and therefore separation.  
Deprotection of the maleimide and the carboxylic acid of the complexes 182a and 182b was 
subsequently achieved with TBAF treatment, providing 183a and 183b in quantitative yields 
(Scheme 6). In this step, some aliphatic impurities from the deprotection could not be removed, 
however those did not affect the following steps and could be eliminated after the conversion to 
the final product. The modification of the carboxylic acid attached to the cyclopentadienyl moiety 
was achieved most rapidly by conversion to activated NHS esters 184a (96%) and 185b (83%), 
followed by the conversion with ethanolamine to yield the diastereomeric complexes 80a (78%) 
and 80b (93%) which were purified via silica gel flash chromatography. Analogue reaction to 93a/b 
by MADDIE SHERLOCK, using 2-picolylamine as reagent yielded in 87% and 42% respectively. The 
NHS esters can also be used to react with amides or esters simply by addition of the corresponding 
amine or alcohol, which may be used for the synthesise of the previously shown amide 
libraries.[49,163]  
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Scheme 6: Synthesis of 80b and 80a. Starting with TBS-protected isoquinolinocarbazole 181, the diastereoisomers 182a and 182b 
were obtained by reaction with the metal precursor 180 in nearly equal amounts. Retention times during separation of diastereomers 
is shown on the used semi-preparative scale using an unmodified silica column with isocratic mixture of hexane/EtOAc 9:1 as 
indicated in the experimental section. The complexes were deprotected using TBAF in THF and further converted to the active 
ester with NHS using an EDCl coupling. The obtained active ester 184a/b can be used for a library synthesis, as in 89a/b-118a/b 
using the respective amine. Compounds 80a and 80b were prepared accordingly using ethanolamine.[213] 
 
Since for this work mainly the N-(2-hydroxyethyl) amide side chain was required, a much cleaner 
approach to the complexes 80a/b, which also would limit the overall consumption of the ligand 
181, is the use of a precursor which inherits the final side chain, meaning less reaction steps of the 
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isoquinolinocarbazole complexes. For that matter it seemed simple to deprotect 179 and convert 
it via EDCl coupling to the active ester and to the side chain modified sandwich complex. After 
photolysis and CO conversion the metal precursor could just be reacted with 181 and the final 
complex only required TBAF deprotection. However, this “simple” approach was misguiding, 
since the sandwich complex seems to be far too water soluble to work up easily or it might have 
formed some kind of polymer in the subsequent photolysis. After flash column chromatography 
of the sandwich complex using CH3CN/H2O/KNO3 aq. 50:3:1 the precipitation with NH4PF6 
yielded in almost no compound. After removal of the solvent and a second flash column, 
precipitation seemed to work with sodium tetraphenylborate. The complex could be extracted with 
CH2Cl2, in a way that no more complex was found in the aqueous layer according to TLC analysis. 
The 1H-NMR spectrum of the complex was not clean but looked promising, so that the subsequent 
photolysis and CO conversion was followed up. However, after the standard reaction and work 
up, the benzene signal in the 1H-NMR spectrum disappeared as expected, but no acetonitrile signals 
were found either. The Cp-signal did broaden as well in the spectra and no matching MS signal 
was found. The compound was not reactive when trying to react it with 181 and K2CO3 in 
CH3CN/CH2Cl2/CH3OH. Therefore, the approach was not followed up, since the original 
reaction conditions leaded to sufficient compound for further experiments. 
 
3.1.3.1. Synthesis of further derivatives of 80b and 93b for the determination of structure 
activity relationship (SAR) 
Based on the hits from NICHOLAS PAGANOs library, structural similarities of all interesting 
compounds could be identified, including a free hydroxy group (80b, 98a, 115b, 117b) or the 
pyridine nitrogen in γ-position of the amide, indicating a probable trend for the importance of H-
bond donor or acceptors in this position for either binding to a target which is responsible for the 
cytotoxicity or for physicochemical properties which might allow the compound to be transported 
or be uptaken. To also allow studying the effect of this position, 15 complexes of the a and b series 
(including 93a/b for comparison) were synthesised by MADDIE SHERLOCK in a small library (Fig. 
28) according to the experimental section. 
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Fig. 28: Structural derivatives synthesised for SAR by MADDIE SHERLOCK. 
 
The synthesised library was further tested in HT-29 cells at the same conditions as the previous 
compounds. The results are shown in Fig. 29. 
 
 
Fig. 29: MTT results of MADDIE SHERLOCKs library, which includes the initial screening hit 93b. Compounds 1-15 represent the 
compounds 185b-198b and 93b, compounds 16-30 the analogue compounds of the a series. 
 
The results confirm the initial assumption that compounds with an H-bond donor (based on OH 
and NH) in the γ-position indeed have generally a higher cytotoxicity (186b, 188b, 190b-192b) if 
the other substituents are not too bulky (197b and 198b are no hits). γ-Cl (185b), SH (187b), OCH3 
(189b) residues and other compounds which miss a H-bond donor at this position (193b-196b) do 
not show any significant cytotoxicity. Still 93b is a hit in this assay, even if only a very small portion 
to none of the pyridine should be protonated at the assay pH of around >7-8, why remains unclear. 
All compounds from the a-series show no significant cytotoxicity as expected, indicating, that 98a 
might have been a wrong hit in the initial series with its cell survival rate of just below 80%. 
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3.1.4. Determination of stereoinformation in 80a 
The assignment of the relative configurations of the coordinated modified η5-N-(2-hydroxyethyl)-
2,4-dimethylcyclopenta-1,3-dienylcarboxamide-ring in relation to the metal centre in 80a and 80b 
was achieved unambiguously with an X-ray crystal structure of the non-cytotoxic isomer 80a. For 
that matter, single crystals were obtained upon slow diffusion of dichloromethane at 22 °C from a 
10 mM DMSO solution of 80a which was diluted with dichloromethane in a ratio of about 1:10. 
The other isomer formed only amorphous precipitate under the same conditions. The intensity 
data of the single crystals were collected at 100 K using a Bruker D8 Quest system. The data were 
corrected for absorption effects using multi-scanned reflections.[214] The structure was solved using 
direct methods (SHELXS-97)[215] and refined using full matrix least squares procedure (SHELXL-
2013). Hydrogen atoms were included at calculated positions. Please be aware that only one 
enantiomer is shown. All previous drawings are based on the assigned stereochemistry of this 
crystal structure. 
 
 
Fig. 30: Crystal structure of the diastereomer 80a revealing the relationship between the facial -coordination of the 
cyclopentadienyl moiety and the metal-centred chirality. ORTEP drawing with 50% probability thermal ellipsoids. 
Only one enantiomer is shown. Solvent is omitted for clarity.[213] 
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3.1.5. Integrity and purity of 80a and 80b 
To verify purity and integrity of the complexes 80a and 80b, also in regards to the possible 
interactions of impurities in biological assays, HPLC-chromatography was performed on an Agilent 
1200 Series HPLC System. Therefore, the 10 mM DMSO stock solutions of 80a and 80b used in 
the biological experiments were diluted 1:99 with CH3CN and 25 µL of the obtained (100 µM) 
solution was injected into the HPLC-system. The runs were performed with a LiChroCART® 
Purospher® STAR RP-8e (particle size 5 µM) column (250 x 4.6 mm): solvent A, CH3CN; solvent 
B, 0.1% TFA in H2O; 80-0% B in 20 min, flow rate 1.0 mL/min at a column temperature of 40 °C. 
UV absorption was detected at 254 nm. In those HPLC traces (Fig. 31) only minor impurities, as 
seen in the according NMR-spectra, can be detected. 
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Fig. 31: HPLC traces of the complexes 80a and 80b, with retention times of 15.5 and 15.6 min respectively. HPLC 
conditions: LiChroCART® Purospher® STAR RP-8e (particle size 5 µM) column (250 x 4.6 mm); solvent A, CH3CN; 
solvent B, 0.1% TFA in H2O; 80-0% B in 20 min; flow rate 1.0 mL/min; column temperature, 40 °C; absorption 
detected at 254 nm. Only minor impurities can be detected in the HPLC-traces.[213] 
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3.1.6. Cytotoxicity determination of 80b and 93b  
To confirm and investigate the different effects of the diastereomers 80a and 80b on the viability 
of cancer cells, different cancer cell lines were exposed to various concentrations of the two 
diastereomers (racemic) for 24 h followed by cell viability determination via the MTT method. 
These cell lines include the afore used HT29 cells, the classical cervical cancer cell line HeLa, and 
two melanoma cell lines, the metastatic WM983B which inherits a natural BRAF mutation (V600E) 
and p53 wild-type (wt), and WM1366 with a NRAS mutation (61L). 
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Fig. 32: Cell survival rates of cancer cells after treatment with racemic 80b or racemic 80a for 24 h. The cell viability 
was determined via the MTT method and calculated as percentage of surviving cells compared to untreated 
controls.[213] 
 
Indeed, Fig. 32 reveals again a different behaviour in terms of cytotoxicity for the different 
diastereomers. Whereas 80b displays quite high cytotoxicities with estimated LD50- or IC50-values 
in the range of 2.9 μM (HT-29) to 0.4 μM (WM983B), 80a is much less cytotoxic with cell survival 
rates of 82.8% (HT-29) to 36.4% (WM983B) at a concentration of 30 μM. Generally highest 
cytotoxicity was seen for both compounds in the p53 wt cell-line WM983B, lowest toxicity in HT-
29 cells, confirming the previous mentioned trend of low sensitivity of these cells for our kinase 
inhibitors. 
In addition to these in-depth cytotoxicity studies of 80b and 80a, also 93b and 93a were tested in 
a concentration dependant MTT assay in HT-29 cells. The results are shown in Fig. 33. 
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Fig. 33: Cell survival rates of HT-29 cells after 24 h treatment with 93a and 93b. The overall cytotoxicity is quiet low in comparison 
to 80b and the a isomer again shows no significant cytotoxicity. 
 
It becomes clear, that 93b is much less cytotoxic than 80b, and its diastereoisomer 93a again shows 
no cytotoxicity at all. One should notice however, that during the experiments for both compounds 
large red crystals were observed in the cell medium, indicating solubility issues for both 
diastereoisomers as a new parameter which might influence cytotoxicity. This leads to further 
studies on 80a and 80b, to see whether differences in solubility might be one reason for their 
different cytotoxic behaviour, since we already experienced different crystallisation behaviour 
during crystal growth for X-ray determination of the stereochemistry. 
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3.1.6.1. Solubility studies in cell medium of 80a and 80b 
To investigate possible solubility issues of 80a and 80b, both compounds were tested again for a 
cell-based cytotoxicity in HeLa cells, since these cells seem to detach later from the solid support 
in comparison to HT-29 cells when undergoing apoptosis. Throughout the incubation time with a 
compound concentration of 30 µM-0.1 µM, a crystallisation of 80a and 80b was monitored. 
Whereas 80a obviously crystallises in the cell medium like 93a and 93b, 80b seems to mainly enter 
the cells and to visibly crystallise inside or attached to the cells at concentrations of 30, 10, 7.5 and 
5 µM (Fig. 34). Interestingly, in the higher concentration range this crystallisation effect, as well as 
first signs of apoptosis, could already be observed only 5-6 h after compound addition. 
 
                
Fig. 34: HeLa cells 24 h after substance addition. A) 30 µM of 80b: the compound seems to mainly enter the cells and crystallises 
until the cells die. A smaller amount forms crystals in the medium. Most of the cells died and only cell fragments remain. B) 
Reference: cells were incubated with 1% DMSO and the cells are healthy. C) 30 µM of 80a: the compound forms large and small 
crystals in the cell medium which seems to have minor effect on the cells. Only a few cells have died, the others look healthy. D) 
10 µM of 80b: the cells show signs of apoptosis (rounding, detachment from the ground, blebing) and obvious red spots inside or 
on top of the cells. E) With the lower concentration (2.5 µM of 80b) some cells look apoptotic as well, most look healthy and no 
obvious localisation of compound can be seen. Samples A)-C) are prepared in medium without phenolred, while D) and E) are 
prepared in phenolred containing medium. 
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To verify our assumption that the crystal formation of 80b occurs inside cells and not on their 
surface, scanning electron microscopy (SEM) experiments were performed by Michael Hellwig at 
the centre for material sciences at the Philipps-Universität Marburg. Accordingly, HeLa cells were 
grown on small cover glasses without surface treatment in 6-well plates, incubated for 14-16 h with 
5-10 µM of 80b and were afterwards either chemically fixed or freeze dried. When simply washing 
and then freezing the cells in liquid nitrogen, they almost completely detach instantly. The 
shortened incubation time was chosen based on the fact, that detachment of the cells is much easier 
on simple glass in comparison to the treated surface of the well plates used previously. For freeze 
dried samples, the cells were first washed with PBS and afterwards quickly with ddH2O to avoid 
the formation of salt crystals on the surface. This however leads to a swelling of the cells due to 
osmotic effects, and following SEM experiments showed large holes in the cell membrane, as well 
as partially broken cells, indicating this method of fixation not suitable for our purposes. 
Using chemical fixation on the other hand, by protein and lipid cross-linking with glutaraldehyde 
and osmium tetroxide followed by dehydration with ethanol,[216] gave good results in cell surface 
and shape, as can be seen by the SEM images shown in Fig. 35. In both samples, freeze dried cells 
and chemically fixed cells, no sign of crystals on the cell surface could be found at compound 
concentrations of 5 µM or 10 µM, which strengthened our assumption that the compound 
crystallises after entering the cell. However, for chemically fixed cells the compound might have 
been dissolved during the washing steps with ethanol and for freeze dried cells disturbance in the 
cell membrane might have released the compound, indicating no final prove for 80b to enter the 
cells before crystallisation. In addition to that, affected cells might have undergone apoptosis and 
thereby been detached from the glass surface before or during treatment. 
 
     
Fig. 35: HeLa cells which were chemically fixed 16 h after addition of 10 µM of 80b. No signs of crystals on the cell 
surface were found in two independent samples. 
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Assuming that 80b indeed enters the cells, a similar crystallisation effect, called crystal-like drug 
inclusions (CLDIs), is known for the approved leprosy drug clofazimine (trade-name: Lamprene). 
The active ingredient accumulates to very high levels in tissue, forming intracellular liquid crystal-
like supramolecular organisations, probably membrane-bound, multi-layered, liquid crystal-like, 
semi-synthetic cytoplasmic structures.[217] Possible ways of crystal-formation discussed for 
clofazimine, including pH-dependant solubility through protonation state, protein-binding and 
associated complex formation with membranes, or precipitation as aggregates/crystals, which may 
be actively phagocytosed,[217,218] are possible explanations for the crystal formation of 80b. 
Whether or not 80b crystallises inside or on top of the cells, this effect is a deal-breaker for finding 
a suitable anticancer drug. Therefore, the classical cytotoxicity-based approach was dropped in 
favour for an approach investigating the drug like abilities of this compound class. 
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3.2. Drug-like properties of metal-based kinase inhibitors 
The afore discussed cytotoxic approach led to a dead end with np829 (80b) and its derivatives. 
Therefore, an up-to-date approach to improve the chance of finding a suitable lead structure for a 
potential cancer drug was required. Since most of the MEGGERS group compounds possess kinase 
inhibitory properties, a screening of a selected range of compounds towards their so-called drug-
like properties seemed to be the right choice. The profiling for these properties was done in 
collaboration with the Novartis Institutes for BioMedical Research (NIBR) in Cambridge, MA, 
USA.  
Early in vitro profiling of drug-like properties has become an essential part of the drug discovery 
process. The term drug-like properties is thereby linked with all properties that affect ADMET 
(absorption, distribution, metabolism, excretion and toxicity) characteristics of the molecule.[219] 
One of the first, and probably most known studies towards physicochemical properties and oral 
absorption has been published by LIPINSKI in 1997, pioneering the field.[220] He defined drug-like 
compounds as those, that have sufficiently acceptable ADME and toxicity properties to survive 
through the completion of human phase I clinical trials.[221] From his original study, LIPINSKI’s rule 
of five were phrased, which describe the molecular properties important for a drug’s 
pharmacokinetics in the human body after oral exposure. Accordingly, an orally active drug should 
have no more than two violations of the following criteria: 1) No more than five hydrogen bond 
donors, 2) No more than ten hydrogen bond acceptors, 3) A molecular mass less than 500 Da and 
4) an octanol-water partition coefficient (logP) not greater than five.[222,223] These properties 
however apply to purely organic molecules and can be considered as a rule of thumb and not 
absolute cut-off values. Organic KIs for example tend to have high molecular weight because of 
the need for special structural features to gain kinase selectivity.[14] A recent study showed that more 
than 30% of FDA approved SMKI actually have a molecular weight exceeding 500 Da, and 50% 
have one greater than 480 Da, while the numbers of H-bond donors and acceptors are well within 
the set range.[26] However metal-based KIs cannot be simply classified by the LIPINSKI rules, as the 
rule of five is empirically determined for approved small molecule drugs, and may not necessarily 
apply for metal-based drugs in the same way.[224] Especially the molecular weight of these 
compounds often is much higher than 500 Da, due to the heavy metal centre, which does not affect 
the overall size as much as an organic fragment of pure organic origin would do. A simple 
estimation of drug-like properties based on these basic rules would therefore be insufficient. 
Drug-like abilities nowadays however cover more than the criteria stated by LIPINSKI. They 
incorporate suitable biopharmaceutical properties such as solubility, stability, permeability, and 
first-pass effect, as well as pharmacokinetic (PK) properties like clearance rates, biological half-life, 
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extent of protein binding and volume of distribution, which are responsible for the entry of a drug 
into the body and across various cellular barriers.[222] The common strategy for the pharmaceutical 
industry today includes the evaluation of a holistic picture with the parallel assessment of efficacy, 
drug-like properties and safety with simple in vitro assays predictive for toxicology and 
pharmacological promiscuity of drug candidates, in order to assist efficient lead optimisation and 
reduce a high attrition rate of drug candidates in development and during early clinical trials due to 
ADME issues.[225] In general achieving a good balance between all these parameters is important, 
since a drug must reach its target in the body and have a reasonable potency to elicit an in vivo 
response.[219] Organic kinase inhibitors tend to have a high MW and during optimisation stages 
often highly hydrophobic and conformationally constrained drugs are derived, which have limited 
drug-like properties and a thermodynamic signature that is characterised by an entropically driven 
binding affinity. These compounds might show poor human pharmacological properties and 
limited in vivo target inhibition and efficacy, which continue to be a major source of clinical attrition 
in the oncology field with 53% from phase I to registration for KIs.[226] These facts highlight the 
importance of monitoring drug-like abilities for KIs. 
Drug-like abilities for metal-based drugs can also be described as metallomics, which characterise 
the entirety of metal and metalloid species present in a cell or tissue type, as well as their interactions 
with the genome, transcriptome, proteome, and metabolome.[227] Metallomics also stands for the 
metabolism of these drugs, transport and interactions with biologically relevant molecules,[228]and 
attempts to understand metal uptake, trafficking, function, and excretion in biological systems.[228] 
In this study however, only very basic concepts of metallomics will be studied and discussed, since 
in depth interaction studies with biological molecules were not intended, but instead a basic 
understanding if the compound might reach its kinase target within a living individual, by studying 
basic PK parameters.  
To get a first impression, the initial focus was set on the drug-like properties of metal-containing 
kinase inhibitors which are part of the composite parameter bioavailability, that is influenced by 
solubility, absorption and clearance as well as permeability.[222,229] Solubility and absorption are 
thereby known to be some of the major issues concerned in the design of new ruthenium 
containing complexes,[191] and may also apply to other metals. For the study an initial set of nine 
different literature known inhibitors, as racemic mixtures, racemic mixtures of single 
diastereoisomers or single enantiomer, have been selected, based on various criteria like positive 
results in the initial cytotoxicity screening, previous results including specifically attractive kinase 
inhibitory properties, special functionalities or additional possible medical or biological applications 
(Fig. 36).  
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Fig. 36: Initial set of inhibitors intended to be tested for their drug-like properties in collaboration with NIBR Cambridge, USA.  
Complexes 199, 76, 53, 80b, 200, 202, 203, and 60 are racemic mixtures. 80b and 202 are thereby a racemic mixture of one of two 
diastereoisomers formed during their synthesis. 202 is a single enantiomer. 
 
In detail, the RuCpCO-complexes 199[147], 76[122], 53[149] (resynthesised by FELIX KLEIN and 
SEBASTIAN WEBER)[230,231] were previously reported as extremely potent inhibitors towards the 
kinases GSK3[121,122,147,154] and Pim1[48,121,122] and showed appealing properties in the original 
cytotoxicity screening as well as in previous in vitro anticancer studies.[162] In addition to that the 
GSK3 inhibitory properties of 76 have been proven to activate p53 and induce apoptosis in 
melanoma cells in vitro and to disturb the embryonic development of Xenopus laevis in vivo, as it is 
expected for a GSK inhibitor and further elucidated in the introductory section.[149] Ru complex 
80b[213] was the most attractive compound from the original cytotoxicity screening in cancer cell 
lines. The compound 200[109,150] (resynthesised by MADDIE SHERLOCK) was included to evaluate 
the solubility and permeability of a charged compound, which should differ from uncharged 
compounds insofar as that the solubility should be improved and the permeability reduced in 
comparison to an uncharged compound.[232] With the inherited CO-ligand it also belongs to the 
class of potent Pim1 and GSK3 inhibitors.[109] Rh-complex 201b (RR97b)[233] (synthesised by 
RAJATHEES RAJARATNAM) belongs to a, at that point, newly developed class of stereoisomerically 
pure Rh-based compounds, which were thought to be good kinase inhibitors. This compound was 
especially alluring due to being isomerically pure, which should affect the results of the assays, e.g. 
solubility. The WALLACH rule states that racemic crystals are more stable and dense than their chiral 
counterparts, indicating, that 201b might show an enhanced thermodynamic solubility c.f. the 
racemic mixtures.[232] The compound 202[109,150] (resynthesised by SEBASTIAN WEBER),[231] is another 
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potent GSK3 and less potent Pim1 inhibitor, which structurally differs from the CpCO-complexes, 
where the Cp ligand binds via a η5-mode, insofar that the bidentate ligand picolylamine and a 
monodentate chloride replace the Cp, whilst the important pharmacophore CO ligand in the plane 
perpendicular to the pyridocarbazole chelate stays in place.[109] The final Re-compounds 60[169] and 
203[169] (synthesised by KATHRIN WÄHLER) were originally developed as bifunctional compounds, 
with potential for photodynamic therapy as photosensitisers, and kinase inhibition. They produce 
1O2 upon light exposure, and are therefore photocytotoxic, as it has been shown in cancer cell 
experiments.[169] Especially the imidazole derivative 60 shows good stability in the presents of β-
mercaptoethanol and has an IC50 against the kinase Pim1 of 58 nm,
[169] even if a kinome scan against 
456 protein kinases showed that the compound is a selective but not very potent kinase 
inhibitor.[234]  
 
3.2.1. Analysis and quantification of compounds in drug-like property assays 
Generally, high-throughput assays like the ones for drug-like abilities, as they are performed at 
NIBR, use a high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
approach for compound quantification and further assay evaluation. For quantification, an internal 
standard for data standardisation and comparison is used, after auto-tuning the MS/MS unit to the 
compound by optimising the compound ionisation polarity, MS/MS transition, cone voltage and 
collision energy. To assist in finding the optimal conditions and to verify their suitability for 
analysis, all compounds were assessed for their retention time, preference for positive ionisation 
using either APCI or ESI and for the major signal in MS (in accordance with isotope pattern), 
depending on ionisation, protonation or ion formation with e.g. sodium ions. The reversed phase 
HPLC runs (CH3CN/ 0.1% AcOH 5:95 to 100:0 in 9 min, hold for 2 min, 100:0 to 5:95 in 9 min, 
flow rate 1 mL/min) were thereby performed using a C18 column (150 x 4.6 mm, particle size 
5 µm) after injection of 10 µL DMSO-solution (25 µM) at a column temperature of 30 °C. For 
LC-MS runs 20 µL of a 100 µM DMSO-solution were used and they were performed in the same 
manner. Retention times were defined from major absorbance at 254 nm. All compounds had 
thereby retention times between 6.1 and 11.4 min and a major mass signal was found as [M+] or 
[M+H+] using at least one of the ionisation techniques. However, some of the compounds had low 
signals and/or a high background in the mass spectrum, probably due to fragmentation, ligand 
exchange reactions or poor ionisation. The full overview of the conditions and results of the 
measurements can be found in the digital supplementary information of the work. 
In the hands of Novartis, the complexes 60, 80b, 200 and 201b could be analysed using a triple 
quadrupole mass spectrometer, while the other compounds caused some problems because of low 
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sensitivity or the observation of signals with an unknown mass. For some of the compounds (e.g. 
199, 56, 73) a direct injection into the mass unit caused a loss of the CO ligand ([M-28]), and an 
CO-CH3CN exchange ([M+13]) in the flow with CH3CN and 0.1% FAaq when using LC conditions 
was observed, indicating instability of the compounds under the given conditions. The mass 
differences indicate an additional oxidation of the compounds in the set-up, either at the metal-
centre or some part of the ligands, which might have been caused by the oxidative environment of 
ion source in positive mode. These ligand loss and exchange reactions were further verified using 
HRMS in the mass department of the Philipps-Universität Marburg. During these experiments, 
very low signal intensities, probably caused by ion suppression, were observed, explaining the low 
signals in all previous experiments. A sample chromatogram with HRMS of the original complex 
(199) and the CO-CH3CN exchange is shown in Fig. 37. As Fig. 37 clearly indicates, in addition to 
ligand exchange (A) or loss reactions, additional signals (e.g. C) appear which further complicate 
the assessment of drug like properties using LC-MS. Similar problems occurred with 202 and 203. 
 
Fig. 37: Example LC-MS chromatogram of 199 showing an CO to CH3CN ligand exchange in exact mass spectra. Additionally, a 
high background of a compound not containing Ru, as indicated by a missing isotopic pattern, can be found. 
 
In summary, due to the described instabilities and analysis issues, only the complexes 80b, 60, 200 
and 201b were further investigated for their solubility, permeability and rat liver microsome stability 
using LC-MS/MS. 
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3.2.2. In vitro solubility, metabolic stability and permeability determination 
3.2.2.1. Thermodynamic solubility assessment 
Solubility and dissolution rate of drug substances are critical for absorption, especially in the 
gastrointestinal (GI) tract, subsequent bioavailability and delivery to cellular targets.[222,225,235]  Low 
aqueous solubility can lead to precipitation in bioassay medium, leading to low or inconsistent 
bioactivity responses for in vitro bioassays,[219] as it has previously been observed for compounds in 
this thesis e.g. 80a. Therefore, solubility is important for proper interpretation of in vitro profiling 
results, as well as PK and PD data. It is most often determined as conventional thermodynamic 
solubility, starting with a solid material and using the “saturation shake-flask”-method, which is 
considered the gold-standard by industry and the FDA, as a result of its accuracy and reliability 
over a reasonable large solubility range.[225] Thermodynamic solubility assays in general start with a 
solid material (either crystalline or obtained by evaporation of a solvent), taking packing 
information of the compound into account. Quantification of solubility and determination of 
purity and stability is monitored either by liquid chromatography coupled with ultraviolet 
spectroscopy (LC-UV) or mass spectrometry (LC-MS).[225] The shake flask method has been further 
miniaturised towards a high-throughput method, saving time, cost and sample material to make it 
more feasible for early drug discovery.[236,237]  
Apart from simple aqueous buffers, solubility is nowadays often determined in biologically relevant 
media like fasted and fed state simulated intestinal fluids (FaSSIF and FeSSIF), which provide a 
better prediction of the in vivo oral absorption behaviour.[238] These buffers contain different 
concentrations of bile salts and phospholipids like lecithin, which are able to form negatively 
charged bile micelles (lecithin is zwitter ionic and tauchloric acid is fully deprotonated at 
physiological pH), as they are present in the intestinal fluid, and which are able to emulsify 
molecules. Thereby these buffers simulate the physiological conditions in the proximal small 
intestine.[239] Even with poor thermodynamic solubility in standard buffers, an addition of bile salts 
can enhance solubility up to a level which is often sufficient for an adequate bioavailability.[238] A 
study with 4148 organic compounds showed increased solubility in 82% of compounds in the 
updated FaSSIF-V2 (version 2) compared to a standard phosphate buffer,[239] which shows the 
power of this kind of buffers. 
Using the miniaturised shake-flask method, solubility of the complexes was determined at NIBR 
Cambridge, MA, USA using solid material obtained by evaporation of the solvent from a DMSO-
stock solution. The solubility was tested at pH 6.8 in aqueous chloride free potassium phosphate 
buffer (KPi) and FaSSIF-V2 and results were quantified using LC-MS/MS (Table 2). 
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Table 2: High throughput thermodynamic solubility data for the first set of complexes tested. KPi is an aqueous chloride free 
phosphate buffer, FaSSIF is fasted state simulated intestinal fluid. *All values < 5 µM are below their respective detection limit. 
 
As can be taken from Table 2 the solubility in potassium phosphate buffer at physiological pH (pH 
6.8) is very low with values below the detection limit of 5 µM. The solubility for 60 and 201b is 
thereby clearly enhanced when using FaSSIF-V2 buffer. In general ionisation, lipophilicity and 
crystal packing seem to play essential roles in controlling solubility in FaSSIF compared to that in 
aqueous buffer, and while lipophilicity driven solubility limitations in aqueous solution are 
improved in FaSSIF buffer, solubility limitations which are related to crystal lattice energy are not 
overcome by the FaSSIF ingredients.[239] This suggests, that the solubility limitations we experienced 
here might be based on the hydrophobic character of the type of coordination compounds and not 
too much on the crystal lattice energy, at least in the crystal form used in the experiment. However 
a high crystal lattice energy induced by a low ratio of sp3 to sp and sp2 carbons, gives the molecules 
increased π-π-stacking opportunities, and contained hydrogen bond donors and acceptors may 
additionally stabilise the crystal packing, indicating the possibility of a low solubility of our KIs 
based on crystal lattice energy.[238] 
Another probable explanation is, that electrostatic interactions might play a part in the solubility of 
these compounds in FaSSIF buffer. While the solubility of acids is generally not enhanced in 
FaSSIF buffer at physiological pH, probably because of the electrostatic repulsion of the 
deprotonated compounds and the FaSSIF micelles, the solubility of positively charged bases may 
undergo favourable electrostatic interactions with the micelles. These electronical repulsions, as 
observed for deprotonated acids, might explain why the solubility of 200 is not enhanced in FaSSIF 
buffer in comparison to KPi buffer. Basic nitrogens from the ligand systems of 60 and 201b 
however, should not contribute in an improved solubility of the compounds, since the basicity is 
lost due to the coordination to the positively charged Re/Rh centre.  
 
 
High 
throughput 
thermo- 
dynamic 
solubility 
 
 
 
80b 
 
 
 
60 
 
 
 
200 
 
 
     201b 
KPi  
FaSSIF-V2 
< 5 µM* 
< 5 µM* 
< 5 µM* 
17 µM 
< 5 µM* 
< 5 µM* 
< 5 µM* 
23 µM 
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3.2.2.2. Determination of metabolic stability in microsomes 
Metabolism and subsequent in vivo clearance of drugs involve a multitude of enzymes and tissues 
including the hepatic, renal and biliary systems and is considered the most difficult ADMET 
parameter to predict.[222] Metabolism thereby refers to the biotransformation process which 
converts drugs into e.g. more polar metabolites to facilitate biliary and renal clearance,[222] where 
clearance describes the process of drug elimination from the body or from a single organ without 
identifying the individual processes involved and may be defined as the volume of fluid cleared of 
drug from the body per unit of time (e.g. mL/min).[240]   
In general, when designing new drugs, metabolic rates of the compounds should be kept minimal 
to achieve low first pass metabolism and a half-life (t1/2) that is suitable for once daily dosing.
[241] A 
metabolically labile drug might never reach adequate systemic exposure. The primary destination 
of orally administered compounds, and thereby the site of metabolism of most drugs, is the liver.[225] 
Therefore hepatic clearance is one of the most important pharmacokinetic parameters influencing 
the clinical success of a molecule. It is fundamental to two of the key parameters that influence the 
in vivo exposure and thereby daily dose and dosage frequency: bioavailability (F) and the elimination 
half-life (t1/2).
[241,242] To be able to determine metabolic rates and the risk that hepatic metabolic 
clearance may pose to pharmacokinetics and systemic exposure in early drug discovery, different 
high-throughput in vitro metabolic screens have been developed, including the usage of 
recombinant cytochrome P450s (CYPs), liver fractions (microsomes, S9 and cytosol), isolated 
hepatocytes and liver slices as source of metabolising enzymes.[232,241] The use of these enzymatic 
sources reduces the requirement of animals (commercial and ethical advantages) and even makes 
it possible to evaluate metabolic rates in higher species like human.[232] Metabolic stability 
assessment using liver microsomes generally has been widely accepted to predict metabolic 
clearance.[243–245] The low cost and minimal interlot variability of microsomes make this model 
additionally amenable to high-throughput investigations.[246] Mainly the contribution of cytochrome 
P450s (CYPs), which are highly enriched in the liver microsomal fraction along with UDP 
glucuronosyltransferases (UGTs), is monitored in liver microsomes, as this family of enzymes is 
known to dominate the metabolic clearance of ~75% of drugs. However, this model system has 
limitations in that extrahepatic and non-metabolic clearance routes are not represented.[225,246]   
Most often metabolic clearance is predicted by probing the disappearance of a compound in an 
incubation with microsomes and co-factors, and reporting the half-life and scaled clearance 
values,[243–245] as it is also done in this study (please refer to the experimental part for complete 
mathematical procedure). The intrinsic clearance (Clint) is thereby the intrinsic ability of hepatic 
enzymes to metabolise a compound, and is expressed, as previously mentioned, as volume per 
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time, extended by the amount of protein present in the incubation (µL/min/mg of microsomal 
protein).[241] It might be calculated either from the slope of the plotted results curve or by 
extrapolation of the substrate disappearance curve.[241] In this compound depletion approach 
substrate concentrations have to be considerably below the MICHAELIS-MENTEN constant KM (the 
substrate concentration at which the reaction rate is half-maximum) to stay in the linear part of 
kinetics. A concentration of 1 µM is thereby believed to be low enough to retain linear kinetics and 
minimise assay solubility challenges without compromising the detection limit for analysis. In 
addition to that, it is assumed that only one metabolite is formed.[241] The in vitro Clint can further be 
scaled to the in vivo hepatic clearance (Clh) via different appropriate liver models like the “well-
stirred” or the “parallel-tube” model, incorporating physiologically based scaling factors relating to 
the complete intact liver.[241,246] The well stirred model thereby is the simplest and most widely used 
model.[241] It accounts for portal blood flow (Qh) and considers both microsomal and plasma (or 
blood) protein binding of the test compounds, if available, since only free, unbound drug may 
undergo ADME-processes.[241,244,246] This clearance prediction however has its limitation due to 
necessary assumptions and caveats. These include, that metabolic clearance in the liver by oxidative 
metabolism is the major mechanism of clearance, that the rates of metabolism and enzyme activities 
in vitro are truly reflective of those that exist in vivo, and that there is no significant product inhibition 
or enzyme deactivation based mechanism.[244] Finally using the obtained hepatic clearance, a 
theoretical hepatic extraction ratio ERh, which accounts for the relative elimination efficiency of 
the liver (theoretical in vivo clearance), can be calculated, taking the portal blood flow into account 
again. The results for intrinsic clearance (Clint) and the hepatic extraction ratio (ERh) calculated from 
rat liver microsome (RLM) stability are summarised in Table 3. 
 
Table 3: Rat liver microsome stability data for the first set of complexes tested by NIBR. Clint is the intrinsic clearance, ERh the 
hepatic extraction ratio. 
 
 
 
 
Rat liver 
microsome-
stability 
 
 
 
80b 
 
 
 
60 
 
 
        200 
 
 
     201b 
Clint  
ERh 
42 µl/min/mg 
58% 
51 µl/min/mg 
62% 
100 µl/min/mg 
77% 
29 µl/min/mg 
48% 
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Taken from Table 3 the intrinsic clearances of the compounds lie in a range of 29-100 µL/min/mg 
which correlates to a low to medium clearance (> 150 high, 50-150 medium, < 50 low) under 
Novartis guidelines, with 201b being the most metabolically stable compound in the series and 200 
the most labile. Taken from these values, the metabolic stability against CYP-enzymes of the 
compounds should not pose a limiting factor for the bioavailability.    
These values however take not into account, whether the metabolic clearance might be low due to 
a possible inhibition of the CYPs responsible for the evaluated form of metabolism. This kind of 
inhibition might also cause a pharmacokinetic drug-drug-interaction, where a second administered 
drug might be metabolised more slowly due to inhibition of the CYP enzymes.[225] Therefore, 80b, 
60 and 200 have been tested towards their inhibition properties against three of the most abundant 
CYP isoforms 3A4, 2D6 and 2C9.[225] 
 
Table 4: Reversible CYP inhibition data (IC50 values) obtained by NIBR for the first set of complexes tested. 
 
 
 
 
 
 
 
 
Generally compounds with an IC50 below 1 µM for at least one CYP isoform are considered a 
possible risk towards CYP inhibition and therefore are likely to be linked to a potential for drug-
drug interactions.[225] In the series tested here (Table 4), only 80b falls into this category, inhibiting 
not one, but two isoforms at IC50 of below 0.5 µM. This means that on the one hand, the metabolic 
stability is probably lower than expected, and that the compound, especially together with its very 
low solubility and very low permeability (see below), is definitively no potential drug-candidate. 
The comparison of the inhibition of these three compounds shows however, that either 
indolocarbazole-based inhibitors are more susceptible to inhibit CYP enzymes than 
pyridocarbazoles, or that the full structure interacts with the enzyme, allowing very different 
inhibition profiles dependant on the further ligands of the metal, as it has been shown for kinase 
inhibition. 
 
 
Reversible 
CYP 
Inhibition 
IC50 
 
 
 
80b 
 
 
 
60 
 
 
 
        200 
3A4 
2D6 
2C9 
< 0.5 µM 
16.8 µM 
< 0.5 µM 
- 
> 20 µM 
6.4 µM 
- 
> 20 µM 
> 20 µM 
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3.2.2.3. Membrane and cell permeability assessment 
Permeability is another important property which generally is evaluated early during drug discovery, 
because a drug has to pass several membrane barriers to reach its target, including possibly the 
gastrointestinal tract (GI-tract), blood capillary walls, hepatocyte membranes, glomeruli, restrictive 
organ barriers, and the target cell membrane.[232]  Permeability assays use chemical or biochemical 
barriers to mimic the physicochemical properties of phospholipid bilayers.[247] The simplest and 
fastest model thereby is the parallel artificial membrane permeability assay (PAMPA),[247–249] which 
is preferably used as pre-screening tool for a permeability ranking.[250] By using an artificial 
membrane without junctions, transporters, metabolism or real phospholipid membranes, it can 
however only be used to estimate permeability for compounds with transcellular diffusion 
mechanism which inherit a MW < 600 Da[250] (based on classic organic compounds). A high-
throughput variant of this assay uses a 9-10 µm hexadecane liquid layer as membrane, which is 
immobilised between two aqueous compartments.[247] The enormous advantage of this robust assay 
is the possibility to measure a pH permeability profile (e.g. pH 4-8),[225,247] which is a critical 
information to predict gastrointestinal absorption of ionisable drugs and very difficult to obtain 
from cell culture experiments.[247] In addition to that, alkane water coefficients can be obtained 
from the assay.[247] The compounds in this study (80b, 60, 200, 201b) were also tested for their 
PAMPA permeability, but resulted in values well below the detection limit, showing that 
permeability, especially transcellular diffusion, is really low. 
In general, different membranes can have different permeabilities for a compound. These 
differences are caused by differences in the membrane lipid mixture (passive diffusion), membrane 
transporter expression (active transport), or tightness of junctions between cells (paracellular 
transport).[232] Permeability models which are closer to real physiological conditions, including 
transporters and cell junctions, involve in vitro cell monolayer assays, with the human colon 
adenocarcinoma cell line Caco-2 probably being the most widely used.[251] Caco-2 assays are 
generally considered the model of choice since they are robust, reliable and the cells show 
morphological as well as functional similarities to human intestinal enterocytes, including tight 
junctions and brush border enzymes.[252,253] Cellular models, in contrast to artificial membrane 
assays, include para- and transcellular permeability routes as well as various transport processes. 
Caco-2 cells for example express a variety of transporter systems normally found in small intestinal 
enterocytes, including efflux proteins from the ATP-binding cassette (ABC) family such as 
P-glycoprotein 1 (Pgp, also called multidrug resistance protein 1 MDR1) and members of the solute 
carrier (SLC) family, such as ion transporters (organic anion-transporting polypeptide (OATP) and 
organic cation transport proteins (OCT)).[254] Therefore this cell-line serves as transepithelial 
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permeability model in cell-monolayers and may be used to predict human oral absorption.[252,253] In 
addition to that, the model, when used as bidirectional assay, may be used for studies of transport 
mechanisms in the gastrointestinal membrane, including transporter interplay and the degree of 
their impact compared to passive transport.[252,253] Permeability of the four complexes of question 
was evaluated by NIBR using the Caco-2 cell model, as monolayers in a bidirectional assay. The 
results for the apparent permeability of the apical (A) to basolateral side (B) and vice versa, which 
connects the amount of complex transported during the incubation time with the surface area and 
the different sizes of the A and B chamber, as well as the calculated fraction absorbed (FA) are 
summarised in Table 5. 
Table 5: Caco-2 permeability data for the first set of complexes tested. Papp is the apparent permeability, calc. FA the calculated 
fraction absorbed. The values for 201b were not confirmed in a repeat experiment and are therefore indicated in grey. 
 
As the numbers in Table 5 show, the permeability in Caco-2 is low to very low for all compounds 
with theoretical in vivo fractions absorbed (FA, derived from an empirical BOLTZMAN equation) 
ranging from 0% to 24%. The ratio of the apparent permeabilities from A (apical) to B (basolateral) 
and vice versa give a first idea about possible mechanisms which are involved in the transport of 
the drug. For 80b, 60 and 200 this is probably efflux, since the B to A values are much larger than 
the A-B values, indicating some kind of additional transport from B to A. For 201b these values 
are much closer to each other, indicating a passive permeability, which is obviously a much more 
appealing result. These results were however not confirmed in repeat experiments as presented 
later. 
In summary, based on all in vitro results we can see that both solubility and permeability of our 
compound class is low, while metabolic stability seems to be fine. 
 
 
 
 
 
Caco2-
permeability 
 
 
 
80b 
 
 
 
60 
 
 
         200 
 
 
      201b 
Papp A-B 
Papp B-A 
calc. FA 
Mechanism       
0.04 x10-6 cm/s 
0.51 x10-6 cm/s 
1% 
efflux 
0 x10-6 cm/s 
0.51 x10-6 cm/s 
0% 
efflux 
0.23 x10-6 cm/s 
0.69 x10-6 cm/s 
9% 
efflux 
0.64 x10-6 cm/s 
0.99 x10-6 cm/s 
24% 
passive 
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3.2.2.4. Drug-like properties of further complexes 
3.2.2.4.1. Metal-based MTH1 inhibitor 
After obtaining the initial results of the four pyridocarbazole-based kinase inhibitors, we were 
curious if the trend on low solubility and permeability, as well as good metabolic stability, holds 
true for other inert metal-based inhibitors using different pharmacophore ligands. Especially a 
highly potent inhibitor for the human repair enzyme 7,8-dihydro-8-oxoguanosine triphosphatase 
(MTH1), which was currently developed in the group,[137] came to mind as a good example 
compound and was therefore subjected to the same assays. The results are listed in Table 6. 
Table 6: Basic in vitro ADME properties of a ruthenium-based MTH1-inhibitor. 
 
If we compare the obtained values towards the ones collected for the kinase inhibitors, we can see 
certain trends, but also differences. As for solubility, 40 has a much larger solubility in comparison 
to the pyridocarbazole-based inhibitors, both in KPi and FaSSIF with a factor of 3 and above. This 
indicates that the pyridocarbazole moiety is indeed the limiting factor, probably due to π-π-stacking 
of the large aromatic system, as well as probable intramolecular H-bonding of the maleimide part. 
The permeability in Caco-2 cells on the other hand is still very low from A-B but much higher than 
B-A, showing that 40 is definitively an efflux compound. The recovery of the compound in the 
assay however was not very good, showing a stability problem which also might lead to distorted 
results, i.e. the solubility might be higher as well as the permeability. PAMPA results however show 
a very low effective membrane permeability in the assay setting. Very high values have been 
obtained for intrinsic clearance and hepatic extraction ratio, correlating to a half-life time of about 
3.8 min in the assay setting. Overall these results show us that the in vitro properties such as 
solubility, permeability and metabolic stability towards CYPs might indeed be manipulated by the 
structure surrounding the metal-centre. The compound shown here is, due to its very low 
microsome stability and probable stability issues, no candidate to further study for its potential as 
drug. 
 
HT- 
Solubility 
RLM 
stability 
PAMPA 
permeability 
Caco-2 
permeability 
  
40 
KPi 
16 µM 
 
FaSSIF 
73 µM 
Clint 
364 µl/ 
min/mg 
 
ERh  
92.5% 
logPe 
<-6.2 
Papp A-B 
0.5 x10-6 cm/s 
 
Papp B-A 
10.4 x10-6 cm/s 
 
calc. FA 19% 
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3.2.2.4.2. Drug-like properties investigations on stereoisomers of 201b 
As 201b seemed to be the most attractive compound so far and belongs to a family of 4 different 
stereoisomers (Fig. 38), of which the three other isomers show much better kinase inhibitory 
properties concerning affinity and selectivity,[233] the other three isomers were resynthesised and 
tested in the same assay setting to compare their drug-like properties and to find a lead structure 
for further improvement of those properties. The two Λ-(R)-complexes 201a and 201b are thereby 
diastereomers, both derived from D-proline, with the Δ-(S)-complexes 204a and 204b being the 
enantiomeric counterparts, being again diastereomers to each other, derived from L-proline. 
 
 
Fig. 38: Correlation between the three stereoisomers of 201b. RR88a (204a) and RR97a (201a) are enantiomers to each other, as 
are RR88b (204b) and RR97b (201b). RR88a is additionally the diastereomer of RR97a, which holds true for the b isomers as well.  
 
It is well known, that physicochemical and biochemical properties of individual stereoisomers can 
differ significantly from each other, making the results appealing on many levels. In a chiral 
environment, as it is provided in any biological system, stereoisomers might experience selective 
absorption, protein binding, transport, enzyme interactions and metabolism, receptor interactions, 
and DNA binding. Thus, each stereoisomer or isomeric mixture can have different 
pharmacokinetic, pharmacodynamic, therapeutic, and adverse effect profiles.[255] The results 
obtained for all three complexes, in comparison to 201b, are summarised in Table 7. 
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Table 7: Basic in vitro ADME properties of 201a, 201b, 204a and 204b. *All values < 5 µM are below their respective detection 
limit. 
 
As the results in Table 7 indicate, all four isomers have quite similar properties, with exception of 
the passive permeability of RR97b (201b). One should keep in mind however, that these are single 
run experiments, which means that at least a factor two deviation is considered normal, and that 
outliners are possible. In detail, thermodynamic solubility of all four isomers is still poor, but 
improved in FaSSIF buffer. The rat liver microsome stability is again good, with 201a maybe being 
more stable compared to the other isomers. The reversible inhibition towards the CYP isoforms 
3A4, 2D6 and 2C9 of 204a and 204b was tested as well, showing values well over 20 µM, and 
thereby being not of consequence. Furthermore, the irreversible inhibition of CYP3A4 was 
evaluated, since time-dependant inhibition (TDI) is the cause of several failures in late-stage clinical 
candidates and is suspected to play a role in liver toxicities often observed in preclinical species.[256]  
Values of kobs = 0.004 min
-1 (204a), 0.012 min-1 (204b) and 0.014 min-1 (201a) were obtained for the 
 
 
 
 
 
 
 
 
204a 
 
 
204b 
 
 
201a 
 
 
201b 
HT-solubility 
KPi 
FaSSIF 
 
6 µM 
19 µM 
 
<5 µM* 
8 µM 
 
16 µM 
29 µM 
 
< 5 µM* 
23 µM 
RLM- stability 
Clint 
ERh 
 
28 µl/min/mg 
47% 
 
24 µl/min/mg 
44% 
 
12 µl/min/mg 
29% 
 
29 µl/min/mg 
48% 
Caco2-
permeability 
Papp A-B 
Papp B-A 
calc. FA 
Mechanism       
 
0.12 x10-6 cm/s 
1.46 x10-6 cm/s 
5% 
efflux 
 
0.18 x10-6 cm/s 
1.04 x10-6 cm/s 
7% 
efflux 
 
0.11 x10-6 cm/s 
6.8 x10-6 cm/s 
4% 
efflux 
 
0.64 x10-6 cm/s 
0.99 x10-6 cm/s 
24% 
passive 
MDCK-MDR1 
Papp A-B 
Papp B-A 
Efflux ratio 
MDR1 efflux       
 
0.83 x10-6 cm/s 
1.33 x10-6 cm/s 
1.6 
little to none 
 
2.17 x10-6 cm/s 
1.49 x10-6 cm/s 
0.7 
little to none 
 
- 
- 
- 
- 
 
0.77 x10-6 cm/s 
1.30 x10-6 cm/s 
1.7 
little to none 
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apparent inactivation rate constant. With a positive/negative bin of kobs = 0.02 min
-1 used as lower 
limit for positive compounds, all compounds are clearly ranked negative for relevant TDI.[256] 
The permeability in Caco-2 cells is low for all four compounds with 201b showing the best 
calculated fraction absorbed and passive diffusion as possible mechanism compared to efflux for 
the other four isomers. Since the experiments of 201b were run at another time point as for the 
other three isomers, they were repeated to exclude a possible outliner. The result indeed showed, 
that the values are outliners as the B-A value obtained was close to the original (0.86 x10-6 cm/s) 
while the exact value from A-B could not be obtained because it was below the detection limit 
(< 0.03% transported).  
To verify these results and to evaluate the possible efflux mechanism further, the isomers were 
tested in another permeability assay using an MDR1 overexpressing cell line. Understanding 
interactions with efflux transporters is thereby important,[257] since efflux mechanisms play a major 
role in protecting the body from harmful substances and can severely limit the oral absorption of 
compounds.[258] Efflux substrates can be identified in assay settings using the efflux ratio (ER), 
which is defined as the ratio of apparent permeability from the basolateral to the apical side to the 
permeability from the apical to the basolateral side.[257,259,260] For the assay the dog kidney epithelial 
cell-line MDCK (Madin-Darby canine kidney) model was used, which is like Caco-2 cells frequently 
used for permeability evaluation of attractive compounds. These cells have a shorter cultivation 
period in comparison to Caco-2 cells, due to the fact that they differentiate much quicker (within 
3-7 days), but transporter expression levels might differ from human intestines.[261] These cells are 
however ideal for transfection,[261] which has been used to create and establish a MDR1 
overexpressing cell line in the late 1990s.[262] The value of this cell line as a model of the human 
intestinal mucosa has been confirmed, even if there are possible differences in kinetics and affinities 
compared to the Caco-2 cell line.[263] It was shown however that similar Papp-values were obtained 
compared for those from Caco-2 assays for potential anti-malarial compounds with low and 
medium permeability, while a higher variability was found for compounds with high permeability 
and compounds that were MDR1 substrates.[264] 
The results of the MDCK-MDR1 assay are also summarised in Table 7, whereby the values for the 
b isomers are the average of two independent experiments. The analytics for 201a could not be 
obtained, due to issues in MS/MS quantification although the assay was run twice for the 
compound. In general, the A to B values are higher in the assay setting compared to the Caco-2 
assay, but the compounds still show very poor permeability. 201b, as expected, shows results which 
are much more in line with the other compounds. With efflux ratios below 2, all tested compounds 
show no to little efflux in the assay, indicating that MDR1 is not involved in a possible efflux. This 
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means that either there are other efflux transporters involved, or that the original assumption that 
efflux plays a role is just not true and arises from the very low values in the assay which leads to 
higher deviations in the ER. In addition to that, results indicate, that either the high MW of the 
compounds or, to some extent solubility issues, might be responsible for the low permeability of 
the compounds, especially since recovery in the experiments was good and therefore no to little 
membrane retention was seen. 
From the results obtained it was very feasible to use one of the isomers for further exploration as 
a lead structure. As previously mentioned the different isomers show very different kinase 
inhibitory properties,[233] as discovered in a kinome scan using a panel of 456 kinases, and verified 
by IC50 determination of potential hits from these screens by RAJATHEES RAJARATNAM. 204a is 
thereby a potent Flt3 (IC50 = 137 nM, 10 µM ATP) inhibitor, 204b an AURKA (IC50 = 121 nM, 
10 µM ATP) inhibitor and 201a a Pim1 (IC50 = 15 nM, 10 µM ATP) inhibitor, while RR97b shows 
no significant inhibitory properties. All values thereby reflect the mean of two independent 
experiments.[233] Since 201a showed the best values concerning solubility and rat liver microsome 
stability, and since there is a lot of experience concerning the kinase Pim1 in the working group, 
including co-crystal structures of similar complexes bound to Pim1, the compound was chosen as 
the lead structure to try to improve its drug-like properties while conserving its inhibitory properties 
towards Pim1. To further test its suitability, the stability and toxicity of 201a was evaluated and 
compared to the inactive compound 201b. 
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3.2.2.4.3. Stability of 201a, 201b, 204a and 204b against light, solvents and physiological 
conditions 
Stability of metal complexes is always an issue that should be addressed. Especially ligand exchange 
reactions and racemisation are major concerns when metal-based compounds are evaluated 
towards their suitability in biological systems. It is well known the e.g. pyridocarbazole-based 
RuCpCO complexes may racemise in solution both in the dark and under influence of light.[265,266] 
To address this issue, a study has been performed to test the stability of this type of rhodium 
complexes against light, ligand exchange reactions and racemisation in presence of light at room 
temperature in DMSO and CH3CN. For the investigation, a few milligrams of 204b, based on the 
availability of the compound, were dissolved to DMSO-d6 and a few microliters of that solution 
were further diluted into CH3CN. Both samples were kept at room temperature in direct proximity 
to a window, to allow irradiation by both daylight and artificial light. Samples from the NMR tube 
were taken and diluted into CH3CN at time points 0 h, 24 h, 4 d, 7 d, 14 d and 24 d and kept at -
20 °C until evaluation. At the same time points 1H-NMR spectra were measured to ensure the 
integrity of the complex. The NMR spectra are summarised in Fig. 39, showing no transformation 
of the compound, which indicates no ligand exchange or racemisation to the respective 
diastereomer. 
 
Fig. 39: 1H-NMR spectra of 204b in DMSO-d6 after 24 h, 4 d, 7 d, 14 d and 21 d, during which the compound was exposed to 
natural and artificial light at room temperature. No change in the aromatic or aliphatic region can be observed whatsoever, which 
also holds true in comparison to the freshly synthesised compound. 
 
As concluded from the NMR spectra, a racemisation to the diastereomer is not occurring, while a 
racemisation to the enantiomer can generally not be observed in NMR, due to the identical 
chemical shifts of enantiomers. This type of racemisation is generally very improbable for the 
complex, since it would include the racemisation of the stereocentre in the proline ligand, for which 
the ligand must probably first be at least partly released from the metal centre. For analysis of 
racemisation, the best conditions for separating all four possible isomers on HPLC, namely 204a, 
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204b, 201a and 201b, using a chiral column, were evaluated. The afore mentioned samples in 
CH3CN were injected and checked for any probable racemisation of 204b to 201b (Fig. 40), 
according to a change in retention time under the given separation conditions.  
         
Fig. 40: Left: chromatogram of an isomeric mixture of the 201a, 201b, 204a and 204b, obtained by RP-HPLC using a CHIRALPAK® 
IC column. The isomers were assigned based on single runs with the respective compound. Right: Chromatograms of RR88b (204b) 
in CH3CN, which was exposed to light and room temperature and of the 0 h and 21 d sample taken from the DMSO solution. 
There is no racemisation observable.                                            
 
As Fig. 40 shows, no change in the chromatograms was observed in the 21 d in CH3CN sample 
nor the sample taken from the DMSO solution after 21 days in comparison to the 0 h sample. This 
means that no racemisation to any other stereoisomer occurs under the given condition and that 
the complex generally does not react with the solvents, since a ligand exchange normally also leads 
to a change in retention time. 
In addition to the stability towards light, DMSO and CH3CN, the behaviour of the complexes 
under physiological conditions was of great interest. After administration, during their passage 
through the blood and eventually into the cells, drug molecules encounter biological substances 
that can modify their composition through ligand exchange reactions. Thereby serum proteins are 
often their first binding partners.[267] To investigate the stability of RR97a and RR97b towards 
physiological conditions, they were incubated as an 5 mM solution in DMSO-d6 /H2O 9:1 with the 
addition of an equimolar amount of β-mercaptoethanol. The thiol is thought to imitate nucleophilic 
thiol-groups of cysteine side chains, as they are present in biological systems. After 48 h, the 
solution was additionally incubated at 37 °C in an atmosphere containing 5% CO2 to imitate the 
conditions used in cell and precision cut liver slice experiments. Fig. 41 and Fig. 42 show the 
aromatic and aliphatic regions of the respective 1H-NMR spectra at the defined time points of 
measurement.  
25 30 35 40
 
retention time
 RR88b CH
3
CN
 RR88b 0 h
 RR88b 21 d
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Fig. 41: Aromatic regions of 1H-NMR spectra of RR97a (201a left) and RR97b (201b right) at defined points after addition of 
β-mercaptoethanol. No changes are observable within 6 weeks at 37 °C. 
 
As Fig. 41 shows, there are no changes in the aromatic region of the two complexes at any point 
in the experiment, indicating no reaction with neither the solvent, nor the thiol. This includes both 
a ligand exchange reaction as well as an addition to the maleimide nitrogen or a ring open of the 
maleimide, since these reactions should shift the signals to some extent. In Fig. 42 no changes in 
the aliphatic signals of the complexes can be observed, leading to the same conclusion. However, 
the signal belonging to β-mercaptoethanol slowly decreases, while two new signals form, as 
indicated in Fig. 43. 
 
Fig. 42: Aliphatic region of 1H-NMR spectra of RR97a and RR97b at defined points after addition of β-mercaptoethanol. No 
changes in signals belonging to the complexes are observable within 6 weeks at 37 °C. Signals at 2.50 ppm belong to the restprotons 
of the solvent DMSO, signals at ~ 3.7 to water. 
 
The β-mercaptoethanol can both be depleted by hydrolysis with water or by reaction with DMSO 
to a 2,2-dimethyl-1,2λ4,3-oxadithiolane, which is promoted by increased temperature. Fig. 43 shows 
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that within the six weeks in which spectra were recorded, the signal belonging to 
β-mercaptoethanol (blue) fully reacts to another species with almost full conversion after 7 days at 
37 °C. In the same ratio as the signal fades, two new signals form, which might belong to the 
described oxadithiolane. 
 
Fig. 43: Section of the 1H-NMR spectra recorded for RR97b, showing the disappearance of the signal belonging to 
β-mercaptoethanol and simultaneous formation of two new signal sets, probably belonging to an oxadithiolane formed by the 
reaction of the β-mercaptoethanol with DMSO. 
 
Overall these experiments show, that the complexes seem to be fully stable towards thiols, heating 
at 37 °C, racemisation and hydrolysis at the given conditions. It should be noted however, that 
when using larger amounts of β-mercaptoethanol (1M; complex/thiol ratio of 1:10000) in aqueous 
buffer, the formation of a compound with an increased retention time can be observed for both 
RR97a and RR97b via HPLC. The new compound has not been further investigated but might be 
a result of either ligand exchange reaction or reaction of the thiol with the maleimide. This result 
shows that the stability of the complex might indeed be limited if high thiol concentrations are 
present, however thiols in e.g. blood are normally found in a micromolar scale rather than a 
molar.[268] 
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3.2.3. Toxicity evaluation of 201a, 201b, 204a and 204b  
3.2.3.1. In vitro cytotoxicity in cancer cells 
All four complexes were tested for their toxicity in a concentration dependant HeLa human cervical 
cancer cell line after incubation of the compound for 24 h using the MTT standard method I. The 
isomer RR97b (201b) thereby always serves as a reference where the cytotoxicity is not related to 
kinase inhibition properties. The results are given in Fig. 44. 
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Fig. 44: Cell viability assay using the MTT method. All four compounds do not affect the cell survival up to a concentration of 
10 µM at 24 h incubation time. The a isomers seem to be more cytotoxic at a concentration of 30 µM in comparison to the b isomers. 
 
As the results in Fig. 44 show, all compounds show no significant cytotoxicity up to a concentration 
of 10 µM under the assay conditions given. For a concentration of 30 µM, the a isomers seem to 
show a small toxicity, while the b isomers seem to be less toxic. However, in the 30 µM wells the 
deviation is very high and allows not much of a definite conclusion. Therefore, RR97a and RR97b 
were further tested in human lung carcinoma A549 cells and human ovarian carcinoma A2780 cells 
using standard method II, including an incubation time of 72 h and a higher concentration range. 
The results of these experiments, which were conducted in Angela Casinis laboratory at the 
Rijksuniversiteit Groningen, are shown in Fig. 45. 
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Fig. 45: Concentration dependant cell viability assay in human cancer cell lines A549 and A2780 using the MTT method. The two 
isomers do not affect the cell survival up to a concentration of 10 µM at 24 h incubation time. Both isomers show a similar trend in 
cytotoxicity in A549 cells with concentrations above 10 µM, which goes down to approximately 50% cell survival at 100 µM. In the 
A2780 cells the a isomers again seem to be more cytotoxic at a concentration of above 10 µM compared to the b isomers going 
down to around 16% for the a isomer at 100 µM and 34% for the b isomer. 
 
Fig. 45 clearly shows a similar trend for the two isomers up to 30 µM in comparison to the HeLa 
experiments with 24 h incubation time. In A549 cells both isomers show a similar trend in 
antiproliferative properties with concentrations above 10 µM, which goes down to approximately 
50% cell survival rate at 100 µM. In A2780 cells the a isomers again seem to be more cytotoxic at 
concentrations of above 10 µM compared to the b isomers going down to around 16% for the a 
isomer at 100 µM, and 34% for the b isomer. Overall the toxicity is comparably low for all 
compounds in all cell lines tested. However, at high concentrations with long incubation times 
some precipitate occurred, maybe falsifying the data insofar that the compound might be more 
toxic than it seems in the experiment. The results not only show low toxicity, but also that these 
cancer types are probably not treatable by the used inhibitors. Based on the Human Protein Atlas[269] 
Pim1 expression in HeLa cells is moderate and for A549 cells low, indicating no obvious relation 
between the shown low cytotoxicity and Pim1 inhibition. As indicated in the introductory section, 
Pim1 inhibition however might rather lead to disease control than tumour killing. The possibility 
of combination treatment and whether RR97a enhances the effect of other cancer drugs was not 
explored further, since it was not the primary goal of this thesis. 
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3.2.3.2. Ex vivo hepatotoxicity of 201a and 201b in precision cut liver slices 
As shown in the previous section, toxicity of is low in different cancer cell lines. In addition to the 
in vitro results, the toxicity towards healthy cells or rather tissue is an important property concerning 
a possible use of the compound as drug. An attractive model is thereby the use of precision cut 
liver slices (PCLS), in which hepatotoxicity can be evaluated. Hepatotoxicity is thereby one of the 
major reasons for termination and for limitations by labelling medicines.[270]  
Precision cut tissue are viable explants of the tissue cultured ex vivo with all cell types in their natural 
environment, providing toxicity results which are expected to be more relevant than those obtained 
in cell cultures. Using this technology, all cells remain in their natural environment with 
maintenance of the original cell-cell and cell-matrix contacts, which is absent in classical 2D cell 
cultures in vitro.[271–276] Notably, the technique is an FDA-approved model for drug toxicity and 
metabolism studies, and it has previously been used for the assessment of toxicity of metal-based 
compounds like cisplatin (kidney),[277] experimental gold compounds (liver, kidney, and colon),[278] 
and amino-ferrocene-containing prodrugs (liver).[279] The tissue in the experiment is sliced with a 
reproducible and well defined thickness, which is small enough to allow sufficient oxygen and 
nutrient supply to the inner cell layers, ensuring the viability of all cells. Slicing thereby allows a 
very efficient use of the organ tissue,[280] since numerous compounds and conditions can be tested 
at the same time with only one organ. Precision cut tissue slices of the liver are frequently used to 
assess hepatotoxicity in healthy tissue.[271–273] This is an enormous advantage compared for testing 
toxicity in single cell cultures, because drug-induced hepatotoxicity often is a multi-cellular process 
involving not only hepatocytes but also other cell types such as Kupffer and stellate cells.[281] 
Based on previously discussed criteria, RR97a (201a) and RR97b (201b) were selected for 
hepatotoxicity investigations at the Rijksuniversiteit Groningen according to established 
procedures using rat precision cut liver slices (PCLS). Again, RR97b as ineffective kinase inhibitor 
serves as control compound, since any toxicity should be induced by other mechanisms than kinase 
inhibition. For the hepatotoxicity evaluation, PCLS were prepared and pre-incubated for 1 h before 
exposing to the rhodium containing complexes as described in the experimental section. The 
preincubation thereby is necessary to allow the tissue to recover from the cold ischemia and the 
slicing procedure. The treatment with RR97a and RR97b was performed at three single 
concentrations of the compounds (1 µM, 10 µM and 50 µM) with a final DMSO concentration of 
less than 0.5% and slices were incubated for 24 h. Afterwards PCLS were collected and their 
viability was determined measuring their ATP content using a bioluminescence assay and 
normalising it to their protein content, obtained by the LAWRY method, and thereby to the size of 
the tissue slice.  
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Fig. 46: Viability of precision cut liver slices (PCLS) after 24 h incubation with the two diastereomeric complexes RR97a and RR97b 
after 1 h of preincubation.  
 
Fig. 46 reports the viability of the PCLS upon treatment with different compound concentrations. 
Based on the obtained results, both compounds are not toxic for the tissue at a concentration of 
1 µM. At 10 µM concentration, some effects on tissue viability can be observed with respect to 
controls, with RR97a being markedly more toxic than RR97b (20% and 69% residual viability, 
respectively). The hepatotoxicity increases with the highest tested compound concentration 
(50 µM), RR97a leading to the most pronounced effect (9% residual viability compared to 30% for 
RR97b). Here again at high concentrations some precipitate occurred, maybe falsifying the data 
insofar that the compound might be more toxic than it seems in the experiment. 
Notably, the inactive isomer RR97b presents reduced hepatotoxicity with respect to cisplatin in the 
same rat liver model. In fact, at 10 µM the anticancer Pt complex has been observed to induce a 
reduction of tissue viability up to 50% (unpublished data from Prof. Angela Casinis laboratory). In 
general anticancer agents are expected to show toxicity at therapeutically active doses, since the 
therapeutic effect and toxicities normally rely on the same mechanisms,[189] so some overall toxicity 
of the more active KI is not surprising. As a general trend with KIs, the severity of organ toxicity 
seems to be associated with increased kinase promiscuity,[22] which also aligns with the fact that 
RR97b does not inhibit kinases well, and RR97a targets more than one kinase.[233] 
Whether this toxicity is actually caused by inhibition of different kinases, or other tissue targets, is 
unclear. However the kinase Pim1, one of the preferred target kinases of RR97a, is known to be 
highly expressed in the fetal human liver but not in adult tissue,[40] indicating that inhibition of Pim1 
may not be the reason. To sum up, the different diastereomers seem to not only possess different 
KI properties, but also different toxicity effects, which seem not to be related to the Pim1 inhibition 
properties of RR97a, at least in the liver tissue, and may therefore arise from different 
physicochemical properties or off-target effects. 
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3.2.3.2.1. Metal uptake of PCLS after treatment with RR97a and RR97b 
To investigate whether the amount of compound, respectively Rh, might influence the toxicity of 
the complexes RR97a and RR97b towards PCLS, the metal uptake after the incubation time was 
studied for the same concentration range. Therefore, PCLS were treated as described for the 
hepatotoxicity study until the end of the 24 h incubation time. The slices were then washed in 
Krebs medium and individually frozen at -80 °C and kept at this temperature until digestion with 
HNO3 as described in the experimental section. The content of Rh was measured via ICP-MS in 
the mass department of the Philipps-Universität Marbug (inductively coupled plasma mass 
spectrometry) and determined using an external Rh calibration curve (Fig. 47). Due to the 
previously shown high stability of the compounds in assay medium, the values are expected to 
reflect the true values for the complex. 
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Fig. 47: Rh content of PCLS (left) and medium (right) after 24 h treatment. It seems that RR97b has a better uptake by the tissue 
compared to RR97a. 
 
Taken from Fig. 47 it seems that RR97b is taken up to a higher degree compared to RR97a. 
However, based on the high deviation these results are rather an estimation than a real value, as 
the samples were weighted in after thawing in its wet states, and not always all tissue was 
transferred. Additionally, similar amounts of Rh is found in the medium for both samples. Both 
compounds precipitated to a certain degree from the solution at high concentrations, so that the 
amount of compound in the medium might not be truly reflective. The trend of a higher uptake of 
RR97b is thereby a disagreement to the higher hepatotoxicity and cytotoxicity obtained in the 
previous assays.  
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3.2.3.2.2. Morphology of PCLS after treatment 
During the treatment of PCLC with RR97a and RR97b some of the compound precipitated in 
wells with high concentrations, as previously described. In addition to that the colour of slices 
changed from its natural brownish colour[280] to an intense pinkish red, indicating the confirmed  
uptake of the compound (see 3.2.3.2.1), as shown in Fig. 48. 
 
Fig. 48: Left: PCLS after 24 h incubation with 10 µM RR97a. The intense pink colour reveals the uptake of the deep red complex. 
Middle and right: Light microscope pictures of the freshly incubated slices showing deep red spots, which might be accumulations 
of RR97a. 
 
Since the colour seemed to be distributed unevenly in the slices, the question arose whether the 
compound accumulates on the surface of the slice, in structural features like blood capillaries or 
inside the cells. Therefore, the tissue was first examined in its wet state using a standard light 
microscope (Fig. 48). The samples indeed showed deep red spots, which were not to be seen in 
untreated samples and which were distributed unevenly. To further verify whether the compound 
accumulates on the surface or penetrates the tissue, morphology studies with tissue cross-sections 
were conducted. Therefore, the slices were treated according to the hepatotoxicity experiment until 
the 24 h incubation with the compound. The slices were then fixed in 4% w/v formalin, dehydrated 
using a graded EtOH series and paraffin embedded. Cross sections of 4 µm thickness of the 
paraffin block were prepared and stained using haematoxylin and eosin. Haematoxylin thereby 
stains the nucleus (chromatin) blue and eosin stains the cytoplasm pink. The cover slips were 
scanned using an Aperio image capture device (LEICA BIOSYSTEMS). The treated sample and the 
24 h reference control are show in Fig. 49. 
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Fig. 49: Comparison of morphology of dried and stained PCLS. Left: After treatment with RR97a for 24 h. Right: 24 h control. 
The cell nuclei were stained blue using haematoxylin, the cytoplasm was stained pink with eosin. No signs of compound 
accumulation can be seen. 
 
As can be seen from Fig. 49 the positon of accumulation could not be verified using this method. 
One possible explanation is, that accumulations were dissolved in one of the solutions used in the 
dehydration, embedding or staining process. This would indicate, that the accumulations were 
located extracellular, so that the solvent could reach and dissolve them. Keeping the results from 
np829 (80b) in mind, the previously observed toxicity for RR7a might be related to accumulations. 
However, an effect like the crystallisation in cells, as it has been detected for 80b, was not seen in 
any experiment with RR97a, pointing to another reason for the observed hepatotoxicity and minor 
cytotoxicity in cancer cells.  
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3.2.4. In vivo studies of RR97a and RR97b 
3.2.4.1. In vivo pharmacokinetic-studies of RR97b in C57BL/6 mice 
RR97b (201b), as previously mentioned, was the most attractive compound in regards to in vitro 
ADME properties from the first series of compounds. Therefore, a single low dose 
pharmacokinetic study of the compound was executed at NIBR Cambridge, USA in C57BL/6 
mice. The compound was administered via three different routes of administration, namely 
intravenous (IV, 1 mg/kg, n = 2), oral (PO, 3 mg/kg, n = 3) and intraperitoneal (IP, 3 mg/kg, 
n = 3) administration. Blood samples were collected at determined time points and the processed 
plasma analysed to quantify the compound via LC-MS/MS. The pharmacokinetic profiles obtained 
are shown in Fig. 50. All animals remained normal throughout the study which indicates that acute 
toxicity is not an issue with the exposures observed and within the time frame of the experiment.  
 
 
Fig. 50: Plasma concentration of compound RR97b after intravenous (IV), oral (PO) and intraperitoneal (IP) administration. 
Samples were taken at the determined time points and the processed plasma was analysed via LC-MS/MS to quantify the compound 
concentration. 
 
Fig. 50 shows the PK profile for all three dosage routes. For IV dosing, the drug concentration-
time profile shows a curve in which there is an initial rapid drop in drug concentration and a 
subsequently slower decline. This effect can be described by the two-compartment model, which 
resolves the body into a central and a peripheral compartment and which was used to calculate the 
values discussed below (please refer to the experimental section for calculations). Although these 
compartments have no direct physiological or anatomical meaning, it is assumed that the central 
compartment comprises tissues that are highly perfused such as heart, lungs, kidneys, liver and 
brain, while the peripheral compartment on the other hand comprises less well perfused tissues 
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such as muscle, fat and skin. A two-compartment model assumes that, following drug 
administration into the central compartment, the drug distributes between that compartment and 
the peripheral compartment, without reaching instantaneous equilibrium.[282] Therefore, the rapid 
drug decline in the beginning can be attributed to elimination from the central compartment and 
distribution into the peripheral compartment. After a while, a distribution equilibrium is achieved 
between the central and peripheral compartments, and elimination of the drug is assumed to occur 
from the central compartment leading to a smaller slope in the PK curve. All rate processes are 
generally described by first-order reactions in the model.[282] For PO and IP administration the 
beginning of the plot shows initially a rise in concentration, before it is distributed between the 
tissues and probably excreted in a similar fashion to the IV injection. This increase in the beginning 
is related to a relatively slow absorption of the compound before it reaches the vascular department.  
From the results obtained and profiles shown in Fig. 50 the following conclusions can be drawn:  
The IV clearance is moderate (ER = 37%), relative to the respective hepatic blood flow. This value 
seems to align with the theoretical ERh of 48% obtained in the rat liver microsome stability 
experiment. The volume of distribution at steady state Vss, which is a theoretical value representing 
the ratio of the total amount of drug in the body to the drug blood/plasma concentration, is also 
moderate (5.1 L/kg) with respect to total body volume (~0.7 L/kg), indicating a diffusion outside 
the vascular department. The half-life time (t1/2) of the compound in plasma is 2.9 h.  
When comparing to other metal-based compounds like NAMI-A and KP1019, which are Ru-based 
compounds tested in clinical trials for their anti-cancer abilities, or the approved dug cisplatin we 
get the following picture: In Swiss CD1 mice NAMI-A is rapidly cleared from blood after IV 
injection, with 3.5-4.7% of the administered dose (15-50 mg/kg) remaining 5 min pd.[283] In CBA 
mice, after administering 200 mg/kg IV, an initial t1/2 from plasma of 1.4 min was calculated using 
a bi-compartment model. These values demonstrate a much quicker clearance from the blood 
compared to 201b. The elimination half-life for NAMI-A was quite long, determined as 12 h,[284] 
probably because the majority of the drug was protein-bound (albumin and transferrin) and 
accumulates in white blood cells.[285] KP1019 is also highly bound to plasma proteins like albumin 
and to a lesser extent transferrin. The Vss in human patients was therefore determined to be small 
(similarly to NAMI-A)[286], while the terminal half-life is also quite long.[286,287]  RR97b in comparison 
has a moderate Vss and seems therefore to be less plasma protein bound. Cisplatin, which was 
administered to dogs at 1 mg/kg, also showed a low t1/2 of considerably less than 1 h, with plasma 
levels being cleared by 90% during the first 4 h of treatment.[288] The half-life in plasma is here again 
smaller compared to RR97b, but for cisplatin again the final phase of clearance is protracted and 
the terminal elimination is not even completed 12 days pd.[288] 
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As Fig. 50 shows, RR97b reaches systemic circulation after PO and IP dosing. It has a low 
(27% PO) to moderate (47% IP) bioavailability, that is the fraction of dose that reaches systemic 
circulation, with PO-dosing showing much more variability among the three animals. Oral 
administration is the most preferable dosage route for drugs in general, but oral absorption includes 
a tandem process of dissolution and intestinal membrane permeation. A low solubility, a low 
dissolution rate and low permeability can thereby all result in incomplete and variable oral 
absorption.[289] Thus, the high variability in the PO profile of RR97b is in accordance with the low 
solubility and very low permeability. However, it is not uncommon for KI to show high intra- and 
interpatient variability in cmax and plasma drug exposure e.g. in phase I clinical trials in cancer 
patients,[226] and the bioavailability still does not seem incompatible with PO or IP delivery, if 
coupled with a reasonable potency against a given target, which is of course not given for RR97b, 
but might be applicable for one of its isomers.  
Especially a possible PO delivery might be a great advantage over other metallodrugs, which often 
show a very limited solubility in oral formulations and are therefore usually given intravenously or 
subcutaneously. These routes of administration however, not only guarantee a smoother PK 
profile, but also allow to avoid the way through varies pH levels and conditions in the stomach and 
intestines, which might pose a threat to the structure of the complex, and allows to administer 
smaller amounts of metal ions avoiding possible toxic side effects.[267,290]  
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3.2.4.2. In vivo pharmacokinetic-studies of RR97a in Sprague Dawley rats 
As RR97a (201a) is a far more potent kinase inhibitor in comparison to RR97b (201b), and targets 
the potential cancer target Pim1, the pharmacokinetic properties of this inhibitor were of great 
interest, since it also showed adequate in vitro ADME properties. Therefore, a single low dose 
pharmacokinetic study of the compound was executed by NIBR in Basel, Switzerland in Sprague 
Dawley rats. The compound was administered via bolus injection intravenously (IV, 3 mg/kg), 
blood samples were collected and the processed plasma analysed to quantify the compound via 
LC-MS/MS in Basel and ICP-MS in the central mass department of the Philipps-Universität 
Marburg. The pharmacokinetic profiles obtained (expressed as ng Rh/g of plasma) are shown in 
Fig. 51. All animals remained normal throughout the study which indicates that acute toxicity is 
not an issue exposures observed and within the time frame of the experiment.  
 
 
Fig. 51: Plasma concentration of 201a after intravenous administration (3 mg/kg) in Sprague Dawley rats. Samples were taken at 
the determined time points and the processed plasma was analysed via LC-MS/MS or ICP-MS (using an internal In stand) to 
quantify the compound concentration. The complex concentration of LC-MS/MS results [nM] were recalculated to express the Rh-
concentration ng Rh/g plasma. 
 
Fig. 51 shows the PK profiles related to ng Rh/mg plasma for both analysis forms. As for IV 
dosing of 201b in C57BL/6 mice, the drug concentration-time profile shows a curve in which there 
is an initial rapid drop in the drug concentration and a subsequently slower decline. This effect can 
again be described by the two-compartment model.  
It is obvious, that for LC-MS/MS the decline in compound concentration is much quicker and 
stronger compared to the results obtained by ICP-MS. One reason might be that ICP-MS is more 
sensitive than LC-MS/MS yielding in higher values for lower concentrations. Also, the higher 
results for ICP-MS might indicate, that metabolites form, which are not detected by LC-MS/MS, 
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because only the parent compound is monitored, but are detected in ICP-MS as long as they 
contain Rh. Another reason seems to be an interference of other metal species (endogenous and 
exogenous metal ions and polyatomic groups),[291] containing e.g. monoatomic (e.g. Ru103 or 
Pd103) or polyatomic isobars (e.g. metal oxides), in ICP-MS measurement, even though an internal 
In standard was used to minimise interference (isobars of In may interfere as well). These 
compounds might have been contaminating the samples during sample preparation, e.g. during 
acidic digestion in plastic tubes, or already been contained in the administered complex. The smaller 
the Rh amount contained in the sample the more interference is expected, yielding in wrongly 
elevated Rh levels in the samples measured. Therefore, all further discussed PK parameters were 
calculated based on the LC-MS/MS plasma profile of 201a. 
From the results obtained and profile shown the following conclusions can be drawn.  The IV 
clearance is high (ER = 97%), relative to the respective hepatic blood flow (100 mL/min/kg).[292] 
This value seems to not align with the theoretical ERh of 27% obtained in the rat liver microsome 
stability experiment. The volume of distribution at steady state Vss is moderate (4.0 L/kg) with 
respect to total body volume (~0.7 L/kg), again indicating a diffusion outside the vascular 
department. The medium residence time (MRT) in plasma is 0.7 h indicating a shorter residence in 
the blood in comparison to RR97b (t1/2 = 2.9 h, MRT = 1.6 h) as also indicated in Fig. 52.  
 
 
Fig. 52: Plasma concentration of compounds RR97a and RR97b after IV administration in Sprague Dawley rats (RR97a, 3 mg/kg)) 
or C57BL/6 mice (201b, 1 mg/kg) over 7 h. Samples were taken at the determined time points and the processed plasma was 
analysed via LC-MS/MS to quantify the compound concentration. The concentration of 201a in rats declines much faster in 
comparison to the concentration of 201b in mice. 
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3.2.4.3. Metabolisation of RR97a in vitro and in vivo 
To study possible metabolism formation, as both RR97a and RR97b are cleared from the blood in 
an unknown way, an in vitro hepatocyte assay with RR97a was performed by NIBR in Basel. 
Additionally, a possible in vivo metabolite formation from samples obtained from the rats which 
were administered 3mg/kg RR97a IV was investigated.  
The compound was first tested in vitro in rat, dog and human hepatocytes and samples were 
analysed by LC-MS/MS. After two hours of incubation time, no oxidative metabolites were 
detected and the recovery rate was 100% for all species. This result aligns with the good stability 
results obtained in rat liver microsomes. However, based on the low permeability of the compound, 
there is the possibility that the compound only entered the hepatocytes to a small extend and 
thereby was not metabolised. 
To qualitatively test a possible metabolic degradation or excretion in rats, 7 h post dose (pd) tissue 
samples (liver, kidney and lung) as well as urine were analysed for their RR97a content by LC-
MS/MS, giving results for the respective parent compound. High levels of RR97a were thereby 
found in liver and lung, while lower concentrations were found in urine. These results are consistent 
with the determined Vss of 4.0 L/kg from the PK studies, showing that the compound indeed 
diffuses outside the vascular department. All samples analysed 24 h pd contained significantly 
decreased levels of RR97a. These results indicate that the renal system is not the main route of 
elimination during that period of time and that metabolite formation is possible based on the drop 
in concentration in samples 24 h pd. 
 
3.2.4.4. Excretion of RR97a in vivo 
The excretion of 201a was also investigated in more depth by means of ICP-MS/MS to study the 
total Rh-content, which also includes possible metabolites in the obtained results. Generally, first 
pass metabolites should be more water soluble in comparison to the parent complex and therefore 
expected in plasma, urine or faeces. While LC-MS/MS investigations found low levels of RR97a 
in urine for both 7 h and 24 h pd, ICP-MS analysis showed slightly elevated levels of Rh in urine 
and significantly higher levels in faeces compared to plasma, however as single determination (Fig. 
53). Plasma and urine where thereby measured as liquids and faeces as dry weight but recalculated 
to the wet weight content. As some samples had a rhodium content above the maximum 
measurable amount, giving values above the highest concentration in the calibration curve, even 
higher levels are expected for urine 7 h and faeces 24 h.  
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After 7 h little Rh containing compound remains in the blood, as indicated previously in the PK 
studies, but is excreted via both urine and faeces, with a strong focus on biliary excretion. After 
24 h additional Rh is excreted mainly as faeces, further reducing the plasma levels to 2 ng Rh/g 
plasma sample. Based on the results outside the calibration curve and a contaminated 24 h urine 
sample, these results have however only a limited information value. 
 
 
Fig. 53: Comparison of plasma, urine and faeces levels of 201a obtained by ICP-MS analysis. Please be aware that the 24 h urine 
sample was contaminated and does not necessarily reflect the total Rh-amount. Additionally, the measured values for urine 7 h and 
faeces 24 h were above the highest value in the calibration curve. A higher total Rh content than shown is expected for both samples. 
 
3.2.4.5. Tissue distribution of rhodium after 7 h and 24 h post IV injection of RR97a 
During assessment of 201a as a potential cancer drug it is important to understand the tissue 
distribution of the compound, as it has to reach its target but also be excreted at some point. This 
holds especially true for any metal species, which might otherwise accumulate in the body. During 
the metabolism studies, high concentrations of the complex were found in lung and liver, but little 
was found in kidney 7h pd by means of LC-MS/MS. These tissues account for highly perfused 
organs. We were therefore also interested in the concentration in other highly perfused tissues like 
brain (blood-brain barrier), heart and spleen, as well as less well perfused tissue like muscle. Tissue 
samples of the rats 7 h or 24 h pd were prepared as indicated in the experimental section and 
analysed for their total Rh content by ICP-MS using an internal Y standard. The results are given 
in Fig. 54. 
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Fig. 54: ICP-MS results (ng Rh/g sample dry or wet weight) for tissue distribution studies. The content for dry weight (left) follows 
the order lung 24 h > lung 7 h > spleen 24 h > faeces 24 h > spleen 7 h > liver 24 h > liver 7 h > kidney 7 h > kidney 24 h using 
Y as internal standard. Taking the wet weight into account (right) the following descending order was obtained: lung 24 h > lung 7 
h > faeces 24 h > spleen 24 h > spleen 7 h > kidney 7 h > liver 24 h > liver 7 h > kidney 24 h. All other samples had results below 
their respective detection limit. 
 
Taken from Fig. 54 the highest concentrations of RR97a by far can be found in lung for both time 
points in accordance with the initial LC-MS/MS results. The second highest concentrations are 
found in spleen (7 and 24 h pd) and faeces (24 h pd). The concentration in faeces is even higher 
compared to the initial results as the sample was further diluted, based on being above the 
calibration curve in the first experiment. This again shows a strong indication of the biliary 
excretion of Rh. The faeces sample 7 h pd showed values below the respective detection limit, 
indicating a much lower Rh content at that time point as also determined in the initial experiment. 
A rather high Rh-concentration is also found in liver and kidney at both time points, while only 
amounts below the respective detection limit were found in muscle, heart and brain, indicating no 
penetration of the blood-brain barrier. Altogether most compound was found in lungs with similar 
content for both 7 and 24 h time points. In the lungs some form of metabolism might take place, 
but it is generally appreciated that the majority of exogenous compounds in the lung are rather 
bound more or less reversibly to some component of the lung tissue than being metabolised.[293] If 
and how the compound is bound and/or metabolised in the lungs was not further investigated in 
this study. 
Compared to the previously mentioned Ru-based NAMI-A differences in organ distribution are 
much more significant. NAMI-A was found by means of AAS mainly in kidney after single IV 
treatment of 200 mg/kg, indicating a selective clearance by the kidney,[284] or in lung > kidney > 
liver after administration of 15, 35 or 50 mg/kg/day for 5 consecutive days to Swiss CD1 mice, 
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where the organs were removed 24 h after the last IV dose.[283] In these studies also no penetration 
of the blood-brain-barrier was concluded for NAMI-A.[283,284] 
Cisplatin also shows highest levels of platinum in kidney after administration of 1 mg/kg in dogs, 
while initial concentrations generally were found in organs of excretion like gonads, spleen and 
adrenals and stayed elevated in kidney, liver, ovary and uterus for some days. The high values in 
kidney are thought to correspond to high urinary levels of platinum which appear immediately after 
administration. These high levels in kidney were found to persist 12 days or longer, irrespectively 
of much lower doses found in urine after that time, indicating a binding to the tissue. However 
while plasma levels after administration fall very quickly, as discussed previously, 60-70% of the 
applied dose could be recovered in urine.[288] In the case of RR97a also high levels of Rh were found 
in urine after 7 h, but much less in kidneys and both not corresponding to high percentages of the 
initial dose given. 
To sum up Rh is at least partially excreted via the biliary system and probably to a much lesser 
extent the renal system. After the 24 h observation time sill very high amounts of Rh are found in 
the lung, indicating binding or side specific metabolism in this organ. As LC-MS determination 
showed decreased levels compared to the 7 h time point, metabolism in the lung might be a 
possibility but further studies are needed to verify these results and to identify possible metabolites. 
In addition to that, an experiment with a longer time-frame might be necessary to study how long 
the compound or other Rh-containing species stay in the lung. A long residence in the lung might 
lead to accumulations of Rh during long-term treatment, which might lead to adverse side-effects. 
Therefore, more in depth studies are indicated. 
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3.3. Upscaling possibilities of RR97a and derivatives 
For the afore mentioned in depth studies, larger amounts of the complexes were required. 
Therefore, upscaling studies were performed during the course of this thesis to evaluate a possible 
improvement of the reported yields and also be able to achieve higher quantities per reaction. The 
final reaction steps, as well as reported yields are given in Scheme 7. The reported yields are based 
on a scale of 44.0 µmol (17.7 mg) pyridocarbazole (205).[233] The reaction towards the 
pyridocarbazole-rhodium precursor was performed in a 1:1 mixture of ethanol/water since the 
substitution of the chlorido ligand in the first reaction step is favoured in aqueous solutions.[294] 
This precursor was then further reacted in a one-pot synthesis to the final complexes 201a and 
201b (or analogous to 204a and 204b) using the proline derived ligand 206. It is generally known 
that this type of coordination chemistry is overall sluggish, indicated by the typical low to moderate 
yields for the ligand exchange reactions.[295] 
 
Scheme 7: Reported reaction scheme and yields for the synthesis of RR97a (201a) and RR97b (201b), using 44.0 µmol of 
pyridocarbazole (205). The pyridocarbazole was first reacted with Rh3Cl in a 1:1 mixture of EtOH/H2O to form the according 
complex precursor which is further reacted in a one-pot synthesis with the proline ligand 206 to the final complexes.[233] 
 
3.3.1. Upscaling of the amount of starting material 
The first choice for upscaling was obviously a simple scale-up of the starting materials under the 
given reaction conditions. This was carried out using 250 µmol pyridocarbazole (100 mg) together 
with an adjusted reaction time of 24 h in the second reaction step to drive the reaction to 
completion. The extended reaction time was thereby validated using a scale of 125 µmol 
pyridocarbazole, which led to a yield of 20% of 201a, in comparison to the reported 15% using a 
period of 16 h. The yield of the enhanced reaction scale (250 µmol of 205) however dropped to 
<10% (~16-24 mg depending on the purity as determined from 1H-NMR spectra). In addition, an 
increased amount of coloured by-products was observed by TLC analysis and a large amount of 
unreacted pyridocarbazole (at least partially deprotected) could be isolated after column 
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chromatography. High amounts of pyridocarbazole were however also isolated in smaller scales. 
Due to the raised number of by-products and a general smearing of both diastereoisomers, as well 
as the by-products, on silica during purification, the compound could only be obtained in a pure 
fashion after multiple flash columns using a gradient of CH2Cl2/MeOH (1:0 to 200:1 to 10:1). 
Hence, this approach was rejected due to the extensive purification procedure and the decreased 
yield. 
Since the yield for the half-scale was obviously larger compared to higher or smaller scales, four 
separate reactions of 125 µmol pyridocarbazole each were performed separately and two reactions 
each were pooled for purification. Flash chromatography separation of the diastereoisomers were 
performed over 40 g silica using the slow gradient of CH2Cl2/MeOH described above. The 
different diastereomers were further repeatedly purified over 1.5-3.0 g of silica. An exact yield for 
these reactions however could not be obtained, since part of the compound got lost during 
purification. The total yield of all reactions described in this chapter combined was 12% for 201a. 
Altogether this second approach of splitting the reactions and pooling them for work-up meant 
again a huge amount of work for purification. Though a smaller extent of by-products was 
qualitatively determined on TLC, compared to the first approach using a larger scale. Therefore, 
the second option was not further pursued and other solutions for the upscaling problem were 
investigated, as described in the following chapter. 
 
3.3.2. Optimisation of reaction conditions 
Since the yields in the complex reactions were generally very low, which is most probably based on 
the sluggish chemistry,[295] a study for improved reaction conditions was performed. The low yields 
in the original reaction are presumably based on a fast deprotection of the pyridocarbazole, 
deactivating it towards coordination. Moreover, this may also cause the formation of numerous 
by-products in the reaction, as indicated earlier by TLC analysis. 
Based on this experience, another approach towards the synthesis of RR97a and RR97b as well as 
its derivatives was required. Conveniently, STEFAN MOLLIN showed in his PhD thesis[296] that upon 
reacting structurally distantly related kinase inhibiting ligands (e.g. phenylquinoline derived ligand) 
first with RhCl3 and afterwards with N-methyl-N-(pyridine-2-ylmethyl)glycine as tridentate ligand, 
the cis-isomer (carboxylate of the ligand is coordinated cis to the phenylquinoline nitrogen) was 
formed to a greater extent than the trans-isomer (~2:1). Reacting the glycine ligand first with RhCl3 
and then adding a benzyl-protected pyridocarbazole, a ratio of cis to trans isomers (carboxylate of 
the ligand is coordinated cis or trans to the indole nitrogen) of 1:3 was obtained. Based on these 
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results, a similar approach was pursued for the given system to obtain RR97a and RR97b (Scheme 
8). 
 
Scheme 8: Proposed reaction sequence for improvement of the cis/trans ratio of the formed complexes 201a and 201b. 
 
To test the hypothesis of positively influencing the ratio of 201a (trans-isomer) to 201b (cis-isomer) 
obtained in the reaction, the proline ligand 206 (38.0 µmol, 1.00 eq) was reacted in a small-scale 
with RhCl3 (38.0 µmol, 1.00 eq) in a 1:1 mixture of CH3CN/H2O (3.8 mL) for 16 h at 90 °C, as 
indicated for the glycine ligand in STEFAN’s thesis. A complex precursor is thereby expected to be 
formed in a way where the rhodium centre of RhCl3 coordinates three acetonitrile ligands before 
one chlorido and two acetonitrile ligands were exchanged by the carboxylate of 206 to form 207 
(Scheme 8). 1H NMR analysis of the complex precursor 207 after flash chromatography 
(CH2Cl2/MeOH) however showed at least two sets of signals in the aromatic region. These might 
be based on either monodentate ligand exchange in the complex 207, two proline ligands 
coordinated to one rhodium centre, or unreacted ligand in the spectrum. Without further 
purification, the precursor mixture was reacted in CH3CN/H2O 1:1 at 90 °C for 16 h with the TBS-
protected pyridocarbazole. Hereby, no reaction was observed by TLC analysis. Therefore, the 
solvent was removed and replaced with EtOH/H2O 1:1 and the reaction mixture was heated to 
90 °C for 72 h. TLC analysis indeed showed the formation of the two expected diastereomers with 
the trans signal giving a more intense colouring, indicating that the reaction conditions shift the 
cis/trans ratio. It was attempted to drive the reaction to completion by adding pyridocarbazole at 
different time points (~0.5 eq directly after precursor synthesis, another 0.5 eq 3 h after the start, 
and extra 0.1 eq at time point 5 h and 0.1 eq after 15 h). However, a completion of the reaction 
could not be achieved. 
Based on these positive results, a screening for the optimal solvent for the second reaction step 
was performed. Especially the high amounts of unreacted pyridocarbazole were of great concern. 
Therefore, 50 µmol of each the ligand and RhCl3 were reacted under stirring in 50 mL 
CH3CN/H2O 1:1 at 90 °C for 16 h. Afterwards, the solvent was removed and either 5 mL EtOH, 
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DMF or EtOH/H2O 1:1 were added together with 1.0 eq of pyridocarbazole 205. All solvents are 
polar and therefore able to coordinate and stabilise possible charged intermediates. The reactions 
were stirred at 90 °C for 65 h and the results were analysed qualitatively via TLC analysis. While 
the reaction with pure EtOH contained large amounts of unreacted pyridocarbazole, some 
complex and various by-products, the reaction using DMF showed hardly any reaction to the 
desired complexes as well as hardly any unreacted pyridocarbazole left (probably based on cleavage 
of the TBS-protecting group and subsequent abolishment of the reactivity of the pyridocarbazole). 
Both reaction conditions showed much lower product formation compared to the original solvent 
mixture, which might be associated to the missing water as aqueous solutions are known to 
promote the substitution of a chlorido-ligand[294] as mentioned earlier. Another possibility for the 
low yields is a faster deprotection of the pyridocarbazole in the changed solvent system. Therefore, 
for both reactions the solvent was removed, replaced by EtOH/H2O 1:1 and stirred for 24 h at 
95 °C. TLC analysis after that reaction time showed a small improvement of the original EtOH 
reaction and no improvement of the DMF reaction, indicating indeed the loss of the TBS-
protection group of the pyridocarbazole. Therefore, the precursor approach was generally 
dismissed for the unsubstituted pyridocarbazole. 
 
In parallel to the studies using unmodified pyridocarbazole, a comparison study of the original one 
pot synthesis reaction conditions and the precursor approach was done by BENEDIKT HEINRICH 
using an indole-5-ol modified pyridocarbazole (208). This investigation was supposed to help 
understanding the influence of the electronic properties of the ligand.[297] 
 
Scheme 9: Different synthetic approaches towards the synthesis of 209a and 209b. On the left-hand side, the reaction conditions 
of the one pot synthesis are shown. On the right-hand side the conditions of the precursor approach. 
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Starting with very small reaction scales, both reaction pathways (Scheme 9) were confirmed to 
result into the desired complexes 209a and 209b as shown qualitatively by TLC analysis. The 
complex formation using the precursor approach was subsequently tested in both solvent systems, 
CH3CN/H2O 1:1 and EtOH/H2O 1:1, for the second reaction step and evaluated qualitatively via 
TLC. Minimal reaction was thereby detected in the original solvent (CH3CN/H2O), even with a 
temperature increase up to 105 °C. The use of EtOH/H2O resulted in the formation of a spot for 
the a isomer 209a that has been much more intense compared to the one of the b isomer 209b. 
When scaling-up the precursor approach (152 µmol pyridocarbazole), 1H- NMR analysis of the two 
isomers after purification via silica flash chromatography using CH2Cl2/MeOH (1:0 to 100:1 to 
10:1) showed an extensive number of by-products, probably unreacted precursor and/or unreacted 
ligands. These by-products were not easily removable by flash chromatography over silica since the 
complexes and by-products have similar retention factors (Rfs) in the given solvents and tend to 
smear on silica. An isolated spot from the 5-hydroxy pyridocarbazole reaction, which was suggested 
to belong to the precursor 207, was analysed by 1H-NMR spectroscopy in DMSO-d6, where it 
showed all signals of the ligand but the expected CH3CN signal. A high-resolution mass spectrum 
however showed the exact mass of LRhCl(DMSO) (with L representing the deprotonated proline 
derived ligand 206), so that the CH3CN ligand might have been exchanged in the NMR tube due 
to its reactivity and excess DMSO present. The missing chlorido ligand in the exact mass was 
probably lost during ionisation. These results indicate a formation of metal precursor as suggested.  
Interestingly, a similar species as the precursor was also found when scaling-up the one-pot 
approach, indicating a lower reactivity of the pyridocarbazole-ligand and therefore leftover RhCl3 
which might react with the later added proline ligand. However, this side product was present to a 
much smaller extent in comparison to the by-products detected in the precursor approach, which 
is probably based on the changed solvent system. Also, the a isomer 209a, which is the isomer of 
interest, could be obtained in a pure fashion, while only the b isomer 209b was inseparable from 
this side product, which was not the case for the precursor approach. Still 209a was formed to a 
much smaller extent, compared to the precursor approach, deeming both reaction pathways as not 
very suitable to form larger amounts of 209a.  
To sum up, the precursor approach indeed leads to the formation of a higher ratio of a (trans) to b 
(cis) isomer, however with the draw-back that also more and partly inseparable by-products were 
formed. Therefore, this variant seems not to offer a suitable possibility to enhance the reaction 
yield, for scale-up or save time in work-up. All in all, no approach helped to scale the reactions or 
yield up to a significant extent.  
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3.4. Solubility and permeability optimisation 
Based on the in vitro and in vivo data, the critical parameters for bioavailability of pyridocarbazole 
derived metal-based kinase inhibitors are solubility and permeability. Since 201a is a potent Pim1 
inhibitor and shows adequate in vitro and in vivo properties, it was considered as an attractive lead 
structure. It was therefore selected as a starting point for improvement of solubility and 
permeability by chemical modification of its structure.  
In general, solubility is affected by physicochemical properties which are based on underlying 
structural properties. These include size (MW, shape), pKa, crystal lattice energy and lipophilicity, 
which itself is based on VAN DER WAALS forces, polarity, number of H-bond acceptors and donors, 
as well as ionic interactions. General strategies to enhance solubility include e.g. the addition of an 
ionisable or polar group, H-bond acceptors or donors, or the reduction of logP or MW. Additional 
strategies might include the addition of an out-of-plane substitution to reduce the crystal packing, 
or to form a prodrug with higher solubility.[232] Permeability on the other hand, as the rate of drug 
passage through a biological membrane barrier, is also influenced by various physicochemical 
parameters like ionisability and lipophilicity, especially with a focus on polarity and hydrogen bond 
donors and acceptors. While solubility limitations in a compound might be overcome by a solubility 
enhancing formulation, the only way to enhance permeability is structural modification. General 
strategies to enhance permeability include the replacement of ionisable groups by non-ionisable 
groups, the isosteric replacement of polar groups, the reduction of hydrogen bonding and polarity, 
the addition of lipophilicity e.g. by addition of nonpolar side chains, the reduction of size, and a 
probable prodrug approach.[232] 
When considering these classical options to improve solubility and permeability, it is obvious that 
most approaches disagree with each other as indicated in Table 8, and it seems almost impossible 
to improve one property without adversely affecting the other. On the other hand, approaches like 
the reduction in size or MW, the addition of an out-of-plane substituent and the addition of a 
nonpolar side chain, as well as the prodrug approach might complement each other. 
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Table 8: General approaches to improve permeability and solubility. Approaches which are mutually exclusive when trying to 
improve both properties in one molecule are marked with a cross. Modifications which might complement each other are marked 
with a check mark. 
Permeability Solubility 
 convert ionisable group 
to non-ionisable group  
 add ionisable 
group (e.g. salts) 
 add lipophilicity  reduce logP (lipophilicity) 
 reduce polarity  add polar groups 
 reduce H-bonding  add H-bonding 
 reduce size  reduce MW 
 add nonpolar side chain  Out-of-plane substitution 
to reduce crystal packing 
 prodrug approach  prodrug approach 
 
When considering the proper strategy, first the prodrug approach was dismissed, since the 
evaluation of drug-like properties, as well as activity of a prodrug, is very complicated depending 
on the prodrug strategy. It was decided that this approach was out of the frame of this work.  
A reduction of size and/or molecular weight sounded very promising in the beginning. However 
with a decrease in size of the largest ligand, the pyridocarbazole, most probably the kinase affinity 
would have gotten lost or at least decreased as SEBASTIAN BLANCK could show in his PhD-thesis 
when using quinolinemaleimides,[298] pyridylnaphtalimides[299] and pyridylphtalimide[158] as 
pharmacophore-ligands.[300] All three ligand classes have been used to develop attractive KIs against 
e.g. MLCK,[299] PKCδ[298] and PAK1,[158] which however were not as potent as pyridocarbazole 
derived inhibitors. The best example might be the work of STEFAN MOLLIN who used a 
phenylquinoline ligand to synthesise structural analogues of 201a, using the exact same tridentate 
proline derived ligands and RhCl3. A kinome screen of an intentionally created racemic mixture of 
the main isomers, showed very low kinase affinity,[296] while only 201b showed very low affinity, 
whereas the other three complexes 201a, 204a and 204b were very potent.[233] 
The second largest ligand is (pyridine-2-ylmethyl)-D-proline (206), which can hardly be reduced in 
size, since its structure is required both for coordination purposes and to decrease the number of 
possible isomers. Therefore, a significant reduction in size was not considered as a realistic option, 
especially in the context that more than 30% of approved SMKIs have a MW above 500, showing 
that the MW is not the sole limiting factor for drug-like properties.[26] The best option to improve 
both solubility and permeability therefore seemed to be the addition of an out-of-plane substituent. 
However, since it was unclear how the compound binds in the Pim1 kinase active pocket, some in 
silico investigations were performed, to specify which position might be suitable for this approach. 
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3.4.1. Structural optimisation – in silico studies 
For our compound of interest RR97a (201a), no co-crystal structure with a protein kinase was 
available at the point of lead optimisation studies. Therefore, very simple docking experiments were 
necessary, to evaluate positions which might be suitable for structural optimisation. It is well 
accepted, that the pyridocarbazole ligand always binds in a similar fashion due to the binding 
interactions explained in the introduction part. Since there are diverse kinase co-crystal structures 
of other pyridocarbazole-based compounds available, the easiest solution was to just pair-fit the 
pyridocarbazole moiety of 201a to the available co-crystal structure to obtain a first impression of 
the orientation of the complex. In addition to a missing co-crystal structure, there was no simple 
crystal structure of RR97a available. Therefore, the complex was generated and optimised via MM3 
geometry using the program CAChe WorkSystem Pro 7.5.0.85 (FUJITSU LIMITED). Given that the 
crystal structure of the diastereomer RR97b was obtained previously by RAJATHEES RAJARATNAM, 
the structure of RR97b (201b) was optimised in the same way as the one for RR97a to test the 
accuracy of the structure optimisation. The result is shown in Fig. 55 and gives an impression of 
how far the calculation of RR97a deviates from reality. 
 
Fig. 55: Comparison of the crystal structure of RR97b (green) and the structure obtained by MM3 geometry optimisation (cyan). 
Obviously, the calculation shows deviations to the true structure, but the results are still rather close to the true values. 
 
The structure obtained (Fig. 55) is obviously not absolutely correct, but was considered satisfactory 
for the planned binding investigation, since the overall accuracy was not expected to be very high, 
but also not required for the purpose of finding possible side pockets or solvent exposed residues. 
The calculated structure of 201a was subsequently superimposed using the pair-fitting operation for 
the maleimide group of the pyridocarbazole ligand in PyMOL 1.5.0.4, to two existing co-crystal 
structures of Pim1 containing pyridocarbazole-based RuCpCO-complexes DW2 ((S)-53) and 
HB1 ((R)-199) (pdb 2BZI (DW2), 2BZH (HB1))[48]. It is well established for this type of complexes, 
that the relatively small monodentate ligand always points in the direction of the glycine rich loop 
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(c.f. pdb files 2OI4, 2IWI, 3CST, 2JLD, 3FXZ, 3PUP, 2YAK amongst others) of the kinase, 
simplifying this approach by dictating the orientation. The results of the pair fittings are shown in 
Fig. 56 and Fig. 57. 
   
Fig. 56: Modelled 201a (cyan) superimposed to the compound DW2 (green) in the Pim1 enzymes active pocket (pdb 2BZI). On 
the right-hand side, all amino acids which seem to prevent a binding of RR97a are shown, namely F49, D128, E171 and N172. 
Kinase active pockets are very dynamic structures, therefore these residues might take different orientations while 201a binds to the 
pocket. 
 
From Fig. 56 it is obvious that RR97a cannot fit into the enzymes active pocket in the conformation 
given, using the surface representation of PyMol (CONNOLLY surface). However, active pockets of 
kinases are very dynamic due to the flexibility of the hinge region. The model shows that there are 
only a few residues present, which conflict with the complex (F49, D128, E171 and N172) and all 
are flexible through rotation around single bonds. The orientation of 201a thereby does not need 
to correlate exactly with DW2. The comparison to the superimposition to HB1 (Fig. 57) shows 
indeed the F49 residue as only conflict. From this figure, it is also obvious, that the space around 
the proline is very limited, while both the pyridines, belonging to the (pyridine-2-ylmethyl)-D-
proline and the pyridocarbazole are at least partially solvent exposed, leaving a good starting point 
for the addition of out-of-plane substituents. Since the 4-pyridine position of the proline-based 
ligand 206 seemed to be much more solvent exposed and possesses no threat towards a sterical 
hindrance in complex formation, this position was selected for the out-of-plane modification. 
Notably, a pair fitting of 201b to the same co-crystal structures did not explain the preference of 
binding of 201a in comparison to 201b.[233] 
 
N172 
E171 D128 
F49 
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Fig. 57: Modelled RR97a superimposed to the compound HB1 in the Pim1 enzymes active pocket (pdb 2BZH). Here again a clash 
of the compound with F49 (orange) was identified. 
 
To also get a first impression on which kind of substituents might help keeping or even improving 
the affinity towards Pim1, we were commited in investigating the surface charge of the protein, to 
find positions for possible attractive interactions.  
For that matter the PyMol Plugin APBS[301,302] (Adaptive Poisson-Boltzmann Solver) was used, after 
the pdb-file was converted to a pqr-file using the pdb2pqr server (Version 1.8)[303,304] via a PARSE-
forcefield (parameters for solvation energy) method,[305,306] which prepares structures for further 
calculations by reconstructing missing atoms, adding hydrogens, assigning atomic charges and radii 
from specified force fields, and generating pqr files. Pqr files are generally pdb files where the 
occupancy and B-factor columns have been replaced by per-atom charge and radius. The Poisson-
Boltzmann equation is used as a basis for a popular continuum model used to describe electrostatic 
interactions between solutes in salty, aqueous media. For the conversion (pdb2pqr) the complex 
had to be removed, because coordination compounds which contain e.g. ruthenium or rhodium 
are not supported by the forcefield methods. After the conversion, the color-coded electrostatic 
surface potential was calculated and presented as negative and positive potentials on the 
isosurfaces, providing information about the atomic surface charges and the shape of the protein 
(Fig. 58). The solvent-accessible surface (obtained by addition of 1.4 Å to every atomic radius 
before calculation of the area)[307] tends to reveal more global features of the surface potential but 
limits the size of the active pocket. Therefore, no further conclusions towards the ligand binding 
and suitable available space could be drawn from that model. As second point of reference, the 
potential on the solvent accessible surface was chosen, which visualises both geometric information 
from the molecular surface and electrostatic potential information from the solvent-accesible 
surface simultaneously (Fig. 58). All potentials are displayed at pH 7.0 with default protonation 
states for all residues. As default thereby only charged residues (Arg, Lsy, Glu, Asp) are taken into 
account, and the charges are located at the corresponding  (non-H) atom positions. Overall the 
active site is negatively charged, as can be seen in Fig. 58, with the exception of an amine in the 
hinge region. 
F49 
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Fig. 58: Molecular surface potential (left) and surface potential on the solvent accessible surface (right) of Pim1 [KbT/ec at pH 7.0] 
calculated using the PyMol plugin APBS, based on the pdb 2BZI, which was converted to a pqr using a PARSE-forcefield after 
removal of the binding complex. White colour indicates a neutral surface potential, blue a positive surface potential as it is induced 
by amines, and red a negative potential as it is found e.g. with carbonyl groups. 
 
The potentials obtained were further aligned with the unmodified pdb-file, to reobtain the position 
of the complex. Afterwards, the optimised structure of RR97a was pair-fitted, to get an impression 
of potential positions where specific intereactions might be obtained. To test the space available at 
the previously discussed 4-pyridine position, a 4-hexyl pyridine derivative of RR97a was calculated 
and pair-fitted (Fig. 59). 
 
Fig. 59: A modelled 4-hexyl-pyridine derivative of RR97a bound to Pim1, which is represented as molecular surface potential. From 
the results a side chain that long should find sufficient space to not impair the binding of the complex. 
 
The model presented in Fig. 59 indicates that there is indeed some space available in the Pim1 
active pocket, to add substituents to the 4-position of the pyridine. The space however is obviously 
limited, so that mainly long but lean residues might be introduced. Overall the surface potential in 
the region is mainly negative (red), with some positive (blue) regions, giving the possibility of 
introducing different types of potentially charged residues to find the perfect fit, which might 
improve the affinity but additional positive interactions. Further considerations on which 
functional groups might be suitable, can be found in the following chapter.  
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3.4.2. Derivatisation of the proline derived ligand 206 – theoretical considerations 
As indicated in the previous section (3.4.1), the largest space available to attach larger substituents 
seems to be in the para-pyridine position of the proline based ligand. Therefore, this position is the 
ideal starting point to add an out-of-plane residue, which is supposed to enhance solubility while 
not interfering with the binding to active site and decreasing the potency of the inhibitor. The 
molecular planarity of the pyridocarbazole ligands with their high degree of π-π-interactions are 
thought to strongly contribute to the low solubility of the complexes by increasing crystal packing. 
Using an out-of-plane residue might at least partially counteract these interactions. By disturbing 
molecular planarity and symmetry, generally the efficiency of crystal packing should be decreased[12] 
and thereby the solubility probably enhanced.[308] This kind of solubility enhancement could also 
avoid potential acute toxicological effects due to crystallisation in vivo,[12] as seen in vitro for np829 
(80b) and which might have been indicated as well for 201a in PCLS studies. 
As previously mentioned, SMKI tend to be quite large and hydrophobic during development 
stages, as increased hydrophobic interactions are a result of an increase in potency towards a given 
target but might also lead to lowered solubility.[12] To improve their drug-like properties, especially 
their solubility, a common strategy for SMKI is the addition of water exposed solubilising side 
chains or appendages located outside of the binding pocket upon binding since the presence of 
strongly hydrophilic or ionisable groups in other positions will often interfere with ligand-protein 
binding.[12] A solubilising appendage can be a basic, acidic, or a neutral group tethered to the drug 
via a linker.[309] Typical structures include linkers which inherit piperidines (e.g. vandetanib (13)), 
piperazines (e.g. dasatinib (5), bosutinib (18) and nintedanib (24)) or morpholines (e.g. gefitinib (2) 
see bound to EGFR in pdb 2ITY[310]), but the concept is also applied with other long solvent 
exposed chains as in erlotinib (3), sunitinib (6), lapatinib (8), axitinib (19) and afatinib (21).[19]  
Since Pim1 is rather negatively charged in its active site, as shown in the in silico section, especially 
appendages which inherit amine groups were thought to enhance the solubility and probably 
simultaneously the affinity of the derivative to the kinase. This assumption is based on the fact that 
amine groups form strong H-bonds with water and might form positively charged species, if the 
conjugated acid is formed at a pH corresponding to the according pKa, which might interact with 
negatively charged side chains of the kinase. Generally this pKa will determine the expected 
increase in solubility,[309] it is however not easily determined for metal-complexes since most tools 
used to easily calculate pKa are not capable to include the shift obtained by electron withdrawal 
when coordinating to a metal. The amount of polar atoms like nitrogen to be added has to be 
carefully considered not to negatively influence membrane permeability[309] as for neutral 
substances the main contributor to membrane permeability are molecular size and H-bond 
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capability.[311] Therefore, to test a possible improvement in solubility by adding a pure aliphatic side 
chain for out-of-plane substitution, according derivatives were planned as well. 
Based on this information as well as the synthetic access according to literature, the following 
complexes (only Λ-(R)-a isomer shown) were planned to be synthesised and tested for their drug-
like properties (Fig. 60). 
 
 
Fig. 60: Selected complexes to explore the possibility of solubilising side-chains outside of the Pim1 active site. Morpholines as in 
210a and 211a are generally known to enhance solubility by their H-bond capability and the linker ensures an out-of-plane behaviour. 
The α-atom in the pyridine 4-position (N or O) is varied to explore possible interactions in the kinase active site. Complex 212a 
thereby inherits a tertiary N in the β-position, which is supposed to be protonated under physiological conditions. The final complex 
213a is an example for a complex with a pure aliphatic side chain. It should represent the solubility enhancement with pure out-of-
plane behaviour while enhancing the permeability at the same time.  
 
As shown in Fig. 60, a small collection of different complexes was planned. In the first two 
complexes 210a and 211a, a morpholine residues is attached by a linker to the 4-pyridine position. 
Morpholines are generally known to enhance solubility by their H-bond capability and the linker 
ensures an out-of-plane behaviour, where the α-atom (O or secondary N) might be used to add 
favourable interactions in or close to the active site. In complex 212a, the tertiary nitrogen is shifted 
to the β-positon, to test favourable interaction in this position. The nitrogen is expected to be at 
least partially protonated at physiological pH since its pKa in the uncoordinated ligand was 
calculated to be ~8.[312] If unprotonated, the amine will not affect permeability, otherwise it should 
affect solubility in a positive way. The final complex 213a inherits a pure aliphatic side chain, which 
should prove the hypothesis for solubility enhancement by out-of-plane substitution, while 
improving permeability as well.  
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3.4.2.1. In silico investigation of possible solubility and permeability improvement 
To measure an improvement in solubility and permeability, mostly the partition coefficient in 
octanol and water (logP) is used,[313] which is often hard to measure because of the low solubility 
of most compounds in alkane/water.[247] This is also true for metal-based kinase inhibitors. To 
assess the theoretical considerations for improvement of solubility and/or permeability of RR97a 
by structural modification, in silico calculations were performed using the software STARDROP 
(Version 5.5 Build 223) at NIBR. 
 
Table 9: Calculated physicochemical properties for selected complexes which are based on considerations for improvement of the 
solubility and/or permeability of RR97a. 
Complex logS [µM] logS (pH 7.4) [µM] logP logD 
201a (RR97a) 2.8 5.6 0.8 2.0 
210a 3.0 5.8 1.3 2.4 
211a 3.1 5.8 1.1 2.3 
212a 3.2 5.9 1.3 2.1 
213a 2.2 5.2 3.0 2.6 
 
In the program, the logarithm of the intrinsic aqueous solubility S is calculated using a continuous 
model predicting aqueous solubility of a neutral undissociated compound based upon in vitro data. 
The indication pH 7.4 stands for the apparent solubility at the given pH for charged and neutral 
species. The logP (octanol/water coefficient) is as the logS calculated based on a continuous model 
obtained from in vitro data, and the logD equals the logP at pH 7.4 for all species present. 
Based on the obtained data (Table 9), the initial complex 201a has an intrinsic solubility of 631 µM, 
which is very high compared to the measured results of 16 µM in KPi and 29 µM in FaSSIF. All 
newly designed compounds, except for the alkyl derivative 213a, have however higher calculated 
solubilities, as expected. The same holds true for the solubility at pH 7.4, which is calculated to be 
even higher, indicating the presence of charged species. The calculated logP of 0.8 indicates that 
the neutral form of 201a is a 6.3 times more soluble in octanol compared to water, while the 
partition coefficient shows that all available species are 100 time more soluble in octanol. All 
derivatives have therefore a higher lipophilicity in comparison to 201a, represented in higher logPs 
and logDs. The logD value is thereby always higher compared to logD except for 213a, in which 
charged species seem to have a much lower lipophilicity. 
These data again show the low suitability of in silico models for metal-based drugs, but gives us still 
a first impression for the right trend, as anticipated for the planned derivatives. 
Solubility and permeability optimisation 
116 
 
3.4.3. Modifications of the pyridocarbazole ligand – theoretical considerations 
For modifying the drug-like abilities of the complexes, while maintaining or even improving Pim1 
affinity, all previous work described in PhD theses and publications concerning Pim1-inhibition by 
pyridocarbazole-based metal-complexes were screened for possible modifications of the 
pyridocarbazole ligand. The results, including the inhibition properties towards Pim1, either as IC50 
value or as rest activity of the enzyme after treatment with a certain concentration of the inhibitor 
compared to the associated unmodified complex, are summarised in Table 10. The list is ordered 
by increased polarity as expected from the added functional groups. Side chains of other ligands 
e.g. cyclopentadiene, which increase Pim1 affinity, were not considered since they are expected to 
have a quite different orientation compared to the 4-pyridine position in the proline derived ligand, 
as can be seen e.g. in pdb file 2BZJ.[314] 
 
Table 10: Pyridocarbazole-based Pim1 inhibitors which show improved kinase affinity compared to the associated complexes with 
unmodified pyridocarbazoles. Values for inhibition of both the complex and the associated unmodified complex are given. 
Structures are sorted according to expected increased polarity of the pyridocarbazole ligand. 
Complex 
 
214 
 
215 
 
216 
Pim1 rest activity after 
treatment (c) or IC50 
IC50 < 0.3 nM (10 µM 
ATP)[315] 
26% (10 nM) 
(100 µM ATP) [ 202] 
35% (10 nM) 
(100 µM ATP)[202] 
unmodified 
pyridocarbazole 
IC50 = 4 nM (100 µM 
ATP)[204] 
52% (10 nM) 
(100 µM ATP) [ 202] 
52% (10 nM) 
(100 µM ATP)[202] 
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Table 10 (continued): Pyridocarbazole-based Pim1 inhibitors which show improved kinase affinity compared to the associated 
complexes with unmodified pyridocarbazoles. Values for inhibition of both the complex and the associated unmodified complex 
are given. Structures are sorted according to expected increased polarity of the pyridocarbazole ligand. 
Complex 
 
217 
 
218 
 
219 
Pim1 restactivity after 
treatment (c) or IC50 
28% (10 nM) 
(100 µM ATP)[202] 
IC50 = 44 nM 
(100 µM ATP)[316] 
IC50 = 0.6 nM 
(100 µM ATP)[204] 
unmodified 
pyridocarbazole 
52% (10 nM) 
(100 µM ATP)[202] 
IC50 = 58 nM 
(100 µM ATP)[316] 
IC50 = 4 nM 
(100 µM ATP)[204] 
Complex 
 
220 
 
53 
 
76 
Pim1 restactivity after 
treatment (c) or IC50 
8% (10 nM) 
(100 µM ATP)[202] 
IC50 = 0.4 nM 
(100 µM ATP)[204] 
8% (10 nM) 
(100 µM ATP)[202] 
unmodified 
pyridocarbazole 
52% (10 nM) 
(100 µM ATP)[202] 
IC50 = 4 nM 
(100 µM ATP)[204] 
52% (10 nM) 
(100 µM ATP)[202] 
Complex 
 
77 
 
221 
 
222 
Pim1 restactivity after 
treatment (c) or IC50 
8% (10 nM) 
(100 µM ATP)[202] 
IC50 = 4 nM 
(100 µM ATP)[315] 
5% (10 nM) 
(100 µM ATP)[202] 
unmodified 
pyridocarbazole 
52% (10 nM) 
(100 µM ATP)[202] 
IC50 = 20 nM 
(100 µM ATP)[315] 
52% (10 nM) 
(100 µM ATP)[202] 
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Taken from the affinity list, six pyridocarbazoles were selected to be reacted to the corresponding 
rhodium complexes (223-228). These ligands cover a wide range of different functional groups and 
three positions of modification. The most polar ligands were avoided to reduce any further decline 
in permeability. In detail, the 3-methylpyridine derivative (see 214) was considered the most unpolar 
ligand, probably not impairing the permeability any further. The 3-fluoro derivative (see 215) adds 
a small polarity, while the 3-methoxy one (see 217) adds some more polarity and a sole hydrogen 
acceptor. The 5-hydroxy indole derivative (see 53) adds both hydrogen donor and acceptor 
functionality. The 6-methanol pyridine derivative (see 220) should have similar polarity to the 
5-hydroxy indole modification but covers yet another position of derivatisation. This position 
might be interesting towards diastereomeric ratios due to possible steric hindrance while 
coordinating the second ligand. The final ligand (see 76) combines properties of the second and 
fourth, being the most polar of all.  
 
Fig. 61: Selected proposed complexes for improved solubility and affinity, while not impairing permeability to a great extent. The 
structures were handpicked for a broad range of polarity and structural diversity. 
 
Both complexes 224a and 227a, using the pyridocarbazoles taken from he complexes 215 and 76, 
were not synthesised successfully neither in a one pot synthesise nor in the precursor approach. 
Probably the electronical properties of the pyridocarbazoles are so much impaired by the fluoro 
residue that complex formation or “stable” coordination with it is no longer possible or much 
slower compared to the TBS deprotection. 
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3.4.3.1. In silico investigation of possible solubility and permeability improvements 
In addition to the selection via expected affinity improvement, solubility as well as partition and 
distribution coefficients were calculated as described previously using STARDROP for selected 
complexes. 
 
Table 11: Calculated physicochemical properties for selected complexes which are based on the pyridocarbazole modifications 
described above. 
Complex logS [µM] logS (pH 7.4) logP logD 
201a (RR97a) 2.8 5.6 0.8 2.0 
223a 2.7 5.5 1.2 2.1 
225a 2.8 5.9 0.7 2.2 
226a 2.8 5.8 0.4 1.8 
227a*  2.9 5.8 0.5 1.9 
* Calculated for -CH3OH residue in 3- not 2-position, which should result in similar properties. 
 
Generally, the calculations show solubility values in the same range as compared to the results of 
201a. LogP and logD values are similar as well, with a maximum of factor 2 difference in logP and 
for 226a. Based on these results, all proposed complexes seemed still attractive and were taken on 
to a synthetic realisation.  
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3.4.4. Synthetic realisation of structural modifications of 201a and 201b 
3.4.4.1. Modifications of (pyridine-2-ylmethyl)-D-proline in the 4-pyridine position 
The probably most obvious and synthetically easiest way to modify the pyridine at the 4-postion is 
the addition of a suitable leaving group for aromatic nucleophilic substitution in that position. In 
literature, mainly nitro[317] and chloro[317] groups were found for substitution reactions with 
nucleophiles like alcoholates, amines or thiols.[317] The chloride group thereby seems to be more 
versatile concerning nucleophiles, and methyl 4-chloropicolinate (230) appeared to be a good 
starting point to prepare the desired ligands. According to literature,[317] it is easily prepared from 
picolinic acid (228) by dual chlorination with thionyl chloride using DMF as catalyst. However, 
after following the procedure with about one third of the original reaction scale, a methyl 
4-chloropicolinate (229)/methyl picolinate ratio of 1:4 (based on 1H-NMR spectrum) was obtained. 
229 could be isolated by taking the mixture up in a small portion of acetone, adding a layer of 
hexane and incubating at 4 °C for about a week, during which the product crystallises in the hexane 
layer. The crystals were filtered off with an overall yield of 8%.  
 
 
Scheme 10: Synthesis methyl 4-chloropicolinate according to a literature procedure[317] using thionyl chloride and methanol. 
 
Since commercially available 4-chloropicolinic acid 231 is inexpensive, it was decided to perform 
the esterification according to another source of literature[318] which yielded in 87% of the desired 
methyl 4-chloropicolinate 230, starting with 4-chloropicolinic acid. Methyl 4-chloropicolinate was 
further reduced in very good yields using sodium borohydride according to a literature 
procedure[317] to yield the hydroxy group (232, Scheme 11) required for a subsequent FINKELSTEIN 
reaction. 
 
 
Scheme 11: Synthesis of (4-chloropyridine-2-yl) methanol starting from 4-chloropicolinate. The starting material was esterified 
using thionyl chloride and MeOH[318] and further reduced using sodium borohydride[317] according to literature procedures.  
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3.4.4.1.1. Synthesis of ((4-chloropyridine-2-yl)methyl)-D-proline 
Since the 4-chloro modified pyridine-2-yl methanol was now available, the 4-chloro modified 
derivative of the original proline derived ligand 206 was synthesised in addition to the planned 
ligands and complexes to investigate whether a change in polarity and/or possible formation of 
halogen-bridges might influence binding to the kinase active site, as well as solubility and 
permeability. Interestingly, chloride groups are hydrophobic and therefore associated with a 
reduction in solubility, but in a significant number of examples in small molecules, the addition of 
a F, Cl, CF3 or even CH3 group leads to an improvement in solubility.
[309] So the chance to improve 
either solubility or permeability by adding a chloride group seemed quite promising. 
The synthesis was partially performed by JOHANNA PLAG during her internship,[319] according to a 
modified procedure of the original ligand, as reported by STEFAN MOLLIN.[298] The hydroxy group 
of  (4-chloropyridine-2-yl) methanol (232) was first chlorinated using thionyl chloride and the 
resulting HCl salt 233 was directly further converted with D-proline methyl ester (234) in a 
FINKELSTEIN reaction (Scheme 12). The obtained methyl ((4-chloropyridine-2-yl)methyl)-D-
prolinate (40% yield over 2 steps) was further reacted by a simple basic ester hydrolysis using 
sodium hydroxide to obtain the desired ligand 236 in 63% yield. 
 
 
Scheme 12: Synthesis of ((4-chloropyridine-2-yl)methyl)-D-proline after a modified literature procedure.[298] First the alcohol was 
chlorinated using thionyl chloride and further converted using a FINKELSTEIN reaction. The final ligand was obtained by basic ester 
cleavage. 
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3.4.4.1.2. Synthesis of ((4-(3-morpholinopropoxy)pyridine-2-yl)methyl)-D-proline and ((4-
((3-morpholinopropyl)amino)pyridine-2-yl)- D-proline 
 
3.4.4.1.2.1. Synthesis of (4-((3-morpholinopropyl)amino)pyridine-2-yl)methanol 
For ligands containing solubilising morpholine-based out-of-plane appendages, nucleophilic 
reactions were planned using 232, for both introducing an hydroxy group or amine in the 4-pyridine 
position. To introduce a structurally complex N-nucleophile, different reaction conditions can be 
found in literature, including the use of N,N-diisopropylethylamine (DIPEA, HÜNIG's base) as 
base in toluene[320] or a simple neat reaction e.g. with pyrrolidine as nucleophile.[317]  
Both conditions were used to introduce N-(3-aminopropyl)-morpholine to the (4-chloropyridine-
2-yl) methanol in para-position (Scheme 13). In the first reaction, the resulting product could not 
be isolated from the HÜNIG's base, its salts or other impurities using flash column chromatography 
or different extraction methods. Any further reaction towards the final ligand yielded in no product. 
For the second reaction conditions, JOHANNA PLAG was able to show during her internship[319] that 
the desired (4-((3-morpholinopropyl)amino)pyridine-2-yl)methanol (238) was formed under neat 
reaction conditions as proven via HRMS and 1H-NMR. However, it was found to be inseparable 
from the starting material 237 by silica flash column chromatography with a CH2Cl2/MeOH 
gradient or reversed phase HPLC (C18 CH3CN/H2O 1:1, 0.5% TFA). 
 
 
Scheme 13: Reaction conditions, based on a modified literature methods[317,320] to synthesise (4-((3-
morpholinopropyl)amino)pyridine-2-yl)methanol. 
 
Using the same reaction conditions, JOHANNA tried to isolate 238 by distilling the starting material 
237 of (boiling point of 224 °C according to the supplier’s information). However, even under fine 
vacuum 238 would decompose (at around 180 °C) before the starting material starts to evaporate. 
The logical consequence seemed to consume all leftover 237 to get a pure product. However, even 
when reacting 232/237 in a 3:1 mixture, the morpholine was not fully converted. Therefore, the 
introduction of various protecting groups was pursued, to influence the retention factors of both 
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starting materials, to enhance chromatographical work-up. These included a TBS group for the 
hydroxy group of 238 (using TBSCl, imidazole, I2), an acetyl group to both the primary and 
secondary amine in all species (using Ac2O and 18-crown-6 for selectivity over the alcohol), a Boc 
group to the secondary amine (using Boc2O and 4-DMAP) or a Cbz group to protect the primary 
amine (using CbzCl and NaH). All reactions were monitored by TLC analysis for conversion and 
a change of the Rf values of the starting materials and products. For both, the TBS and acetyl 
protection groups no change in Rf values was observed in the most polar combination 
CH2Cl2/MeOH 10:1, so that these groups were excluded. With the Boc group, a single protection 
of the starting material and a double protection of the product was achieved, accomplishing a 
change in Rf values. However, separation on silica using silica flash chromatography with a 
CH2Cl2/MeOH gradient was not possible. The same holds true for the Cbz protection group, 
where both starting material and product were protected. Since all these affords did not succeed in 
obtaining 238 in a pure fashion, the product and therefore ligand and final complex 211 were not 
further pursued. 
 
3.4.4.1.2.2. Synthesis of (4-(3-morpholinopropoxy)pyridine-2-yl)methanol 
Similar effort as for (4-((3-morpholinopropyl)amino)pyridine-2-yl)methanol was invested into the 
synthesis of (4-(3-morpholinopropoxy)pyridine-2-yl)methanol by JOHANNA,[319] successfully.  
 
Scheme 14: Reaction conditions derived from modified literature methods[321] to synthesise (4-((3-
morpholinopropyl)amino)pyridine-2-yl)methanol. 
 
The best procedure was modified from a literature known nucleophilic aromatic substitution[321] 
using NaH to first prepare sodium 3-morpholinopropan-1-olate before adding 232 at low 
temperatures (0 °C). After reacting further at 100 °C for 16 h, 240 was isolated by doubly silica 
flash chromatography (5 g/3 g silica, CH2Cl2 to CH2Cl2/MeOH 10:1) with a yield of 23%. 
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3.4.4.1.3. Synthesis of ((4-(3-morpholinopropoxy)pyridine-2-yl)methyl)-D-proline 
The final ligand ((4-(3-morpholinopropoxy)pyridine-2-yl)methyl)-D-proline (243) was prepared 
analogous to the previously described ligand by chlorination of the hydroxy group, a subsequent 
FINKELSTEIN reaction with D-proline methyl ester (234, 38% over both steps) and basic ester 
hydrolysis (95%) using aqueous sodium hydroxide (Scheme 15). 
 
Scheme 15: Synthesis of ((4-(3-morpholinopropoxy)pyridine-2-yl)methyl)-D-proline after a modified literature procedure.[298] First 
the hydroxy group was chlorinated using thionyl chloride and further converted with methyl-D-prolinate using a FINKELSTEIN 
reaction. The final ligand was obtained by basic ester cleavage. 
 
3.4.4.1.4. Synthesis of ((4-((dimethylamino)methyl)pyridine-2-yl)methyl)-D-proline 
The synthesis of the dimethylamino-ligand was performed by HENRIK LÖW and JOHANNA PLAG 
during their internships in the group.[319,322] They both started with a radical hydroxymethylation of 
4-cyanopyridine (244) to 2-hydroxymethyl-4-cyanopyridine (245) according to a reported 
procedure (Scheme 16).[323] Mechanistically, this is a radical substitution where a nucleophilic 
hydroxymethyl radical is added to the heterocycle.[323,324] The lower yield (20%) in comparison to 
the literature (28%) can be explained by aged starting materials. However, the yield was still much 
better in comparison to a radical hydroxymethylation using ammonium persulfate and methanol in 
aqueous sulphuric acid (6% as determined by HENRIK LÖW).[325] 
 
Scheme 16: Radical hydroxymethylation of 4-cyanopyridine using HOSA and Fe(II) in H2SO4 as catalyst. 
 
The cyanopyridine 245 was further reduced using hydrogen and Pd on carbon (10%) in acetic acid 
(Scheme 17).[326] Based on contained acetic acid in the raw 1H-NMR spectrum with an unknown 
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stoichiometry to the product (probably due to salt formation), the (aminomethyl)pyridine 246 was 
directly used for the next step without further purification. N-alkylation using paraformaldehyde 
in formic acid in a microwave mediated reaction, according to a modified literature procedure,[327] 
resulted in 28% of 247 as a yellow oil. Cleaner reaction paths, like reduction of 245 with lithium 
aluminium hydride in THF,[325] did not lead to any yield in the reaction, based on the need for 
aqueous work-up and a high solubility of 246in water, from which the product cannot be extracted 
or isolated.  
 
Scheme 17: Synthesis of 2-hydroxymethyl-4-((dimethylamino)methyl)pyridine from 2-hydroxymethyl-4-cyanopyridine by 
reduction using H2 and 10% Pd/C and subsequent N-alkylation using paraformaldehyde in a microwave (MW) mediated 
synthesis. 
 
The final ligand ((4-((dimethylamino)methyl)pyridine-2-yl)methyl)-D-proline (250) was prepared 
analogously to the previously described ligands by chlorination of the hydroxy group (50%), a 
subsequent FINKELSTEIN reaction with D-proline methylester (234, 11%) and basic ester hydrolysis 
(65%) using aqueous sodium hydroxide (Scheme 18). 
 
Scheme 18: Synthesis of ((4-((dimethylamino)methyl)pyridine-2-yl)methyl)-D-proline after a modified literature procedure.[298] First 
the hydroxy group was chlorinated using thionyl chloride and further converted using a FINKELSTEIN reaction. The final ligand was 
obtained by basic ester cleavage. 
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3.4.4.1.5. Synthesis of methyl ((4-hexylpyridine-2-yl) methyl)-D-proline 
To explore the possibilities of a pure aliphatic side chain, a modified ligand was synthesised by 
MATTHIAS TRIPP during his bachelor thesis.[328] Originally starting from 4-picoline (251), he was 
able to synthesis and 4-hexylpyridine (87%, Scheme 19) according to a modified literature synthesis 
using lithium diisopropylamine to deprotonate 4-picoline and the according iodoalkane in a SN2 
reaction.[329]  
 
Scheme 19: Synthesis of  4-hexylpyridine using a literature derived SN2 reaction[329] was performed by MATTHIAS TRIPP during his 
bachelor thesis.[328]  
 
The 4-alkylpyridine 252 was further converted to the N-oxide using hydrogen peroxide according 
to literature procedures (Scheme 20).[330] A subsequent 2-hydroxymethylation was conducted using 
trimethyloxonium tetrafluoroborate and ammonium persulfate in methanol.[331] Mechanistically, it 
is thought that (CH3)3OBF4 methylates the oxygen of the N-oxide, while the persulfate is 
homolytically cleaved in the heat resulting in a radical which reacts with the solvent and forms a 
methanol radical. These methanol radicals might then react with the pyridines and are directed into 
ortho position, based on the electron donating methoxy group. The radical from the resulting 
compound is finally passed on to another methanol molecule in the solvent, after cleavage of the 
N-methanol group or by directly cleaving a methanol radical from the pyridine nitrogen. The 
hydroxymethylated product, in which the pyridine nitrogen is no longer oxidised, is thereby less 
reactive compared to the starting material, making a follow up reaction improbable.[331] 
 
 
Scheme 20: N-oxidation using hydrogen peroxide[330] and subsequent 2-hydroxymethylation of 4-hexylpyridine according to a 
literature described radical reaction mechanism[331] was performed by MATTHIAS TRIPP.[328] 
 
This reaction however resulted (4-hexylpyridine-2yl)-methanol (254) only in a low yield of 18% 
over both steps (Scheme 20).  
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The final ligand, methyl ((4-hexylpyridine-2-yl)methyl)-D-proline (257), was prepared according to 
a modified literature procedure (Scheme 21).[332] Analogous to the previously described ligands, first 
the hydroxy group was chlorinated (50%), followed by a FINKELSTEIN reaction with D-proline 
methylester (74%) and basic ester hydrolysis (73%) using aqueous sodium hydroxide to get to the 
final ligand (Scheme 21) in 11% yield over six steps.[328] 
 
Scheme 21: Synthesis of methyl ((4-hexylpyridine-2-yl) methyl)-D-proline after a modified literature procedure.
[332]
 First the 
hydroxy group was chlorinated using thionyl chloride and further converted using a FINKELSTEIN reaction. The final ligand was 
obtained by basic ester cleavage. 
 
The final ligand however contained some ethanol, which could not be removed by extensive drying, 
the yield is hence based on the ethanol free ligand according to 1H-NMR.[328] As the following 
complex reactions were conducted in a mixture of EtOH/H2O 1:1, this posed however no 
problem. 
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3.4.4.2. Complex synthesis with modified (pyridine-2-ylmethyl)-D-proline ligands 
 
3.4.4.2.1. Synthesis of the 4-chloro pyridine modified complexes 
The 4-chloro modified complexes 258a and 258b were obtained using the standard reaction 
procedure reported by RAJATHEES RAJARATNAM (Scheme 22).[233] One equivalent of the TBS-
protected pyridocarbazole (105) was reacted with one equivalent of RhCl3  in EtOH/H2O 1:1 for 
90 min at 90 °C before the 4-chloro modified ligand 236 was added and the mixture further reacted 
for 16 h at 90 °C to yield the final complexes in 6% (a isomer) and 7% (b isomer) yield after 
separation and purification using silica flash chromatography. 
 
Scheme 22: Reaction conditions of the synthesis of the 4-chloro derivatives of RR97a and RR97b. 
 
Both complexes however have not been isolated in a pure fashion using the reaction conditions 
and standard purification procedures (double flash chromatography for each isomer) given, with 
impurities in both the aliphatic and aromatic regions of the 1H-NMR spectra. Since the main 
products were the complexes, both were carried to the drug-like abilities and kinase inhibition 
assays anyway, to get a first impression of their properties since all drug-like abilities assays were 
“normalised” to a pure sample as described in the experimental section. 
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3.4.4.2.2. Synthesis of 4-(3-morpholinopropan-1-ol) pyridine derivatised complexes 
The 4-(3-morpholinopropan-1-ol) modified complex were obtained using the standard reaction 
procedure (Scheme 23).[233] Briefly, one equivalent of TBS-protected pyridocarbazole (105) was 
reacted with one equivalent of RhCl3 in EtOH/H2O 1:1 for 90 min at 90 °C before the modified 
ligand 243 was added and the mixture further reacted for 16 h at 90 °C. The diastereomers were 
separated and purified using silica flash chromatography obtaining 14% (a, cis-isomer) and 26% (b, 
trans-isomer) as deep red solids.  
 
Scheme 23: Reaction conditions of the synthesis of the 4-(3-morpholinopropan-1-ol) pyridine derivatives of RR97a and RR97b. 
 
3.4.4.2.3. Synthesis of the 4-((dimethylamino)methyl) pyridine derivatised complexes 
The 4-((dimethylamino)methyl) pyridine derivatives of the complexes were obtained using the 
standard reaction procedure reported.[233] One equivalent of the TBS-protected pyridocarbazole 
(105) was reacted with one equivalent of RhCl3 in EtOH/H2O 1:1 for 90 min at 90 °C before the 
modified ligand 250 was added and the mixture further reacted for 24 h at 90 °C to yield the final 
complexes in 9% (212a) and 14% (212b) yield (Scheme 24) after separation and purification using 
silica flash chromatography. 
 
Scheme 24: Reaction conditions of the synthesis of the 4-((dimethylamino)methyl) pyridine derivatives of RR97a and RR97b. 
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3.4.4.2.4. Synthesis of the 4-hexyl pyridine derivatised complexes 
The 4-hexyl pyridine derivatives of the complexes were obtained using the standard reaction 
procedure reported (Scheme 25).[233] Briefly, 1.0 eq of TBS-protected pyridocarbazole (105) was 
reacted with 1.0 eq of RhCl3 in EtOH/H2O 1:1 for 90 min at 90 °C under stirring before 1.1 
equivalents of the modified ligand 257 were added in the one-pot synthesis and the mixture further 
reacted for 24 h at 90 °C. The diastereomers were separated and purified using silica flash 
chromatography, obtaining 9% (a, trans-isomer) and 30% (b, cis-isomer).  
 
Scheme 25: Reaction conditions of the synthesis of the 4-hexyl pyridine derivatives of RR97a and RR97b. 
 
3.4.4.3. Complex synthesis with modified pyridocarbazole ligands 
3.4.4.3.1. Synthesis of 5-methylpyridine derivatised complexes 
Pyridocarbazole 259 was synthesised by HENRIK LÖW during his internship in the group according 
to a modified procedure by STEFAN MOLLIN.[296,322] Taking the pyridocarbazole, 223a and 223b 
were synthesised using slight variations of the previously described one-pot synthesis (Scheme 
26).[233] Briefly, one equivalent of 259 and RhCl3 each were reacted under stirring for 90 min at 
95 °C in 1:1 EtOH/H2O. Ligand 206 was added and the reaction mixture further stirred for 16 h 
at 90 °C. The diastereomers were separated and purified using silica flash chromatography 
obtaining 8% of 223a and 13% of 223b in a slightly impure form.  
 
Scheme 26: Reaction conditions of the synthesis of the 5-methylpyridine derivatives of RR97a and RR97b. 
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3.4.4.3.2. Synthesis of 5-methoxypyridine derivatised complex 
Pyridocarbazole 260 was prepared by KATJA KRÄLING. When reacting the pyridocarbazole in the 
classical one-pot synthesis, many side-products were formed and a separation via flash 
chromatography was not possible for 225a. Even separation on preparative TLC did not yield pure 
complex, due to at least 10 different smearing species. Therefore, the complex 225a was synthesised 
using the precursor approach described earlier (Scheme 27). Briefly, one equivalent of 206 and 
RhCl3 each were stirred in 1:1 CH3CN/H2O for 3 h at 90 °C. The solvent was removed and the 
crude precursor was further reacted with 260 in 1:1 EtOH/H2O for 40 h at 95 °C under stirring. 
After purification using silica flash chromatography 9% of 225a were obtained. 225b was obtained 
as a 3:1 mixture with the precursor or a similar species in < 5% yield. 225b could however obtained 
in a clean fashion from the previously mentioned one-pot reaction in a yield of 18% as described 
in the experimental section. 
 
Scheme 27: Reaction conditions of the synthesis of the 5-methoxypyridine derivatives of RR97a and RR97b. 
 
The complex was additionally successfully crystallised and the first crystal structure for an Λ-(R)-a 
isomer could be obtained. Single crystals suitable for X-ray analysis were obtained by slow 
evaporation of CH2Cl2 from a DMSO/ CH2Cl2 solution. The intensity data of the single crystals 
were collected at 100 K using a Bruker D8 Quest system. The data were corrected for absorption 
effects using multi-scanned reflections.[214] The structure was solved using direct methods 
(SHELXS-97)[215] and refined using full matrix least squares procedure (SHELXL-2013). Hydrogen 
atoms were included at calculated positions. All measurement and structure determination was 
performed by KLAUS HARMS from the central crystal structure analysis department at the Philipps-
Universität Marburg. 
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Fig. 62: Crystal structure of Λ-(R)-225a revealing the metal-centred chirality. ORTEP drawing with 50% probability thermal 
ellipsoids. Solvent is omitted for clarity. 
 
3.4.4.3.3. Synthesis of indole-5-ol derivatised complex 
Pyridocarbazole 208 was synthesised by BENEDIKT HEINRICH during his internship in the group 
according to a modified procedure by DOUG WILLIAMS.[265,297] Taking the pyridocarbazole, 226a 
and 226b were synthesised using slight variations of the previously described one-pot synthesis 
(Scheme 26).[233] Briefly, one equivalent of 208 and RhCl3 each were reacted under stirring for 
90 min at 93 °C in 1:1 EtOH/H2O. Ligand 206 was added and the mixture further stirred for 16 h 
at 93 °C. The diastereomers were separated, combined with some complex obtained using the 
precursor approach and purified using silica flash chromatography obtaining 7% (based on the 
amount of starting material for both reactions) of 226a in a pure fashion and 6% of 226b with 
roughly 30% impurity from the precursor approach.  
 
Scheme 28: Reaction conditions of the synthesis of the indole-5-ol derivatives of RR97a and RR97b. 
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3.4.4.3.4. Synthesis of pyridine-6-yl methanol derivatised complex 
Pyridocarbazole 261 was synthesised by BENEDIKT HEINRICH during his internship in the group 
according to a modified procedure by NICHOLAS PAGANO.[202,297] Taking the pyridocarbazole 261, 
226a and 226b were synthesised using slight variations of the previously described one-pot 
synthesis reported by RAJATHEES RAJARATNAM (Scheme 29).[233] Briefly, one equivalent of 261 and 
RhCl3 each were reacted under stirring for 135 min at 92 °C in 1:1 EtOH/H2O. Ligand 206 was 
added and the reaction mixture further stirred for 16 h at 93 °C. The diastereomers were separated 
and purified using silica flash chromatography obtaining 7% of 226a and 5% of 226b in a slightly 
impure form. The diastereomeric ratio thereby indeed shows that a sterical hindrance leads to a 
lower yield of the b isomer, as expected. In the a isomer, the smaller chloride ligand seems 
favourable for that position. 
 
Scheme 29: Reaction conditions of the synthesis of the pyridine-6-yl methanol derivatives of RR97a and RR97b. 
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3.4.5. Drug-like properties of (4-pyridine-2-ylmethyl)-D-proline derivatives 
The drug-like properties of all derivatives were tested at NIBR using the afore mentioned assay 
conditions for solubility and rat liver microsome stability to compare the data to the original 
complexes RR97a and RR97b. To determine the permeability a MDCK cell line was used instead 
of the Caco-2 cell line, based on the easier model. 
 
3.4.5.1. Drug-like properties of trans-isomers (a isomers) 
The determined in vitro drug-like abilities of all newly synthesised trans-isomers, based on 
pyridocarbazole modifications, are summarised in Table 12. 
 
Table 12: Drug-like properties of (4-pyridine-2-ylmethyl)-D-proline derivatives of RR97a. 
 
The solubility of 258a and 213a is not improved c.f. the original compound 201. For both the 4-
(3-morpholinopropan-1-ol) as the (dimethylamino)methyl derivative the solubility is highly 
elevated at pH 4, indicating a protonation of the tertiary amine. Sadly, at physiologically pH the 
amines seem not to be protonated, as it was assumed for the dimethylamine derivative. The 
 
 
 
 
 
 
 
 
 
258a 
 
 
210a 
 
 
213a 
 
 
 
212a 
HT-solubility 
KPi (pH 6.8) 
KPi (pH 4.0) 
FaSSIF 
 
17 µM 
23 µM 
45 µM 
 
86 µM 
713 µM 
70 µM 
 
6 µM 
10 µM 
10 µM 
 
43 µM 
381 µM 
38 µM 
RLM- stability 
Clint 
ERh 
 
<25 µl/min/mg 
<50% 
 
125 µl/min/mg 
79% 
 
138 µl/min/mg 
82% 
 
<25 µl/min/mg 
<50% 
MDCK-
permeability 
Papp A-B 
calc. FA    
 
0.77 x10-6 cm/s 
<40% 
 
- 
- 
 
- 
- 
 
- 
- 
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solubility of 210a is the most elevated in the series both in FaSSIF and KPi and the most soluble 
derivative in KPi at pH 6.8 while it is worse than the later discussed 209a in FaSSIF. For both 
tertiary amine containing compounds no improvement of solubility in FaSSIF buffer compared to 
KPi was observable. The microsome stability is good for 258a and 212a, while it is medium for the 
other two compounds, probably related to the easier access of the CYP enzymes to the elevated 
side chains. Permeability of all compounds is really low with amounts which were not even 
quantifiable by LC-MS/MS for all compounds except 258a. 
 
3.4.5.2. Drug-like properties of cis-isomers (b isomers) 
The determined in vitro drug-like abilities of all newly synthesised cis-isomers, based on 
pyridocarbazole modifications, are summarised in Table 13. 
 
Table 13: Drug-like properties of (4-pyridine-2-ylmethyl)-D-proline derivatives of 201b. 
 
The cis-derivatives show the same trend in solubility as the trans-derivatives with the same 
modifications, except that the FaSSIF solubility of 210b and 212b are more obviously below that 
 
 
 
 
 
 
 
 
 
258b 
 
 
210b 
 
 
213b 
 
 
 
212b 
HT-solubility 
KPi (pH 6.8) 
KPi (pH 4.0) 
FaSSIF 
 
4 µM 
10 µM 
7 µM 
 
65 µM 
149 µM 
8 µM 
 
<4 µM 
<4 µM 
<4 µM 
 
42 µM 
140 µM 
23 µM 
RLM- stability 
Clint 
ERh 
 
<25 µl/min/mg 
<50% 
 
<25 µl/min/mg 
<50% 
 
82 µl/min/mg 
73% 
 
<25 µl/min/mg 
<50% 
MDCK-
permeability 
Papp A-B 
calc. FA    
 
1.17 x10-6 cm/s 
<40% 
 
0.75 x10-6 cm/s 
<40% 
 
<1.5 x10-6 cm/s 
<40% 
 
0.59 x10-6 cm/s 
<40% 
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of their KPi solubility. Microsome stability is good for 210b, 212b and 258b, and medium for 213b, 
which is in accordance with expectations as it is predicted, that the hexyl side chain is easily oxidised 
by CYP enzymes. The permeability is again very low, showing that no derivatisation at all which 
was tested in this study helped to raise permeability. 
 
3.4.6. Drug-like properties of pyridocarbazole derivatives 
3.4.6.1. Drug-like properties of trans-isomers (a isomers) 
The determined in vitro drug-like abilities of all newly synthesised trans-isomers, based on 
pyridocarbazole modifications, are summarised in Table 14. 
Table 14: Drug-like properties of pyridocarbazole derivatives of RR97a. 
 
According to Table 14 the solubility is not significantly improved for 223a and 226a but clearly 
improved with factor >6 both in KPi and FaSSIF for 209a. However, this improvement comes 
with decreased metabolic stability. Stability values for 225a and 226a are very good, while 223a 
possesses a high risk of having exposure problems due to high metabolic conversion. All 
compounds still have very low permeability. Overall metabolic stability and solubility seem to be 
tuneable by modifying the pyridocarbazole, while the permeability stays low. 
 
 
 
 
 
 
 
 
223a 
 
 
225a 
 
 
226a 
 
 
209a 
HT-solubility 
KPi (pH 6.8) 
KPi (pH 4.0) 
FaSSIF 
 
15 µM 
23 µM 
27 µM 
 
< 4 µM 
6 µM 
<4 µM 
 
9 µM 
15 µM 
24 µM 
 
72 µM 
167 µM 
164 µM 
RLM- stability 
Clint 
ERh 
 
159 µl/min/mg 
84% 
 
<25 µl/min/mg 
<50% 
 
<25 µl/min/mg 
<50% 
 
114 µl/min/mg 
79% 
MDCK-
permeability 
Papp A-B 
calc. FA    
 
<1.5 x10-6 cm/s 
<40% 
 
1.07 x10-6 cm/s 
<40% 
 
1.28 x10-6 cm/s 
<40% 
 
1.32 x10-6 cm/s 
<40% 
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3.4.6.2. Drug-like properties of cis-isomers (b isomers) 
The determined in vitro drug-like abilities of all newly synthesised cis-isomers, based on 
pyridocarbazole modifications, are summarised in Table 15. 
 
Table 15: Drug-like properties of pyridocarbazole derivatives of RR97b. 
 
For solubility, the same trends as for the trans-isomers is valid with a less obvious result in KPi 
buffer (pH 6.8) for 209b. Metabolic stability shows a high metabolic risk for 226b and low risks 
for the other compounds. This result is especially appealing as 226a shows a very high metabolic 
stability and 209a a medium stability. This indicates that the stereoinformation of the complexes 
might be important for binding to the CYP enzyme and making a transformation somewhere at 
the complex possible only in a certain orientation. Since 209b and 226b incorporate hydroxy 
groups at the opposite sides of the pyridocarbazole, and these are probably the enzymatically labile 
groups as indicated earlier,[122] this information might help to prevent the design of metabolically 
labile compounds for certain isomers.  For permeability, all compounds display very low 
permeability in MDCK cells with 226b showing such a low amount that quantification was not 
even possible. 
 
 
 
 
 
 
 
 
223b 
 
 
225b 
 
 
226b 
 
 
209b 
HT-solubility 
KPi (pH 6.8) 
KPi (pH 4.0) 
FaSSIF 
 
36 µM 
62 µM 
19 µM 
 
9 µM 
32 µM 
8 µM 
 
24 µM 
59 µM 
44 µM 
 
7 µM 
132 µM 
155 µM 
RLM-  
stability 
Clint 
ERh 
 
35 µl/min/mg 
54% 
 
30 µl/min/mg 
50% 
 
183 µl/min/mg 
86% 
 
<25 µl/min/mg 
<50% 
MDCK-
permeability 
Papp A-B 
calc. FA    
 
1.11 x10-6 cm/s 
<40% 
 
1.31 x10-6 cm/s 
<40% 
 
- 
- 
 
1.25 x10-6 cm/s 
<40% 
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3.4.7. Kinase inhibition properties of derivatives 
To further verify and test whether the addition of functional groups to both, the pyridocarbazole 
or the para-position of the pyridine belonging to the proline derived ligand, changes the inhibitory 
properties towards Pim1, all trans-isomers were tested in a two concentration setting towards Pim1 
using the commercially available ATP-GloTM assay. The kit was previously tested towards its 
suitability using the compounds RR97a (201a) and RR97b (201b), as well as an ADP/ATP 
calibration curve, and showed decent results, with up to 4-fold deviation in IC50 from results 
obtained by radioactive assays. The Pim1 activity is low in the assay conditions used and would 
need further optimisation for more accurate tests and further experiments. The assay conditions 
were required due to concentration limits of the buffer ingredients by the assay provider. Activity 
of Pim1 in the assay seemed to have even worsened probably due to long storage times of the 
enzyme (Pim1 can e.g. undergo autophosphorylation)[17] and assay kit. Therefore, about three times 
the amount of protein was used in the assay compared to the original IC50 determination. 
In the assay setting derivatives were tested at 50 nM and 1 µM for their Pim1 inhibition, since the 
previous IC50 for RR97a in this assay was determined to be 50-60 nM. Three controls were 
introduced in quadruplicate, in which ingredients were replaced by the according buffer or solvent, 
including control 1 (without inhibitor) which represents 100% activity, control 2 (without inhibitor 
and without enzyme) which was used for background correction and control 3 (using the inactive 
isomer of the 4-hexylpyridine derivative without enzyme) to test possible self-luminescence of the 
complex. The obtained results are shown in Fig. 63. 
 
 
Fig. 63: Inhibition of Pim1 expressed as enzyme restactivity after treatment with the synthesised derivatives of RR97a (201a). 
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Taken from the results obtained, there was little inhibition of Pim1 by all complexes, including 
121a, at 50 nM. This result might be a consequence of the high amount of Pim1 used, so that the 
effective concentration of the inhibitor compared to Pim1 was lower in this assay in comparison 
to the previously performed one. However, in the inhibition at 1 µM an obvious trend can be 
observed, with control 213b showing similar values to the background, indicating little to no 
interference of the compound with the assay. While all derivatives containing a modified 
pyridocarbazole showed obvious inhibition with 226a being the most effective and 223a the worst 
inhibitor, all derivatives containing derivatisation at the pyridine show little to no inhibition. Since 
the assay was only performed once, this result represents just a trend and no absolute numbers. 
However, it seems that derivatisation at the given pyridine position might lead to a decline in 
inhibition properties. A further determination of IC50 values towards Pim1 is required to verify 
these results and show how much the inhibition properties are impaired. A co-crystal structure of 
201a or one of the derivatives might help to find better substituents and maybe positions to modify 
the complex further. 
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3.5. Gold-based HDAC inhibitors as potential anticancer drugs 
As a side project in this thesis, the HDAC inhibitory properties of the gold(III) compound 
[Au2(µ-O)2(6,6’-(CH3)2bpy2](PF6)2 (262 Fig. 64) was investigated, since HDACs are another 
attractive cancer target as described in the introduction. All experiments in this chapter were 
conducted in Angela Casinis laboratory at the Rijksuniversiteit Groningen.  
The compound 262 belongs to a class of µ-oxo-bridged dinuclear gold(III) compounds with 
different bipyridine derived ligands, which were developed and reported as antiproliferative 
compounds over the last decade.[333,334] Complex 262 has previously been suggested to have a 
“DNA-independent” mechanism, different from that of platinum drugs, with promising 
antiproliferative properties and a high score of selectivity.[334] A compare analysis of the 
antiproliferative properties of this compound against 36 human cell lines to approximately 110 
reference compounds with a known mechanism of action revealed that it might be a HDI,[334] since 
it showed striking similarities to various HDIs, i.e. ρ = 0.72 for both the benzamide acetyldinaline 
and the cyclic peptide apicidin and a ρ-value of 0.61 for suberic bishydroxamate on the IC70 level. 
The ρ-values are thereby SPEARMAN correlation coefficients. High correlations (> 0.6) between the 
sensitivity patterns of two compounds indicate a similar mechanism of action.[334,335] 
 
3.5.1. Toxicity evaluation 
3.5.1.1. In vitro cytotoxicity in cancer cell lines 
To verify the compounds antiproliferative behaviour, first 262, as well as other compounds 
including the structural analogues including [Au2(µ-O)2(NᴖN)2](2PF6)2 with NᴖN=bipyridine (bpy) 
(263), 6-methyl-2,2’-bipyridine (bpyMe) (264) and 6-ethyl-2,2’-bipyridine (bpyEt) (265) and other 
gold(III)-complexes like [Au(bnpy)](Cl)2 (bnpy = 2-benzylpyridine) (266) and 
[Au(bpydmb)(OH)](PF6) (bpy
dmb=6-(1,1-dimethylbenzyl)-2,2’-bipyridine) (267), were tested in the 
human lung carcinoma cell line A549, which has been used previously to investigate the cytotoxicity 
of metal-containing HDAC-inhibitors,[172,183] using the MTT standard method II. 
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Fig. 64: Structures of gold-complexes studied for their antiproliferative properties. Some were further investigated towards their 
HDAC inhibition properties. 
 
Indeed, compound 262 showed superior antiproliferative behaviour (IC50 = 1.2 ± 0.2 µM) 
compared to the other five compounds after treatment for 72 h (Table 16). Further comparison of 
its cytotoxicity to its most related structural analogue (264) in A2780 human ovarian carcinoma and 
the p53+/+ human colorectal carcinoma cell line HCT116++ yielded similarly good results (Table 
16). 
 
Table 16: Overview of the antiproliferative properties for compounds 262-267 obtained via the MTT method after treatment for 
72 h in the human lung carcinoma cell line A549, the human ovarian carcinoma cell line A2780 and the p53+/+ human colorectal 
carcinoma cell line HCT116++. As can be seen compound 262 is superior compared for all other compounds tested and in all cell 
lines tested. 
Compound A549 [µM] A2780 [µM] HCT116++ [µM] 
262       1.2 ± 0.2* 0.8 ± 0.1# 1.3# 
263 > 50# - - 
264     22.8 ± 1.0* 6.4 ± 0.2* 44.3 ±1.7# 
265     10.7 ± 1.8# - - 
266       9.5 ± 1.8# - - 
267 > 50# - - 
* 8000 cells/well; # 10000 cells per well 
 
Interestingly, 262 has been reported to show antiproliferative activity comparable to cisplatin 
(IC50 ~ 2 µM) in A2780 cells, with being five times more active in the cisplatin resistant analogue, 
and an order of magnitude more effective in comparison to similar compounds.[333,336] The much 
higher potency of 262 compared to compounds 263-267 was confirmed, with 262 being even 2.5 
times more effective in A2780 cells in comparison to the previous study.  
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The type of gold-compounds used in this study are thought to be prodrugs with their biological 
activities based on gold coordination to biomolecules, or on redox reactions and consequent 
oxidative damage.[336] It is well established, that these compounds are generally stable against 
dissociation in aqueous solution, but are reduced and activated by ascorbic acid, glutathione, human 
serum albumin (hSA) and cytochrome c (cyt c).[333,337] It has been suggested that by reduction, the 
dinuclear gold(III) compounds break down and release their bipyridyl ligands and possibly naked 
gold(I) ions. These ions form adducts with proteins, as it has been shown by ICP measurements 
and by the ESI-MS features of gold(III)-treated cyt c.[333] This type of interaction seems also to hold 
true for bigger target proteins.[338] While the compounds generally bind to proteins, a similar 
reaction with calf-thymus DNA has only been shown for compound 262 as confirmed by 
spectroscopic and analytical determinations including inductively coupled plasma optical emission 
spectroscopy (ICP-OES), where more than 80% of total gold from 262 was found associated with 
DNA. 263 on the other hand did not bind to DNA.[333] Compound 262 generally deviates most 
from similar derivatives, not only concerning antiproliferative behaviour, but also in terms of 
structural features, thermal stability, and redox properties,[337] related to a small but significant 
modification in the Au2O2 core and higher oxidising character.
[334,337] Reduction by hSA and cyt c 
of 262 for example is about five times faster than reduction of 263.[333] In the previously mentioned 
36 cell line study 262, the compound with the highest redox potential, was also ranked top on the 
basis of tumour selectivity and antitumor potency[334]  
 
3.5.1.2. Ex vivo hepatotoxicity of 262 
In addition to the antiproliferative behaviour, a toxicity study of 262 towards healthy tissue was 
pursued. The previously described precision cut liver slices (PCLS) model was used to study the 
hepatotoxicological properties of 262. For the hepatotoxicity evaluation according to established 
procedures, PCLS were prepared and pre-incubated for 1 h before exposing to 262 as described in 
the experimental section. The treatment was performed at three single concentrations of the 
compounds (1 µM, 10 µM and 50 µM) with a final DMSO concentration of less than 0.5% and slices 
were incubated for 24 h. Afterwards PCLS were collected and their viability was determined 
measuring their ATP content and normalising it to their protein content. 
Fig. 65 reports the viability of the PCLS upon treatment with different compounds’ concentrations. 
According to the obtained results, compound 262 shows low to no hepatotoxicity in the 
concentration range of 1–10 µM. At 50 µM concentration, some effects on tissue viability can be 
observed with respect to controls, however 262 presents reduced hepatotoxicity with respect to 
cisplatin as also previously discussed for RR97b (201b). These results indicate a more tissue specific 
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activity of compound 262, which seems to be limited to cancer cells. One hypothesis for this 
observation is, that the behaviour might be related to the hypoxic environment of cancer cells, 
which might facilitate the reductive activation of the compound.  
 
 
Fig. 65: Viability of precision cut liver slices (PCLS) following 24 h incubation with compound 262 after 1 h of preincubation.  
 
A previous proteomic study with A2780 human ovarian carcinoma cells showed, that the protein 
expression after treatment of 262 for 24 h showed limited changes with only 11 out of 1300 
monitored protein types altered. This implies that cell damage, at least in the early phases of 
treatment, is quite selective and limited. Some of the altered proteins were found to be mainly 
involved in the redox metabolism and stress response, suggesting that cell damage probably is a 
consequence of severe oxidative stress.  This theory is also proved by the fact that two proteins 
that are biomarkers of apoptosis were found to be greatly perturbed. The mode of action hereby 
relates directly to that of auranofin. This result again strongly suggests that reduction of 262 to a 
gold(I) species takes place within the biological milieu.[339] 
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3.5.2. HDAC inhibitory properties 
To determine the grade of HDAC inhibition of 262, firstly its potential, as well as that of 
compounds 263–267 and [Au(phen)(Cl)2](Cl) (268) for comparison, was tested at single 
concentrations of 5, 10 and 50 µM in A549 nuclear cell extract with a commercially available 
fluorometric assay kit (MOLECUTOOLS FluoroFire HDAC Activity Assay Kit). The kit and its reliability 
towards metal-based compounds was previously tested with HDIs designed by FLORIAN 
RITTERBUSCH[340] and showed good correlations with previously obtained data.  
Briefly, A549 nuclear extract was obtained by a method described in literature.[172] Its protein 
content was determined via LAWRY-assay and 5 µg nuclear protein was used per well in the assay. 
Each condition was tested in duplicate. The results of the assay, with the compounds being 
preincubated with the nuclear extract for 1 h, were compared to the values of untreated nuclear 
extract and a rest activity was calculated respectively. As negative control for the assay, TSA was 
used. In the assay setting, by using nuclear cell extract a reductive environment including 
biomolecules like the previously mentioned glutathione and cytochrome c is present, making an 
activation of the gold-compounds possible. 
The results illustrated in Fig. 66 indicate that 262 is indeed the best HDAC inhibitor with rest 
activities of 51.8 ± 1.9% for 5 µM, 31.5 ± 5.0% for 10 µM and 4.1 ± 0.6% for 50 µM. Especially at 
the highest concentration 268 falls into the same range with a rest activity of -7.5 ± 4.4 µM. The 
next best inhibitors from these preliminary results are 266 and 267 with 17.2 ± 4.1% and 18.0 ± 
1.7% rest activity at 50 µM respectively as well as rest activities below 50% at 10 µM. These results 
suggest, that inhibition of HDACs by gold complexes is indeed structure dependant and not based 
on the pure presence of gold-ions. 
 
 
Fig. 66: Screening results for the HDAC restactivity in A549 nuclear extract after 1 h of incubation with compounds 262–268 at 
5, 10 and 50 µM obtained by using the FluoroFire HDAC Activity Assay Kit. 
-10
0
10
20
30
40
50
60
70
80
90
100
neg
cont.
262 263 264 265 266 267 268 262 263 264 265 266 267 268 262 263 264 265 266 267 268
A
c
ti
v
it
y
 c
.f
. 
p
o
s
it
iv
e
 c
tr
l 
[%
]
5 µM 10 µM 50 µM
Results and discussion 
 
145 
After having these preliminary results, the IC50 values of 262 compared to its structural analogue 
264 and the other potentially attractive compounds 266 and 267 were determined under the same 
assay conditions. Table 17 summarises these results, showing, that the best two inhibitors 262 and 
267 inhibit the HDAC activity in A549 nuclear extract in the low micromolar region. 
 
Table 17: Determined IC50 values after preincubating A549 nuclear extract with ten different concentrations of the compound for 
one hour before measuring the HDAC activity. Each value reflects the results of two independent experiments (logistics dose 
response fitting, areas are given for values were the concentration limits were insufficient). 
Compound HDAC IC50  
262 1.2 ± 3.2 µM 
264 ~12.8–27.0 µM 
266 ~5–30 µM 
267 3.9 ± 1.3 µM 
TSA 7.5 ± 11.7 nM 
 
Here again 262 stands out as the best HDAC inhibitor in the series, closely followed by 267, and 
at least an order of magnitude better than 264 and 266. In general, these gold-based compounds 
inhibit HDACs in a low micromolar region and are therefore less potent compared to e.g. TSA, 
which inhibits in the nanomolar region. With the results for TSA the assay setting was evaluated 
under the given conditions. TSA has been shown to in inhibit HDAC1–4 with 2 ± 0; 3 ± 0, 4 ± 1 
and 6 ± 2 nM and HDAC6–9 with 3 ± 1, 5 ± 2, 456 ± 59 and 6 ± 5 nM respectively,[76] showing 
that we are well within the range of inhibition expected for this inhibitor in our experiments. 
To further assess whether the antiproliferative behaviour and HDAC inhibitory activity are related 
to each other, the HDAC activity of A549 and A2780 nuclear extract of cells, which have been 
treated with defined concentrations of 262 or 264 was tested. It is thought that gold-ions might 
replace the zinc-ion in the active site forming “gold-fingers”, and therefore serve as a kind of 
irreversible inhibitor, similar to Cys4 zinc-finger domains for which such a mechanism has been 
elucidated recently.[341] For the assay, A549 or A2780 cells were cultured in 6-well plates and treated 
according the MTT-test conditions, with the exception, that after 72 h of incubation with the 
compound, cells were harvested and nuclear extracts obtained, which were further used in the 
HDAC activity assay after normalising to the protein content.  
The experimental results however were somewhat inconclusive, since the HDAC activity, although 
the protein content of the nuclear extracts is normalised, varies strongly with the cell number and 
from experiment to experiment, so that in a first experiment with A549 cells, it was observed that 
the lower the cell number was, the higher the HDAC activity seemed to be. In a second experiment 
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the 10 µM samples (low cell number due to high cytotoxicity) showed lower HDAC activity 
compared to the control. Samples containing 5 µM of 262 showed intermediate HDAC activity 
compared to the control and a control using half the number of cells during seeding, and samples 
using 5 µM of the control 264 showed the highest HDAC activity. In A2780 cells (single 
experiment), the control with a smaller number of cells showed lower HDAC activity compared to 
the control, as well as all treated samples. Overall, we were not able to show any significant 
inhibition of HDAC activity in A549 cells, on the contrary, it seems that HDAC activity might 
even be upregulated. A similar effect has been described for cis-[Pt(NH3)2(malSAHA)] (63) in CH1 
cells, when the level of histone 3 and 4 acetylation was determined via western blot analysis, which 
was considerably decreased for the Pt-compound, indicating an increase in HDAC-activity. A 
somewhat smaller increase could also be observed for cisplatin and cis-[Pt(NH3)2(mal)]. The same 
trend has been further observed in a colorimetric HDAC activity assay using CH1 nuclear extract 
of cells treated for 24 h with isotoxic concentrations of the compounds.[172] 
The reason for such results might be the cell cycle and cell density dependency of HDAC 
expression, which has been shown for instance for the catalytically most active class I HDACs in 
different cancer cell lines.[342] Using two different cell numbers in the controls of the experiment, 
we could already indicate that the cell density might play an important role in this kind of assay 
setting. Cells with a lower density might be more involved in cell division and thereby occupy 
different percentages in the cell cycle distribution. Another possibility might be a potential 
delocalisation of HDACs from the nucleus to the cytoplasm. Since solely nuclear extracts were 
examined and compared such a shift cannot be ruled out. Even if the catalytically most active class I 
HDACs are solely localised in the nucleus, it is unclear how much influence other isoforms have 
in the obtained results. Since the histone acetylation grade only focusses on HDAC activity in the 
cell nucleus, it was decided to compare the expression level of a single HDAC isoform in a whole 
cell sample after treatment for 72 h via western blot analysis. Therefore HDAC4 was chosen, since 
it has been previously shown to be upregulated after treatment with some platinum drugs, as well 
as being involved in platinum chemotherapy resistance.[343] For direct western blot analysis, the cells 
were treated as previously described and lysed them in radioimmunoprecipitation assay (RIPA) 
buffer, before resolving the proteins using SDS-PAGE with 30 µg of total protein per sample and 
blotting to a polyvinylidene fluoride membrane electrophoretically. The membranes were treated 
with the primary monoclonal HDAC4 antibody. After washing, the membrane was further 
incubated with relevant gate-keeper monoclonal antibodies (β-actin and GADPH) as loading 
controls, and with a secondary peroxidase antibody accordingly. The protein bands were developed with 
an enhanced chemoluminescence detection kit and quantified using the GeneSnap program. Results are 
shown in Fig. 67. 
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A) 
 
 
 
 
 
 
Fig. 67: Western blot analysis of HDAC4 activity in A549 cell extracts treated with 262 and 264 for 72 h previous to harvesting. 
A) HDAC4 expression level of the control and in response to compound treatment with different concentrations. B) 
Normalisation of HDAC4 expression levels to GADPH and β-actin, which were used as loading controls. 
 
As can be taken from Fig. 67, HDAC4 with a size of 119 kDa, is expressed in all samples to various 
extends. The intensity integration was done over both bands, which are indicated in the 
manufacturer’s protocol. However, the signals were very faint probably due to not optimal 
experimental conditions. The expression patterns for the housekeeping proteins GADPH and β-
actin varied as well, with a higher level of GADPH than β-actin in treated cells c.f. the control cells. 
Therefore, the results from HDAC4 (pixel intensities) were normalised to both housekeeping genes 
individually. The results show various HDAC4 expression patterns, with lower HDAC4 contents 
the lower the concentration of 262 and the higher the concentration of 264 if correlated to both 
GADPH and β-actin. In general, HDAC4 expression is indeed downregulated for most treated 
samples compared to the control in contrast to the results previously obtained by comparing the 
overall HDAC activity in nuclear cell extracts, where the general HDAC activity seemed to be 
upregulated. The experiments were discontinued due to time reasons, so that a verification of the 
results remains to be done. 
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4. Summary and outlook  
4.1. Summary and outlook metal-based kinase inhibitors 
Kinases are a large family of transferase enzymes, of which at least 538 different members are 
present in the human body.[11] By catalysing the transfer of the γ-phosphate group of ATP onto a 
specific side chain of their substrate, they mediate most cellular signal transductions in the body, 
thereby regulating various critical cellular activities. These include proliferation, survival, apoptosis, 
metabolism, transcription, differentiation, and a wide array of other cellular processes.[9,10] It is no 
surprise that the kinome has been extensively investigated as a family of potential drug targets[12] 
and the development of kinase inhibitors has therefore become an essential part of biological and 
medical research. Small molecule kinase inhibitors have been studied to treat various human 
diseases including cardiovascular diseases,[23] autoimmune disorders such as rheumatoid arthritis,[24] 
neurodegenerative conditions like Alzheimer’s disease, diabetes or liver disorders.[25] Originally 
based on unselective natural product inhibitors like staurosporine (51), research has led to almost 
30 FDA approved inhibitors by the middle of 2016.[26] Most of them were developed to treat 
oncological conditions, which are still a major focus of kinase inhibitor research today. 
Over the last decade the MEGGERS group has established highly potent and selective kinase 
inhibitors using inert metal centres as unique structural templates, thus mimicking and enhancing 
the globular shape of the non-selective inhibitor staurosporine (51).[120]  
 
Fig. 68: The natural product staurosporine (51) served as structural template for the development of various inert metal based 
kinase inhibitors. The indolo[2,3-α]carbazole of 51 is thereby displaced by pyrido[2,3-α]carbazole which serves as a bidentate ligand 
for easy metal-coordination, and both groups occupy the hydrophobic adenine-binding cleft, mimicking the hydrogen-bonding 
pattern of the adenine base in ATP.[48,109,119,120] 
 
The use of this type of inert metal complexes as kinase inhibitors has repeatedly been demonstrated 
in vitro.[151,162,166] In addition, some selected complexes have also been proven to successfully inhibit 
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kinases in vivo in species of the chordate phylum.[121,149,171] This includes the in vivo inhibition of GSK-
3 in the development of xenopus laevis[149] and danio rerio embryos[121] by two different Ru-complexes 
(S-53 and R-61, see introduction for structures and more details), as well as the Flt4 inhibition 
related antiangiogenic properties in a xenotransplanted proangiogenic human cancer cell 
experiment in living zebrafish by an Ir-complex (62).[171] Based on these properties, and many more 
different kinase targets of the compound group, these inhibitors might be regarded as potential 
anti-cancer drugs. In addition to that, various ATPase inhibitors have been developed in the group, 
using the same concept. Further studies towards their suitability as potential therapeutic drugs 
concerning their ADME properties were however not conducted previous to this thesis. 
To address this issue, in a first approach it was attempted to find a suitable lead structure for 
ADME investigations by a classical empiric screening for cytotoxicity against cancer cells. This 
approach was chosen due to the fact that all complexes possess known kinase and ATPase 
inhibitory properties, thereby combining this classical approach with the appreciation of their 
activity as molecularly targeting agents. For that matter, a compound library with all available 
inhibitors was created, and all complexes (441 compounds), some only synthesised during the 
thesis, were tested in a single dose experiments in HT-29 human colorectal adenocarcinoma cells 
for their effect on cell viability via the MTT method. An exception were 33 compounds which were 
previously tested by ANJA LUDEWIG in HeLa human cervical cancer cells and deemed unsuitable. 
The most interesting compound from that screening (np829 (80b) Fig. 69), based on highest 
cytotoxicity, was additionally tested in different cancer cell lines in concentration dependent 
cytotoxicity assays resulting in LD50 values of 0.4 to 2.9 µM after 24 h incubation time.  
 
Fig. 69: The most interesting hit found in the classical cytotoxic approach is 80b, which induced the highest amount of cell death 
as indicated by apoptotic cells. It is a mixture of enantiomers, as is its diastereomeric counterpart 80a, which is much less cytotoxic 
as indicated by healthy cells. Absolute configuration was determined by a single crystal X-ray structure of 80a.   
 
Its diastereomer (80a) showed cytotoxicity to a much lesser extent, indicating that the geometrical 
structure of 80b is important for its cytotoxicity and therefore its mode of action is probably based 
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on kinase inhibition. To verify the exclusiveness of its structure, another 44 compounds with side 
chain modifications were tested, but np829 still remained as the most cytotoxic complex in HT-29 
cells. However, the compound, as well as some of its derivatives, showed toxicity, which might not 
solely be explainable by kinase inhibition, as it seems to crystallise inside or on the surface of cells. 
Therefore, the approach was terminated in favour of another way to identify a suitable lead 
structure. 
As a second approach a focus was set on the drug-like abilities of this kind of kinase inhibitors, to 
move forward towards an application in cancer treatment. Therefore, selected compounds were 
tested for basic in vitro drug-like properties like solubility, permeability and metabolic stability 
towards CYP enzymes in rat liver microsomes in collaboration with the Novartis Institutes for 
BioMedical research (NIBR). Other interesting inhibitors were excluded from the study due to 
problems in MS quantification. 
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Fig. 70: Summary of simple ADME properties (thermodynamic solubility, cell membrane permeability and metabolic stability) as 
determined by in vitro assays at NIBR. 201b has the best properties in the series tested and was therefore investigated further.  
 
After identifying an enantiopure rhodium complex (201b) with adequate properties concerning in 
vitro rat liver microsome stability, permeability and solubility, some properties of its three remaining 
stereoisomeric counterparts were tested and yielded in comparable results. However, permeability 
was lower than expected from the initial results for all four compounds. One diastereoisomer of 
the identified complex is a potent Pim1 inhibitor (IC50 = 15 nM), as determined by RAJATHEES 
RAJARATNAM, while 201b is a very unpotent kinase inhibitor.[233] Since Pim1 is one of the major 
Summary and outlook 
 
151 
targets covered by the research in the MEGGERS group during the development of their promising 
kinase inhibitors, it seemed as a good starting point to improve the compounds properties while 
maintaining its kinase inhibitory properties as discussed below. The inhibitor 201a and some of its 
isomers were at the same time investigated for their overall ADME properties. Starting with a 
stability study against solvents (e.g. CH3CN, DMSO), no change in 
1H-NMR spectra and HPLC 
traces was observed after 3 weeks for 204b. When exposing to an equimolar amount of thiols at 
37 °C, again no change could be observed within 6 weeks in the 1H-NMR spectra of 201a and 
201b, indicating a strong stability of the tested complexes. 
Both diastereomers showed low cytotoxicity in three different cancer cell lines within 24 or 72 h 
as determined by the MTT method, with 201a demonstrating a more pronounced effect compared 
to 201b. This effect might be related to the expected problems in cancer treatment with Pim1 as 
single target and might correlate to a low expression of Pim1 in these cell lines. Another explanation 
is the previously discussed possible compensation mechanisms by the other Pim family members. 
Based on a KINOMEscan[233] Pim1 and Pim3 are inhibited by 201a to a similar extent (1.8% rest 
activity), but Pim2 is inhibited much less (50% rest activity) and might therefore compensate for 
the inhibition of the other two isoforms. The toxicity in an ex vivo rat PCLS experiment was quite 
low for 201b, but again showing a markedly higher degree for 201a, indicating an overall toxicity 
of the complex, which is however not surprising for a functional kinase inhibitor. One has to 
consider that other kinases like HIPK2 and HIPK3 (3.3 and 2.4% rest activity respectively) and 
PRKG2 (2.4% rest activity) are probably strongly inhibited as well, as determined in the 
KINOMEscan. Therefore, the observed toxicity might be based on the inhibition of other kinases. 
Still other causes that might be responsible cannot be excluded without further studies. When 
measuring the uptake of the complexes in PCLS, 201b shows a higher metal content in the liver 
tissue compared to 201a as determined by ICP-MS measurements. In morphology PCLS samples, 
no changes compared to a control tissue were observed, even if strong localisations of the 
compound were prepared in freshly incubated samples. 
In parallel to these basic in vitro and ex vivo studies, first in vivo pharmacokinetic studies in mice were 
conducted with 201b and gave encouraging results. The compound was dosed by three different 
routes of administration (IV, PO, IP) and plasma samples were obtained at determined time points. 
From the IV results over 7 h, a moderate clearance and volume of distribution at steady state were 
observed, indicating adequate stability and a diffusion outside the vascular department. The half-
life time in plasma was determined to be 2.9 h. Based on PO and IP results, a systemic circulation 
after administration by these routes was concluded possible, with low (PO) to moderate (IP) 
bioavailability. These results show, that our complexes might even be dosed by different routes of 
administration than IV, which is a major advantage over other drugs, especially metal-based ones. 
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As 201a is the more interesting stereoisomer, additional PK studies were performed in rats. The 
IV results obtained are in a similar range compared to 201b in mice, however 201a is eliminated 
somewhat more quickly from plasma. As the fate of the metal is an important aspect in this 
compound class, according investigations were pursued using ICP-MS to determine the total metal 
content of different organs and bodily fluids after IV injection. Since 201a shows high stability in 
various solvents, liver microsomes, hepatocytes and against thiols, the total metal content was 
assumed to reflect true values of the complex concentration. These studies show that 201a is 
partially excreted via the biliary and probably the renal system, but that high amounts are present 
in the lungs within the 24 h time frame of the experiment. It can be speculated that the complex 
or metabolites are tissue-bound. Further studies are needed to determine if this effect is reversed 
after some time and whether the bound rhodium belongs to the parent complex or possible 
metabolites. 
All obtained results show a certain suitability of the complex 201a as a lead structure for a potential 
anti-cancer drug. However, reported yields and batch sizes are low.[233] Therefore, the upscaling 
possibilities of 201a, as well as a possible optimisation of reaction conditions were investigated, but 
did not deliver the expected improvements. Both simple upscaling and access of a different reaction 
path, as well as screening for optimised reaction conditions were without success. 
Finally, 201a was used as a lead structure for the development of structurally modified complexes 
with regard to improved properties concerning ADME, while maintaining its original kinase 
activity. Based on in silico considerations, the para pyridine position of (pyridine-2-ylmethyl)-D-
proline was identified as potentially solvent exposed, with additional space for large solubility 
and/or permeability-enhancing appendages. These studies were conducted using a simplified 
model of pair-fitting the originally selected compound 201a into an existing co-crystal structure of a 
pyridocarbazole based inhibitor in the active site of Pim1. After careful consideration, including 
attention to the surface charges of Pim1’s active site, different potential side chains to enhance 
solubility, while at least maintaining permeability, were proposed. Some of the proposed side chains 
were successfully introduced in 201a yielding in the selected complexes given in Fig. 71. 
The synthesised complexes include solubility-enhancing side chains like a pure aliphatic side chain 
in 213a or a linker-connected morpholine in 210a. While morpholine itself is generally referred to 
as solubility enhancing based on its H-bond capacity, the linker ensures an additional out of plane 
behaviour, loosening up the crystal packing of the complex. The pure aliphatic hexyl side chain in 
213a is supposed to enhance the permeability by its lipophilic character and meanwhile enhancing 
the solubility by out of plane behaviour. Dimethylamine substituents as in 212a are thought to be 
at least partially protonated under physiological conditions, thereby enhancing the solubility of the 
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complex as well as the affinity to Pim1 by interacting with its generally negatively charged surface 
in and around the active site. Finally, 258a was synthesised to evaluate the influence of possible 
halogen-bridges, as well as the influence of a change in polarity and hydrophobicity in the ligand. 
 
Fig. 71: Successfully synthesised derivatives of 201a which were supposed to improve the drug-like properties of the original 
compound by modification of the (pyridine-2-ylmethyl)-D-proline ligand. 
 
The solubility was enhanced for 210a (86 µM) and 212a (43 µM) in phosphate buffer, especially at 
a low pH of 4, indicating indeed a positive effect of protonation of the tertiary amines, although 
only at low pH. This enhancement in solubility was however not further improved in FaSSIF. 
Permeability of all compounds was not enhanced by the modifications, still resulting in very low 
permeabilities, most often below the respective detection limit. Additionally, the rat liver 
microsome stability was tested and showed good results for 258a and 212a, while the other two 
compounds showed only medium stability, probably related to the easier access of the CYP 
enzymes to the elevated side chains. All compounds are therefore no real improvement to 201a. 
Additionally, taking the affinity for Pim1 into consideration, modifications of the pyridocarbazole 
ligand were pursued. These modifications were based on previously designed pyridocarbazole- 
based Pim1 inhibitors, which showed enhanced Pim1 affinity in comparison to their unmodified 
counterparts, and which might be able to enhance solubility and/or permeability, while not 
negatively impairing the other property too much. Therefore, a selection of complexes was 
prepared (see Fig. 72). 
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Fig. 72: Successfully synthesised derivatives of 201a, which were supposed to improve the drug-like properties of the original 
compound by modification of the pyridocarbazole ligand. 
 
After subjecting the compounds to the drug-like abilities assays as the previous series, especially 
209a stood out with an enhanced solubility of 72 µM in phosphate buffer at pH 7, while both 
solubilities in FaSSIF and in phosphate buffer at pH 4 were raised to >160 µM. All other complexes 
showed no enhanced solubility and again all complexes had low permeability. Both 209a and 223a 
had a medium to high risk concerning metabolic stability, while the other two compounds are quite 
stable in microsomes. Again none of the compounds is a real improvement concerning drug-like 
abilities compared to 201a, because while improving one property, another is negatively affected. 
The results of both series of compounds synthesised however show a certain margin in influencing 
the properties of the complex, so that only the best combination has to be found in future 
investigations. 
For testing the structure activity relationship of the newly designed complexes towards inhibition 
of Pim1, a quantitative inhibitory assay was conducted for all trans-isomers. Based on the obtained 
results 209a, 225a and 226a are similarly good inhibitors compared to 201a, but all derivatives with 
modifications in the (pyridine-2-ylmethyl)-D-proline showed little to no inhibition, indicating that 
the initial in silico considerations and assumed space opportunity actually was a misconception. 
Therefore, the strategy for modifying the complex 201a has to be reconsidered and optimally based 
on an actual co-crystal structure.  
In summary, different approaches for the discovery of a potential lead complex have been 
conducted. A screening for cytotoxic compounds thereby led to a dead end. Using an in vitro 
investigation of ADME properties, an interesting complex was pointed out and its properties were 
further improved by structural optimisation. The kinase inhibitory properties might thereby be 
retained. A combination of the different modifications might lead to a structure with sufficient 
properties to be tested in further preclinical settings. Additionally, studies concerning PK 
parameters in vivo yielded promising results. The fate of the metal was partially determined, but 
needs more investigations in the future to study possible tissue binding and metabolisation. Overall 
many insights into ADMET parameters of inert metal based compounds were obtained, which is 
a solid basis for further investigations in the future. 
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4.2. Summary and outlook gold-based HDIs 
In a side project, the anticancer and histone deacetylase (HDAC) inhibitory properties of a well-
established dinuclear gold(III)-complex 262 (Fig. 73) in comparison to structural analogues as well 
as distinct gold complexes were evaluated. HDACs are another potential target to treat cancer, as 
covered in more detail in the introductory section.  
 
 
Fig. 73: Structures of two of the gold-complexes studied for their antiproliferative and HDAC inhibition properties. 
 
It was demonstrated that the compound 262, which was previously described as antiproliferatively 
active compound and possible HDAC inhibitor, indeed is the most cytotoxic compound against 
cancer cells in the series tested. Additionally, it was the best HDAC inhibitor with a single digit 
micromolar activity in A549 nuclear extract. While 262 is quite toxic against cancer cells, it showed 
little toxicity against rat liver tissue, indicating a very good selectivity. These results confirm 
previously suggested evidence for 262s HDAC inhibitory properties, which was based on a 
comparative analysis of the cytotoxicity against 36 different cancer cell lines.[334] A correlation of 
the interconnection of that HDAC inhibitory activity with the antiproliferative behaviour of 262 
however failed, as the HDAC activity in A549 lung cancer cells nuclear extract is rather elevated 
than lowered after the treatment of the cells for 72 h. Such a phenomenon has been previously 
described for particular platinum compounds.[172] Since controls with a lower cell number also 
showed higher HDAC activity, effects like cell cycle distribution and elevated cell-cell contacts 
might play a role in these results, leaving the need for other tools to elucidate the HDAC inhibitory 
properties in living cells, which excludes such factors. Western Blot results for HDAC4 indicated 
that this single HDAC isoform was inhibited in A549 cells after 72 h of treatment with both 262 
and to a smaller extent its less toxic derivative 264. Further tools and studies to understand the 
assay conditions to a greater extent might be needed, before follow-up experiments can fully 
elucidate the underlying HDAC inhibitory mechanism of 262. 
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5. Experimental part 
5.1. General methods 
Reactions were carried out under an atmosphere of nitrogen unless otherwise specified. Water and 
oxygen sensitive reactions were carried out in dried glassware using SCHLENK techniques. For 
oxygen but not moisture sensitive reactions the solvent was purged with N2 for 5-20 min. Solvents 
used for reactions were distilled under an N2 atmosphere from calcium hydride (CH3CN, CH2Cl2, 
CHCl3), sodium/benzophenone (THF), or sodium (benzene) using standard techniques,
[344] or 
directly used in HPLC quality. If not stated otherwise, commercially available reagents were used 
without further purification. Commercial thionyl chloride was distilled and stored under N2 on 
dried mole sieve (4 Å) at 4 °C under exclusion of light. 
Microwave reactions were performed with a mono-mode Discover LabMate (CEM GmbH). 
Photolysis reactions were performed in a photoreactor using a medium pressure Hg lamp (150 W 
or 700 W).  
 
5.1.1. Chromatography methods 
Flash column chromatography was performed on freshly packed silica gel 60 (particle size 
0.040-0.063 mm, MERCK KGAA) or neutral Al2O3 (BROCKMANN activity I, particle size 0.05-
0.15 mm, FLUKA) columns at room temperature under positive pressure (0.5-2 bar) as described in 
the experimental section. All solvents used for flash chromatography were distilled before usage. 
Thin layer chromatography for reaction control, chromatography control, or semi preparative 
separation was performed on aluminium TLC plates with silica 60 F254 coating (MERCK KGAA or 
MACHERY NAGEL) or neutral Al2O3 F254 coating (MERCK KGAA or MACHERY NAGEL). Eluted 
compounds were visualised by their intrinsic colour, self-fluorescence (λ = 254 nm or 366 nm) or 
fluorescence quenching (λ = 254 nm or 366 nm). In all other cases, TLC sheets were immersed in 
a KMnO4 dip and stained by subsequent heating treatment (~200 °C). 
Analytical and semi-preparative HPLC chromatography was performed on an Agilent 1200 Series 
HPLC System using different columns and flow rates as indicated in the according discussion or 
experimental sections. UV absorption was detected at 254 nm. Preparative HPLC was performed 
on a PLC 2020 Personal Purification System (Gilson) as described in the according discussion or 
experimental section. UV absorption was detected at λ = 254 nm if not stated otherwise. 
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5.1.2. Analytical methods 
5.1.2.1. Nuclear magnetic resonance spectroscopy 
NMR spectra were recorded using deuterated NMR-solvents on a Bruker DPX-250 (1H-NMR 
resonance: 250.1 MHz, 13C-NMR resonance: 62.9 MHz), a Bruker Avance 300 (1H-NMR resonance: 
300.1 MHz, 13C-NMR resonance: 75.5 MHz) as automated systems, and on a Bruker DRX 400 
(1H-NMR resonance: 400.0 MHz, 13C-NMR resonance: 100.6 MHz), a Bruker DRX 500 (1H-NMR 
resonance: 500.2 MHz, 13C-NMR resonance: 125.8 MHz), or a Bruker Avance 500 (1H-NMR 
resonance: 500.2 MHz, 13C-NMR resonance: 125.8 MHz) spectrometer by the staff of the NMR 
department of the Philipps-Universität Marburg. Chemical shifts of compounds and solvents are 
indicated in relation to tetramethylsilane in ppm on a δ-scale.[345] The spectra were calibrated using 
the rest proton signal of the solvents as indicated in Table 18. 
Table 18: Rest proton signals of deuterated NMR-solvents used for calibration of NMR-spectra. 
 
 
 
 
 
Spectra were analysed using BRUKER Topspin 3.0. Coupling constants nJ, over n bonds, are given 
in Hertz (Hz). Multiplicities are given as found in the spectra and are not necessarily in accordance 
to the theoretically expected multiplicities. They are given as s (singulet), d (dublet), t (triplet), q 
(quartet), quin. (quintet) or combinations thereoff. Broad signals are indicated by br. Signals with 
insufficient resolution or overlayed signals are given as as an area m (multiplet). Signals were 
allocated by coupling constants and in more difficult cases using 2D spectra (COSY, HSQC, 
HMBC).  
 
5.1.2.2. Infrared spectroscopy  
Infrared spectra were recorded from neat compounds using a Bruker Alpha-P FTIR spectrometer 
and ATR (attenuated total reflection) sampling technique. The spectra were analysed using BRUKER 
Opus 6.5. The locations of absorption bands are given in wavenumbers ~ in cm-1. The relative 
intensity and characteristics of the bands are given as s (strong), m (medium), w (weak), and if 
necessary additionally specified as br (broad) or v (very). 
CDCl3 
1H:  δ = 7.26 ppm 13C: δ = 77.16 ppm 
DMSO-δ6 
1H:  δ = 2.50 ppm 13C: δ = 39.52 ppm 
CD3CN  
1H:  δ = 1.94 ppm 13C: δ = 1.32 ppm, 118.26 ppm 
(CD3)2CO  
1H:  δ = 2.05 ppm 13C: δ = 29.84 ppm, 206.26 ppm 
CD3OD 
1H:  δ = 3.31 ppm 13C: δ = 49.00 ppm 
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5.1.2.3. Mass spectrometry 
High-resolution mass spectra were obtained on a THERMO FINNIGAN LTQ FT instrument using 
ESI or APCI ionisation by the staff of the MS department of the Philipps-Universität Marburg. 
The ionic masses m/z are given in u for the most abundant isotopes. It was ensured that the 
observed isotopic patterns were in accordance with the expected isotopic patterns. 
Reaction controls and investigations of best ionisation techniques were performed on an LC-MS 
(AGILENT 1200 series, 6120 quadrupole system) as indicated in the according discussion or 
experimental section. 
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5.2. Compound preparation for toxicity approach 
5.2.1. Synthesis of structural derivatives of np829 (80b) and np830 (80a) 
5.2.1.1. Synthesis of (η6-benzene)(η5-N-(2-methoxyethyl)cyclopentadienyl carboxamide) 
ruthenium hexafluorophosphate 
 
The sandwich complex 120[49] (250 mg, 0.58 mmol, 1.00 eq) was dissolved in 10.5 mL DMF and 
degassed for 10 min. 88 mg NHS (0.77 mmol, 1.33 eq) and 147 mg EDCl (0.77 mmol, 1.33 eq) 
were added and the solution stirred for 20 h at 20 °C. Afterwards, 60.5 µL 2-methoxyethan-1-
amine (ρ = 0.86, 0.70 mmol, 1.2 eq) in 0.75 mL DMF were added and stirred for another 2 h at 
20 °C. The solvent was removed under reduced pressure and azeotroped with CH3CN. The 
complex was purified via flash chromatography (27 g silica, CH3CN/H2O/KNOaq., sat. 50:3:1). After 
removal of the solvent, the residue was taken up in 20 mL H2O and some drops of NH4PF6 aq.sat 
were added and the aqueous layer was extracted with CH2Cl2 (3 x 20 mL). The combined organic 
layers were washed with H2O (2x 10 mL) and dried over Na2SO4. After removal of the solvent 
under reduced pressure, 116 mg of the complex 121 (0.23 mmol, 41%) was obtained. 
1H-NMR (300.1 MHz, CD3CN): δ = 6.84 (s, 1H, NH), 6.11 (s, 6H, Hbenzene), 5.77 (t, 2H, 
3J = 1.9 Hz, 
HCp), 5.40 (t, 2H, 
3J = 1.9 Hz, HCp), 3.50-3.46 (m, 2H), 3.44-3.39 (m, 2H), 3.35 (s, 3H, OCH3) ppm. 
13C-NMR (75.5 MHz, CD3CN): δ = 163.6, 118.3, 88.3 (6C), 82.6 (2C), 80.6 (2C), 71.2, 58.7, 
40.0 ppm. 
 
5.2.1.2. Synthesis of η5-N-(2-methoxyethyl)cyclopentadienyl carboxamide precursor 123 
 
The sandwich complex 121 (116 mg, 0.23 mmol, 1.00 eq) was dissolved in 600 mL CH3CN and 
irradiated with a medium pressure Hg lamp (750 W) for 15.5 h with a stream of N2 flowing through 
the solution throughout the photolysis. The solvent was removed in vacuo and the tris-acetonitrile 
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complex 122 was redissolved in 20 mL CH3CN. The resulting solution was purged with CO (g) for 
5 min and stirred under CO atmosphere for 18 h at 20 °C. After removal of the solvent under 
reduced pressure, 124 mg of the complex 123 (0.24 mmol, quant.) was obtained as a brown oil. 
1H-NMR (300.1 MHz, CD3CN): 6.84 (s, 1H, NH), 5.75 (t, 2H, 
3J = 2.1 Hz, HCp), 5.13 (t, 2H, 
3J = 2.1 Hz, HCp), 3.47-3.86 (m, 4H), 3.31 (s, 3H, OCH3) ppm. 
13C-NMR (75.5 MHz, CD3CN): δ = 163.5, 118.3, 86.7 (2C), 81.1 (2C), 71.4, 58.8, 40.2 ppm. 
 
5.2.1.3. Synthesis of TBS-protected η5-N-(2-methoxyethyl)cyclopentadienyl carboxamide 
complex 125 
 
A mixture of 45 mg TBS-protected isoquinolinocarbazole 124 (101 µmol, 0.90 eq), 58 mg of the 
Ru-precursor 123 (112 µmol, 1.00 eq), and 16 mg K2CO3 (112 µmol, 1.00 eq) were dissolved in 5 
mL CH3CN/CH2Cl2/CH3OH (15:4:1) and degassed with N2 for 10 min. The reaction was stirred 
for 16 h and additional 0.5 mL CH2Cl2 were added before it was further stirred for 5.5 h. Another 
0.3 mL CH2Cl2, 0.25 mL MeOH, and 2 mL CH3CN were added before the reaction was stirred 
further for 17.5 h. Since some side product appeared, the reaction was terminated and the solvent 
was removed in vacuo. The complex was diluted in CH3CN to remove some of the less soluble 
unreacted ligand and the solvent was again removed under reduced pressure. The complex was 
purified via flash column chromatography (silica, CH2Cl2 to CH2Cl2/MeOH 10:1). After removal 
of the solvent in vacuo a pure fraction of 20 mg and an impure fraction of 21 mg of the complex 
125 as racemic mixture (54.9 µmol, 54%) was obtained as a deep red solid. 
1H-NMR (300.1 MHz, CD3CN): δ = 10.48 (d, 
3J = 8.6 Hz, 1H), 9.63 (s, 1H), 8.90 (d, 3J = 7.8 Hz, 
1H), 8.16 (d, 3J = 8.0 Hz, 1H), 8.01 (ddd, 3J = 8.3 Hz, 3J = 7.2 Hz, 4J = 1.3 Hz, 1H), 7.86-7.81 (m, 
3J = 7.5 Hz, 1H), 7.62-7.55 (m, 2H), 7.35 (ddd, 3J = 7.9 Hz, 3J = 6.0 Hz, 4J = 1.8 Hz, 1H), 6.50 (t, 
3J = 5.66 Hz, 1H), 6.03-6.03 (m, 1H, HCp), 5.92-5.92 (m, 1H, HCp), 5.36-5.34 (m, 2H, HCp), 3.00 (q, 
J = 6.0 Hz, 2 H), 2.88 (s, 3H, CH3), 2.72-2.68 (m, 2H), 1.04 (s, 9H, TBS), 0.60 (s, 6H, TBS) ppm. 
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13C-NMR (62.9 MHz, CD3CN): δ = 201.4, 176.1, 175.6, 164.4, 161.8, 156.7, 154.6, 141.0, 134.2, 
133.5, 133.0, 130.2, 130.0, 129.4, 129.0, 127.7, 126.0, 124.7, 121.3, 120.2, 117.4, 117.2, 116.1, 90.0, 
88.9, 86.1, 80.3, 78.9, 71.0, 58.5, 39.5, 26.9, 19.8, -3.4 ppm.  
ATR-IR (neat): ~ = 3088 (vw), 3060 (vw), 2928 (w), 2888 (vw), 2856 (vw), 2055 (vw), 1954 (s), 
1737 (w), 1679 (m), 1636 (w), 1575 (w), 1533 (m), 1466 (w), 1436 (w), 1368 (w), 1328 (w), 1293 (s), 
1226 (m), 1153 (vw), 1118 (w), 1080 (w), 1023 (vw), 969 (vw), 917 (vw), 821 (m), 732 (s), 693 (w), 
657 (w), 583 (vw), 554 (vw), 515 (vw), 475 (vw), 438 (vw), 411 (vw) cm-1. 
HR-MS (ESI): C37H36N4O5RuSiNa (M+Na)
+ calcd.: 769.1401, found: 769.1396. 
 
5.2.1.4. Synthesis of η5-N-(2-methoxyethyl)cyclopentadienyl carboxamide complex 119 
 
The TBS-protected complex 125 (20 mg, 26.8 µmol, 1.00 eq) was dissolved in 2.5 mL THF, and 
cooled to 0 °C. 134 µL of a 1 M solution of TBAF in THF (134 µmol, 5.00 eq) was added and the 
solution was heated to 45 °C for 2 h. Afterwards, the solution was cooled to 0 °C, and 7.7 µL acetic 
acid were added. After warming to 20 °C, the solvent was removed under reduced pressure and 
the complex was purified via flash column chromatography (5 g silica, CH2Cl2 to CH2Cl2/MeOH 
40:1). After removal of the solvent in vacuo, 16 mg of the racemic complex 119 (25.3 µmol, 94%) 
were obtained as a deep red solid. 
1H-NMR (300.1 MHz, DMSO-d6): δ = 11.35 (s, 1H, NH), 10.54 (d, 
3J = 8.5 Hz, 1H), 9.88 (s, 1H), 
8.85 (d, 3J = 7.9 Hz, 1H), 8.35 (d, 3J = 7.4 Hz, 1H), 8.19-8.13 (m, 4J = 1.4 Hz, 1H), 8.02-7.97 (m, 
4J = 0.8 Hz, 1H), 7.64-7.57 (m, 4J = 1.2 Hz, 2H), 7.17 (ddd, 3J = 7.8 Hz, 3J = 6.4 Hz, 4J = 1.8 Hz, 
1H), 6.28-6.27 (m, 3J = 1.3 Hz, 1H, HCp), 6.21-6.21 (m, 
3J = 1.3 Hz, 1H, Cp), 5.62-5.59 (m, 2H, 
HCp), 3.09-3.02 (m, 2 H), 2.89 (s, 3H, CH3), 2.81-2.71 (m, 2H) ppm. 
13C-NMR (125.8 MHz, DMSO-d6): δ = 200.8, 171.0, 170.0, 163.1, 160.8, 155.1, 153.3, 139.1, 132.9, 
131.4, 131.3, 129.4, 128.9, 128.6, 127.6, 126.8, 124.7, 123.1, 120.0, 119.1, 116.3, 115.3, 114.1, 89.2, 
87.9, 85.0, 79.9, 79.5, 70.0, 57.6, 38.4 ppm. 
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ATR-IR (neat): ~ = 3073 (vw), 2931 (vw), 2845 (vw), 2765 (vw), 1946 (s), 1740 (w), 1692 (m), 
1667 (m), 1623 (vw), 1578 (w), 1550 (m), 1487 (vw), 1463 (vw), 1438 (vw), 1378 (w), 1327 (m), 
1293 (m), 1224 (m), 1155 (vw), 1108 (vw), 1082 (m), 1017 (w), 969 (vw), 923 (vw), 848 (w), 815 
(vw), 754 (m), 694 (w), 645 (m), 595 (vw), 556 (w), 527 (w), 501 (vw), 488 (vw), 464 (w), 
433 (vw) cm-1. 
HR-MS (ESI): C31H22N4O5RuNa (M+Na)
+ calcd.: 655.0534, found: 655.0523. 
 
5.2.2. Preparation of 80b 
5.2.2.1. Synthesis of E/Z-ethyl 4-bromo-3-methylbut-2-enoate  
 
The synthesis was modified from a well-established literature protocol,[205–207] to avoid the use of 
CCl4. To a solution of 5.42 mL ethyl-3-methylbut-2-enoate (39.0 mmol, 1.00 eq) in 40 mL CH2Cl2, 
which was degassed for 15 min with N2, was added a mixture of 6.85 g N-bromosuccinimide (38.5 
mmol, 0.99 eq) and 85 mg dibenzoyl peroxide (0.35 mmol, 0.01 eq) portionwise. The suspension 
was heated to 65 °C (oil bath temperature) for 16 h. After cooling the yellow suspension to 20 °C, 
the precipitated succinimide was filtered off and the reaction mixture was concentrated under 
reduced pressure. The starting material 170 (55 °C, 30 mbar) was removed from the E/Z-ethyl 4-
bromo-3-methylbut-2-enoate (171) (103 °C, 30 mbar/67 °C, 4.6 mbar) by fractional distillation and 
171 was obtained as colourless liquid in good yields 66% (5.29 g, 25.5 mmol) by distillation. 
Analytical data was in accordance to reported data.[346–349] 
1H-NMR (300.1 MHz, CDCl3): δ = 5.95-5.95 (m, 1H, E CHCO), 5.77 (d, J = 1.4 Hz, 1H, Z 
CHCO), 4.55 (s, 2H, Z CH2Br), 4.21-4.13 (m, 4H, E/Z CH3CH2), 3.94 (d, J = 0.6 Hz, 2H, E 
CH2Br), 2.27 (d, J = 1.3 Hz, 3H, E CH3Cq), 2.04 (d, J = 1.4 Hz, 3H, Z CH3Cq), 1.28 (dt, J = 7.1 Hz, 
J = 0.4 Hz, 6H, E/Z CH3CH2) ppm. 
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5.2.2.2. Synthesis of ethyl-2,4-dimethylcyclopenta-1,2-diencarboxylate 
 
E/Z-ethyl 4-bromo-3-methylbut-2-enoate (171) was treated according to a modified literature 
procedure.[208] 4.27 g of the enoate (20.6 mmol, 1.00 eq) was dissolved in 65 mL CH3CN and 5.41 g 
triphenylphosphine (20.6 mmol, 1.00 eq) was added and stirred until a clear solution remained. 
This solution was heated to 95 °C for 90 min, then cooled to 20 °C and the solvent was slowly 
removed under reduced pressure to yield (E/Z)-(4-ethoxy-2-methyl-4-oxobut-2-en-1-yl)  
triphenylphosphoniumbromide quantitatively (9.61 g, 20.5 mmol, 99%). The phosphonium salt 
172 was converted to the cyclopentadiene without characterisation according to a modified 
literature procedure.[209,210] The phosphoniumbromide 172 (9.61 g, 20.5 mmol, 1.00 eq) was 
dissolved in 170 mL CH2Cl2 and 205 mL of a saturated NaHCO3 aq. solution was added and the 
biphasic system was stirred vigorously.  A solution of 1.91 mL 95% chloroacetone (22.5 mmol, 
ρ = 1.15, 1.10 eq) in 35 mL of CH2Cl2 was added, the mixture was degassed with N2 for 20 min, 
and stirred vigorously for 16 h at 20 °C. The layers were separated and the aqueous layer was 
extracted two times with 100 mL CH2Cl2. The combined organic layers were washed with 200 mL 
of H2O, dried over MgSO4, filtered and concentrated in vacuo. The product was pre-purified via 
rapid short column flash chromatography (silica, hexane/Et2O 1:1, loading with CH2Cl2) and 
further purified via flash chromatography (dry load, silica, hexane/EtOAc 10:1 → 6:1). The pure 
fractions were concentrated under reduced pressure to obtain 1.84 g (11.6 mmol, 55%) of the 
cyclopentadiene 174 as a light yellow oil. Analysis was in accordance with the reported literature 
data.[210] 
1H-NMR (300.1 MHz, CDCl3): δ = 6.05 (s, 1H, CHCp), 4.19 (q, J = 7.1 Hz, 2H, CH3CH2), 3.21 (d, 
J = 2.3 Hz, 2H, CH2Cp), 2.30 (t, J = 2.3 Hz, 3H, CH3Cp), 2.07 (s, 3H, CH3Cp), 1.30 (t, J = 7.1 Hz, 
CH3CH2) ppm. 
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5.2.2.3. Synthesis of (η6-benzene)(η5-ethyl 2,4-dimethylcyclopentadienylcarboxylate) 
ruthenium hexafluorophosphate  
 
A modified literature procedure was used in order to avoid the use of Tl2SO4.
[203] A solution of 
1.00 g of ethyl-2,4-dimethylcyclopenta-1,3-dienecarboxylate 174 (6.00 mmol, 1.00 eq) in 6 mL THF 
was added dropwise to a suspension of 276 mg sodium hydride (mineral oil dispersion, 6.90 mmol, 
1.15 eq) in 3 mL THF at 0 °C. The suspension was stirred for 60 min at room temperature and 
added to a N2-purged suspension of 1.50 g [Ru(benzene)2Cl2] 176
[211] (3.00 mmol, 0.50 eq) in 
160 mL CH3CN under N2 atmosphere. The reaction mixture was stirred for 48 h at room 
temperature and then filtered over celite. The solvent was removed in vacuo and the residue was 
redissolved in water. Excess NH4PF6 was added and the product was extracted with CH2Cl2. The 
organic layer was dried over MgSO4, filtered, and the solvent removed under reduced pressure. 
The residue was subjected to flash chromatography with aluminium oxide as stationary phase and 
acetone as eluting solvent. The combined product eluents were dried in vacuo to result in 1.28 g 
(2.62 mmol, 44%) of the sandwich complex 177 as a light brown solid.  
1H-NMR (300.1 MHz, (CD3)2CO): δ = 6.33 (s, 6H), 5.88 (d, 
4J = 1.4 Hz, 1H), 5.73 (d, 4J = 1.1 Hz, 
1H), 4.35-4.25 (m, 2H), 2.30 (s, 3H), 2.08 (s, 3H), 1.34 (t, 3J = 7.1 Hz, 3H) ppm. 
13C-NMR (75.5 MHz, (CD3)2CO): δ = 166.4 (Cq), 101.1 (Cq), 100.4 (Cq), 89.0, 86.8, 84.4 (Cq), 82.7, 
62.3, 14.4, 13.6, 13.5 ppm.  
ATR-IR (neat): ~ = 3110 (vw), 3094 (vw), 2987 (vw), 2924 (vw), 2854 (vw), 1703 (m), 1480 (vw), 
1461 (w), 1440 (w), 1414 (w), 1391 (w), 1373 (vw), 1307 (w), 1234 (m), 1181 (w), 1120 (vw), 1079 
(w), 1048 (vw), 1015 (w), 977 (vw), 950 (vw), 921 (vw), 904 (vw), 878 (vw), 829 (vs), 781 (m), 742 
(vw), 704 (w), 624 (vw), 611 (vw), 583 (vw), 555 (s), 446 (w), 419 (w), 390 (m) cm-1. 
HR-MS (ESI+): C16H19O2Ru (M)
+ calcd.: 345.0428, found: 345.0418. 
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5.2.2.4. Synthesis of (η6-benzene)(η5-2,4-dimethylcyclopentadienylcarboxylic acid) 
ruthenium hexafluorophosphate 
 
The deprotection was performed according to a similar literature procedure using a non-methylated 
cyclopentadiene.[49] A solution of 1.90 g of the sandwich complex 177 (3.88 mmol, 1.00 eq) in 
CH3CN (61 mL) was prepared and a solution of 3.22 g K2CO3 (23.3 mmol, 6.01 eq) in 61 mL H2O 
was added. The reaction mixture was stirred at 100 °C for 3 h and then cooled to 0 °C. The solution 
was acidified to pH 1-2 with 6 N HClaq. and excess solid NH4PF6 was added. The CH3CN was 
removed under reduced pressure and the aqueous solution was left at 4 °C over night. The resulting 
precipitate was filtered, washed with H2O and diethyl ether, and dried in vacuo to give 1.62 g of the 
carboxylic acid 178 (3.51 mmol, 91%) as a light brown solid. 
1H-NMR (300.1 MHz, CD3CN): δ = 9.82 (br s, 1H), 6.06 (s, 6H), 5.69 (d, 
4J = 1.5 Hz, 1H), 5.49 
(d, 4J = 1.4 Hz, 1H), 2.20 (s, 3H), 1.97 (s, 3H) ppm. 
13C-NMR (75.5 MHz, CD3CN): δ = 167.3 (Cq), 101.4 (Cq), 100.4 (Cq), 88.9, 86.8, 84.0 (Cq), 83.0, 
13.8, 13.7 ppm.  
ATR-IR (neat) ~ = 3095 (vw), 2611 (vw), 1707 (m), 1443 (w), 1385 (vw), 1306 (vw), 1265 (w), 
1074 (vw), 1040 (vw), 924 (vw), 825 (vs), 744 (m), 616 (vw), 553 (m), 480 (m) cm-1. 
HR-MS (ESI+): C14H15O2Ru (M)
+ calcd.: 317.0114, found: 317.0109.  
 
5.2.2.5. Synthesis of (η6-benzene)(η5-2-(trimethylsilyl)ethyl-2,4-dimethylcyclopenta-
dienylcarboxylat) ruthenium hexafluorophosphate 
 
The ester coupling was performed according to a similar literature procedure using a non-
methylated cyclopentadiene.[49] A solution of 800 mg of the carboxylic acid 178 (1.73 mmol, 
1.00 eq) in 7.8 mL CH3CN was purged with N2 before 497 μL 2-(trimethylsilyl)ethanol (3.47 mmol, 
2.00 eq), 283 μL pyridine (3.47 mmol, 2.00 eq) and 352 mg N-(3-dimethylaminopropyl)-N′-
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ethylcarbodiimide hydrochloride (2.27 mmol, 1.31 eq) were added. The reaction mixture was left 
to stir over night at room temperature. The mixture was diluted with 80 mL CH2Cl2, washed with 
saturated NH4Claq, solution and brine (each 20 mL) dried over Na2SO4 and filtered. The solvent 
was removed in vacuo and the crude material was subjected to silica gel chromatography 
(CH3CN/H2O/KNO3 aq, sat 50:3:1 to 50:6:2). The combined product eluents were dried under 
reduced pressure and the remaining residue was dissolved in 50 mL H2O. Excess NH4PF6 was 
added and the product extracted with CH2Cl2 (250 mL). The organic layer was washed with 40 mL 
H2O, dried over Na2SO4, filtered, and removed in vacuo to result in 669 mg (1.19 mmol, 69%) of 
the ethyl-TMS-ester 179 as brown solid. 
1H-NMR (300.1 MHz, CD3CN): δ = 6.05 (s, 6H), 5.68 (d, 
4J = 1.5 Hz, 1H), 5.48 (d, 4J = 1.4 Hz, 
1H), 4.35-4.28 (m, 2H), 2.21 (s, 3H), 1.97 (s, 3H), 1.13-1.07 (m, 2H), 0.08 (s, 9H, TMS) ppm.  
13C-NMR (75.5 MHz, CD3CN): δ = 166.7 (Cq), 101.2 (Cq), 100.4 (Cq), 88.8, 86.7, 84.7 (Cq), 82.6, 
65.0, 18.0, 13.8, 13.7, -1.5 (3C) ppm.  
ATR-IR (neat) ~ = 3096 (vw), 2952 (vw), 2928 (vw), 1725 (m) 1492 (vw), 1442 (w), 1417 (w), 
1386 (w), 1301 (vw), 1251 (w), 1224 (s), 1174 (w), 1062 (m), 1041 (w), 943 (vw), 929 (vw), 825 (vs), 
781 (w), 761 (w), 717 (w), 695 (w), 627 (w), 613 (vw), 556 (s), 464 (w), 414 (w), 396 (w) cm-1. 
HR-MS (ESI+): C19H27O2RuSi (M)
+ calcd.: 417.0823, found: 417.0839. 
 
5.2.2.6. Synthesis of η5-2-(trimethylsilyl)ethyl-2,4-dimethylcyclopentadienyl carboxylate) 
ruthenium hexafluorophosphate 
 
A clear solution of 669 mg of the TMS-ester 179 (1.19 mmol, 1.00 eq) in 800 mL CH3CN was 
irradiated with a medium pressure Hg lamp (750 W) for 5.5 h with a stream of N2 flowing through 
the solution throughout the photolysis. The solvent was removed in vacuo and the tris-acetonitrile 
complex was redissolved in 80.5 mL CH3CN. The resulting solution was purged with CO (g) for 
10 min and stirred under CO atmosphere for 16 h at room temperature. After removal of the 
solvent under reduced pressure, 691 mg of the desired product 180 (1.16 mmol, 97%) was obtained 
as a brown solid. 
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1H-NMR (300.1 MHz, CD3CN): δ = 5.36 (d, 
4J = 1.7 Hz, 1H), 5.00 (d, 4J = 1.7 Hz, 1H), 4.31-4.25 
(m, 2H), 2.39 (s, 3H), 2.39 (s, 3H), 2.06 (s, 3H), 1.81 (s, 3H), 1.08-1.02 (m, 2H), 0.06 (m, 9H) ppm.  
13C-NMR (75.5 MHz, CD3CN): δ = 198.8 (Cq), 167.0 (Cq), 129.2 (Cq), 114.5 (Cq), 102. (Cq), 82.4, 
80.9, 75.2 (Cq), 64.8, 18.1, 13.3, 12.9, 4.4, 1.5 (3C) ppm.  
ATR-IR (neat) ~ = 2954 (vw), 2924 (vw), 2854 (vw), 1994 (m), 1712 (m), 1491 (vw), 1415 (w), 
1377 (vw), 1298 (vw), 1248 (w), 1223 (m), 1177 (w), 1067 (w), 1037 (w), 945 (vw), 827 (vs), 775 
(w), 740 (w), 697 (w), 611 (vw), 556 (s), 508 (w), 456 (w), 422 (vw), 389 (vw). 
HR-MS (ESI+): C18H27N2O3RuSi (M)
+ calcd.: 449.0834, found: 449.0831. 
 
5.2.2.7. Synthesis of η5-2-(trimethylsilyl)ethyl-2,4-dimethylcyclopentadienyl carboxylate) 
diastereomeric complexes 182a and 182b 
 
A suspension of 452 mg TBS-protected isoquinolinocarbazole 181[148] (1.00 mmol, 1.00 eq), 669 mg 
precursor 180 (1.12 mmol, 1.12 eq), and 152 mg K2CO3 (1.10 mmol, 1.10 eq) in a 15:4:1 mixture 
of CH3CN/CH2Cl2/2-TMS-EtOH (35 mL, 9.3 mL, 2.3 mL) was stirred at 30 °C over night. The 
solvent was removed in vacuo and the crude material was subjected to silica gel chromatography 
with toluene as eluent. The combined product eluents were dried resulting in 565 mg of the 
diastereomeric mixture 182a and 182b (0.69 mmol, 69%) as a dark red solid. Before HPLC 
separation, the material was dissolved in 3.5 mL CH2Cl2 and filtered through a syringe filter (PVDF, 
0.2 μm). The diastereomers were separated via semipreparative HPLC using a 100-5 
NUCLEODUR® silica column (10 x 250 mm, MACHEREY-NAGEL, 30 °C, 93:7 hexane/ethyl acetate, 
flow rate = 6.0 mLmin-1). For each run 50 μL of the prepared CH2Cl2 solution was injected which 
resulted in a clean separation of the two diastereomers.  
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182a: 
1H-NMR (300.1 MHz, CDCl3): δ = 10.58 (dd, 
3J = 8.5 Hz, 4J = 0.5 Hz, 1H), 9.47 (s, 1H), 9.10 (d, 
3J = 7.8 Hz, 1H), 8.14-8.05 (m, 2H), 7.84 (ddd, 3J = 7.9 Hz, 3J = 7.0 Hz, 4J = 0.9 Hz, 1H), 7.62-7.52 
(m, 2H), 7.38 (ddd, 3J = 7.9 Hz, 3J = 6.7 Hz, 4J = 1.4 Hz, 1H), 5.48 (d, 4J = 1.6 Hz, 1H), 4.92 (d, 
4J = 1.6 Hz, 1H), 3.78 (ddd, 2J = 12.2 Hz, 3J = 10.9 Hz, 3J = 5.6 Hz, 1H), 3.61 (ddd, 2J = 12.2 Hz, 
3J = 10.9 Hz, 3J = 5.6 Hz, 1H), 2.14 (s, 3H, Cp-CH3), 1.91 (s, 3H, Cp-CH3), 1.09 (s, 9H, TBS), 0.67 
(s, 6H, TBS), 0.21-0.00 (m, 2H),  -0.25 (s, 9H, TMS) ppm. 
13C-NMR (125.8 MHz, CDCl3): δ = 200.6 (Cq), 175.4 (Cq), 174.8 (Cq), 165.9 (Cq), 159.6, 156.0 (Cq), 
152.4 (Cq), 140.0 (Cq), 133.6 (Cq), 133.0, 132.8 (Cq), 130.3, 128.5, 128.2, 128.2 (Cq), 126.6, 126.2, 
124.5 (Cq), 120.4 (Cq), 119.6, 117.3 (Cq), 116.2 (Cq), 116.1 (Cq), 114.9, 100.0 (Cq), 82.6 (Cq), 79.5, 73.5, 
63.0, 26.8, 19.4 (Cq), 17.2, 14.4, 13.9, -1.7, -3.4 ppm. 
ATR-IR (neat) ~ = 3121 (vw), 3089 (vw), 3062 (vw), 2952 (w), 2892 (w), 2856 (w), 1952 (vs), 
1737 (w), 1683 (vs), 1619 (w), 1577 (w), 1533 (w), 1465 (w), 1433 (w), 1370 (w), 1327 (m), 1293 
(vs), 1254 (w), 1221 (s), 1172 (w), 1069 (m), 1034 (w), 938 (w), 827 (vs), 756 (s), 690 (w), 659 (w), 
612 (vw), 581 (vw), 550 (vw), 502 (vw), 438 (vw), 407 (vw) cm-1. 
HR-MS (ESI+): C41H45N3O5RuSi2Na (M+Na
+) calcd.: 840.1844, found: 840.1838. 
182b: 
1H-NMR (300.1 MHz, CDCl3): δ = 10.58 (d, 
3J = 8.5 Hz, 1H), 9.36 (s, 1H), 9.09 (d, 3J = 7.9 Hz, 
1H), 8.12-8.03 (m, 2H), 7.82 (ddd, 3J = 8.0 Hz, 3J = 7.0 Hz, 4J = 0.9 Hz, 1H), 7.65-7.58 (m, 2H), 
7.38 (ddd, 3J = 8.0 Hz, 3J = 5.9 Hz, 4J = 2.1 Hz, 1H), 5.72 (d, 4J = 1.4 Hz, 1H), 5.11 (d, 4J = 1.7 Hz, 
1H), 4.24-4.05 (m, 2H), 2.30 (s, 3H), 1.69 (s, 3H), 1.09 (s, 9H, TBS), 0.77-0.69 (m, 2H), 0.67 (s, 6H, 
TBS), 0.02 (s, 9H, TMS) ppm. 
13C-NMR (125.8 MHz, CDCl3): δ = 200.1 (Cq), 175.4 (Cq), 174.7 (Cq), 168.2 (Cq), 158.1, 155.6 (Cq), 
152.7 (Cq), 140.2 (Cq), 133.6 (Cq), 133.0 (Cq), 133.0, 130.3, 128.4, 128.2 (Cq), 128.0, 126.8, 126.2, 
124.5 (Cq), 120.7 (Cq), 119.6, 117.1 (Cq), 116.4 (Cq), 114.7, 107.5 (Cq), 104.7 (Cq), 90.4, 75.9 (Cq), 73.7, 
63.3, 26.8, 19.4 (Cq), 17.4, 14.3, 13.2, -1.4, -3.4 ppm. 
ATR-IR (neat) ~ = 3120 (vw), 3091 (vw), 3061 (vw), 2950 (w), 2892 (w), 2855 (w), 1954 (vs), 
1738 (w), 1682 (vs), 1619 (w), 1577 (w), 1533 (w), 1466 (w), 1431 (w), 1368 (w), 1327 (m), 1293 
(vs), 1255 (w), 1220 (s), 1069 (m), 1034 (w), 935 (w), 826 (s), 755 (s), 690 (w), 658 (w), 612 (vw), 
581 (vw) cm-1. 
HR-MS (ESI+): C41H45N3O5RuSi2Na (M+Na)
+ calcd.: 840.1844, found: 840.1831. 
Experimental part 
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5.2.2.8. Synthesis of η5-2,4-dimethylcyclopentadienylcarboxylic acid complex 183a  
 
To a solution of the bisprotected complex 182a (140 mg, 171 μmol, 1.00 eq) in 14 mL THF was 
added 685 μL tetrabutylammoniumfluoride (1 M in THF, 685 μmol, 4.00 eq) and the reaction 
mixture was heated to 45 °C for 2 h under nitrogen atmosphere. After cooling to 0 °C, 7 mL 
saturated NH4Claq solution was added. The complex was extracted with EtOAc (2x 20 mL) and 
washed with 15 mL HClaq. (1 M), 20 mL water, and 15 mL brine. The organic layer was dried using 
MgSO4, filtered, and the solvent in vacuo. The crude material was subjected to silica gel 
chromatography (dry load, CH2Cl2 to CH2Cl2/MeOH 50:1 to 10:1). The combined product eluents 
were dried to provide carboxylic acid 183a (107 mg, quant.) as a red-purple solid. Small aliphatic 
impurities were carried over to the next step.  
1H-NMR (300.1 MHz, DMSO-d6): δ = 12.35 (br s, 1H), 11.35 (s, 1H), 10.55 (d, 
3J = 8.5 Hz, 1H), 
10.06 (s, 1H), 8.88 (d, 3J = 7.8 Hz, 1H), 8.43 (d, 3J = 7.6 Hz, 1H), 8.16 (ddd, 3J = 8.8 Hz, 
3J = 7.2 Hz, 4J = 1.0 Hz, 1H), 8.02-7.97 (m, 1H), 7.68 (d, 3J = 8.2 Hz, 1H), 7.60-7.54 (m, 1H), 7.36-
7.31 (m, 1H), 5.87 (d, 4J = 1.0 Hz, 1H), 5.44 (d, 4J = 1.2 Hz, 1H), 2.01 (s, 3H), 1.92 (s, 3H) ppm. 
13C-NMR (100.6 MHz, DMSO-d6): δ = 201.8 (Cq), 170.9 (Cq), 170.0 (Cq), 166.8 (Cq), 161.3, 
154.9 (Cq), 151.9 (Cq), 138.8 (Cq), 132.9, 131.5 (Cq), 131.3 (Cq), 129.4, 128.9, 128.6, 128.0 (Cq), 126.6, 
125.0, 123.4 (Cq), 119.8 (Cq), 119.1, 116.3 (Cq), 115.3, 114.7 (Cq), 114.3 (Cq), 101.4 (Cq), 82.7, 82.0 
(Cq), 72.3, 13.6, 13.3 ppm. 
ATR-IR (neat) ~ = 2922 (w), 2853 (vw), 2736 (vw), 1940 (s), 1740 (w), 1692 (s), 1618 (vw), 1577 
(m), 1533 (w), 1483 (w), 1459 (w), 1433 (w), 1377 (w), 1328 (w), 1294 (w), 1223 (m), 1164 (vw), 
1124 (vw), 1019 (m), 996 (m), 863 (vw), 818 (w), 752 (s), 691 (m), 639 (m), 582 (vw), 549 (w), 512 
(w), 494 (w), 461 (m), 440 (w) cm-1. 
HR-MS (ESI+): C30H19N3O5RuNa (M+Na)
+ calcd.: 626.0269, found: 626.0260. 
 
Compound preparation for toxicity approach 
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5.2.2.9. Synthesis of η5-2,4-dimethylcyclopentadienylcarboxylic acid complex 183b 
 
To a solution of 181 mg of the TMS-ester 182b (222 μmol, 1.00 eq) in 18.1 mL THF was added 
886 μL of tetrabutylammoniumfluoride in THF (1 M, 886 μmol, 4.00 eq). The reaction mixture was 
stirred for 2 h at 45 °C under nitrogen atmosphere and was than cooled to 0 °C. The reaction was 
quenched by dropwise addition of 9 mL saturated NH4Claq solution. The product was extracted 
with EtOAc (2 x 20 mL) and the combined organic layers were washed with 1 M HCl and brine 
(each 20 mL), dried over Na2SO4, filtered, and evaporated. The solvent was removed under reduced 
pressure and the crude product was subjected to silica gel chromatography (CH2Cl2 to 
CH2Cl2/MeOH 40:1 to 5:1). Insoluble residues were washed from the column with acetone and 
subjected to a second silica gel chromatography. The combined product eluents were dried to 
provide carboxylic acid 183b (157 mg, quant.) as a red-purple solid. Small aliphatic impurities were 
carried over to the next step.  
1H-NMR (300.1 MHz, DMSO-d6): δ = 11.35 (s, 1H, NH), 10.52 (d, 
3J = 8.6 Hz, 1H), 9.82 (s, 1H), 
8.88 (d, 3J = 7.8 Hz, 1H), 8.38 (d, 3J = 7.7 Hz, 1H), 8.14-8.09 (m, 1H), 7.94-7.89 (m, 1H), 7.79 (d, 
3J = 8.2 Hz, 1H), 7.63-7.58 (m, 1H), 7.37-7.32 (m, 1H), 5.87 (s, 1H, HCp), 5.49 (d, J = 1.5 Hz, 1H, 
HCp), 2.23 (s, 3H, Cp-CH3), 1.65 (s, 3H, Cp-CH3) ppm. 
13C-NMR (100.6 MHz, DMSO-d6): δ = 201.6 (Cq), 171.0 (Cq), 170.0 (Cq), 169.3 (Cq), 158.9, 
154.7 (Cq), 152.2 (Cq), 139.2 (Cq), 132.8, 131.5 (Cq), 131.4 (Cq), 129.2, 128.9, 128.5, 127.5 (Cq), 126.7, 
124.9, 123.4 (Cq), 120.0 (Cq), 119.1, 116.3 (Cq), 115.3, 114.2 (Cq), 108.2 (Cq), 104.8 (Cq), 89.7, 77.9 
(Cq), 74.1, 13.5, 12.6 ppm. Signals belonging to the Cp-system appear as tiny broad signals in the 
spectrum and are indicated as bold characters.          
ATR-IR (neat) ~ = 3091 (vw), 3048 (vw), 2957 (vw), 2870 (vw), 1972 (s), 1939 (m), 1740 (w), 
1684 (s), 1621 (vw), 1579 (m), 1536 (vw), 1460 (w), 1436 (m), 1376 (w), 1345 (w), 1327 (m), 1298 
(w), 1261 (w), 1225 (m), 1157 (vw), 1125 (vw), 1069 (w), 1019 (w), 972 (vw) 911 (vw), 867 (w), 742 
(m), 691 (w), 638 (m), 612 (vw), 580 (vw), 546 (w), 506 (w), 463 (m), 436 (w) 395 (vw) cm-1.  
HR-MS (ESI+): C30H19N3O5RuNa (M+Na)
+ calcd.: 626.0265, found: 626.0256. 
Experimental part 
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5.2.2.10. Synthesis of NHS-ester complex 184a 
 
A solution of the carboxylic acid 183a (85 mg, 141 μmol, 1.00 eq) in 5 mL DMF was purged with 
nitrogen and cooled to 0 °C. N-hydroxysuccinimide (24 mg, 212 μmol, 1.50 eq) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (41 mg, 212 µmol, 1.50 eq) were added and the mixture was 
stirred at room temperature overnight. The solution was cooled to 0 °C, diluted with 10 mL 
CH2Cl2, and 6 mL saturated NH4Claq solution were added dropwise. The organic layers were 
separated and the aqueous layer was extracted with CH2Cl2 (15 mL). The combined organic layers 
were washed with water (2 x 15 mL) and brine (15 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude material was purified via silica gel chromatography (CH2Cl2 to 
CH2Cl2/MeOH 200:1 to 100:1). The combined product eluents were dried to provide the active 
ester 184a (95 mg, 136 µmol, 96%) as a dark red solid. Small aliphatic impurities were carried over 
to the next step. 
1H-NMR (300.1 MHz, DMSO-d6): δ = 11.35 (s, 1H), 10.55 (d, 
3J = 8.6 Hz, 1H), 10.08 (s, 1H), 
8.87 (d, 3J = 7.2 Hz, 1H), 8.36 (dd, 3J = 8.2 Hz, 4J = 0.9 Hz, 1H), 8.14 (ddd, 3J = 8.5 Hz, 
3J = 7.1 Hz, 4J = 1.4 Hz, 1H), 7.99-7.94 (m, 2H), 7.66 (d, 3J = 8.2 Hz, 1H), 7.56 (ddd, 3J = 8.0 Hz, 
3J = 7.0 Hz, 4J = 1.1 Hz, 1H), 7.33 (ddd, 3J = 7.8 Hz, 3J = 7.1 Hz, 4J = 0.8 Hz, 1H), 6.26 (d, 
4J = 1.2 Hz, 1H), 5.66 (d, 4J = 1.3 Hz, 1H), 2.16 (s, 3H), 2.07 (s, 3H) ppm. The signals of the 
succinimide CH2 groups are located under the DMSO signal. 
13C-NMR (100.6 MHz, DMSO-d6): δ = 200.8 (Cq), 171.1 (2Cq), 170.0 (2Cq), 161.6 (Cq), 161.5, 
155.2 (Cq), 151.5 (Cq), 139.1 (Cq), 132.8, 131.7 (Cq), 131.3 (Cq), 129.3, 128.9, 128.4, 128.3 (Cq), 126.6, 
125.0, 123.5 (Cq), 120.5 (Cq), 119.1, 116.5 (Cq), 116.2, 115.2 (Cq), 114.7 (Cq), 100.7 (Cq), 83.6, 75.4 
(Cq), 73.8, 25.1 (2C), 14.0, 13.4 ppm. 
ATR-IR (neat) ~ = 3051 (vw), 2961 (vw), 2923 (vw), 2854 (vw), 1956 (s), 1735 (s), 1697 (s), 1660 
(s), 1578 (m), 1533 (w), 1484 (w), 1459 (w), 1433 (w), 1404 (w), 1378 (w), 1330 (w), 1328 (w), 1295 
(w), 1263 (w), 1224 (w), 1197 (m), 1158 (w), 1093 (w), 1062 (s), 1017 (m), 964 (w), 935 (w), 865 
(vw), 804 (w), 747 (s), 689 (w), 639 (w), 608 (w), 549 (vw), 515 (vw), 462 (w), 438 (w), 393 (w) cm-1. 
HR-MS (ESI+): C34H22N4O7RuH (M+H)
+ calcd. 701.0614, found 701.0610. 
Compound preparation for toxicity approach 
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5.2.2.11. Synthesis of NHS-ester complex 184b 
 
A solution of the carboxylic acid 183b (52 mg, 86.3 μmol, 1.00 eq) in 5 mL DMF was purged with 
nitrogen and cooled to 0 °C. N-hydroxysuccinimide (15 mg, 129 μmol, 1.50 eq) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (25 mg, 129 µmol, 1.50 eq) were added and the mixture was 
stirred at room temperature overnight. The solution was cooled to 0 °C, diluted with 5 mL CH2Cl2, 
5 mL saturated NH4Cl solution were added dropwise and further diluted with 5 mL H2O. The 
organic layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL). The 
combined organic layers were washed with water (2 x 20 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude material was purified via silica gel chromatography (eluent 
hex/EtOAc 10:1 to 1:1). The combined product eluents were dried to provide the active ester 184b 
(50 mg, 83%) as a dark red solid. Small aliphatic impurities were carried over to the next step. 
1H-NMR (300.1 MHz, DMSO-d6): δ = 11.40 (s, 1H), 10.56 (d, 
3J = 8.6 Hz), 9.96 (s, 1H), 8.89 (d, 
3J = 7.6 Hz, 1H), 8.44 (dd, 3J = 8.3 Hz, 4J = 0.9 Hz, 1H), 8.18 (ddd, 3J = 8.6 Hz, 3J = 7.1 Hz, 
4J = 1.4 Hz, 1H), 8.00 (ddd, 3J = 8.0 Hz, 3J = 7.0 Hz, 4J = 0.8 Hz, 1H), 7.83 (d, 3J = 8.3 Hz, 1H), 
7.63 (ddd, 3J = 8.2 Hz, 3J = 7.1 Hz, 4J = 1.2 Hz, 1H), 7.37 (ddd, 3J = 7.8 Hz, 3J = 7.1 Hz, 
4J = 0.7 Hz, 1H), 6.19 (d, 4J = 1.0 Hz, 1H), 6.00 (d, 4J = 1.6 Hz, 1H), 2.98 (br s, 4H), 2.40 (s, 3H), 
1.46 (s, 3H) ppm. 
13C-NMR (100.6 MHz, DMSO-d6): δ = 200.0 (2Cq), 170.9 (2Cq), 169.9 (2Cq), 164.5 (Cq), 159.4, 
154.6 (Cq), 151.8 (Cq), 139.0 (Cq), 133.2, 131.6 (2Cq), 129.3, 128.9, 128.7, 127.8 (Cq), 127.0, 125.0, 
123.5 (Cq), 120.4 (Cq), 119.3, 116.3 (Cq), 114.9, 114.7 (Cq), 109.6 (Cq), 106.5 (Cq), 94.7, 75.1 (Cq), 66.9, 
25.6 (2C), 14.0, 11.9 ppm. 
ATR-IR (neat) ~  = 3441 (w), 3110 (vw), 304 (vw), 2925 (vw), 1934 (s), 1734 (vs), 1621 (w), 1580 
(w), 1534 (w), 1483 (w), 1462 (w), 1433 (w), 1405 (w), 1373 (w), 1329 (w), 1296 (w), 1204 (m), 1158 
(w), 1064 (m), 1013 (w), 968 (w), 936 (w), 875 (vw), 814 (vw), 743 (s), 691 (w), 642 (m), 609 (w), 
556 (w), 496 (m), 461 (m), 432 (vw), 395 (vw) cm-1. 
HR-MS (ESI+): C34H22N4O7RuH (M+H)
+ calcd.: 701.0614, found: 701.0610. 
Experimental part 
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5.2.2.12. Synthesis of np830 (80a) 
 
A solution of the active ester 184a (46 mg, 65.7 μmol, 1.00 eq) and ethanolamine (235 μL, 
240 μmol, 3.65 eq) in 5 mL DMF was purged with nitrogen for 10 min and stirred at room 
temperature for 7 h. The reaction mixture was diluted with CH2Cl2 and washed with water 
(2 x 10 mL) and brine (5 mL). The aqueous layer was extracted with CH2Cl2 and the combined 
organic layers were dried over MgSO4 and filtered. The solvent was removed in vacuo after addition 
of 300 mg silica gel and the crude material was purified via silica gel chromatography using CH2Cl2 
and CH2Cl2/MeOH (100:1 to 50:1). The combined product eluents were concentrated, extensively 
washed with water and subjected a second time to silica gel chromatography to provide the desired 
complex 185a (33 mg, 51.1 μmol, 78%) as a red-purple solid.  
1H-NMR (300.1 MHz, DMSO-d6): δ = 11.33 (s, 1H), 10.54 (d, 
3J = 8.6 Hz, 1H), 9.97 (s, 1H), 8.87 
(d, 3J = 7.8 Hz, 1H), 8.37 (dd, 3J = 8.1 Hz, 4J = 1.0 Hz, 1H), 8.15 (ddd, 3J = 8.6, 3J = 7.1, 4J = 1.5 Hz 
1H), 8.01-7.96 (m, 2H), 7.62 (d, 3J = 8.0 Hz, 1H), 7.57 (ddd, 3J = 6.8 Hz, 3J = 8.2 Hz, 4J = 1.2 Hz, 
1H), 7.33 (ddd, 3J = 6.8 Hz, 3J = 7.9 Hz, 4J = 1.2 Hz, 1H), 5.89 (d, 4J = 1.2, 1H), 5.36 (d, 
4J = 1.3 Hz, 1H), 4.47 (t, 3J = 4.4 Hz, 1H), 3.04-2.69 (m, 4H), 1.94 (s, 3H), 1.93 (s, 3H) ppm.  
13C-NMR (125.8 MHz, DMSO-d6): δ = 202.0 (Cq), 171.0 (Cq), 170.0 (Cq), 164.1 (Cq), 160.6, 
155.0 (Cq), 152.2 (Cq), 138.8 (Cq), 132.8, 131.5 (Cq), 131.2 (Cq), 129.1, 128.9, 128.6, 127.9 (Cq), 126.5, 
124.9, 123.4 (Cq), 119.8 (Cq), 119.0, 116.3 (Cq), 115.3, 114.1 (Cq), 112.9 (Cq), 102.5 (Cq), 86.6, 78.7 
(Cq), 72.1, 59.2, 41.4, 13.3, 13.2 ppm.  
ATR-IR (neat) ~ = 3303 (vw), 3183 (vw), 3074 (vw), 2919 (vw), 2852 (vw), 1927 (s), 1745 (w), 
1697 (m), 1631 (m), 1577 (w), 1537 (m), 1464 (w), 1434 (w), 1378 (w), 1335 (m), 1296 (m), 1261 
(w), 1224 (m), 1168 (vw), 1110 (vw), 1071 (w), 1016 (w), 939 (vw), 866 (vw), 807 (w), 758 (s), 719 
(m), 690 (m), 639 (m), 507 (w), 559 (w), 513 (w), 463 (m), 435 (w) cm-1. 
HR-MS (ESI+): C32H24N4O5RuNa (M+H)
+ calcd.: 669.0691, found.: 669.0669. 
Compound preparation for toxicity approach 
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5.2.2.13.  Synthesis of np829 (80b) 
 
A solution of the active ester 184b (50 mg, 71.5 μmol, 1.00 eq) and ethanolamine (210 μL, 
214 μmol, 3.00 eq) in 5 mL DMF was purged with nitrogen for 10 min and stirred at room 
temperature for 3 h. The reaction mixture was diluted with CH2Cl2 and washed with water 
(2 x 15 mL) and brine (15 mL). The aqueous layer was extracted with CH2Cl2 and the combined 
organic layers were dried over MgSO4, filtered, and the residue was washed extensively with CH2Cl2 
and traces of acetone. The solvents were removed in vacuo after addition of 200 mg silica gel and 
the crude material was purified via silica gel chromatography using CH2Cl2 and CH2Cl2/MeOH 
(100:1 to 50:1). The combined product eluents were dried to provide the desired complex 185b 
(43 mg, 66.6 μmol, 93%) as a red-purple solid. 
1H-NMR (300.1 MHz, DMSO-d6): δ = 11.35 (s, 1H), 10.56 (d, 
3J = 8.7 Hz, 1H), 9.66 (s, 1H), 8.87 
(d, 3J = 7.5 Hz, 1H), 8.40 (d, 3J = 7.2 Hz, 1H), 8.16 (ddd, 3J = 7.0 Hz, 3J = 8.6 Hz, 4J = 1.4, 1H), 
8.02-7.95 (m, 2H), 7.78 (d, 3J = 8.2 Hz, 1H), 7.60 (ddd, 3J = 7.1 Hz, 3J = 8.2 Hz, 4J = 1.2 Hz, 1H), 
7.36-7.31 (m, 1H), 5.96 (d, 4J = 1.4 Hz, 1H), 5.42 (d, 4J = 1.5 Hz, 1H), 4.69 (t, 3J = 5.5 Hz, 1H), 
3.33-3.23 (m, 2H), 3.22-3.11 (m, 2H), 2.21 (s, 3H), 1.63 (s, 3H) ppm.  
13C-NMR (100.6 MHz, DMSO-d6): δ = 201.6 (Cq), 171.0 (Cq), 170.0 (Cq), 165.4 (Cq), 159.1, 
154.7 (Cq), 152.0 (Cq), 139.1 (Cq), 132.8, 131.5 (Cq), 131.4 (Cq), 129.4, 128.9, 128.6, 127.6 (Cq), 126.6, 
124.9, 123.4 (Cq), 120.0 (Cq), 119.1, 116.3 (Cq), 115.3, 114.1 (Cq), 107.6 (Cq), 106.4 (Cq), 84.9, 81.9(Cq), 
72.4, 59.4, 41.7, 13.4, 12.8 ppm.  
ATR-IR (neat) ~ = 3456 (vw), 3361 (vw), 3173 (vw), 3085 (vw), 2929 (vw), 1943 (s), 1742 (m), 
1688 (m), 1628 (w), 1577 (w), 1527 (m), 1481 (vw), 1459 (w), 1434 (w), 1378 (w), 1330 (w), 1293 
(m), 1268 (w), 1224 (m), 1162 (vw), 1123 (vw), 1063 (w), 1020 (w), 905 (vw), 864 (vw), 847 (vw), 
811 (vw), 743 (s), 691 (w), 642 (w), 579 (vw), 555 (w), 498 (w), 462 (w), 433 (vw). 
HR-MS (ESI+): C32H24N4O5RuH (M+H)
+ calcd.: 647.0872, found: 647.0866. 
 
Experimental part 
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5.2.3. Synthesis of structural derivatives of 80a and 80b 
5.2.3.1. Synthesis of picolylamine derivative (93a) 
 
A solution of the active ester 184a (10 mg, 14.3 μmol) and 2-picolylamine (4.6 μL, 44.6 μmol) in 
1 mL DMF was purged with nitrogen for 10 min and stirred at room temperature for 16 h. The 
reaction mixture was diluted with CH2Cl2 and washed with H2O (2x10 mL) and brine (5 mL). The 
solvent was removed in vacuo and the crude material was purified via silica gel chromatography 
using CH2Cl2 and CH2Cl2/MeOH (100:1 to 40:1). The combined product eluents were 
concentrated to provide the desired complex 93a (8.6 mg, 12.4 μmol, 87%) as a red-purple solid.  
1H-NMR (300.1 MHz, DMSO-d6): δ = 11.35 (s, 1H), 10.54 (d, 
3J = 7.6 Hz, 1H), 10.0 (s, 1H), 8.88 
(d, 3J = 7.5 Hz, 1H), 8.56 (t, 3J = 5.9 Hz, 1H), 8.29 (dd, 3J = 8.1 Hz, 4J = 0.8 Hz, 1H), 8.22 (dq, 
3J = 4.8 Hz, 4J = 0.9 Hz, 1H), 8.14 (ddd, 3J = 7.0 Hz, 3J = 8.5 Hz, 4J = 1.4 Hz, 1H), 7.95 (ddd, 
3J = 7.1 Hz, 3J = 7.9 Hz, 4J = 0.9 Hz, 1H), 7.66 (d, 3J = 8.2 Hz, 1H), 7.56 (ddd, 3J = 7.0 Hz, 
3J = 8.1 Hz, 4J = 1.1 Hz, 1H), 7.33 (ddd, 3J = 7.9 Hz, 3J = 7.0 Hz, 4J = 0.9 Hz, 1H), 7.13 (td, 
3J = 7.6 Hz, 4J = 1.8 Hz, 1H), 7.16 (ddd, 3J = 7.4 Hz, 3J = 4.8 Hz, 4J = 1.1 Hz, 1H), 6.49 (d, 
3J = 8.1 Hz, 1 H), 6.01 (d, 4J = 1.2 Hz, 1H), 5.39 (d, 4J = 1.2 Hz, 1H), 4.04 (t, 3J = 6.1 Hz, 2H), 2.02 
(s, 3H), 1.96 (s, 3H) ppm.  
13C-NMR (100.6 MHz, DMSO-d6): δ = 201.9 (Cq), 171.0 (Cq), 170.0 (Cq), 164.3 (Cq), 160.8, 157.9, 
155.0 (Cq), 152.0 (Cq), 148.4, 138.9 (Cq), 136.0, 132.8, 131.5 (Cq), 131.3 (Cq), 129.2, 128.9, 128.5, 
127.8 (Cq), 126.6, 124.9, 123.4 (Cq), 121.7, 120.1, 119.8 (Cq), 119.0, 116.3 (Cq), 115.3, 114.3 (Cq), 
114.2 (Cq), 101.4, 86.5, 78.5, 72.0, 44.2, 13.6, 13.5 ppm.  
HR-MS (ESI+): C36H25N5O4RuH (M+H)
+ calcd.: 694.1033, found: 694.1020. 
ATR-IR (neat): ~ = 3059 (vw), 2923 (vw), 2851 (vw), 2724 (vw), 1942 (s), 1745 (w), 1695 (m), 
1643 (w), 1578 (w), 1534 (w), 1479 (vw), 1461 (w), 1435 (w), 1377 (w), 1340 (w) 1325 (w), 1295 
(w), 1271 (w), 1226 (m), 1167 (vw), 1149 (vw), 1078 (m), 1128 (vw), 1074 (vw), 1048 (vw), 1021 
(m), 1006 (w), 971 (w), 945 (vw), 865 (vw), 748 (s), 690 (w), 645 (w), 634 (w), 610 (vw), 552 (w), 
514 (vw), 500 (w), 463 (m) cm-1. 
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5.2.3.2. Synthesis of picolylamine derivative (93b) 
 
A solution of 10 mg of the active ester 184b (14.3 μmol) and 4.6 μL 2-picolylamine (44.6 μmol) in 
1 mL DMF was purged with nitrogen for 10 min and stirred at room temperature for 16 h. The 
reaction mixture was diluted with CH2Cl2 and washed with H2O (2 x 10 mL) and brine (5 mL). The 
solvent was removed in vacuo and the crude material was purified via flash chromatography (3 g 
silica, CH2Cl2 to CH2Cl2/MeOH 100:1 to 10:1). The combined product eluents were concentrated 
to provide the desired complex 93b (4.2 mg, 6.1 μmol, 42%) as a red-purple solid.  
1H-NMR (300.1 MHz, DMSO-d6): δ = 11.36 (s, 1H), 10.54 (d, 
3J = 8.6 Hz, 1H), 9.73 (s, 1H), 8.89 
(d, 3J = 7.5 Hz, 1H), 8.57 (t, 3J = 5.8 Hz, 1H), 8.39 (ddd, 3J = 4.7 Hz, 4J = 1.7 Hz, 4J = 0.8 Hz, 1H), 
8.28 (dd, 3J = 8.4 Hz, 4J = 0.9 Hz, 1H), 8.15 (ddd, 3J = 7.1 Hz, 3J = 8.5 Hz, 4J = 1.4 Hz, 1H), 7.96 
(ddd, 3J = 7.0 Hz, 3J = 7.9 Hz, 4J = 0.9 Hz, 1H), 7.78 (d, 3J = 8.2 Hz, 1H), 7.59 (ddd, 3J = 7.1 Hz, 
3J = 8.2 Hz, 4J = 1.1 Hz, 1H), 7.41 (td, 3J = 7.7 Hz, 4J = 1.8 Hz, 1H), 7.34 (ddd, 3J = 7.1 Hz, 
3J = 7.9 Hz, 4J = 0.7 Hz, 1H), 7.16 (ddd, 3J = 7.5 Hz, 3J = 4.8 Hz, 4J = 0.9 Hz, 1H), 6.67 (d, 
3J = 7.8 Hz, 1 H), 6.13 (d, 4J = 1.2 Hz, 1H), 5.38 (d, 4J = 1.3 Hz, 1H), 4.32 (t, 3J = 5.0 Hz, 2H), 2.18 
(s, 3H), 1.78 (s, 3H) ppm.  
13C-NMR (100.6 MHz, DMSO-d6): δ = 201.6 (Cq), 171.0 (Cq), 170.0 (Cq), 165.4 (Cq), 159.2, 158.3, 
154.8 (Cq), 152.3 (Cq), 148.6, 139.2 (Cq), 136.4, 132.9, 131.5 (Cq), 131.4 (Cq), 129.3, 128.9, 128.6, 
127.7 (Cq), 126.8, 124.9, 123.4 (Cq), 121.9, 120.4, 119.9 (Cq), 119.1, 116.3 (Cq), 115.3, 114.2 (Cq), 
109.4 (Cq), 103.5, 83.5, 82.5, 73.7, 44.3, 13.1, 13.0 ppm.  
HR-MS (ESI+): C36H25N5O4RuH (M+H)
+ calcd.: 694.1033, found: 694.1020. 
ATR-IR (neat): ~ = 3345 (vw), 2962 (vw), 2923 (vw), 2733 (vw), 1949 (s), 1746 (w), 1687 (m), 
1651 (w), 1579 (w), 1525 (m), 1479 (vw), 1461 (w), 1438 (w), 1378 (w), 1342 (w) 1325 (w), 1309 
(w), 1294 (w), 1258 (m), 1227 (m), 1149 (vw), 1078 (m), 1017 (s), 865 (vw), 795 (s), 747 (s), 711 
(vw), 691 (w), 642 (w), 579 (vw), 555 (w), 500 (w), 463 (m), 432 (vw) cm-1. 
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5.2.3.3. Libraries of derivatives of np829 (80b) 
For the synthesis of the amide libraries 100 µM stock solutions of the according primary amine in 
DMF were prepared. In the case of availability as HCl salts, they were dissolved in 4:1 
DMF/0.5 M LiOHaq. A mixture of 14.0 µL DMF, 10.0 µL NHS-ester solution (32.8 µM in DMF, 
final c = 8.2 µM,) and 16.0 µL of the 100 µM amine stock solution (100 µM, final c = 40 mM) was 
prepared in a 96-well polypropylene plate, mixed, heat-sealed and left to react overnight. After TLC 
analysis, the reactions were terminated by addition of 40 µL of 16.4 µM acetic acid in DMSO and 
stored at -78 °C. All assays with the compound were executed without further purification. 
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5.3. Compound preparation for the drug-like abilities approach 
5.3.1. General working procedures for complex synthesis 
 
5.3.1.1. Standard working procedure I 
The appropriate TBS-protected pyridocarbazole ligand was suspended in a 1:1 mixture of 
EtOH/H2O (~5 mM) and purged with nitrogen for 10-15 min before an equimolar amount of 
RhCl3·3 H2O was added, the flask was sealed, and the suspension heated to 90-95 °C for at least 
90 min. The flask was cooled to 20 °C and the tridentate ligand (1.10 eq) was added before the 
solution or suspension reacted for at least another 16 h. After cooling to 20 °C, the solvent was 
removed under reduced pressure, the dry residue was redissolved in CH2Cl2 and MeOH and 
adsorbed on silica. The diastereomers were separated by silica flash chromatography with CH2Cl2 
to CH2Cl2/MeOH 100:1 to 10:1 as eluent. The separated isomers were further purified 1-3 times 
via flash chromatography over 1-3 g silica using the same eluents and a dry load. 
 
5.3.1.2. Standard working procedure II 
The tridentate ligand was dissolved in a 1:1 mixture of CH3CN/H2O (~5.6 mM) and degassed for 
10-15 min before an equimolar amount of RhCl3·3 H2O was added, the flask sealed, and the 
suspension heated to 90-95 °C for at least 3 h. After cooling to 20 °C, the solvent was removed 
under reduced pressure, the TBS-protected pyridocarbazole ligand was added (1.10 eq), the residue 
taken up in a 1:1 mixture of EtOH/H2O (~0.18 mL/µmol), and the suspension heated for at least 
40 h at 95 °C. After cooling, the solvent was removed under reduced pressure, the dry residue 
redissolved in CH2Cl2 and MeOH, and adsorbed on silica. The diastereomers were separated by 
silica flash chromatography with CH2Cl2 to CH2Cl2/MeOH 100:1 to 10:1 as eluent with very slow 
increase of MeOH content until the first diastereomer was eluted from the column. The separated 
isomers were further purified 1-3 times via flash chromatography over 1-3 g silica using the same 
eluents and a dry load. 
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5.4. Compound preparation drug-like abilities approach 
5.4.1. Modification of the (pyridine-2-ylmethyl)-D-proline in the 4-pyridine position 
5.4.1.1. 4-chloropyridine modification 
5.4.1.1.1. Synthesis of methyl 4-chloropicolinate 
 
The procedure was modified from a literature known esterification.[318] Thionyl chloride (1.11 mL, 
ρ = 1.64 g/cm3, 15.2 mmol, 1.20 eq) was added dropwise to a solution of 2.00 g 4-chloropicolinic 
acid (12.7 mmol, 1.00 eq) in 54 mL CH2Cl2. The solution was cooled to 0 °C and 220 µL of DMF 
were added dropwise. The solution was allowed to come to 20 °C and was stirred for 90 min before 
the solvent was removed in vacuo. The residue was taken up in 22 mL MeOH and the resulting 
solution was stirred for 30 min at 20 °C. The solvent was removed under reduced pressure, the 
residue taken up in 20 mL of aqueous 5% NaHCO3 solution, and extracted three times with 10 mL 
EtOAc. The combined organic layers were washed with brine (3 x 5 mL) and dried over MgSO4. 
After removal of the solvent under reduced pressure 1.89 g (11.0 mmol, 87%) of the ester 230 was 
obtained as slightly off-white crystals. 
1H-NMR (300.1 MHz, CDCl3): δ = 8.63 (dd, 
3J = 5.2 Hz, 4J = 1.9 Hz, 1H, H6), 8.12 (dd, 
4J = 2.0 Hz, 5J = 0.5 Hz, 1H, H3), 7.48 (dd, 
3J = 5.2 Hz, 4J = 2.1 Hz, 1H, H5), 4.00 (s, 3H, 
OCH3) ppm. 
13C-NMR (75.5 MHz, CDCl3): δ = 164.8 (CO), 150.7 (C6), 149.4 (C2), 145.6 (C4), 127.3 (C5), 125.8 
(C3), 53.3 (CH3) ppm.      
ATR-IR (neat): ~ = 2959 (vw), 1800 (vw), 1714 (s), 1640 (vw), 1574 (m), 1556 (m), 1489 (vw), 
1439 (m), 1392 (m), 1297 (m), 1263 (m), 1239 (m), 1190 (w), 1145 (w), 1088 (w), 1046 (vw), 993 
(m), 965 (w), 900 (m), 846 (m), 782 (m), 747 (m), 703 (w), 686 (w), 619 (vw), 523 (m), 425 (vw) cm-1. 
HR-MS (ESI): C7H6ClNO2Na (M+Na)
+ calcd.: 193.9979, found: 193.9978. 
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5.4.1.1.2. Synthesis of (4-chloropyridine-2-yl)methanol 
 
The procedure was taken from literature.[317] Anhydrous CaCl2 (3.07 g, 27.6 mmol, 4.04 eq) and 
1.15 g methyl 4-chloropicolinate (6.84 mmol, 1.00 eq) were suspended in a mixture of 6.6 mL 
MeOH and 3.9 mL THF and cooled down to 0 °C. NaBH4 (518 mg, 13.7 mmol, 2.00 eq) was added 
portionwise and the resulting suspension was stirred for 2 h at 0 °C and 60 min at 20 °C. The 
reaction was quenched by addition of 11 mL H2O and stirred for 2 h at 20 °C. The mixture was 
extracted with EtOAc (3 x 35 mL) and CH2Cl2 (35 mL), and the combined organic layers were 
dried over Na2SO4. After removal of the solvent in vacuo 916 mg of the alcohol 232 (6.38 mmol, 
93%) was obtained as a white solid.  
1H-NMR (300.1 MHz, CDCl3): δ = 8.46 (d, 
3J = 5.4 Hz, 1H, H6), 7.35 (s, 1H, H3), 7.21 (dd, 
3J = 5.3 Hz, 4J = 1.8 Hz 1H, H5), 4.77 (s, 2H, CH2-OH), 3.49 (br s, 1H, OH) ppm. 
13C-NMR (75.5 MHz, CDCl3): δ = 161.1 (C2), 149.2 (C4), 123.1 (C3/5), 121.2 (C3/5), 64.0 (CH2) ppm. 
ATR-IR (neat): ~ = 3172 (br m), 3072 (vw), 2902 (vw), 2846 (vw), 2667 (vw), 1581 (s), 1557 (s), 
1470 (w), 1453 (w), 1399 (m), 1390 (m), 1361 (vw), 1264 (vw), 1221 (m), 1108 (m), 1094 (m), 1057 
(s), 1000 (m), 878 (m), 832 (m), 823 (s), 759 (vw), 722 (vw), 705 (s), 603 (m), 539 (vw), 433 (m), 416 
(vw), 397 (vw) cm-1. 
HR-MS (ESI): C6H6ClNOH (M+H)
+ calcd.: 144.0211, found: 144.0209. 
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5.4.1.1.3. Synthesis of methyl ((4-chloropyridine-2-yl)methyl)-D-prolinate 
 
(4-chloropyridine-2-yl)methanol (232) was chlorinated by dissolving 100 mg (697 µmol, 1.00 eq) in 
700 µL EtO2, cooling to 0 °C and adding 101 µL (166 mg, ρ = 1.64 g/cm
3, 1.39 mmol, 2.00 eq) 
SOCl2 dropwise, during which a white precipitate formed. The suspension was allowed to warm to 
room temperature and was further stirred at 20 °C for 18 h. Solvent and excess SOCl2 were 
removed under reduced pressure. 163 mg anhydrous Na2CO3 (1.53 mmol, 2.20 eq) and 5 mg NaI 
(30.7 µmol, 4.4 mol%), and 1.6 mL DMF were added. A solution of 138 mg D-proline methylester 
(836 µmol, 1.2 eq) in 1.6 mL DMF was added to the first suspension at 50 °C. The resulting 
suspension was stirred for 18 h at 50 °C and subsequently diluted with 3 mL H2O. The solution 
was extracted with CH2Cl2 (3 x 10 mL) and the organic layer dried over Na2SO4. The solution was 
concentrated under reduced pressure and the crude product purified by flash column 
chromatography (25 g silica gel, CH2Cl2 to CH2Cl2/MeOH 50:1 to 10:1). After removal of the 
solvent in vacuo, the compound was further purified via reversed phase preparative HPLC (C18 
HTec-column (5 µm, 250x16 mm, MACHERY-NAGEL), H2O to CH3CN over 20 min, flow rate 
10 mL/min).  After removal of the solvent under reduced pressure, 70 mg (275 µmol, 40%) of 235 
was obtained as colourless oil over two steps. 
1H-NMR (300.1 MHz, CDCl3): δ = 8.41 (d, 
3J = 5.4 Hz, 1H, H6), 7.54 (d, 
4J = 2.0 Hz, 1H, H3), 
7.18 (dd, 3J = 5.4 Hz, 4J = 2.0 Hz, 1H, H5), 4.07 (d, 
2J = 14.0 Hz, 1H, proCH2pyr), 3.81 (d, 
2J = 14.0 Hz, 1H, proCH2pyr), 3.69 (s, 3H, CH3), 3.48 (dd, 
3J = 8.8 Hz, 3J = 5.7 Hz, 1H, H2’), 3.16-3.10 
(m, 1H, H5a’), 2.62-2.54 (m, 1H, H5b’), 2.26-2.19 (m, 1H, H3a’), 2.08-1.79 (m, 3H, H3b’, H4’) ppm. 
13C-NMR (75.5 MHz, CDCl3): δ = 174.2 (COO), 150.0 (C6), 144.9 (C4), 123.8 (C3/5), 122.8 (C3/5), 
65.5 (proCH2pyr), 59.7 (C2’), 53.7 (CH3), 52.0 (C5’), 29.4 (C3’), 23.4 (C4’) ppm. One signal (C2) either 
overlaps with the C6 signal or is not obvious due to little concentration and insufficient 
measurement time of the sample. 
ATR-IR (neat): ~ = 3049 (w), 2950 (vw), 2877 (vw), 2812 (vw), 1732 (m), 1574 (s), 1554 (m), 
1463 (vw), 1434 (w), 1389 (w), 1360 (w), 1274 (vw), 1198 (m), 1171 (m), 1133 (w), 1092 (w), 1038 
(vw), 993 (vw), 931 (vw), 889 (w), 825 (w), 765 (vw), 706 (m), 604 (vw), 537 (vw), 439 (w), 400 
(vw), 392 (vw), 383 (vw) cm-1. 
HR-MS (ESI+): C12H15ClN2O2H (M+H)
+ calcd.: 255.0895, found: 255.0903. 
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5.4.1.1.4. Synthesis of ((4-chloropyridine-2-yl)methyl)-D-proline 
 
Ligand 236 was obtained by saponification. Therefore, methyl ((4-chloropyridine-2-yl)methyl)-D-
prolinate was dissolved in 830 µL 1 M NaOHaq, which was previously purged with N2 for 10 min. 
The solution was stirred at 20 °C for 16 h, before the mixture was diluted with 3 mL H2O and 
CH2Cl2 each. The aqueous layer was separated and set to pH 7 by addition of 1 M HClaq and the 
solution further stirred for 30 min at 20 °C. Afterwards the aqueous layer was washed with 10 mL 
CH2Cl2 and the solvent removed under reduced pressure. The residue was dissolved in 5 mL EtOH 
and treated by sonication for 15 min. The insoluble salts were removed by filtration.  After 
removing the solvent under reduced pressure 41.8 mg (174 µmol, 63%) of the prolinate 236 was 
obtained as colourless oil. 
1H-NMR (300.1 MHz, CD3OD): δ = 8.59 (d, 
3J = 5.4 Hz, 1H, H6), 7.67 (d, 
4J = 1.7 Hz, 1H, H3), 
7.53 (dd, 3J = 5.4 Hz, 4J = 1.8 Hz, 1H, H5), 4.80 (d, 
2J = 14.3 Hz, 1H, proCH2pyr), 4.63 (d, 
2J = 14.2 Hz, 1H, proCH2pyr), 4.62 (dd, 
3J = 9.2 Hz, 3J = 7.0 Hz, 1H, H2’), 3.86-3.78 (m, 1H, H5a’), 
3.47-3.38 (m, 1H, H5b’), 2.71-2.57 (m, 1H, H3a’), 2.30-2.18 (m, 2H, H3b’, H4a’), 2.13-2.06 (m, 1H, H4a’) 
ppm. 
13C-NMR (75.5 MHz, CD3OD): δ = 170.9 (COO), 153.7 (C2), 151.8 (C6), 146.6 (C4), 125.7 (C3/5), 
125.7 (C3/5), 68.4 (C2’), 59.6 (proCH2pyr), 57.0 (C5’), 29.3 (C3’), 23.7 (C4’) ppm.  
ATR-IR (neat): ~ = 3366 (br w), 2962 (w), 2815 (w), 2513 (br w), 2340 (br w), 1726 (m), 1695 
(vw), 1616 (vw), 1579 (s), 1558 (m), 1403 (s), 1299 (vw), 1228 (s), 1104 (w), 1062 (vw), 996 (vw), 
932 (vw), 878 (w), 836 (m), 710 (m), 662 (vw), 575 (vw), 526 (vw), 433 (vw), 394 (w) cm-1. 
HR-MS (ESI+): C11H13ClN2O2H (M+H)
+ calcd.: 241.0738, found: 241.0742. 
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5.4.1.1.5. Synthesis of the 4-chloro-pyridine modified complexes 258a and 258b 
 
The 4-chloro pyridine derivatives of the complexes 201a and 201b were prepared according to 
standard procedure I using 52.6 mg TBS-protected pyridocarbazole (131 µmol, 1.00 eq) and 
34.4 mg RhCl3 · 3H2O (131 µmol, 1.00 eq) in 25.0 mL H2O/EtOH 1:1 for 90 min at 90 °C, before 
adding 34.8 mg of the proline ligand 236 (145 µmol, 1.10 eq) and reacting for another 22 h. After 
removal of the solvent in vacuo the complexes were adsorbed on silica (~0.5 g) and the 
diastereomers were separated according to the standard procedure on 5 g silica. The isomers were 
combined with the according isomers obtained from a smaller scale of 25 µmol and every isomer 
was further purified twice (2 g and 1.5 g silica) via flash column chromatography. 258a (5.8 mg, 
8.73 µmol, 6%) and 258b (6.8 mg, 10.2 µmol, 7%) were obtained as deeply red solids. 
258a: 
1H-NMR (500.1 MHz, DMSO-d6): δ = 11.26 (br s, NH), 9.61 (d, 
3J = 6.3 Hz, 1H, H6), 9.29 (dd, 
3J = 8.4 Hz, 4J = 1.1 Hz, 1H, H3’’), 8.84 (d, 
3J = 5.2 Hz, 1H, H1’’), 8.70-8.68 (m, 1H, H4’’), 8.22 (dd,
 
3J = 5.0 Hz, 4J = 1.4 Hz, 1H, H5), 8.19 (d, 
4J = 2.2 Hz, H?), 8.08 (dd, 
3J = 8.4 Hz, 3J = 5.2 Hz, 1H, 
H2’’), 7.30-7.28 (m, 2H, H6’’, H5’’), 5.88-5.86 (m, 1H, H7’’), 4.55 (d, 
4J = 15.9 Hz, 1H, proCH2pyr), 4.33 
(d, 4J = 15.9 Hz, 1H, proCH2pyr), 3.88 (dd, 
3J = 9.6 Hz, 3J = 4.2 Hz, 1H, H2’), 2.21-2.16 (m, 2H, H5b’, 
H3‘a), 2.02-1.97 (m, 1H, H3’b),), 1.58-1.53 (m, 1H, H4’a), 1.06-1.01 (m, 1H, H4’b) ppm. The missing 
H5a’ signal overlaps with the DMSO signal as confirmed by 
1H-13C-HSQC-spectroscopy. 
ATR-IR (neat): ~ = 2923 (w), 2853 (vw), 1751 (w), 1703 (s), 1651 (m), 1624 (m), 1602 (m), 1556 
(w), 1522 (w), 1496 (w), 1472 (w), 1418 (m), 1403 (vw), 1342 (s), 1293 (m), 1263 (w), 1229 (s), 1150 
(m), 1133 (vw), 1107 (vw), 1082 (vw), 1022 (m), 1008 (m), 936 (vw), 902 (vw), 880 (w), 819 (m), 
796 (w), 743 (m), 724 (vw), 710 (w), 688 (vw), 639 (m), 593 (vw), 575 (vw), 521 (vw), 495 (m), 482 
(w), 441 (w), 407 (vw), 387 (m) cm-1. 
HR-MS (APCI+): C28H20Cl2N5O4RhH (M+H)
+ calcd.: 664.0020, found: 664.0019. 
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258b: 
1H-NMR (500.2 MHz, DMSO-d6): δ = 11.24 (br s, NH), 9.46 (d, 
3J = 6.3 Hz, 1H, H6), 9.18 (dd, 
3J = 8.4 Hz, 4J = 0.9 Hz, 1H, H3’’), 8.70 (d, 
3J = 7.9 Hz, 1H, H4’’), 8.13 (dd, 
3J = 6.2 Hz, 4J = 2.3 Hz, 
1H, H5), 8.11-8.19 (m, 2H, H1‘‘, H3) 7.82 (d, 
3J = 8.3 Hz, 1H, H7’’), 7.74 (dd, 
3J = 8.4 Hz, 3J = 5.2 Hz, 
1H, H2’’), 7.54 (ddd, 
3J = 8.3 Hz, 3J = 7.1 Hz, 4J = 1.3 Hz, 1H, H6’’), 7.37 (ddd, 
3J = 7.9 Hz, 
3J = 7.1 Hz, 4J = 0.9 Hz, 1H, H5’’), 4.58 (d, 
2J = 16.4 Hz, 1H, pyrCH2Npro), 4.51 (d, 
4J = 16.4 Hz, 1H, 
pyrCH2Npro), 3.86 (dd, 
3J = 9.4 Hz, 3J = 4.6 Hz, 1H, H2’), 2.48-2.45 (m, 1H, H5a’), 2.22-2.12 (m, 2H, 
H5b’, H3‘a), 1.89-1.83 (m, 1H, H3‘b), 1.46-1.39 (m, 1H, H4a’), 1.10-1.03 (m, 1H, H4b’) ppm. 
13C-NMR (125.8 MHz, DMSO-d6): δ = 182.3 (COO), 170.7 (CO), 170.3 (CO), 161.6 (Cq), 152.5 
(C6), 152.2 (Cq), 150.9 (C1’’), 149.8 (Cq), 147.3 (Cq), 142.3 (Cq), 134.9 (C3’’), 131.2 (Cq), 126.6 (C6’’), 
126.5 (C5), 124.5 (C3), 124.3 (C4’’, C2’’), 123.1 (Cq), 121.1 (Cq), 119.7 (C5’’), 115.0 (C7’’), 114.9 (Cq), 
114.1 (Cq), 73.6 (C2’), 69.0 (pyrCH2Npro), 61.5 (C5‘), 30.3 (C3’), 23.9 (C4’) ppm. 
ATR-IR (neat): ~ = 3230 (vw), 3059 (vw), 2958 (vw), 2921 (w), 2853 (vw), 1754 (w), 1710 (m), 
1624 (s), 1523 (vw), 1499 (w), 1470 (vw), 1422 (w), 1342 (s), 1302 (w), 1265 (w), 1230 (m), 1132 
(vw), 1102 (w), 1018 (m), 933 (vw), 876 (w), 854 (vw), 797 (m), 751 (m), 713 (w), 686 (vw), 640 
(m), 579 (vw), 523 (vw), 492 (m), 441 (m), 397 (m) cm-1. 
HR-MS (APCI+): C28H20Cl2N5O4RhH (M+H)
+ calcd.: 664.0020, found: 664.0021. 
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5.4.1.2. 4-(3-(pyridine-4-yloxy)propyl)morpholine modification 
5.4.1.2.1. Synthesis of (4-(3-morpholinopropoxy)pyridine-2-yl)methanol 
 
The synthesis was modified from a literature procedure.[321] Sodium 3-morpholinopropan-1-olate 
was prepared by adding 85 mg of sodium hydride dispersion in mineral oil (2.13 mmol, 3.05 eq) to 
a solution of 289 µL 3-morpholinopropan-1-ol (2.09 mmol, ρ = 1.05, 3.00 eq) in DMF (600 µL) at 
0 °C. The suspension was stirred for 60 min at 0 °C. A solution of 100 mg (4-chloropyridine-2-
yl)methanol (697 µmol, 1.00 eq) in DMF (360 µL) was added dropwise at 0 °C. While warming to 
20 °C the suspension turned dark green. The reaction mixture was heated to 100 °C for 16 h, 
during which time the colour changed to red and later brown. After cooling the reaction mixture 
to 20 °C the solvent was removed in vacuo, the residue was taken up in Et2O and sonicated for 
5 min before it was filtered. The solvent of the filtrate was removed in vacuo and the residue was 
subjected to flash chromatography twice (5 g/3 g silica, CH2Cl2 to CH2Cl2/MeOH 10:1, loading 
with CH2Cl2 plus a few drops of MeOH). The combined product eluents were dried to provide 
240 (40 mg, 159 µmol, 23%) as a yellow oil. 
1H-NMR (300.2 MHz, (CD3)2CO): δ = 8.28 (d, 
3J = 5.7 Hz, 1H, H6), 7.04 (d, 
4J = 2.3 Hz, 1H, H3), 
6.78 (d, 3J = 5.70 Hz, 4J = 2.6 Hz, 1H, H5), 4.63 (s, 2H, CH2OH), 4.16 (t, 
3J = 6.4 Hz, 2H, H8), 3.99 
(br s, 1H, OH), 3.64-3.58 (m, 4H, H13, H15), 2.49 (t, 
3J = 7.0 Hz, 2H, H10), 2.45-2.36 (m, 4H, H12, 
H16,), 1.97 (quin., 
3J = 6.7 Hz, 2 H, H9) ppm. 
13C-NMR (75.5 MHz, (CD3)2CO): δ = 166.8 (C4), 164.3 (C2), 150.8 (C6), 109.7 (C3), 107.0 (C5), 67.5 
(C13, C15), 66.9 (C8), 65.3 (proCH2pyr), 55.9 (C10), 54.7 (C12, C16), 26.9 (C9) ppm.  
ATR-IR (neat): ~ = 3239 (vw), 2953 (w), 2854 (w), 2691 (w), 1597 (s),1567 (m), 1448 (m), 1393 
(w), 1359 (w), 1303 (s), 1271 (m), 1208 (vw), 1165 (w), 1142 (w), 1114 (vs), 1031 (s), 1002 (m), 917 
(vw), 899 (vw), 861 (m), 827 (w), 747 (w), 631 (vw), 612 (vw), 562 (vw), 529 (vw), 505 (vw), 490 
(vw), 446 (w), 394 (w) cm-1. 
HR-MS (ESI+): C13H20N2O3H (M+H)
+ calcd.: 253.1547, found: 253.1545. 
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5.4.1.2.2. Synthesis of methyl ((4-(3-morpholinopropoxy)pyridine-2-yl)methyl)-D-
prolinate 
 
To a solution of (4-(3-morpholinopropoxy)pyridine-2-yl)methanol (40 mg, 159 µmol, 1.00 eq) in 
300 µL Et2O at 0 °C was added SOCl2 (17.3 µL, ρ = 1.64, 238, 1.50 eq) dropwise during which a 
white precipitation formed. The solution was brought to 25 °C and another 300 µL Et2O and 8 µL 
SOCl2 (111 µmol, 0.70 eq) were added due to evaporation of the Et2O in the N2 stream. The 
reaction mixture was stirred at 25 °C for 16 h and the solvent and excess SOCl2 were removed in 
vacuo to yield the chloride salt 241 as white solid, which was then subjected to an nucleophilic 
substitution using a modification of an reported method.[332] The obtained crude product was 
dissolved in 0.4 mL DMF and Na2CO3 (37.0 mg, 348.7 µmol, 2.20 eq) and NaI (~1 mg, 7.0 µmol, 
4 mol%) were added and the flask protected against light and heated to 50 °C.  Methyl D-prolinate 
(24.6 mg, 190.2 µmol, 1.2 eq) was dissolved in 0.4 mL DMF and the solution added to the 
suspension. The reaction was stirred for 24 h at 50 °C and for 48 h at 25 °C before the solvent was 
removed under reduced pressure. The residue was taken up in CH2Cl2, MeOH and acetone to 
remove insoluble side products and the solvent was decanted and collected each time. The solvent 
of the collected fractions was removed in vacuo and the crude product was subjected to flash 
chromatography twice (5 g silica each, CH2Cl2 to CH2Cl2/MeOH 10:1, loading with CH2Cl2 plus a 
few drops of MeOH). The combined product eluents were dried to provide 242 (22 mg, 38%) as 
a yellow oil. 
1H-NMR (300.2 MHz, CD3OD): δ = 8.23 (d, 
3J = 5.9 Hz, 1H, H6), 7.14 (d, 
4J = 2.4 Hz, 1H, H3), 
6.86 (d, 3J = 5.9 Hz, 4J = 2.5 Hz, 1H, H5), 4.16 (t, 
3J = 6.2 Hz, 2H, H8), 3.94 (d, 
2J = 13.8 Hz ,1H, 
proCH2pyr), 3.75-3.68 (m, 5H, H13, H15, proCH2pyr), 3.63 (s, 1H CH3), 3.38 (dd, 
3J = 9.0 Hz, 3J = 5.6 Hz, 
H2’) 3.08-3.02 (m, 1H, H5a’), 2.58-2.47 (m, 7 H, H10, H12, H16, H5b’), 2.21-2.15 (m, 1H, H3a’), 2.07-1.98 
(m, 2H, H4a’, H3b’), 1.95-1.80 (m, 3H, H4b’, H9) ppm. 
13C-NMR (75.5 MHz, CD3OD): δ = 176.1 (CO), 167.8 (C4), 161.6 (C2), 150.5 (C6), 110.9 (C3), 110.8 
(C5), 67.7 (C13, C15), 67.4 (C2’), 66.5 (C8), 60.8 (C5’), 56.4 (C10), 54.8 (C12, C16), 54.7 (proCH2pyr), 52.2 
(OCH3), 30.3 (C3’), 26.9 (C9), 24.2 (C4’) ppm.  
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ATR-IR (neat): ~ = 2951 (w), 2851 (vw), 2811 (w), 2689 (w), 1733 (m), 1644 (vw), 1594 (s), 1565 
(m), 1459 (w), 1435 (m), 1360 (w), 1301 (m), 1198 (w), 1169 (m), 1142 (w), 1116 (s), 1069 (vw), 
1035 (w), 1002 (vw), 918 (vw), 895 (vw), 862 (w), 828 (vw), 752 (vw), 684 (vw), 634 (vw), 611 (vw), 
451 (w), 416 (vw), 396 (vw), 385 (vw) cm-1. 
HR-MS (ESI+): C19H29N3O4H (M+H)
+ calcd.: 364.2231, found: 364.2230. 
 
5.4.1.2.3. Synthesis of ((4-(3-morpholinopropoxy)pyridine-2-yl)methyl)-D-proline 
 
A solution of 22 mg (60.5 µmol, 1.00 eq) methyl ((4-(3-morpholinopropoxy)pyridine-2-yl)methyl)-
D-prolinate (242) in 1 M NaOHaq (182 µmol, 3.00 eq) was stirred for 3 h at 20 °C. The solution was 
diluted with 400 µL H2O and washed with 180 µL CH2Cl2. The pH was adjusted to 7 using 1 M 
aqueous HCl. The solution was further stirred for 30 min and finally washed again with 180 µL 
CH2Cl2. The solvent was removed in vacuo and the remaining residue was suspended in 3 mL EtOH 
and insoluble salts were filtered off. The solvent was removed in vacuo to yield in 20 mg (57.2 µmol, 
95%) of the ligand 243 as a colourless film. 
1H-NMR (300.2 MHz, CD3OD): δ = 8.42 (d, 
3J = 5.8 Hz, 1H, H6), 7.14 (d, 
4J = 2.3 Hz, 1H, H3), 
6.98 (d, 3J = 5.9 Hz, 4J = 2.4 Hz, 1H, H5), 4.52 (d, 
2J = 13.8 Hz, 1H, proCH2pyr), 4.39 (d, 
2J = 13.8 Hz, 
1H, proCH2pyr), 4.20 (t, 
3J = 6.1 Hz, 2H, H8), 4.04 (dd, 
3J = 9.0 Hz, 3J = 5.8 Hz, 1H, H2’), 3.76 (t, 
3J = 4.7 Hz, 4 H, H13, H15), 3.72-3.67 (m, 1H, H5a’), 3.27-3.17 (m, 1H, H5b’), 2.75-2.69 (m, 6 H, H10, 
H12, H16), 2.53-2.40 (m, 1H, H3/4’), 2.22-1.96 (m, 5H, H9, H3’, H4’) ppm. 
13C-NMR (75.5 MHz, CD3OD): δ = 173.5 (CO), 167.6 (C4), 154.0 (C2), 152.0 (C6), 112.0 (C3), 111.9 
(C5), 70.6 (C2’), 67.5 (C8), 67.1 (C13, C15), 59.9 (C5’), 56.2 (proCH2pyr/ C10), 56.1 (proCH2pyr/ C10), 54.4 
(C12, C16), 30.1 (C3’), 26.3 (C9), 24.5 (C4’) ppm.   
ATR-IR (neat): ~  = 3387 (m), 2957 (w), 2868 (vw), 2821 (vw), 1599 (s), 1567 (m), 1486 (vw), 
1448 (w), 1392 (m), 1361 (w), 1308 (m), 1208 (vw), 1183 (vw), 1142 (vw), 1112 (m), 1067 (w), 1043 
(w), 997 (w), 974 (vw), 919 (vw), 897 (vw), 861 (w), 775 (vw), 739 (vw), 634 (vw), 563 (vw), 477 
(vw), 416 (vw) cm-1. 
HR-MS (ESI+): C18H27N3O4H (M+H
+) calcd.: 350.2074, found: 350.2071. 
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5.4.1.2.4. Synthesis of 3-morpholinopropan-1-ol derivatised complexes 210a and 210b 
 
The complexes 210a and 210b were prepared according to standard procedure I using 20.9 mg 
TBS-protected pyridocarbazole (52.0 µmol, 1.00 eq) and 13.7 mg RhCl3·3H2O (52.0 µmol, 1.00 eq) 
in 10.5 mL H2O/EtOH 1:1 for 90 min at 90 °C before adding this suspension to 20 mg of the 
proline-ligand 243 (57.2 µmol, 1.10 eq) and reacting for another 16 h. After removal of the solvent 
under reduced pressure, the compound was adsorbed on silica (~500 mg) and the diastereomers 
were separated according to the standard procedure using 3 g silica. Isomer a and b were both 
further purified twice over 1 g silica gel each, yielding in 5.8 mg of 210a (7.50 µmol, 14%) and 10.3 
mg 210b (13.3 µmol, 26%) as deep red solids. 
210a: 
1H-NMR (500.1 MHz, DMSO-δ6): δ = 11.23 (br s, 1H, NH), 9.37 (d, 
3J = 6.7 Hz, 1H, H6), 9.28 
(dd, 3J = 8.5 Hz, 4J = 1.1 Hz, 1H, H3’’), 8.85 (d, 
3J = 4.8 Hz, 1H, H1’’), 8.70-8.68 (m, 1H, H4’’), 8.07 
(dd, 3J = 8.4 Hz, 3J = 5.2 Hz, 1H, H2’’), 7.61 (dd, 
3J = 6.8 Hz, 4J = 2.8 Hz, 1H, H5), 7.56 (d, 
4J = 2.8 Hz, 1H, H3), 7.29-7.27 (m, 2H, H5’’, H6’’), 5.96- 5.95 (m, 1H, H7’’), 4.44-4.39 (m, 3H, 
proCH2pyr, H8), 4.24 (d, 
3J = 15.3 Hz, 1H, proCH2pyr), 3.74 (dd, 
3J = 9.7 Hz, 3J = 4.4 Hz, 1H, H2’), 3.61 
(t, J = 4.5 Hz, 4 H, H13, H15), 2.48-2.46 (m, 1H, H5’a), 2.41 (br s, 4 H, H12, H16), 2.28-2.16 (m, 2H, 
H5b’, H3a’), 2.07-1.97 (m, 3H, H3b’, H9), 1.59-1.52 (m, 1H, H4’b), 1.06-1.03 (m, 1H, H4’a) ppm. The 
missing H10 proton signal overlaps with the DMSO signal as confirmed by COSY and HSQC-
NMR-spectroscopy.  
13C-NMR (125.8 MHz, DMSO-δ6): δ = 182.0 (COO), 170.6 (CO), 170.2 (CO), 167.7 (Cq), 161.8 
(Cq), 153.0 (C6), 152.7 (Cq), 148.9 (Cq), 148.7 (C1’’), 142.1 (Cq), 135.1 (C3’’), 131.2 (Cq), 126.7 (C6’’), 
124.7 (C4’’), 123.8 (C2’’), 123.4 (Cq), 121.3 (Cq), 119.6 (C5’’), 115.1 (Cq), 114.5 (Cq), 112.8 (C5), 112.1 
(C7’’), 110.1 (C3), 72.8 (C2’), 69.9 (proCH2pyr), 67.9 (C8), 66.2 (C13, C15), 61.2 (C5’), 54.5 (C10), 53.4 (C12, 
C16), 30.4 (C3’), 25.3 (C9), 24.3 (C4’) ppm.  
Experimental part 
 
189 
ATR-IR (neat): ~ = 3056 (vw), 2924 (w), 2852 (vw), 2187 (vw), 2120 (vw), 1753 (w), 1704 (m), 
1651 (m), 1617 (s), 1523 (vw), 1492 (w), 1461 (w), 1419 (w), 1338 (s), 1262 (m), 1226 (m), 1180 (w), 
1113 (m), 1019 (m), 929 (vw), 890 (vw), 856 (w), 825 (w), 795 (w), 747 (m), 708 (vw), 637 (w), 493 
(w), 438 (vw) cm-1. 
HR-MS (ESI): C35H34ClN6O6RhH (M+H)
+ calcd.: 773.1356, found: 773.1364. 
 
210b: 
1H-NMR (500.1 MHz, DMSO-δ6): δ = 11.20 (br s, 1H, NH), 9.25 (d, 
3J = 6.7 Hz, 1H, H6 ), 9.17 
(dd, 3J = 8.4 Hz, 4J = 1.0 Hz, 1H, H3’’), 8.70 (d, 
3J = 8.0 Hz, 1H, H4’’), 8.01 (d, 
3J = 5.4 Hz, 1H, H1’’), 
7.82 (d, 3J = 8.3 Hz, 1H, H7’’), 7.75 (dd, 
3J = 8.4 Hz, 3J = 5.2 Hz, 1H, H2’’), 7.54-7.52 (m, 2H, H, H5, 
H6’’), 7.48 (d, 
4J = 2.7 Hz, 1H, H3), 7.37 (ddd, 
3J = 8.0 Hz, 3J = 7.0 Hz, 4J = 1.0 Hz, 1H, H5’’), 4.48 
(d, 3J = 15.9 Hz, 1H, proCH2pyr), ) 4.41 (d, 
3J = 16.0 Hz, 1H, proCH2pyr), 4.33 (td, 
3J = 6.4 Hz, 
4J = 1.1 Hz, 2H, H8), 3.74 (dd, 
3J = 9.5 Hz, 3J = 4.8 Hz, 1H, H2’), 3.60 (t, 
3J = 9.1 Hz, 4 H, H13, 
H15), 2.51-2.46 (m, 3H, H5’a, H10), 2.40 (br s, 4 H, H12, H16), 2.21-2.15 (m, 2H, H5b’, H3a’), 2.03-1.98 
(m, 2H, H9), 1.90-1.85 (m, 1H, H3’b), 1.44-1.40 (m, 1H, H4’b), 1.14-1.04 (m, 1H, H4’a) ppm. The H10 
proton signal partially overlaps with the DMSO signal as confirmed by COSY and HSQC-NMR-
spectroscopy. 
13C-NMR (125.8 MHz, DMSO-δ6): δ = 182.3 (COO), 170.6 (CO), 170.3 (CO), 167.4 (Cq), 161.0 
(Cq), 152.3 (C6), 152.2 (Cq), 150.4 (C1’’), 149.9 (Cq), 142.4 (Cq), 134.7 (C3’’), 131.2 (Cq), 126.5 (C6’’), 
124.2 (C4’’, C2’’), 123.0 (Cq), 121.1 (Cq), 119.6 (C5’’), 114.9 (C7’’, Cq), 113.9 (Cq), 112.5 (C5), 110.4 (C3), 
73.4 (C2’), 69.2 (proCH2pyr), 67.7 (C8), 66.2 (C13, C15), 61.4 (C5’), 54.5 (C10), 53.3 (C12, C16), 30.3 (C3), 
25.3 (C9), 23.8 (C4’) ppm. 
ATR-IR (neat): ~ = 2921 (w), 2853 (vw), 1751 (vw), 1705 (m), 1648 (m), 1617 (m), 1524 (vw), 
1493 (w), 1454 (w), 1419 (w), 1339 (s), 1301 (m), 1264 (m), 1230 (m), 1175 (vw), 1112 (w), 1020 
(m), 894 (vw), 855 (w), 824 (w), 796 (w), 753 (m), 708 (vw), 636 (w), 532 (vw), 492 (w), 
439 (vw) cm-1. 
HR-MS (ESI): C35H34ClN6O6RhH (M+H)
+ calcd.: 773.1356, found: 773.1369. 
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5.4.1.3. ((4-((dimethylamino)methyl)pyridine-2-yl)methyl) modification 
5.4.1.3.1. Synthesis of 2-hydroxymethyl-4-cyanopyridine 
 
The hydroxymethylation of 4-cyanopyridine was performed according to a reported procedure.[323] 
1.04 g of 244 (10 mmol, 1.00 eq) was dissolved in 10 mL MeOH, 5 mL H2O, and 0.5 mL conc. 
H2SO4 and the solution degassed for 10 min. Afterwards, 91 mg FeSO4 (0.30 mmol, 0.03 eq) was 
added, the solution treated for 20 min with sonication and finally 1.13 g hydroxylamine-O-sulfonic 
acid (10.0 mmol, 1.00 eq) was added. The mixture was stirred for 5 h at 20 °C. Afterwards, 1.8 g 
Na2CO3 (17.0 mmol, 1.70 eq) and 10 mL water were added to quench the reaction. The suspension 
was filtered, the solvent was removed under reduced pressure from the filtrate and the residue was 
taken up in H2O and EtOAc. The layers were separated and the aqueous layer was extracted 
(5 x 25 mL) with EtOAc. The combined organic layers were dried over MgSO4 and the solvent 
was removed in vacuo. The residue was adsorbed on 0.5 g silica gel and purified via flash column 
chromatography (20 g silica gel, CH2Cl2/acetone 10:1 to 4:1). The solvent was removed under 
reduced pressure to obtain 278 mg 2-hydroxymethyl-4-cyanopyridine (2.07 mmol, 20%) as a 
colourless solid. 
1H-NMR (300.1 MHz, CDCl3): δ = 8.71 (dd, 
3J = 5.0 Hz, 4J = 0.5 Hz, 1H, H6), 7.61 (d, 
4J = 0.6 Hz, 
1H, H3), 7.43 (dt, 
3J = 5.0 Hz, 3J = 0.7 Hz, 1H, H5), 4.82 (s, 2H, H7), 3.53 (br s, 1H, OH) ppm. 
13C-NMR (75.5 MHz, CDCl3): δ = 161.7 (C2), 149.8 (C6), 123.9 (C3/5), 122.4 (C3/5), 121.2 (C7), 116.5 
(C4), 64.3 (CH2OH) ppm.  
ATR-IR (neat): ~ = 3235 (br w), 2954 (vw), 2914 (vw), 2845 (vw), 1727 (s), 1603 (w), 1561 (w), 
1432 (m), 1393 (m), 1363 (m), 1301 (s), 1208 (s), 1104 (m), 1056 (s), 979 (m), 895 (w), 852 (w), 798 
(vw), 759 (m), 680 (m), 609 (m), 475 (vw), 434 (m) cm-1.  
HR-MS (ESI+): C7H6N2OH (M+H)
+ calcd.: 135.0553, found: 135.0552. 
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5.4.1.3.2. Synthesis of 2-hydroxymethyl-4-(dimethylamino)pyridine 
 
Nitrile 245 was reduced according to a modified reported procedure using Pd/C.[326] 270 mg of the 
starting material (2.01 mmol, 1.00 eq) was dissolved in 24 mL HOAc and the solution was degassed 
for 15 min. To that solution 80 mg Pd/C (10%, 0.75 mmol, 0.40 eq) was added and an additional 
5 min degassed. The reaction was placed under an atmosphere of hydrogen gas (balloon) and 
stirred for 3 h at 20 °C under an H2 atmosphere. The resulting suspension was filtered over celite 
and washed with warm HOAc. The solvent was removed under reduced pressure and the product 
246 subjected to a reported dimethylation procedure[327] without characterisation. 2-hydroxymethyl-
4-(aminomethyl)pyridine was dissolved in 400 mg formic acid (8.68 mmol, 4.32 eq) and 220 mg 
paraformaldehyde (5.43 mmol, 2.70 eq) were added. The mixture was reacted for 10 min in a 
microwave (95 °C, 30 W), before H2O was added. The solution was washed with Et2O, and the 
pH was adjusted to 12 with aqueous KOH. The aqueous solution was extracted with Et2O 
(4 x 50 mL) and the combined organic layers were dried over Na2SO4. The solvent was removed 
in vacuo and 247 was obtained as a yellow oil (95 mg, 0.57 mmol, 28%) over two steps. 
1H-NMR (300.1 MHz, CDCl3): δ = 8.44 (d, 
3J = 5.1 Hz, 1H, H6), 7.26 (d, 
4J = 0.5 Hz, 1H, H3), 
7.14 (d, 3J = 4.9 Hz 1H, H5), 4.72 (s, 2H, CH2OH), 4.02 (br s, 1H, OH), 4.41 (s, 2H, H7), 2.22 (s, 
6H, N(CH3)2) ppm. 
13C-NMR (75.5 MHz, CDCl3): δ = 159.8 (C2), 149.0 (C4), 148.6 (C6), 122.7 (C3/5), 120.7 (C3/5), 64.3 
(CH2OH), 64.2 (C7), 45.6 (N(CH3)2) ppm.  
ATR-IR (neat): ~ = 3235 (br m), 2943 (vw), 2862 (vw), 2823 (w), 2777 (w), 1665 (vw), 1607 (s), 
1562 (w), 1456 (m), 1411 (m), 1362 (w), 1265 (w), 1172 (w), 1149 (w), 1106 (vw), 1037 (s), 996 (w), 
900 (vw), 858 (m), 821 (m), 775 (vw), 601 (m), 533 (w), 432 (w) cm-1. 
HR-MS (ESI+): C9H14N2OH (M+H)
+ calcd.: 167.1179, found: 167.1176. 
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5.4.1.3.3. Synthesis of methyl((4-((dimethylamino)methyl)pyridine-2-yl)methyl)-D-
prolinate 
 
2-hydroxymethyl-4-(dimethylamino)pyridine (78 mg, 0.47 mmol, 1.00 eq) was dissolved in 3 mL 
Et2O The solution was cooled to 0 °C and thionyl chloride (0.05 mL, ρ = 1.64, 0.69 mmol, 1.47 eq) 
was added. The reaction was stirred at room temperature for 18 h. The solvent was removed and 
2 x 7 mL cold Et2O was added to coevaporate remaining thionyl chloride. After removal of the 
solvent under reduced pressure 2-chlormethyl-4-(dimethylamino)pyridine (248) was obtained as a 
pale rose solid (52.3 mg, 0.24 mmol, 50%), which was directly taken on to the next step without 
characterisation. Hence Na2CO3 (27.0 mg, 0.25 mmol, 1.10 eq), NaI (1.50 mg, 0.01 mmol, 
4.4 mol%), and 1.5 mL DMF were added, the mixture degassed for 10 minutes and heated to 50 °C. 
Methyl D-prolinate (78.0 mg, 0.47 mmol, 1.97 eq) was added. The reaction was stirred for 24 h at 
50 °C. 4 mL water were added and the solvent was removed under reduced pressure. The brown 
solid was taken up in 5 mL EtOH and the precipitating salts were removed by filtration. The 
solvent was removed under reduced pressure and the product was combined with other batches 
(0.62 mmol + 0.68 mmol). The combined batches were purified by flash column chromatography 
(silica gel, CH2Cl2/MeOH 100:1→10:1) to obtained 249 as a brown solid (56 mg, 0.20 mmol, 11%). 
1H-NMR (300.1 MHz, CDCl3): δ = 8.49 (d, 
3J = 4.9 Hz, 1H, H6), 7.39 (s, 1H, H3), 7.21 (d, 
3J = 4.6 Hz 1H, H5), 4.02 (d, 
2J = 13.4 Hz, 1H, pyrCH2Npro), 3.77 (d, 
2J = 13.4 Hz, 1H, pyrCH2Npro), 
3.66 (s, 3H, COOCH3), 3.49 (s, 2H, H7), 3.41 (dd, 
3J = 8.8 Hz, 3J = 5.8 Hz, H2’), 3.13-3.06 (m, 1H, 
H5a’), 2.57-2.49 (m, 1H, H5b’), 2.30 (s, 6H, N(CH3)2), 2.21-2.13 (m, 1H, H3a’), 2.04-1.75 (m, 3H, H3b’, 
H4’) ppm. 
13C-NMR (75.5 MHz, CDCl3): δ = 174.6 (COO), 159.1 (C2), 149.3 (C6), 147.3 (C4), 123.8 (C3/5), 
122.6 (C3/5), 65.5 (C2’), 62.9 (proCH2pyr), 60.4 (C7), 53.7 (C5’), 51.8 (OCH3), 45.2 (N(CH3)2), 29.5 (C3’), 
23.3 (C4’) ppm.  
ATR-IR (neat): ~ = 2947 (w), 2817 (w), 2775 (w), 1737 (s), 1604 (w), 1561 (vw), 1447 (w), 1361 
(w), 1267 (w), 1169 (s), 1092 (vw), 1036 (m), 996 (vw), 910 (vw), 857 (w), 818 (w), 728 (vw), 607 
(vw), 528 (vw), 436 (w) cm-1. 
HR-MS (APCI+): C15H23N3O2H (M+H)
+ calcd.: 278.1863, found: 278.1864. 
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5.4.1.3.4. Synthesis of ((4-((dimethylamino)methyl)pyridine-2-yl)methyl)-D-proline 
 
An aqueous 1 M NaOH solution was purged with N2 for 10 min and 705 μL were added to 65.2 mg 
methyl prolinate 249 (0.235 mmol, 1.00 eq). The solution was stirred for 24 h at 20 °C before 3 mL 
H2O and 3 mL CH2Cl2 were added and the layers separated. The aqueous layer was washed with 
10 mL CH2Cl2 and neutralised with 1 M HClaq until pH = 7 was reached. The solution was stirred 
for 30 min and washed with another 10 mL CH2Cl2. The solvent was removed under reduced 
pressure and the yellow residue was dissolved in 5 mL EtOH and treated by sonication for 15 min. 
The white precipitate was removed by filtration and the filtrate was concentrated under reduced 
pressure to yield the ligand 250 as a yellow oil (35.8 mg, 0.15 mmol, 65%).  
1H-NMR (300.1 MHz, CD3OD): δ = 8.68 (d, 
3J = 5.0 Hz, 1H, H6), 7.65 (s, 1H, H3), 7.52 (d, 
3J = 5.0 Hz, 4J = 1.3 Hz 1H, H5), 4.64 (d, 
2J = 13.9 Hz, 1H, pyrCH2Npro), 4.54 (d, 
2J = 13.9 Hz, 1H, 
pyrCH2Npro), 4.10 (dd, 
3J = 9.0 Hz, 3J = 5.8 Hz, H2’), 4.07 (s, 2H, H7), 3.82-3.74 (m, 1H, H5a’), 3.29-
3.23 (m, 1H, H5b’), 2.65 (s, 6H, N(CH3)2), 2.53-2.42 (m, 1H, H3a’), 2.24-2.08 (m, 2H, H3b’, H4a’), 2.05-
1.95 (m, 1H, H4b’) ppm. 
13C-NMR (75.5 MHz, CD3OD): δ = 173.3 (COO), 153.3 (C2), 151.5 (C6), 145.4 (C4), 126.5 (C3/5), 
126.4 (C3/5), 70.6 (C2’), 61.6 (proCH2pyr), 59.9 (C7), 56.4 (C5’), 44.4 (N(CH3)2), 30.1 (C3’), 24.5 (C4’) ppm. 
ATR-IR (neat): ~ = 3319 (br m), 2942 (w), 2831 (w), 1450 (vw), 1114 (vw), 1021 (s), 625 (br m) 
cm-1. 
HR-MS (ESI+): C14H21N3O2H (M+H)
+ calcd.: 264.1707, found: 264.1707. 
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5.4.1.3.5. Synthesis of the 4-((dimethylamino)methyl) pyridine complexes 212a and 212b 
 
The 4-((dimethylamino)methyl) pyridine derivatives of the complexes 201a and 201b were prepared 
according to standard procedure I using 49.6 mg TBS-protected pyridocarbazole (124 µmol, 
1.00 eq) and 32.4 mg RhCl3·3H2O (124 µmol, 1.00 eq) in 25.0 mL H2O/EtOH 1:1. The mixture 
was reacted for 90 min at 90 °C before adding the solution to 35.8 mg of the modified proline-
ligand 250 (136 µmol, 1.10 eq) and reaction for another 24 h. After removal of the solvent under 
reduced pressure, the complex was adsorbed on silica gel (~0.5 g) and the diastereomers were 
separated according to the standard procedure by flash chromatography (6 g silica). The b isomer 
eluted very late after washing heavily with CH2Cl2/MeOH 5:1, acetone and iPrOH, probably due 
to basic interactions with the positively charged silica. Each isomer was further subjected to twofold 
purification by flash chromatography (212b 2 x 1.2 g, 212a 1.5 g and 1.2 g silica) via flash column 
chromatography. 212a yielded in 7.8 mg (11.4 µmol, 9%), 212b in 11.7 mg (17.0 µmol, 14%) as 
deep red solids. 
212a: 
1H-NMR (500.1 MHz, DMSO-d6): δ = 11.26 (br s, NH), 9.57 (d, 
3J = 6.0 Hz, 1H, H6), 9.29 (dd, 
3J = 8.4 Hz, 4J = 1.1 Hz, 1H, H3’’), 8.86 (d, 
3J = 5.1 Hz, 1H, H1’’), 8.68 (d, 
3J = 7.8 Hz, 1H, H4’’), 
8.08 (dd, 3J = 8.4 Hz, 3J = 5.2 Hz, 1H, H2’’), 7.95 (dd,
 3J = 6.0 Hz, 4J = 1.4 Hz, 1H, H5), 7.91 (s, 1H, 
H3), 7.26 (ddd, 
3J = 7.9 Hz, 3J = 7.1 Hz, 4J = 0.9 Hz, 1H, H5’’), 7.26 (ddd, 
3J = 8.3 Hz, 3J = 7.1 Hz, 
4J = 1.2 Hz, 1H, H6’’), 5.66 (d, 
3J = 8.4 Hz, 1H, H7’’), 4.58 (d, 
4J = 16.5 Hz, 1H, proCH2pyr), 4.29 (d, 
4J = 15.7 Hz, 1H, proCH2pyr), 3.82 (dd, 
3J = 9.6 Hz, 3J = 4.2 Hz, 1H, H2’), 3.78 (s, 2H, H7), 2.47-2.45 
(m, 2H, H5a’), 2.33 (s, 6 H, N(CH3)2), 2.22-2.17 (m, 2H, H5b’, H3‘a), 2.04-1.98 (m, 1H, H3’b), 1.60-
1.55 (m, 1H, H4’a), 1.10-1.07 (m, 1H, H4’b) ppm.  
13C-NMR (125.8 MHz, DMSO-δ6): δ = 182.1 (COO), 170.7 (CO), 170.3 (CO), 161.0 (Carom), 154.2 
(Carom), 152.7 (C6), 152.1 (C3/q), 148.9 (Cq), 148.8 (C1’’), 142.1 (Cq), 135.2 (C3’’), 131.3 (Cq), 126.5 (C6’’), 
125.8 (Carom), 124.8 (C4’’), 124.0 (C2’’), 123.5 (Cq), 122.7 (Carom), 121.4 (Cq), 119.6 (C5’’), 115.1 (Cq), 114.6 
Experimental part 
 
195 
(Cq), 111.8 (C7’’), 72.9 (C2’), 69.9 (proCH2pyr), 61.6 (C7), 61.3 (C5’), 45.2 (N(CH3)2), 30.4 (C3’), 24.4 (C4’) 
ppm.   
ATR-IR (neat): ~ = 2920 (m), 2852 (w), 1751 (w), 1703 (s), 1646 (m), 1626 (m), 1581 (w), 1521 
(vw), 1494 (vw), 1464 (vw), 1415 (w), 1339 (s), 1262 (m), 1226 (m), 1172 (vw), 1127 (vw), 1087 
(vw), 1018 (s), 932 (vw), 858 (vw), 823 (w), 796 (m), 747 (m), 705 (w), 636 (m), 581 (vw), 520 (vw), 
491 (s), 439 (m), 412 (vw) cm-1. 
HR-MS (APCI+): C31H28ClN6O4RhH (M+H)
+ calcd.: 687.0988, found: 687.0989. 
212b: 
1H-NMR (500.2 MHz, DMSO-d6): δ = 11.23 (br s, NH), 9.43 (d, 
3J = 5.9 Hz, 1H, H6), 9.17 (dd, 
3J = 8.4 Hz, 4J = 0.9 Hz, 1H, H3’’), 8.71 (d, 
3J = 8.0 Hz, 1H, H4’’), 7.95 (d, 
3J = 5.2 Hz, 1H, H1‘‘), 
7.95 (d, 3J = 5.2 Hz, 1H, H5), 7.84 (s, 1H, H3), 7.81 (d, 
3J = 8.2 Hz, 1H, H7’’), 7.74 (dd, 
3J = 8.4 Hz, 
3J = 5.3 Hz, 1H, H2’’), 7.53 (ddd, 
3J = 8.3 Hz, 3J = 7.1 Hz, 4J = 1.3 Hz, 1H, H6’’), 7.37 (ddd, 
3J = 7.9 Hz, 3J = 7.1 Hz, 4J = 0.9 Hz, 1H, H5’’), 4.55 (s, 2H, pyrCH2Npro), 3.79 (dd, 
3J = 9.5 Hz, 
3J = 4.8 Hz, 1H, H2’), 3.72 (s, 2H, H7), 2.48-2.42 (m, 1H, H5a’), 2.23-2.12 (m, 2H, H5b’, H3‘a), 1.91-
1.83 (m, 1H, H3‘b), 1.47-1.40 (m, 1H, H4a’), 1.11-1.05 (m, 1H, H4b’) ppm. 
13C-NMR (125.8 MHz, DMSO-d6): δ = 182.4 (COO), 170.7 (CO), 170.4 (CO), 159.9 (Cq), 152.3 
(Cq), 151.2 (Cq, C6), 150.5 (C1’’), 149.9 (Cq), 142.4 (Cq), 134.8 (C3’’), 131.2 (Cq), 126.6 (C6’’), 125.5 (C5), 
124.3 (C4), 124.3 (C2’’), 123.1 (Cq), 123.0 (C3), 121.1 (Cq), 119.7 (C5’’), 115.0 (C7’’), 114.9 (Cq), 114.0 
(Cq), 73.5 (C2’), 69.3 (pyrCH2NPro), 61.6 (C7), 61.5 (C5‘), 45.4 (N(CH3)2), 30.3 (C3‘), 23.9 (C4‘) ppm.  
ATR-IR (neat): ~ = 2921 (m), 2852 (w), 1752 (w), 1706 (s), 1649 (m), 1524 (vw), 1497 (vw), 1467 
(vw), 1420 (m), 1342 (s), 1300 (w), 1268 (w), 1229 (m), 1178 (vw), 1130 (vw), 1020 (m), 944 (vw), 
864 (vw), 825 (w), 795 (w), 748 (m), 709 (w), 638 (m), 575 (vw), 520 (m), 493 (w) cm-1. 
HR-MS (APCI+): C31H28ClN6O4RhH (M+H)
+ calcd.: 687.0988, found: 687.0989. 
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5.4.1.4. 4-hexylpyridine modification 
5.4.1.4.1. Synthesis of 4-hexylpyridine 
 
4-hexylpyridine (251) was prepared according to a modified literature procedure.[329] To a solution 
of 4.6 mL diisopropylamine (32.7 mmol, 1.02 eq) in 200 mL THF at 0 °C were slowly added 
13.3 mL of an n-BuLi solution (2.5 M in hexane, 33.2 mmol, 1.03 eq). The yellow reaction mixture 
was stirred for 30 min at 0 °C before it was cooled to ‒50 °C and 3.00 g 4-methylpyridine 
(32.2 mmol, 1.00 eq) was added slowly. The resulting red solution was stirred at ‒50 °C for 30 min. 
Subsequently a solution of 4.2 mL 1-iodopentane (32.2 mmol, 1.00 eq) was added dropwise 
at -50 °C and the resulting mixture stirred for 60 min at ‒50 °C before it was allowed to warm-up 
to 20 °C under stirring for 17 h. The reaction was quenched by addition of 200 mL saturated 
aqueous NH4Cl solution and the layers were separated. The aqueous layer was further extracted 
with Et2O (3 x 30 mL) and the combined organic layers were washed with 150 mL H2O and 
150 mL brine, dried over MgSO4 and reduced in vacuo. The crude productwas purified using flash 
column chromatography with neutral aluminium oxide as stationary phase using hexane/Et2O 9:1. 
After solvent removal in vacuo the desired product 252 (4.57 g, 28.0 mmol, 87%) was obtained as 
an off-white liquid. 
1H-NMR (300.1 MHz, CDCl3): δ = 8.46 (dd, 
3J = 4.6 Hz, 5J = 1.5 Hz, 2H, H2, H6), 7.08 (dd, 
3J = 
4.6 Hz, 5J = 1.6 Hz, 2H, H3, H5), 2.57 (t, 
3J = 7.7 Hz, 2H, H7), 1.65-1.55 (m, 2H, H8), 1.35-1.24 (m, 
6H, H9, H10, H11), 0.89-0.84 (m, 3H, H12) ppm. 
13C-NMR (75.7 MHz, CDCl3): δ = 151.9 (C4), 149.7 (2C, C2, C6), 124.0 (2C, C3, C5), 35.3 (C7), 31.7 
(C10), 30.3 (C8), 28.9 (C9), 22.6 (C11), 14.1 (C12) ppm. 
ATR-IR (neat): ~ = 3066 (w), 3026 (w), 2926 (vs), 2858 (s), 2019 (w), 1932 (w), 1846 (w), 1650 
(w), 1600 (vs), 1558 (m), 1459 (s), 1415 (s), 1374 (w), 1264 (w), 1218 (w), 1174 (w), 1111 (w), 1070 
(w), 993 (m), 801 (vs), 726 (m), 673 (w), 585 (s), 506 (s), 421 (w) cm-1. 
HR-MS (ESI+): C11H17NH (M+H)
+ calcd.: 164.1434; found: 164.1433.  
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5.4.1.4.2. Synthesis of (4-hexylpyridine-2yl)-methanol 
  
(4-hexylpyridine-2yl)-methanol (254) was prepared according to modified literature 
procedures.[330,331] 4-hexylpyridine (4.57 g, 28.0 mmol, 1.00 eq) was dissolved in 20 mL acetic acid 
and aqueous hydrogen peroxide (30%, 27.3 mmol, 0.98 eq) was added. The resulting yellow 
solution was heated to 75 °C for 4 h. After cooling to 20 °C, an additional 3.3 mL of H2O2 aq. 
(29.1 mmol, 1.04 eq) were added and the solution stirred at 75 °C for 48 h. After cooling to 20 °C, 
the solvent was removed under reduced pressure and the resulting oil was taken up in 110 mL 
CH2Cl2. To this solution 4.18 g Me3OBF4 (28.0 mmol, 1.00 eq) was added and the resulting solution 
stirred for 90 min at 20 °C, before the solvent was removed under reduced pressure. The remaining 
residue was taken up in 60 mL of boiling MeOH and 6 mL of a solution of 1.92 g ammonium 
persulfate (8.40 mmol, 0.30 eq) in 9 mL H2O was added. The reaction was heated to 75 °C for 
30 min, before the remaining persulfate solution was added and the solution stirred at 75 °C for 
another 40 min. After cooling to 20 °C, the solvent was removed in vacuo and the residue was taken 
up in 85 mL brine, 85 mL H2O and 60 mL of a 3 M HClaq solution and stirred for 60 min at 20 °C. 
The pH of the solution was adjusted to pH 9 with aqueous NH3 solution and extracted with CHCl3 
(1 x 100 mL, 3 x 30 mL). The combined organic layers were dried over MgSO4 and the solvent was 
removed in vacuo. The crude product was subjected to flash column chromatography (170 g silica, 
CH2Cl2/MeOH 50:1 to 10:1) and the product fractions were dried under reduced pressure to obtain 
971 mg (5.02 mmol, 18%) of the methanol derivative 254 as a brown oil over 2 steps. 
1H-NMR (300.1 MHz, CDCl3): δ = 8.42 (d, 
3J = 5.2 Hz, 1H, H6), 7.11 (s, 1H, H3), 7.06 (dd, 
3J = 
5.1 Hz, 5J = 1.6 Hz, H5), 4.75 (s, 2H, CH2OH), 4.23 (s, 1H, OH), 2.62 (t, 
3J = 7.7 Hz, 2H, H7), 
1.67-1.57 (m, 2H, H8), 1.35-1.26 (m, 6H, H9, H10, H11), 0.89-0.84 (m, 3H, H12) ppm. 
13C-NMR (75.7 MHz, CDCl3): δ = 158.9 (Cq), 153.3 (Cq), 148.0 (C6), 122.9 (C3), 120.8 (C5), 64.1 
(CH2OH), 35.5 (C7), 31.7 (C10), 30.4 (C8), 29.0 (C9), 22.7 (C11), 14.2 (C12) ppm. 
ATR-IR (neat): ~ = 3224 (br, w), 3055 (w), 3013 (w), 2925 (vs), 2857 (s), 1925 (w), 1650 (w), 1606 
(vs), 1560 (m), 1457 (s), 1415 (s), 1367 (m), 1261 (w), 1222 (w), 1159 (w), 1112 (m), 1058 (vs), 1001 
(s), 896 (w), 832 (s), 769 (w), 728 (m), 598 (m), 543 (m), 440 (s) cm-1. 
HR-MS (ESI+): C12H19NOH (M+H)
+ calcd.: 194.1539; found: 194.1537.  
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5.4.1.4.3. Synthesis of methyl ((4-hexylpyridine-2-yl)methyl)-D-prolinate 
 
Methyl ((4-hexylpyridine-2-yl)methyl)-D-prolinate was prepared according to a modified literature 
procedure.[332] A solution of 486 mg (4-hexylpyridine-2yl)-methanol (2.51 mmol, 1.00 eq) in 2.5 mL 
Et2O was cooled to 0 °C and 0.30 mL SOCl2 (ρ = 1.64g/cm
3, 3.77 mmol, 1.50 eq) were added 
dropwise. The reaction was stirred for 16 h at 20 °C before the solvent and excess SOCl2 were 
removed under reduced pressure. The resultant brown solid 255 was dissolved in 6 mL DMF, 
587 mg powdered NaCO3 (5.54 mmol, 2.20 eq) and 19 mg NaI (0.13 mmol, 0.04 eq) were added 
and the suspension was heated to 50 °C under exclusion from light. To the suspension a solution 
of 502 mg D-proline methylester hydrochloride (3.03 mmol, 1.20 eq) in 6 mL DMF was added 
dropwise and the resulting suspension was stirred at 50 °C for 16 h. After cooling to 20 °C, 30 mL 
H2O were added. The aqueous layer was extracted with CH2Cl2 (3 x 20 mL), the combined organic 
layers were dried over MgSO4, and the solvent removed in vacuo. The crude residue was purified 
using flash column chromatography (silica 66 g, CH2Cl2/MeOH 50:1 to 10:1). After removal of 
the solvent in vacuo 565 mg (1.86 mmol, 74%) of the prolinate 256 were isolated as a yellow oil. 
1H-NMR (300.1 MHz, CDCl3): δ = 8.39 (dd, 
3J = 5.1 Hz, 5J = 0.4 Hz, 1H, H6), 7.29 (s, 1H, H3), 
7.00 (dd, 3J = 5.1 Hz, 4J = 1.8 Hz, 1H, H5), 4.04 (d, 
2J = 13.4 Hz, 1H, pyrCH2Npro), 3.79 (d, 
2J = 13.4 
Hz, 1H, pyrCH2Npro), 3.66 (s, 3H, COOCH3), 3.43 (dd, 
3J = 8.8 Hz, 5J = 5.9 Hz, 1H, H2’), 3.14-3.17 
(m, 1H, H5’a),  2.62-2.51 (m, 3H, H7, H5’b), 2.24-2.10 (m, 1H, H3’a), 2.04-1.75 (m, 3H, H4’, H3’b), 1.66-
1.56 (m, 2H, H8), 1.34-1.24 (m, 6H, H9, H10, H11), 0.87 (t, 3H, 
3J = 6.9 Hz, H12) ppm.  
13C-NMR (75.7 MHz, CDCl3): δ = 174.4 (COOCH3), 158.1 (Cq), 153.1 (Cq), 148.5 (C6), 123.9 (C3), 
122.6 (C5), 65.5 (C2’), 60.1 (pyrCH2NPro), 53.7 (C5‘), 51.9 (OCH3), 35.5 (C7), 31.7 (C10), 30.4 (C8), 29.4 
(C3‘), 29.1 (C9), 23.3 (C4‘), 22.7 (C11), 14.2 (C12) ppm.   
ATR-IR (neat): ~ = 2928 (s), 2857 (m), 1739 (vs), 1679 (vs), 1603 (s), 1558 (m), 1441 (m), 1412 
(m), 1379 (m), 1266 (m), 1195 (vs), 1170 (vs), 1089 (s), 1040 (w), 997 (m), 902 (w), 835 (m), 767 
(w), 725 (w), 659 (w), 598 (w), 539 (w), 443 (m) cm-1. 
HR-MS (ESI+): C18H28N2O2H (M+H)
+ calcd.: 305.2224; found: 305.2220. 
Experimental part 
 
199 
5.4.1.4.4. Synthesis of ((4-hexylpyridine-2-yl)methyl)-D-proline 
 
256 (565 mg, 1.86 mmol, 1.00 eq) was dissolved in 5.6 mL aqueous NaOH (1 M, 3.00 eq) and the 
resulting solution was stirred for 16 h at 20 °C. Then, the solution was diluted by addition of 10 mL 
H2O and the solution washed with 10 mL CH2Cl2, which resulted in the precipitation of a white 
solid, which was removed by filtration. The aqueous layer was neutralised by addition of 1 M HClaq 
and further stirred for 30 min at 20 °C. The solution was washed again with 10 mL CH2Cl2 and the 
resulting precipitate was removed. The solvent of the aqueous layer was removed under reduced 
pressure, and the resulting residue was taken up in 20 mL EtOH with the help of sonication for 
15 min. The precipitate was filtered off, washed with some EtOH, and the filtrate concentrated 
in vacuo to yield in 498 mg of a brownish resin, which contained residual EtOH (factor 1.65:1) 
resulting in a yield of 73% (1.36 mmol) of the desired ligand 257 in its ethanol free form. 
1H-NMR (500.2 MHz, CDCl3): δ = 8.42 (d, 
3J = 5.1 Hz, 1H, H6), 7.06 (s, 1H, H3), 7.00 (d, 
3J = 5.0 
Hz, 1H, H5), 4.77 (br s, 1H, COOH), 4.21 (d, 
2J = 12.4 Hz, 1H, pyrCH2Npro), 3.79 (br s, 1H, 
pyrCH2Npro), 3.56 (br s, 1H, H2’), 3.32-3.29 (m, 1H, H5’a), 2.66-2.60 (m, 1H, H5’b),  2.53 (t, 
3J = 7.9 
Hz, 2H, H7)  2.25-2.17 (m, 1H, H3’a), 2.15-2.08 (m, 1H, H3’b), 1.93-1.84 (m, 1H, H4’a), 1.82-1.79 (m, 
1H, H4’b), 1.59-1.53 (m, 2H, H8), 1.31-1.23 (m, 6H, H9, H10, H11), 0.85 (t, 3H, 
3J = 6.9 Hz, H12) ppm.  
13C-NMR (75.7 MHz, CDCl3): δ = 175.8 (COOH), 155.5 (C2), 153.3 (C4), 149.5 (C6), 123.7 (C3), 
123.3 (C5), 68.5 (C2‘), 59.6 (pyrCH2NPro), 53.9 (C5‘), 35.3 (C7), 31.6 (C10), 30.3 (C8), 29.7 (C3‘), 29.0 (C9), 
23.7 (C4‘), 22.6 (C11), 14.1 (C12) ppm. 
ATR-IR (neat): ~ = 3380 (br, w), 3053 (w), 2927 (s), 2861 (m), 1703 (w), 1602 (vs), 1452 (m), 
1400 (s), 1307 (m), 1210 (w), 1175 (w), 1091 (m), 1049 (s), 998 (w), 919 (w), 885 (w), 840 (w), 775 
(w), 717 (w), 690 (w), 599 (w), 437 (m) cm-1. 
HR-MS (ESI+): C17H26N2O2H (M+H)
+ calcd.: 291.2067; found: 291.2064.  
  
Compound preparation drug-like abilities approach 
200 
 
5.4.1.4.5. Synthesis of the hexyl derivatised complexes 213a and 213b 
 
The 4-hexyl-pyridine derivatives of the complexes 201a and 201b were prepared according to 
standard procedure I using 50 mg TBS-protected pyridocarbazole (125 µmol, 1.00 eq) and 33 mg 
RhCl3·3H2O (125 µmol, 1.00 eq) in 25.0 mL H2O/EtOH 1:1. The reaction mixture was reacted 
for 90 min at 90 °C before addition of 40 mg of the proline-ligand 257 (137 µmol, 1.10 eq) and 
reacting for another 16 h. After removal of the solvent under reduced pressure, the compound was 
adsorbed on silica (~1.00 g) and the diastereomers were separated by flash chromatography (12 g 
silica gel).1 213b (cis-isomer) was further purified twice over 2 g silica each yielding in 16.1 mg of 
the complex as a deep red solid. The extensive purification of mixed fractions yielded in additional 
11.0 mg giving a total yield of 27.1 mg (38.0 µmol, 30%). 213a (trans-isomer) was further purified 
twice over 4 g silica using CH2Cl2/MeOH and 2 g using CH2Cl2/CH3CN (2:1 to 1:1) yielding in 
8.1 mg (11.3 µmol, 9%) of the complex as a deep red solid. 
1Please be aware that both isomers have the same Rf on TLC in CH2Cl2/MeOH 10:1. They will be separated if you 
run the TLC twice or use a mixture of CH2Cl2/CH3CN 2:1 or 1:1 
213b: 
1H-NMR (500.1 MHz, DMSO-d6): δ = 11.24 (br s, NH), 9.50 (d, 
3J = 6.0 Hz, 1H, H6), 9.29 (dd, 
3J = 8.4 Hz, 4J = 1.0 Hz, 1H, H3’’), 8.84 (d, 
3J = 5.2 Hz, 1H, H1’’), 8.68 (d, 
3J = 7.9 Hz, 1H, H4’’), 
8.07 (dd, 3J = 8.2 Hz, 3J = 5.2 Hz, 1H, H2’’), 7.89 (dd,
 3J = 5.0 Hz, 4J = 1.4 Hz, 1H, H5), 7.84 (s, 1H, 
H3), 7.26 (t, 
3J = 7.2 Hz, 1H, H6’’), 7.16 (ddd, 
3J = 8.3 Hz, 3J = 7.2 Hz, 4J = 1.2 Hz, 1H, H5’’), 5.69 
(d, 3J = 8.3 Hz, 1H, H7’’), 4.52 (d, 
4J = 15.6 Hz, 1H, proCH2pyr), 4.28 (d, 
4J = 15.7 Hz, 1H, proCH2pyr), 
3.79 (dd, 3J = 9.6 Hz, 3J = 4.2 Hz, 1H, H2’), 2.98-2.90 (m, 2H, H7), 2.47-2.45 (m, 1H, H5a’), 2.24-
2.16 (m, 2H, H5b’, H3‘a), 2.03-1.97 (m, 1H, H3’b), 1.83-1.75 (m, 2H, H8), 1.60-1.55 (m, 1H, H4’a), 1.42-
1.36 (m, 4H, H9, H10), 1,27-1.26 (m, 2H, H11), 1.10-1.02 (m, 1H, H4’b), 0.92 (t, 3H, H12) ppm. 
13C-NMR (125.8 MHz, DMSO-d6): δ = 73.0 (C2’), 69.9 (CH2Npro), 61.3 (C5‘), 34.4 (C7), 31.0 (C10), 
30.4 (C3’), 29.4 (C8), 28.1 (C9), 24.3 (C4’), 22.0 (C11), 14.0 (C12) ppm. Not all carbon atoms could be 
found due to low signal to noise ratio (solubility issue). 
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ATR-IR (neat): ~ = 2922 (m), 2851 (m), 1754 (w), 1705 (s), 1665 (s), 1621 (m), 1582 (vw), 1559 
(vw), 1522 (w), 1492 (w), 1465 (vw), 1414 (w), 1400 (w), 1378 (vw), 1340 (s), 1294 (m), 1259 (m), 
1228 (s), 1177 (vw), 1129 (w), 1079 (vw), 1066 (vw), 1045 (vw), 1011 (m), 973 (vw), 953 (vw), 936 
(vw), 874 (vw), 829 (m), 803 (m), 747 (s), 725 (vw), 709 (m), 639 (m), 496 (m), 440 (m), 388 (m) 
cm-1. 
HR-MS (ESI+): C34H34ClN5O4Rh (M+H)
+ calcd.:714.1349, found: 714.1350. 
213a: 
1H-NMR (500.2 MHz, DMSO-d6): δ = 11.20 (br s, NH), 9.37 (d, 
3J = 6.0 Hz, 1H, H6), 9.17 (dd, 
3J = 8.4 Hz, 4J = 1.0 Hz, 1H, H3’’), 8.71 (dt, 
3J = 8.0 Hz, 4J = 0.9 Hz, 1H, H4’’), 7.92 (d, 
3J = 5.3 Hz, 
1H, H1‘‘), 7.83-7.80 (m, 2H, H7’’, H5), 7.76 (d, 
4J = 1.8 Hz, 1H, H3), 7.74 (dd, 
3J = 8.4 Hz, 
3J = 5.3 Hz, 1H, H2’’), 7.54 (ddd, 
3J = 8.3 Hz, 3J = 7.1 Hz, 4J = 1.2 Hz, 1H, H6’’), 7.37 (ddd, 
3J = 8.0 Hz, 3J = 7.0 Hz, 4J = 1.0 Hz, 1H, H5’’), 4.55 (d, 
2J = 16.0 Hz, 1H, pyrCH2Npro), 4.49 (d, 
4J = 16.1 Hz, 1H, pyrCH2Npro), 3.76 (dd, 
3J = 9.4 Hz, 3J = 4.9 Hz, 1H, H2’), 2.88-2.85 (m, 2H, H7), 
2.48-2.43 (m, 1H, H5a’), 2.23-2.13 (m, 2H, H5b’, H3‘a), 1.88-1.83 (m, 1H, H3‘b), 1.77-1.71 (m, 2H, H8), 
1.45-1.39 (m, 3H, H4a’, H9), 1.36-1.33 (m, 4H, H10, H11), 1.09-1.04 (m, 1H, H4b’), 0.92-0.89 (m, 3H, 
H12) ppm. 
13C-NMR (125.8 MHz, DMSO-d6): δ = 182.3 (COO), 170.6 (CO), 170.3 (CO), 159.6 (Cq), 156.8 
(Cq), 152.2 (Cq), 150.9 (C6), 150.3 (C1’’), 149.9 (Cq), 142.4 (Cq), 134.8 (C3’’), 131.2 (Cq), 126.5 (C6’’), 
126.0 (C5), 124.3 (C4’’), 124.2 (C2‘‘), 123.5 (C3), 123.1 (Cq), 121.1 (Cq), 119.6 (C5’’), 114.9 (C7’’), 114.9 
(Cq), 113.9 (Cq), 73.5 (C2’), 69.2 (pyrCH2Npro), 61.4 (C5‘), 35.0 (C7), 31.0 (C10), 30.3 (C3’), 29.3 (C8), 28.4 
(C9), 23.8 (C4‘), 22.0 (C11), 13.9 (C12) ppm.  
ATR-IR (neat):~ = 3108 (w), 2923 (m), 2853 (m), 2719 (w), 1750 (w), 1710 (m), 1648 (m), 1520 
(w), 1493 (w), 1449 (w), 1415 (m), 1340 (s), 1296 (m), 1267 (w), 1230 (m), 1174 (vw), 1134 (w), 
1084 (vw), 1018 (m), 934 (w), 853 (w), 823 (w), 797 (w), 754 (m), 706 (w), 635 (m), 571 (vw), 521 
(vw), 493 (m), 442 (w), 416 (w) cm-1. 
HR-MS (ESI+): C34H33ClN5O4RhNa (M+Na)
+ calcd.:736.1179, found: 736.1179. 
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5.4.2. Modification of the pyridocarbazole ligand 
5.4.2.1. Synthesis of 5-methylpyridine derivatised complexes 223a and 223b 
 
The methyl-derivatives 223a and 223b were prepared according to standard procedure I using 
50 mg (120 µmol, 1.00 eq) of TBS-protected methyl-pyridocarbazole (259) and 32 mg (120 µmol, 
1.00 eq) RhCl3·3 H2O in 24 mL H2O/EtOH 1:1, which were reacted for 90 min at 95 °C. After 
cooling to 20 °C, 27.3 mg of proline ligand 206 (133 µmol, 1.10 eq) was added and further reacted 
for 16 h at 90 °C. This batch was combined with a small scale reaction (24.0 µmol) for purification. 
The diastereoisomers were separated by flash chromatography (8 g silica gel) using the standard 
procedure and each isomer was further purified twice (2 g and 1.5 g of silica) yielding in 223a 
(7.1 mg, 11.0 µmol, 8%) and 223b (11.9 mg, 18.5 µmol, 13%) as orange-red solids. However, after 
repetitive purification both diastereomers still contained some traces of impurities. 
223a: 
1H-NMR (300.1 MHz, DMSO-d6): δ = 11.23 (s, NH), 9.67 (d, 
3J = 5.7 Hz, 1H, H6), 9.09 (dd, 
4J = 1.5 Hz, 4J = 1.1 Hz, 1H, H3’’), 8.66 (m, 
3J = 7.5 Hz, 2H, H1’’, H4’’), 8.47 (td, 
3J = 7.8 Hz, 
4J = 1.5 Hz, 1H, H4), 8.03 (ddd, 
3J = 7.3 Hz, 3J = 6.4 Hz, 4J = 0.9 Hz, 1H, H5), 7.98 (d, 
3J = 7.7 Hz, 
1H, H3), 7.25 (ddd, 
3J = 8.0 Hz, 3J = 7.0 Hz, 4J = 0.9 Hz, 1H, H5’’), 7.17 (ddd, 
3J = 8.3 Hz, 
3J = 7.1 Hz, 4J = 1.3 Hz, 1H, H6’’), 5.65 (d, 
3J = 8.3 Hz, 1H, H7’’), 4.60 (d, 
4J = 15.7 Hz, 1H, 
proCH2pyr), 4.33 (d, 
4J = 15.5 Hz, 1H, proCH2pyr), 3.79 (dd, 
3J = 9.6 Hz, 3J = 4.5 Hz, 1H, H2’), 2.76 (s, 
3H, CH3), 2.24-2.20 (m, 2H, H5’b, H3’a), 2.05-2.02 (m, 1H, H3’b), 1.61-1.57 (m, 1H, H4’a), 1.16-1.07 
(m, 1H, H4’b) ppm. The missing H5’a signal overlaps with the DMSO signal. 
13C-NMR (125.8 MHz, DMSO-d6): δ = 182.1 (COO), 170.7 (CO), 170.3 (CO), 161.2 (Cq), 153.0 
(Cq), 152.6 (C6), 149.2 (C1’’), 148.8 (Cq), 141.2 (C4), 140.5 (Cq), 134.3 (C3’’), 134.1 (Cq), 131.4 (Cq), 
126.5 (C6’’), 126.3 (C5), 124.7 (C4’’), 123.6 (Cq), 123.5 (C3), 121.3 (Cq), 119.6 (C5’’), 114.6 (Cq), 114.0 
(Cq), 111.7 (C7’), 73.0 (C2’), 70.0 (proCH2pyr), 61.3 (C5’), 30.5 (C3’), 24.4 (C4’), 19.3 (CH3) ppm. 
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ATR-IR (neat): ~ = 3051 (vw), 2922 (w), 2854 (w), 1749 (w), 1711 (m), 1649 (m), 1486 (w), 1419 
(w), 1341 (m), 1295 (m), 1231 (w), 1149 (w), 1017 (w), 933 (vw), 896 (vw), 857 (vw), 820 (w), 747 
(m), 639 (w), 514 (w), 483 (w), 450 (vw), 401 (vw) cm-1. 
HR-MS (ESI+): C29H23ClN5O4RhH (M+H)
+ calcd.: 644.0566, found: 644.0561. 
223b: 
1H-NMR (500.1 MHz, DMSO-d6): δ = 11.18 (s, NH), 9.53 (d, 
3J = 5.7 Hz, 1H, H6), 8.97 (dd, 
4J = 1.4 Hz, 4J = 1.0 Hz, 1H, H3’’), 8.68 (d, 
3J = 7.8 Hz, 1H, H4’’), 8.37 (td, 
3J = 7.8 Hz, 4J = 1.5 Hz, 
1H, H4), 7.96-7.91 (m, 
3J = 6.3 Hz, 3J = 8,1 Hz, 2H, H5, H3), 7.79 (d, 
3J = 8.3 Hz, 2H, H7’’, H1’’), 
7.52 (ddd, 3J = 8.3 Hz, 3J = 7.1 Hz, 4J = 1.3 Hz, 1H, H6’’), 7.17 (ddd, 
3J = 8.0 Hz, 3J = 7.1 Hz, 
4J = 0.9 Hz, 1H, H5’’), 4.67 (d, 
4J = 15.1 Hz, 1H, proCH2pyr), 4.55 (d, 
4J = 16.0 Hz, 1H, proCH2pyr), 3.77 
(dd, 3J = 9.5 Hz, 3J = 4.9 Hz, 1H, H2’), 2.47-2.43 (m, 1H, H5’a), 2.24-2.14 (m, 2H, H5’b, H3’a), 1.87-
1.82 (m, 1H, H3’b), 1.47-1.41 (m, 1H, H4’a), 1.11-1.04 (m, 1H, H4’b) ppm. The missing signal 
belonging to the -CH3 group overlaps with the DMSO signal as confirmed by 
1H-1H-COSY-NMR 
spectroscopy. 
13C-NMR (125.8 MHz, DMSO-d6): δ = 182.4 (COO), 170.7 (CO), 170.4 (CO), 160.2 (Cq), 152.5 
(Cq), 151.7 (C6), 151.2 (C1’’), 149.8 (Cq), 140.7 (C4), 134.6 (Cq), 133.9 (C3’’), 131.2 (Cq), 126.4 (C6’’), 
126.1 (C5), 124.1 (C4’’), 123.9 (C3), 123.1 (Cq), 121.0 (Cq), 119.6 (C6’’), 114.8 (C7’’), 114.4 (Cq), 113.3 
(Cq), 73.5 (C2’), 69.5 (proCH2pyr), 61.5 (C5’), 30.4 (C3’), 23.8 (C4’), 19.0 (CH3) ppm.    
ATR-IR (neat): ~  = 3052 (vw), 2922 (w), 2856 (vw), 1750 (w), 1708 (m), 1643 (s), 1573 (vw), 
1493 (vw), 1418 (w), 1339 (s), 1296 (m), 1268 (w), 1231 (m), 1153 (vw), 1112 (vw), 1017 (m), 933 
(vw), 891 (vw), 858 (vw), 822 (w), 751 (s), 712 (w), 635 (w), 569 (vw), 506 (w), 484 (vw), 452 (w), 
432 (vw), 421 (vw), 410 (vw), 401 (w) cm-1. 
HR-MS (ESI+): C29H23ClN5O4RhNa (M+Na)
+ calcd.: 666.0386, found: 666.0381. 
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5.4.2.2. Synthesis of 5-methoxypyridine derivatised complexes 225a and 225b 
 
225a was prepared according to standard procedure II by heating a solution of 21 mg of proline-
ligand 206 (99.6 µmol, 1.00 eq) and 26 mg RhCl3·3H2O (99.6 µmol, 1.00 eq) in 18.0 mL 
H2O/CH3CN 1:1 for 3 h at 90 °C. After cooling to 20 °C, the solvent was removed under reduced 
pressure, 47 mg TBS-protected methoxy pyridocarbazole 260 (110 µmol, 1.10 eq) and 18 mL 
H2O/EtOH 1:1 were added and further reacted for 40 h at 95 °C. After solvent removal, the 
compound was adsorbed on silica, and the diastereomers were separated using flash 
chromatography according to the standard procedure on 15 g silica. The diastereomer a was further 
purified over 1.5 g silica respectively yielding in 5.6 mg (8.49 µmol, 9%) of 225a as a deep red solid. 
225b was obtained with a trace of the corresponding precursor (3:1 mixture, ~3 mg). 
225a: 
1H-NMR (300.1 MHz, DMSO-d6): δ = 11.25 (s, NH), 9.66 (d, 
3J = 5.7 Hz, 1H, H6), 8.64-8.62 (m, 
2H, H3’’, H4’’), 8.47 (td, 
3J = 7.8 Hz, 4J = 1.4 Hz, 1H, H5), 8.40 (dd, 
4J = 2.4 Hz, 4J = 0.7 Hz, 1H, 
H1’’), 8.04-7.99 (m, 1H, H4), 7.98 (d, 
3J = 7.9 Hz, 1H, H3), 7.24 (m, 
4J = 0.9 Hz, 1H, H6’’), 7.17 (ddd, 
3J = 8.3 Hz, 3J = 6.9 Hz, 4J = 1.4 Hz, 1H, H5’’), 5.63 (d, 
3J = 7.9 Hz, 1H, H7’’), 4.61 (d, 
4J = 15.5 Hz, 
1H, proCH2pyr), 4.32 (d, 
4J = 15.6 Hz, 1H, proCH2pyr), 4.14 (s, 3H, OCH3), 3.82 (dd, 
3J = 9.4 Hz, 
3J = 4.7 Hz, 1H, H2’), 2.58-2.53 (m, 1H, H5’), 2.29-2.16 (m, 2H, H5’, H3’), 2.06-1.98 (m, 1H, H3’), 
1.67-1.60 (m, 1H, H4’a), 1.18-1.09 (m, 1H, H4’b) ppm. 
13C-NMR (125.8 MHz, DMSO-d6): δ = 182.0 (COO), 170.8 (CO), 170.2 (CO), 161.2 (Cq), 155.0 
(Cq), 153.5 (Cq), 152.6 (C6), 148.9 (C1’’), 141.2 (C5), 140.7 (Cq), 136.9 (C3’’), 131.5 (Cq), 126.4 (C5‘‘), 
126.3 (C4), 124.6 (C4‘‘), 123.6 (2C, Cq + C3), 122.1 (Cq), 119.5 (C6‘‘), 114.0 (Cq), 113.4 (Cq), 113.3 (Cq), 
111.5 (C7‘‘), 72.8 (C2‘), 69.9 (proCH2pyr), 61.1 (C5’), 56.7 (OCH3), 30.1 (C3‘), 24.4 (C4‘) ppm. 
ATR-IR (neat): ~ = 2917 (w), 2850 (w), 1752 (w), 1703 (m), 1661 (m), 1607 (w), 1568 (w), 1518 
(vw), 1491 (vw), 1474 (vw), 1459 (vw), 1450 (vw), 1407 (w), 1347 (m), 1299 (w), 1259 (m), 1223 
(m), 1162 (vw), 1114 (vw), 1070 (vw), 1058 (vw), 1010 (m), 972 (vw), 933 (vw), 881 (vw), 855 (vw), 
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826 (w), 790 (vw), 743 (m), 713 (w), 682 (vw), 660 (vw), 639 (w), 569 (vw), 521 (w), 471 (w), 451 
(vw), 438 (w), 428 (vw), 400 (m), 383 (w) cm-1. 
HR-MS (ESI+): C29H23ClN5O5RhNa (M+Na)
+ calcd.: 682.0335, found: 682.0351. 
 
 
225b was prepared according to standard procedure I using 36 mg TBS-protected methoxy 
pyridocarbazole 260 (83.4 µmol, 1.00 eq) and 22 mg RhCl3·3H2O (83.4 µmol, 1.00 eq) in 16.6 mL 
H2O/EtOH 1:1 for 90 min at 90 °C before adding the resulting suspension to 19 mg of proline-
ligand 206 (91.8 µmol, 1.10 eq) in 0.5 mL EtOH and reacting the mixture for 40 h. After removal 
of the solvent under reduced pressure, the compound was adsorbed on silica gel (~500 mg) and 
the diastereomers were separated according to the standard procedure. Isomer b was further 
purified twice (1.5 g silica gel each) yielding 225b (9.8 mg, 15.0 µmol, 18%) as a deep red solid. 
225a could not be obtained purely with this procedure, even when using preparative TLC and 
additional flash column chromatography for purification. 
225b: 
1H-NMR (300.1 MHz, DMSO-d6): δ = 11.19 (s, NH), 9.52 (d, 
3J = 5.3 Hz, 1H, H6), 8.66 (d, 
3J = 7.7 Hz, 1H, H4’’), 8.53 (s, 1H, H3’’), 8.36 (t, 
3J = 7.7 Hz, 1H, H4), 7.96-7.90 (m, 2H, H5, H3), 
7.76 (d, 3J = 7.9 Hz, 1H, H7’’), 7.53-7.48 (m, 2H, H1’’, H6’’), 7.34 (t, 
3J = 7.3 Hz, H5’’), 4.74 (d, 
2J = 15.6 Hz, 1H, proCH2pyr), 4.56 (d, 
2J = 16.3 Hz, 1H, proCH2pyr), 3.99 (s, 3H, OCH3), 3.79 (dd, 
3J = 8.8 Hz, 3J = 4.2 Hz 1H, H2’), 2.29-2.22 (m, 2H, H5b’, H3‘a), 2.22-2.12 (m, 1H, H3‘b), 1.89-1.83 
(m, 1H, H3‘b), 1.48-1.44 (m, 1H, H4a’), 1.14-1.00 (m, 1H, H4’b) ppm. The missing H5a’ proton overlaps 
with the DMSO-signal. 
13C-NMR (75.5 MHz, DMSO-d6): δ = 182.4 (COO), 170.8 (CO), 170.2 (CO), 160.3 (Cq), 155.1 
(Cq), 153.0 (Cq), 151.6 (C6), 149.8 (C1’’), 143.1 (C5), 140.7 (Cq), 137.2 (C3’’), 131.3 (Cq), 126.3 (C5’’), 
126.1 (C4), 124.1 (C4’’), 123.9 (C3), 123.1 (Cq), 121.7 (Cq), 119.5 (C6’’), 114.6 (C7’’), 113.9 (Cq), 112.8 
(Cq), 112.6 (Cq), 73.5 (C2‘), 69.4 (proCH2pyr), 61.6 (C5‘), 56.3 (OCH3), 30.4 (C3‘), 23.9 (C4‘) ppm. 
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ATR-IR (neat): ~ = 2922 (w), 1748 (w), 1704 (m), 1649 (m), 1570 (m), 1495 (w), 1449 (vw), 1413 
(w), 1345 (s), 1299 (w), 1262 (m), 1222 (s), 1110 (vw), 1016 (s), 940 (vw), 876 (vw), 824 (vw), 750 
(m), 708 (w), 663 (vw), 635 (m), 568 (vw), 519 (vw), 469 (w), 441 (w), 405 (w) cm-1. 
HR-MS (ESI): C29H23ClN5O5RhNa (M+Na)
+ calcd.: 682.0335, found: 682.0342. 
 
5.4.2.3. Synthesis of indole-5-ol derivatised complexes 226a and 226b 
 
The complexes were prepared according to standard procedure I using 60 mg doubly TBS-
protected 5-TBS-1H-indole derivatised pyridocarbazole 208 (113 µmol, 1.00 eq), 30 mg 
RhCl3·3H2O (113 µmol, 1.00 eq) and 23 mL EtOH/H2O, which was reacted for 90 min at 93 °C, 
before 26 mg proline ligand 206 (124 µmol, 1.10 eq) was added and further reacted for 16 h at 
93 °C. The diastereoisomers were separated by flash chromatography (18 g silica gel). The isomers 
a and b were further purified individually by flash chromatography (1.0 g silica gel each). Isomer a 
was further purified over 1.5 g silica and pooled with previously heavily purified complex from two 
scales using a total of 37.6 µmol RhCl3·3H2O via the standard approach I and one scale with 
38.0 µmol using standard procedure II, yielding in 8.5 mg of 209a (13.2 µmol, 7%) as deep reddish 
purple solid. Isomer b was combined with complex obtained from the same scales as isomer a and 
was further purified over 1.0 g silica to yield 209b (7.6 mg, 11.8 µmol, 6%) with roughly 30% (1H-
NMR) non pyridocarbazole containing impurity as a deep red-purple solid.  
226a: 
1H-NMR (500.1 MHz, DMSO-d6): δ = 11.16 (s, NH), 9.66 (d, 
3J = 5.7 Hz, 1H, H6), 9.24 (s, 1H, 
OH), 9.23 (dd, 3J = 8.5 Hz, 4J = 1.1 Hz, 1H, H3’’), 8.79 (d, 
3J = 5.1 Hz, 1H, H1’’), 8.46 (td, 
3J = 7.8 Hz, 4J = 1.5 Hz, 1H, H4), 8.12 (d, 
4J = 2.5 Hz, 1H, H4’’), 8.03-8.00 (m, 2H, H5, H2’’), 7.97 
(d, 3J = 7.8 Hz, 1H, H3) 6.72 (dd, 
3J = 8.8 Hz, 3J = 2.5 Hz, 1H, H6’’), 5.52 (d, 
3J = 8.8 Hz, 1H, H7’’), 
4.58 (d, 4J = 15.7 Hz, 1H, proCH2pyr), 4.31 (d, 
4J = 15.6 Hz, 1H, proCH2pyr), 3.79 (dd, 
3J = 9.6 Hz, 
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3J = 4.2 Hz, 1H, H2’), 2.48-2.45 (m, 1H, H5a’), 2.25-2.17 (m, 2H, H5b’, H3a’), 2.02-1.97 (m, 1H, H3b’), 
1.61-1.54 (m, 1H, H4a’), 1.08-1.00 (m, 1H, H4b’) ppm. 
13C-NMR (125.8 MHz, DMSO-d6): δ = 182.1 (COO), 170.6 (CO), 170.3 (CO), 161.1 (Cq), 152.6 
(Cq), 152.5 (Cq), 151.6 (C6), 148.2 (C1’’), 142.8 (Cq.), 142.4 (Cq), 141.1 (C4), 135.0 (C3’’), 131.5 (Cq), 
126.2 (C5), 124.1 (C2’’), 123.5 (Cq), 123.5 (C3), 121.4 (Cq), 116.8 (C6‘‘), 114.8 (Cq), 113.2 (C7‘‘), 112.2 
(Cq), 109.1 (C4’’), 72.9 (C2’), 70.0 (proCH2pyr), 61.2 (C5’), 30.5 (C3’), 24.3 (C4’) ppm.  
ATR-IR (neat): ~ = 3112 (vw), 3056 (vw), 2991 (vw), 2954 (vw), 2922 (w), 2855 (vw), 2729 (w), 
1750 (w), 1705 (s), 1652 (s), 1608 (m), 1563 (w), 1523 (vw), 1493 (vw), 1466 (w), 1415 (w), 1337 
(s), 1299 (vw), 1238 (vw), 1212 (w), 1123 (w), 1017 (s), 895 (vw), 859 (w), 827 (w), 779 (m), 694 (s), 
637 (w), 580 (vw), 529 (vw), 497 (m), 443 (vw) cm-1. 
HR-MS (APCI+): C28H21ClN5O5RhH (M+H)
+ calcd.: 646.0359, found: 646.0360. 
 
226b: 
1H-NMR (500.2 MHz, DMSO-d6): δ = 11.17 (s, NH), 9.52 (d, 
3J = 5.6 Hz, 1H, H6), 9.32 (s, 1H, 
OH), 9.10 (dd, 3J = 8.3 Hz, 4J = 0.9 Hz, 1H, H3’’), 8.37 (td, 
3J = 7.8 Hz, 4J = 1.5 Hz, 1H, H4), 8.12 
(d, 4J = 2.5 Hz, 1H, H4’’), 8.03-8.00 (m, 2H, H5, H3), 7.86 (d, 
3J = 5.2 Hz, 1H, H1’’) 7.68 (dd, 
3J = 8.4 Hz, 3J = 5.3 Hz, 1H, H2’’), 7.61 (d, 
3J = 8.8 Hz, 1H, H7’’), 7.06 (dd, 
3J = 8.8 Hz, 3J = 2.5 Hz, 
1H, H6’’), 4.56 (s, 1H, proCH2pyr), 3.78 (dd, 
3J = 9.5 Hz, 3J = 4.8 Hz, 1H, H2’), 2.45-2.41 (m, 1H, H5a’), 
2.20-2.15 (m, 2H, H5b’, H3a’), 1.87-1.82 (m, 1H, H3b’), 1.49-1.41 (m, 1H, H4a’), 1.11-1.07 (m, 1H, H4b’) 
ppm. 
13C-NMR (125.8 MHz, DMSO-d6): δ = 182.4 (COO), 170.7 (CO), 170.4 (CO), 160.2 (Cq), 152.1 
(Cq), 151.7 (Cq), 151.6 (C6), 149.8 (C1’’), 143.8 (Cq), 142.7 (Cq), 140.7 (C4), 134.6 (C3’’), 131.5 (Cq), 
126.1 (C5), 123.9 (C3, C2’’), 123.8 (Cq), 121.1 (Cq), 117.0 (C6’’), 115.4 (C7’’), 114.7 (Cq), 112.6 (Cq), 108.5 
(C4’’), 73.5 (C2’), 69.4 (proCH2pyr), 61.4 (C5‘), 30.4 (C3‘), 23.8 (C4‘) ppm. 
ATR-IR (neat): ~ = 2923 (m), 2854 (w), 2727 (vw), 1747 (vw), 1707 (m), 1634 (m), 1501 (vw), 
1422 (w), 1337 (s), 1241 (w), 1214 (w), 1181 (vw), 1129 (w), 1016 (s), 951 (w), 863 (vw), 823 (w), 
767 (m), 696 (m), 635 (w), 576 (vw), 525 (vw), 496 (m), 442 (vw), 398 (w) cm-1. 
HR-MS (APCI+): C28H21ClN5O5RhH (M+H)
+ calcd.: 646.0359, found: 646.0374. 
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5.4.2.4. Synthesis of pyridine-6-yl methanol derivatised complexes 209a and 209b 
 
The complexes were prepared according to the standard procedure I using 73 mg doubly TBS-
protected methanol-pyridocarbazole 261 (133.7 µmol, 1.00 eq), 35 mg RhCl3·3H2O (133.7 µmol, 
1.00 eq), and 27 mL EtOH/H2O, which was reacted for 135 min at 92 °C, before 30 mg proline 
ligand 206 (147.1 µmol, 1.10 eq) was added and further reacted for 16 h at 93 °C. The 
diastereoisomers were separated via flash chromatography (18 g silica gel). The isomers a and b 
were further purified twice over 2 g for a/1.5 g for b and 1.0 g silica each respectively, yielding in 
5.7 mg 226a (8.6 µmol, 7%) and 4.5 mg 226b (6.8 µmol, 5%) as deep red solids.  
209a: 
1H-NMR (300.1 MHz, DMSO-d6): δ = 11.21 (s, NH), 9.66 (dt, 
3J = 5.8 Hz, 4J = 0.6 Hz, 1H, H6), 
9.34 (d, 3J = 8.7 Hz, 1H, H3’’) 8.71 (ddd, 
3J = 7.9 Hz, 4J = 1.2 Hz, 4J = 0.7 Hz, 1H, H4’’),  8.48 (td, 
3J = 7.8 Hz, 4J = 1.5 Hz, 1H, H4), 8.23 (d, 
3J = 8.7 Hz, 1H, H2’’), 8.05 (t, 
3J = 6.5 Hz, 1H, H5), 7.94 
(d, 3J = 7.8 Hz, 1H, H3), 7.24 (ddd, 
3J = 7.8 Hz, 3J = 7.2 Hz, 2J = 0.9 Hz, 1H, H5’’), 7.14 (ddd, 
3J = 8.4 Hz, 3J = 7.1 Hz, 4J = 1.3 Hz, 1H, H6’’), 6.07 (t, 
3J = 5.4 Hz, 1 H, OH), 5.42 (d , 3J = 8.4 Hz, 
1H, H7’’), 5.36 (dd, 
2J = 17.8 Hz, 3J = 4.4 Hz, 1H, CH2OH), 4.88 (dd, 
2J = 17.9 Hz, 3J = 5.4 Hz, 1H, 
CH2OH), 4.48 (d, 
4J = 15.5 Hz, 1H, proCH2pyr), 4.16 (d, 
4J = 15.6 Hz, 1H, proCH2pyr), 3.74 (dd, 
3J = 10.1 Hz, 3J = 5.1 Hz, 1H, H2’), 2.45-2.40 (m, 1H, H5b’), 2.31-2.26 (m, 1H, H5b’) 2.24-2.18 
(m,1H, H3a’), 1.98-1.92 (m, 1H, H3b’), 1.59-1.55 (m, 1H, H4’a), 1.05-0.99 (m, 1H, H4’b) ppm. The 
missing H5a’ signal overlaps with the DMSO signal. 
13C-NMR (500.2 MHz, DMSO-d6): δ = 182.1 (COO), 170.8 (CO), 170.3 (CO), 168.9 (Carom), 161.2 
(Carom), 152.7 (Carom), 152.3 (Carom), 148.1 (Carom), 141.7 (Carom), 141.5 (Carom), 135.6 (Carom), 130.2 (Carom), 
126.6 (Carom), 126.5 (Carom), 124.8 (Carom), 123.6 (Carom), 123.5 (Carom), 121.7 (Carom), 120.4 (Carom), 119.5 
(C5/6‘‘), 115.3 (Cq), 114.9 (Cq), 111.4 (C7‘‘), 73.3 (C2‘), 69.9 (proCH2pyr), 62.2 (CH2OH), 61.3 (C5’), 30.9 
(C3‘), 24.1 (C4‘) ppm.  
ATR-IR (neat): ~  = 3214 (br, w), 2921 (m), 2852 (w), 1752 (w), 1701 (m), 1615 (m), 1534 (vw), 
1496 (w), 1447 (vw), 1419 (w), 1341 (s), 1295 (w), 1230 (m), 1188 (vw), 1164 (vw), 1115 (vw), 1078 
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(w), 1013 (m), 934 (vw), 901 (vw), 834 (w), 739 (m), 671 (vw), 636 (w), 581 (vw), 494 (vw), 452 (w), 
398 (w) cm-1. 
HR-MS (APCI+): C29H23ClN5O5RhH (M+H
+) calcd.: 660.0516, found: 660.0517. 
209b: 
1H-NMR (300.1 MHz, DMSO-d6): δ = 11.17 (s, NH), 9.63 (d, 
3J = 5.4 Hz, 1H, H6), 9.25 (d, 
3J = 8.6 Hz, 1H, H3’’) 8.73 (d, 
3J = 8.0 Hz, 1H, H4’’),  8.37 (td, 
3J = 7.8 Hz, 4J = 1.5 Hz, 1H, H4), 
8.01 (m, 3J = 7.3 Hz, 3J = 5.9 Hz, 4J = 1.4 Hz 1H, H5), 8.00 (d,
 3J = 8.7 Hz, 1H, H2’’), 7.88 (d, 
3J = 7.7 Hz, 1H, H3), 7.87 (d, 
3J = 8.4 Hz, 1H, H7’’), 7.50 (ddd, 
3J = 8.4 Hz, 3J = 7.0 Hz, 4J = 1.3 Hz, 
1H, H6’’), 7.35 (ddd, 
3J = 8.0 Hz, 3J = 7.1 Hz, 4J = 0.9 Hz, 1H, H5’’), 5.81 (t, 
3J = 5.4 Hz, 1 H, OH), 
4.69 (d, 4J = 15.8 Hz, 1H, proCH2pyr), 4.52 (d, 
4J = 15.9 Hz, 1H, proCH2pyr), 4.28 (dd, 
2J = 15.7 Hz, 
3J = 4.4 Hz, 1H, CH2OH), 3.77 (dd, 
2J = 15.7 Hz, 3J = 5.9 Hz, 1H, CH2OH), 3.66 (dd, 
3J = 9.3 Hz, 
3J = 6.9 Hz, 1H, H2’), 2.45-2.40 (m, 1H, H5a’), 2.13-2.06 (m, 1H, H5b’) 2.02-1.96 (m,1H, H3a’), 1.56-
1.47 (m, 1H, H3b’), 1.41-1.35 (m, 1H, H4a’), 0.72-0.65 (m, 1H, H4b’) ppm. 
13C-NMR (125.8 MHz, DMSO-d6): δ = 182.7 (COO), 170.8 (CO), 170.4 (CO), 167.5 (Carom), 160.5 
(Carom), 151.9 (Carom), 151.7 (Carom), 149.5 (Carom), 142.3 (Carom), 140.9 (Carom), 135.4 (Carom), 130.3 
(Carom), 126.6 (Carom), 126.5 (Carom), 124.2 (Carom), 123.8 (Carom), 123.1 (Carom), 121.9 (Carom), 120.4 
(Carom), 119.6 (C5/6’’), 115.2 (C7’’), 114.9 (Cq), 114.4 (Cq), 73.5 (C2’), 70.9 (CH2NPro), 61.6 (C5‘), 60.8 
(CH2OH), 30.4 (C3‘), 23.3 (C4‘) ppm.    
ATR-IR (neat): ~ = 3224 (br, w), 2920 (m), 2852 (w), 1750 (w), 1707 (m), 1649 (m), 1615 (m), 
1534 (vw), 1498 (vw), 1447 (vw), 1418 (w), 1341 (s), 1294 (w), 1261 (vw), 1233 (w), 1187 (vw), 1150 
(vw), 1081 (w), 1006 (m), 936 (vw), 901 (vw), 827 (vw), 744 (m), 671 (vw), 632 (w), 583 (vw), 519 
(vw), 489 (vw), 451 (w), 403 (w) cm-1. 
HR-MS (APCI+): C29H23ClN5O5RhH (M+H)) calcd.: 660.0516, found: 660.0516. 
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5.5. Preparation of single crystals for X-ray analysis 
5.5.1. Preparation of single crystals of 80a 
Single crystals of np830 (80a) were obtained upon slow diffusion of dichloromethane at 22 °C 
from a 10 mM DMSO solution which was diluted with dichloromethane in a ratio of about 1:10. 
The intensity data were collected at 100 K using a Bruker D8 Quest system. The data were 
corrected for absorption effects using multi-scanned reflections.[214] The structure was solved using 
direct methods (SHELXS-97)[215] and refined using full matrix least squares procedure (SHELXL-
2013). Hydrogen atoms were included at calculated positions. All data collection and processing 
was done by KLAUS HARMS from the central x-ray department of the chemistry department of the 
Philipps-Universität Marburg. 
 
5.5.2. Preparation of single crystals of 225a 
Single crystals of the 5-methoxy derivatised complex 225a were obtained upon slow diffusion of 
dichloromethane at 4 °C from a DMSO solution of undefined concentration, which was diluted 
with dichloromethane in a ratio of about 1:10. The intensity data were collected at 100 K using a 
Bruker D8 Quest system. The data were corrected for absorption effects using multi-scanned 
reflections.[350] The structure was solved using direct methods (SHELXS-97)[215] and refined using 
full matrix least squares procedure (SHELXL-2013). Hydrogen atoms were included at calculated 
positions. All data collection and processing was done by KLAUS HARMS from the central x-ray 
department of the chemistry department of the Philipps-Universität Marburg. 
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5.6. Cell experiments 
5.6.1. Cell cultures 
Cell lines utilised in standard method I were HeLa human cervical cancer cells, HT-29 human 
colorectal adenocarcinoma cells, WM1366 human primary malignant melanoma cells and WM983B 
human metastatic malignant melanoma cells. HeLa cells were cultured in DULBECCO´s Modified 
Eagle´s Medium (DMEM) containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, 
100 units/mL penicillin and 100 μg/mL streptomycin. For cell documentation experiments 
DMEM without the pH-indicator phenolred was used. HT-29 cells were cultured in Roswell Park 
Memorial Institute medium (RPMI) 1640 with the same supplements as above, plus an additional 
50 mg gentamycin per 560 mL medium. WM1366 and WM983B were cultured in tumour (tu) 2% 
containing 80% molecular cellular and developmental biology (MCDB) 153 medium, 
20% LEIBOVITZ’s L-15 medium, 2% FBS and 1.68 mM calcium chloride. Cells were maintained in 
75 cm2 flasks with 25 mL medium in a 5% CO2-humidified atmosphere at 37 °C. Passage took 
place every 2-3 days.  All cell culture ingredients were purchased from SIGMA-ALDRICH. 
For maintenance or plating, old cell culture medium was discarded, the cells were washed with 
6 mL PBS (phosphate buffered saline) and 4 mL trypsin solution was added. The cells were 
incubated at 37 °C and 5% CO2 atmosphere until detached (3-6 min). The suspension was diluted 
with 4 mL of fresh medium and the cells centrifuged for 5 min at 1000 rpm and 20 °C. The 
supernatant was discarded and the cells resuspended in 3-6 mL of fresh medium, depending on the 
cell pellet size. For plating (see according experimental sections), cells were diluted 1:10 in medium, 
counted using a haemocytometer and diluted accordingly to the cell number needed. 
Cell lines utilised for standard method II were A549 human lung carcinoma cells, SK-OV-3 human 
ovarian adenocarcinoma cells, A2780 human ovarian carcinoma and HCT-116 (p53 +/+) human 
colorectal carcinoma cells. A549, SK-OV-3 and HCT-116 (p53 +/+) cells were cultured in DMEM 
GlutaMAX™ containing 10% FBS, 4 units/mL penicillin and 4 μg/mL streptomycin. A2780 cells 
were cultured in RPMI with the same supplements as above. Cells were maintained in 75 cm2 or 
25 cm2 flasks in a 5% CO2-humidified atmosphere at 37 °C. Passage took place every 3-4 days 
using enzyme free solution. All cell culture ingredients were purchased from GIBCO. 
In detail, cells were cultured in 75 cm2 flasks with 12 mL or in 25 cm2 flasks with 6 mL medium. 
For maintenance or plating, the old cell culture medium was discarded, the cells were washed with 
10 mL (5 mL) DPBS (Dulbecco´s phosphate buffered saline) respectively and 3 mL (1 mL) enzyme 
free solution was added. The cells were incubated at 37 °C and 5% CO2 atmosphere until detached 
(5-15 min). The suspension was diluted with 8 mL (2mL) of fresh medium and the cells centrifuged 
for 5 min at 1000 rpm and 20 °C. The supernatant was discarded and the cells resuspended in 
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2-3 mL of fresh medium. For plating cells were diluted 1:10 in medium, then 1:1 in a 4% tryphan 
blue solution (SIGMA ALDRICH), counted using a haemocytometer and diluted accordingly to the 
cell number needed. 
 
5.6.2. Determination of cell viability 
The toxicity effect of the synthesised compounds was determined using the 3-(4,5- dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay method. Using standard method I, 
cells were cultured in 96-well plates with a density of 90 cells/μL (100 µL/well) for HeLa and 
WM1366 cells, 200 cells/μL for HT-29 and WM983B cells and incubated in a 5% CO2-humidified 
atmosphere at 37 °C for 24 h. For library testing the cell medium was diluted 1:1 with medium 
containing 2 µM amide and 2% DMSO, for concentration dependant assays with increasing 
concentrations of the synthesised compounds and 2% DMSO in quadruplicate. Cells were left to 
grow 24 h before the medium was replaced by MTT (SIGMA-ALDRICH for HeLa and HT-29, 
BIOMOL for WM1366 and WM983B) solution (5 mg/mL in PBS further diluted in culture medium 
(1:11)). The cells were incubated for another 3 h under normal culture conditions. Afterwards 
155 μL of the solution was discarded and 90 μL of DMSO was added. The plates were incubated 
for 10 min at 37 °C and 150 rpm for complete dissolving of the formed formazan salts. The 
formazan was then quantified by measuring the absorbance at 535 nm with a Spectramax M5 
microplate reader (MOLECULAR DEVICES). The cell viability was calculated as percentage of 
surviving cells compared to untreated control cells using 1% DMSO in the cell medium. Data show 
the mean of at least two independent experiments for concentration dependant assays and one 
experiment for library screening.  
Using standard method II cells were cultured in 96-well plates (COSTAR) with a density of 8000 or 
10000 cells/well in 200 μL medium and incubated in a 5% CO2-humidified atmosphere at 37 °C 
for 24 h. The medium was then replaced by medium containing the testing substance, with 
increasing concentrations and DMSO of up to 1%, in quadruplicate. Cells were left to grow 72 h 
before the medium was replaced by MTT (SIGMA-ALDRICH) solution (500 μg/mL in DPBS). The 
cells were incubated for another 3-4 h under normal culture conditions. Afterwards the solution 
was removed by aspiration and 200 μL DMSO was added. The plates were incubated for 20 min 
at 20 °C and 600 rpm for complete dissolution of the formed formazan salts. The formazan was 
then quantified by measuring the absorbance at 550 nm with a Thermomax microplate reader 
(MOLECULAR DEVICES). The cell viability was calculated as percentage of surviving cells compared 
to untreated control cells. Data show the mean of at least two independent experiments for 
concentration dependant assays with little toxicity and at least three independent experiments for 
IC50 determination.  
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5.6.3. Scanning electron microscopy 
5.6.3.1. Chemical fixation 
For chemical fixation HeLa cells were grown on small cover glasses, incubated for 16 h after 
addition of 10 µM of the compound and afterwards chemically fixed.[216] Each cover glass was 
washed with 1 mL PBS after aspiration of the medium, and fixed for 1 h with 2.5% glutaraldehyde 
in 0.1 M cacodylic acid (CAC, pH 7.4). It was then washed three times for 5 min with each 1 mL 
0.1 M CAC and fixed with 1 mL aqueous 1% osmium tetroxide/ 8% potassium ferrocyanide (pH 
7.4). After washing once with 1 mL 0.1 M CAC and twice with ddH2O, the samples were dehydrated 
once with 95% EtOH for 1 min and three times with 100% EtOH for 5 min followed by 
dehydration with 1:1 EtOH/HDMS (15 min) and 100% HDMS (two times 15 min each). The 
supernatant was discarded and excess liquid was removed with a filter paper. The samples were 
dried over night at room temperature and measured with a cold-field emission scanning electron 
microscope JEOL JSM-7500 by Michael Hellwig at the centre for material sciences at the Philipps-
Universität University Marburg. 
 
5.6.3.2. Freeze drying of cells 
For freeze dried samples HeLa cells were grown on small cover glasses, incubated for 16 h after 
addition of 30 µM, 15 µM and 7.5 µM of the compound and afterwards washed and freeze dried. 
The wells were washed with PBS (1.5 mL) and ddH2O after aspiration of the medium, and the 
entire plate was frozen in liquid nitrogen before lyophilisation over night. Due to a defect with the 
lyophiliser, the plates were kept at ~ 30 °C during that time. The samples were measured with a 
cold-field emission scanning electron microscope JEOL JSM-7500 by Michael Hellwig at the centre 
for material sciences at the Philipps-Universität Marburg. 
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5.7. Enzyme inhibition assays 
5.7.1. Pim1 inhibition assay 
Inhibition of Pim1 was determined using the commercially available ATP-GloTM assay (PROMEGA). 
The kit was previously tested towards its suitability using the compounds RR97a (201a) and RR97b 
(201b), as well as an ADP/ATP calibration curve, and showed decent results, with up to 4-fold 
deviation in IC50 from results obtained by radioactive assays as performed by RAJATHEES 
RAJARATNAM. The exact assay conditions were chosen due to concentration limits of the buffer 
ingredients by the assay provider. The Pim1 activity is low in the assay conditions used and would 
need further optimisation for more accurate tests and further experiments.  
In the assay setting derivatives were tested at 50 nM and 1 µM for their Pim1 inhibition, since the 
previous IC50 for 201a in this assay was determined as 50-60 nM. Therefore, a 10 mM DMSO stock 
solution was diluted 1:1000 (10 µM) and further 1:20 (500 nM) in DMSO, since the inhibitor is 
further diluted 1:10 in the assay. A solution of a 1:1 mixture of the substrate P70S6 (500 µM in 
5x P1) and ultrapure ATP (100 µM in ddH2O) was prepared. Pim1 solution (10 µL, 1.0 ng) was 
diluted in 160 µL PA and kept at 4 °C until the experiment. Please be aware that about one third 
of the amount of Pim1 should be sufficient in the assay setting. The high amount was chosen due 
to very low activity of the Pim1 batches available and thereby falsifies the obtained results to a 
certain degree. Each kinase reaction was prepared according to the following list (Table 19) in 
duplicate. 
Table 19: Composition of P1, PA and kinase reaction mixture in Pim1 ATP-GloTM assay. 
5 x P1 (pH 7.0)  PA (pH 7.5)  kinase reaction mixture 
Mops/NaOH  40 mM  Tris/HCl  40 mM 
 
ddH2O 1.5 µL 
MgOAc 50 mM  MgCl2 20 mM 
 
inhibitor (10 mM) 0.75 µL 
   BSA 0.1 mg/mL 
 
Pim1 in PA 3.75 µL 
     
 
ATP/P70S6 1:1 1.5 µL 
 
Three controls were introduced in quadruplicate, in which the ingredient was replaced by the 
according buffer or solvent, including control 1 (without inhibitor) which represents 100% activity, 
control 2 (without inhibitor and without enzyme) which was used for background correction and 
control 3 (using the inactive isomer of the hexyl derivative without enzyme) to test possible self-
luminescence of the complexes.  
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The kinase reactions were prepared in 200 µL PCR- tubes, spun down, and incubated for 40 min 
at 20 °C and 200 rpm. Afterwards 5 µL of each mixture was transferred to a white flat bottom 
384-well plate (GREINER BIO-ONE) and 5 µL ADP-Glo reagent (equilibrated to room temperature) 
was added. The mixture was incubated for another 40 min at 20 °C and 10 µL kinase detection 
reagent (equilibrated to room temperature) was added to each well. The plate was further incubated 
for 30 min at 20 °C in the dark. Afterwards the luminescence was measured using Spectramax M5 
microplate reader (MOLECULAR DEVICES, integration time 1500 ms). The obtained values were 
averaged and background corrected using control 2, and compared to control 1, which represents 
100% Pim1 activity in the assay setting. Results were thereby calculated as percent activity 
compared to the untreated enzyme sample, using the formula 
(test sample RLU – control2 RLU) / (control1 RLU – control2 RLU) x 100 with RLU = relative 
luminescence units. Values given are a percentage of rest-activity of the enzyme after inhibitor 
treatment at an ATP concentration of 10 µM.  
 
5.7.2. HDAC inhibition assay 
5.7.2.1. Preparation of A549 nuclear extracts 
Nuclear extracts for HDAC-activity assays were prepared according to a modified protocol from 
literature.[172] A549 cells were grown in a 75 cm2 cell culture flask for 3-4 days in 12 mL medium. 
After aspiration of the medium, the flask was washed with 5 mL DPBS, 3 mL enzyme free solution 
was added and the flask incubated for 10 min at 37 °C and 5% CO2. After detachment of the cells, 
5 mL ice-cold DPBS was added and the cells centrifuged 5 min at 4 °C (1000g). The supernatant 
was discarded, the cells resuspended in 1 mL cold DPBS and centrifuged 5 min at 4 °C. The pellets 
were resuspended in five times the packed cell volume (~250 µL) of ice-cold lysis buffer (Table 
20), incubated for 10 min on ice and centrifuged for 4 min at 4 °C (1000g). Be aware that DTT and 
PMSF should be added to the lysis buffer right before usage, since the final buffer is not stable and 
should only be used during the same day.  
Table 20: Composition of used lysis and nuclear extraction buffers. DTT and PMSF have to be added right before use. 
lysis buffer/washing buffer*  nuclear extraction buffer 
Tris/HCl (pH 8.0) 10 mM  Tris/HCl (pH 8.0) 20 mM 
KCl 60 mM  NaCl 420 mM 
EDTA 1.2 mM  MgCl2 0.7 mM 
DTT 1 mM  EDTA 0.25 mM 
PMSF (0.25 mM in iPrOH) 0.1 mM  glycerol 25% (v/v) 
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Igepal CA-630 0.05% (v/v)  * washing buffer equals lysis buffer 
   without DTT and PMSF 
The pellets were resuspended with 80 µL of washing buffer (Table 20) and centrifuged for 4 min 
at 4 °C and 1000g. The resulting nuclei were resuspended in 80 µL nuclear extraction buffer (Table 
20) and incubated for 30 min on ice before they were ultracentrifuged for 15 min at 4 °C and 
15000g. The protein content was determined via LAWRY assay and compared to BSA according to 
the supplier’s protocol (DC™ Protein Assay, BIO-RAD). The total protein content was in the range 
of 5-10 µg/µL and the nuclear extracts were stored at -80 °C until further use after quick freezing 
in liquid nitrogen. 
Nuclear extracts of treated cells were obtained in a similar fashion. Cells were grown in 6-well plates 
(COSTAR) in 5.94 mL medium (50 cells/µL) for 24 h, compounds were added at defined 
concentrations and after another 72 h incubation time, the cells were harvested. Each well was 
washed with 1 mL DPBS and 380 µL of enzyme free solution was added. The cells were incubated 
at 37 °C and 5% CO2 for 10 min and 1 mL ice-cold DPBS was added after detachment of the cells. 
The suspension was transferred to 1.5 mL tubes and centrifuged for 10 min at 4 °C (1000g). The 
supernatant was discarded, the cells resuspended in 150 µL cold DPBS, the content of two wells 
each was combined and the suspension was spun down for 5 min at 4 °C. The remaining pellets 
were resuspended in 65 µL of cold lysis buffer, incubated for 10 min on ice and centrifuged for 
4 min at 4 °C (1000g). The pellets were resuspended in 20 µL washing buffer and centrifuged for 
4 min at 4 °C (1000g). The resulting nuclei were resuspended in 20 µL nuclear extraction buffer 
and incubated for 30 min on ice before they were ultracentrifuged for 15 min at 4 °C (15000g). 
The protein content was determined via LAWRY assay and compared to BSA according to the 
supplier’s protocol (DC™ Protein Assay, BIO-RAD). 
 
5.7.2.2. HDAC activity assay 
To determine the HDAC inhibition rate of gold-compounds, the commercially available 
fluorometric FluoroFire HDAC Activity Assay (MOLECUTOOLS) was used. HDAC activity was 
measured according to the supplier’s protocol in a 96-well plate format. Briefly, 10 mM or 1 mM 
DMSO-stock solutions of the compounds were diluted in assay buffer to 10x the final assay 
concentration. Nuclear protein extract derived from A549 cells was diluted in the supplied assay 
buffer to a final concentration of 0.125 µg/µL. To 40 μL of the nuclear extract dilution in a black 
96-well plate (COSTAR) was added either 10 μL assay buffer (positive control), 10 µL of a 30 μM 
trichostatin A solution (negative control) or 10 µL of test compound in duplicate. For the blank 
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50 μL pure assay buffer was used. The plate was incubated for 60 min at 20 °C and afterwards 
50 μL of freshly prepared HDAC Emerald Substrate working solution (0.2 μL of HDAC Emerald 
Substrate, and 1.0 μL of signal enhancer in 50 μL of assay buffer) was added per well. The plate 
was incubated at 20 °C for 60 min and the fluorescence (Ex/Em = 490/525 nm) was monitored 
with a Spectramax GeminiXPS microplate reader (MOLECULAR DEVICES). All wells were 
background corrected and compared to the positive control which represents 100% HDAC 
activity. Results were thereby calculated as % activity compared to the untreated enzyme, using the 
formula (test sample RFU - blankRFU) / (untreated controlRFU - blankRFU) x 100. 
For the HDAC-activity of nuclear extracts obtained from pretreated cells, the extract was diluted 
to 0.1 µg/µL protein in assay buffer and 50 µL each were incubated for 20 min at 20 °C. To each 
well 50 µL freshly prepared substrate working solution was added and the plate incubated for 
60 min at 20 °C before monitoring the fluorescence. 
 
5.7.2.3. Quantification of HDAC 4 expression in treated cells 
5.7.2.3.1. Cell treatment and protein extracts for Western Blot 
For HDAC4 quantification via western blot, A549 cells were grown and treated in 6-well plates as 
described for nuclear extracts of treated cells. Cells were harvested, after discarding the medium, 
using 250 µL RIPA buffer per well by incubating for 10 min on ice and scraping the cells of two 
wells each into a 1.5 mL tube. The protein content was determined via LAWRY assay and compared 
to BSA according to the supplier’s protocol (DC™ protein assay, BIO-RAD). Extracts were stored 
at -80 °C until further use. 
 
Table 21: Composition of radioimmunoprecipitation assay (RIPA) buffer. 
RIPA buffer 
Tris/HCl (pH 7.5) 50 mM 
NaCl 150 mM 
sodiumdeoxycholate 1.0% 
sodium dodecyl sulphate 0.1% 
Igepal CA-630 1% 
one miniROCHE protease inhibitor cocktail tablet/10 mL 
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5.7.2.3.2. SDS-PAGE and Western Blot 
For separating the proteins of the whole cell sample by their molecular weight the SDS-PAGE 
technique was used. Therefore, a 1.5 mm thick 10% SDS gel was prepared according to Table 22. 
Briefly the separation gel was added to the caster, a layer of iPrOH was added and the gel left to 
harden for 60 min. The alcohol layer was discarded, the top layer washed with water and the 
stacking fluid added, followed by the addition of a comb. The gel was left to harden for 45 min 
and stored in moist environment and 4 °C over night. The SDS-PAGE was performed as 
previously described in literature.[351] 
 
Table 22: Composition of 1.5 mm 10% SDS-gel. 
 Separating gel (2x) Stacking gel (2x) 
ddH2O 7.26 mL 6.30 mL 
1.5 M Tris/HCl (pH 8.8) 3.75 mL 2.50 mL 
10% (v/w) SDS 150 µL 100 µL 
Acrylamide/bis 3.75 mL 1.00 mL 
10% APS 75.0 µL 50 µL 
TEMED 22.5 µL 15 µL 
 
The protein samples (40 µg total protein as derived from the LAWRY assay) were further diluted 
with the appropriate amount of 4x loading buffer, the samples were sonicated at 50% amplitude 
for 5 s (SONICS VIBRACELLTM), heated to 95 °C for 5 min, spun down for 30 s and an amount which 
contained 15 µg of protein was loaded to the gel. A Precision Plus Protein All Blue Standard ladder 
(BIO-RAD) was added to two remaining pockets. Gels were run for ~ 40 min at 150 V in SDS 
running buffer (24.8 mM Tris, 0.2 M glycine, 3.5 mM SDS). 
For Western-Blot, the separated protein bands were transferred onto an activated PVDF 
membrane by semi-dry blotting (25 mM Tris, 192 mM glycine, 5% methanol) for 90 min at 100 V. 
The membranes were dried and stored at -20 °C until further use. All further steps were performed 
by ANDREIA DE ALMEIDA at the Rijksuniversiteit Groningen. For antibody incubation, the 
membranes were reactivated with methanol and, to avoid unspecific binding, further washed with 
blocking buffer (5% w/v non-fat milk in TBST (Tris buffered saline + 0.2% Tween 20)) for 1 h. 
Afterwards the buffer was discarded, the HDAC4 monoclonal antibody (ABNOVA) in blocking 
buffer (1:500) was added and the membrane incubated at 4 °C over night under motion. The 
membrane was then washed with TBST for 30 min and further incubated with the monoclonal 
house-keeping gene antibodies (anti-β-actin (SIGMA-ALDRICH) and anti-GADPH (SIGMA-
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ALDRICH)) diluted 1:10000 in blocking buffer accordingly. Afterwards the membrane was further 
incubated with a secondary polyclonal rabbit anti-mouse peroxidase-labelled antibody (DACO), that 
was diluted 1:2000 In blocking buffer, for 2 h at room temperature under motion. The membrane 
was washed again with first TBST and secondly with TBS over night at 4 °C. The membrane was 
treated with chemoluminescent reagents (ECL detection reagent Perkin-Elmer) and the 
chemoluminescence of the immune complexes was detected using the GeneSnap program 
(SYNGENE) with an exposure time of 5 ms. 
 
5.8. Assays for drug-like abilities determination 
5.8.1. Stability studies 
5.8.1.1. Ligand exchange and racemisation studies of 204b 
RR88b (204b) was tested for its ligand exchange and racemisation properties at standard laboratory 
conditions (20 °C, daylight and electric lighting) for 24 days. The sample was therefore dissolved 
in DMSO-d6, 
1H-NMR spectra were recorded at time points 0 h, 24 h, 4 d, 7 d, 14 d and 24 d and 
compared for ligand exchange reaction by superimposition of the spectra. The NMR-tube was 
stored directly next to the laboratory window to ensure exposure to light. At each time point, a 
small sample was extracted from the NMR tube and diluted into CH3CN. These samples were 
frozen at -20 °C until analysis, except for an additional 0 h sample, which was stored next to the 
NMR tube at room temperature to ensure exposure to light. Possible ligand exchange and 
racemisation reactions were examined using reversed phase analytical HPLC (Chiralpak ® IC 
column 250mm x 4.6 mm), with a program previously tested to be able to separate all 4 isomers of 
the series (flow rate 0.5 mL, 0.1%TFAaq./CH3CN 80:20 to 50:50 in 30 min, 50:50 for 10 min, 50:50 
to 80:20 over 20 min, column temperature 40 °C). The CH3CN samples were injected and the 
HPLC spectra obtained were compared for elution time and the appearance of new signals. 
 
5.8.1.2. Stability of 201a and 201b at physiological conditions 
The stability of RR97a and RR97b at physiological conditions was tested as 5 mM solutions of the 
compound in a 9:1 mixture of DMSO-d6/D2O in the presence of 5 mM β-mercaptoethanol. The 
solution was kept in an NMR-tube at 37 °C under an atmosphere of 5% CO2 during the time of 
study, except during NMR-measurement. 1H-NMR spectra were recorded at time points 30 min, 
6 h, 24 h, 48 h, 4 d, 7 d and 6 weeks. The spectra were compared by superimposition. 
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5.8.2. Equilibrium solubility assay (miniaturised shake-flask method) 
The thermodynamic solubility of the metal-based compounds has been determined by an upgraded 
version of a method previously described in literature[237] by staff of NIBR Cambridge, MA, USA. 
Briefly the solvent of 20 µL of a 10 mM DMSO-stock solution in a 96-well microtiter plate 
(CORNING 3363) was removed under reduced pressure and high-rotor speed centrifugation 
(GENEVAC HT4X) for 1.6 h at 30 °C. Afterwards, 200 µL of the appropriate buffer was added 
(nominal concentration of 1 mM), the plate heat-sealed and shacked overnight at 800-900 rpm on 
an orbital shaker at room temperature to reach an equilibrium between solid and saturated solution. 
Buffers used were chloride free potassium phosphate buffer (KPi, 67 mM KH2PO4, pH 6.8) and 
fasted state simulated intestinal fluid version 2 (FaSSIF-V2[352], 3 mM sodium taurocholate, 
0.2 mM lecithin, 19.12 mM maleic acid and 68.62 mM NaCl at pH 6.8). The plate was then 
ultracentrifuged for 18 min at 3600 rpm (HETTICH high speed robotic centrifuge) for phase 
separation. Afterwards, 5µL of the supernatant were transferred to a new plate and backfilled with 
1:1 CH3CN/H2O to 1 mL. For LC-MS/MS quantification the internal standard glyburide (final 
concentration 1 µM) was added previous to the analysis. The concentration of samples was 
quantified via LC-MS/MS using the software QuickQuan (intensity data of all fragments related to 
the MW of the test compound). The ratio of peak area of the compounds to the internal standard 
was calculated to standardise the data for comparisons. For best results, the LC-MS/MS unit was 
auto-tuned to give maximum results for the compounds previously to assay analysis. For 
compounds with trouble in MS/MS quantification LC/UV detection was used and the area under 
the curve compared to a standard curve as described previously.[237] 
 
5.8.3. Metabolic stability in rat liver microsomes (in vitro half-life approach) 
The CYP-mediated metabolic stability of the complexes was determined via an in vitro half-life assay 
using rat liver microsomes, related to literature reported assays[353] by staff of NIBR Cambridge, 
MA, USA. Briefly a 10 mM stock solution of the compound in DMSO was diluted 1:1000 with 
0.6% CH3CNaq. (v/v), of which 35 µL were added to 140 µL microsomal protein suspension 
(1 mg/mL) in 50 mM KPi (pH 7.4). This mixture was preincubated for 15 min on a thermoshaker 
at 37 °C. One aliquot (25 µL) was used as time zero (t = 0) sample. Therefore, it was quenched 
with 50 µL of CH3CN containing 2 µM alprenolol as internal MS standard, and 25 µL of cofactor 
solution (50 mM KPi supplemented with 2mM NADPH and 4 mM MgCl2) was added to simulate 
the complete reaction mixture. Another aliquot (25 µL) was mixed with an equal amount of 
50 mM KPi containing MgCl2 but no cofactor, and further treated as the main sampled. This 
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negative control was used to assess CYP-unrelated stability issues (e.g. chemical instability and 
CYP-independent metabolism). The main reaction, used to determine the metabolism after 5, 15 
and 30 min, was started by addition of 125 µL of cofactor solution to the remaining 125 µL 
complex/enzyme mixture. The mixture was and further incubated at 37 °C and vertical shaking. 
Incubation mixtures contained a final concentration of 50 mM potassium phosphate buffer (pH 
7.4), 2.0 mM MgCl2, 1.0 mM NADPH, 0.5 mg/mL liver microsomes, 1.0 µM test compound, 0.06% 
CH3CN (v/v) and 0.01% DMSO (v/v). At the specific reaction time points, aliquots of 50 µL were 
removed and the reaction was terminated by addition of 50 µL CH3CN containing 2 µM alprenolol. 
All samples were stored at 4 °C until completion of the assay and then centrifuged at 3400 x g and 
4 °C for 10 min to pellet precipitated protein. The parent compound in the supernatant was 
analysed via a high-performance liquid chromatography-tandem mass spectrometry system (LC-
MS/MS) consisting of a Thermo TSQ mass spectrometer and a H-ESI ion source. Samples were 
separated on a WATERS XTerra C18 column (2.1x20 mm, 3.5 µm) using a fast mobile phase 
gradient at 0.8 mL/min (A 0.1% formic acid in H2O, B 0.1% formic acid in CH3CN; 2% B in 
0.5 min to 98%, hold for 0.25 min, in 0.27 min back to 2% and hold for 1.21 min) and quantified 
using the software QuickQuan (intensity data of all fragments related to the MW of the test 
compound). The ratio of peak area of the compounds to the internal standard was calculated to 
standardise the data for comparisons. For best results the LC-MS/MS unit was auto-tuned to give 
maximum results for the compounds previously to assay analysis.  
The concentration of the reaction time points (0, 5, 15 and 30 min) tested in singlet were plotted 
versus the natural logarithm of percent test compound remaining relative to 0 minutes (based on 
relative peak area ratio). The slope of this clearance plot, which equals the microsomal elimination 
rate (kmic), was determined and used to calculate the in vitro half-life (t1/2). Data points 
representing < 10% remaining test compound were generally excluded from the definition of the 
clearance plot slope, to focus on linear reaction kinetics. The relationship between the in vitro half-
life and the kinetic constants is derived by the integrated MICHAELIS-MENTEN equation at one time 
point (t1/2),
[245] which is simplified to eq. 1 since the initial complex concentration is supposed to be 
much lower than KM. 
t1/2=
1
-kmic
∙(0.693+
0.5[C]t=0
Km
) for [C]t=0<<Km is valid t1/2=
ln2
-kmic
          eq. 1 
Equation 1: kmic is the in vitro elimination rate constant (-kmic = Vmax/KM), [C]t=0 is the initial concentration of complex and KM is 
the MICHAELIS-MENTEN constant. 
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Using the in vitro half-life (t1/2), the intrinsic clearance CLint (µL/min/mg microsomal protein) can 
be calculated. This value standardises the observed t1/2 for the used in vitro reaction conditions, 
adding the incubation volume (V) and the microsomal protein content (M). 
     CLint=
0.693
t1/2
∙
V
M
=
1386
t1/2
                                                  eq. 2 
Equation 2: V is the incubation volume (µL) and M the microsomal protein content in the incubation (mg). 
 
This data can further be used for IVIVC (in vitro-in vivo correlation) giving a theoretical hepatic 
extraction ratio (ERh) for the test compounds in vivo. Therefore the experimental results are scaled 
to normalise for the whole liver microsomal content (CLint,s) using two scaling factors accounting 
for milligrams microsomal protein per gram liver (SF1 = 45
[354–357]) and gram liver per kilogram 
animal (SF2 = 40
[357,358]). Since the whole liver intrinsic clearance is expressed in mL/min/kg this 
gives: 
              CLint,s=(CLint∙
mL
1000µL
)∙SF1∙SF2=1.8CLint              eq. 3 
Equation 3: SF1 is the scaling factor accounting mg microsomal protein per g liver, SF2 for g liver per kg animal.                     
        
This value can further be used to calculate the hepatic clearance (CLh [mL/min/kg) via the “well-
stirred model”, assuming that CYP metabolism limits clearance rates. The fub/fum (fractions 
unbound in blood or plasma (ub) and microsomes (um)) term captures ratio of compound binding 
to blood/plasma and microsomes, and therefore captures whether the drug is available for 
extraction in metabolic tissue. Often these terms are set to be equal.[244] The portal blood flow 
(Qh [mL/min/kg]) is another empirical scaling factor required for eq. 4 and equals 100
[292] for rats. 
CLh=
Qh
fub
fum
∙CLint,s
Qh+
fub
fum
∙CLint,s
=
Qh 
fub
fum
∙CLint,s
Qh+
fub
fum
CLint,s
=
180∙
fub
fum
∙CLint
100+1.8
fub
fum
∙CLint
        eq. 4 
Equation 4: Qh is the portal blood flow, fub is the fraction unbound in blood or plasma, fum the fraction unbound in microsomes 
and are set equal for simplicity and due to missing values for most complexes 
 
The theoretical hepatic extraction ratio (ERh) for the test compound during in vivo clearance equals 
the ratio of CLh to the portal blood flow (Qh):
[243] 
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ERh=
CLh
Qh
=
CLh
100
=
1.8
fub
fum
∙CL
int
1+0.018
fub
fum
∙CL
int
             eq. 5 
Equation 5: Calculation of the theoretical hepatic extraction ratio using the previously calculated values.  
 
The values obtained were used to identify potential exposure-limiting metabolic clearance using 
the Novartis guidance summarised in the following table. 
 
Table 23: Guidance for interpretation of t1/2 values and the assessment of a potential metabolic risk. 
t1/2 
(min) 
CLint 
(mL/min/mg) 
estimated ERh potential metabolic risk 
<10 >150 >0.7 high 
10-30 50-150 0.5-0.7 medium 
>30 <50 <0.5 low 
 
 
5.8.4. Metabolic stability in hepatocytes 
The metabolic stability towards hepatocytes was tested cross-species in rat, dog and human 
hepatocytes by NIBR staff in Basel. Before use, the cells, which were stored under liquid nitrogen, 
were thawed in a 37 °C water bath for up to 2 min and then transferred to a tube of 40 mL of pre-
warmed (37 °C) medium (WME supplemented with 10% FBS). The cell-suspension was 
centrifuged for 1 min at 50 x g, the supernatant was discarded and the cell-pellet resuspended by 
gentle agitation in a small volume (2-5 mL) of medium. Cell viability was tested by mixing one 
aliquot (50 µL) of cell suspension with one aliquot (50 µL) of tryphan blue and living cells were 
counted. The cell suspension was further diluted to obtain a suspension with a final concentration 
of 1∙106 cells/mL. Of that suspension, 1 mL per well was transferred to a 12-well plate and RR97a 
(201a) was added as 2 mM stock solution in DMSO to a final concentration of 10 µM. The cells 
were incubated at 37 °C and 50 rpm under an atmosphere of 75% O2, 5% CO2 and 20% N2, and 
98% humidity in a HERAcell 240i incubator (THERMO FISCHER SCIENTIFIC). At time points 0 h 
and 2 h, 200 µL of incubation sample each was collected and added to one volume of cold CH3CN. 
The internal MS standard was added (8 µL, final concentration 5 µM) and the mixture frozen 
at -80 °C until analysis. After thawing, the samples were centrifuged (5 min at 10000g) and 100 µL 
of supernatant was diluted with 400 µL water and filtered (0.45 µm) if necessary to remove 
precipitate. LC separation was performed using a binary syringe pump at a flow rate of 4.5 µL/min, 
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a 150 mm x 0.3 mm capillary HPLC column containing C18 material at 40 °C. The column effluent 
is directly injected into the ion source of a linear ion trap-Orbitrap hybrid mass spectrometer 
(THERMO FISCHER SCIENTIFIC) using positive ion electrospray ionisation.  
 
5.8.5. Permeability assessment via hexadecane membrane (HDM)-PAMPA 
The permeability in this assay was assessed by staff of NIBR Cambridge using a 9-10 µm thick 
hexadecane layer and 100 mM KCl buffers containing 5% DMSO at different pH values (4.0, 6.8, 
8.0). The layer was prepared freshly previously to the experiment by addition of 5 µL of a 15% 
hexadecane/hexane solution to a 96-well polycarbonate filterplate (0.4 µm PCTE membrane) 
followed by 15 min incubation at room temperature, during which the hexane evaporates. The final 
hexadecane volume in each well is thereby 0.75 µL and represents a minimal membrane volume to 
reduce membrane retention in the experiment. To each filterwell 300 µL buffer and 4.5 µL of three 
300 µM sample solution (final concentration 5 µM) in DMSO was added in triplicate and the insert 
assembled with a teflon acceptor plate which also contained 300 µL buffer/well. The plate was 
then incubated at 150 rpm for 4 h and the membrane integrity was tested at the end of the 
incubation time (electrical resistance must be above 25 kΩ). The well with the highest resistivity 
was chosen and 37.5 µL taken of, mixed with a second sample and 75 µL of internal standard 
solution. Quantification of the sample was performed via a high-performance liquid 
chromatography-tandem mass spectrometry system (LC-MS/MS) using propranolol as control 
substance. The apparent permeability, which is identical to the effective membrane permeability 
Pe, was calculated per the following equation: 
Pa=-
VD
VD+VR
∙
VR
A∙Δt
∙ln(1-r)                                                              eq. 6 
Equation 6: VR is the volume of the acceptor compartment (0.3 cm3), VD of donor compartment (0.3 cm3), A is the accessible filter 
area (total area 0.24 cm2, multiplied by a porosity of 20%), Δt is the incubation time (240 min) and r is peak area of compound in 
the acceptor compartment divided by the theoretical equilibrium peak area ((cD(0) replaced by independent equilibrium 
concentration). 
 
PAMPA mimics pure transcellular permeability. Paracellular contribution can be added 
mathematically[359] via a hydrodynamic model.[360–362] Since the calculation was not possible for 
coordination compounds using the available resources, the paracellular contribution was not 
determined. Therefore, also logPAMPA, which contains para- and transcellular components, was 
not determined which is necessary to obtain a calculated fraction absorbed and to rank the 
compounds according to high, medium or low permeability.  
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5.8.6. Permeability assessment in Caco-2 cells 
The cell permeability of the complexes was assessed by staff of NIBR Cambridge using a well 
evaluated human epithelial colorectal adenocarcinoma cell-line (Caco-2 cells) based assay.[257] The 
cells (11.840 cells/well in 75 µL) were seeded on PET filters in a 96-well format (BD BIOSCIENCE) 
and cultured (37 °C, 5% CO2, > 95% RH; medium change every 2-3 days) for 21 days during which 
optimally differentiated properties developed. Medium used in this assay is DMEM containing 10% 
FBS, MEM non-essential amino acid solution, MEM sodium, penicillin and streptomycin solution. 
The complexes were used as 2 mM DMSO stock solution, of which 7 µL was diluted to a 10 µM 
solution in transport buffer (Hank's Balanced Salt Solution (HBSS) pH 7.4 supplemented with 
10 mM HEPES). The Caco-2 cells were rinsed three times with transport buffer (75 μL in the apical 
and 250 μL in the basolateral chambers) and the electronic resistance across the monolayer was 
measured via TEER (trans epithelial electric resistance) with an EVOM ohmmeter. Wells with a 
TEER < 200 Ω·cm2 were excluded from the assay. The complex dilution was added either to the 
apical (A: 75 µL) or basolateral (B: 250 µL) side of the cells and the other side filled accordingly 
with transport buffer. Samples for t = 0 were taken from the compound plate before the assay 
plate was incubated for 120 min at 37 °C and 40 rpm. At the end of the incubation time, samples 
were taken from the donor (10 µL) and acceptor (40 µL) chamber. To the donor samples 30 µL 
transport buffer was added and all samples were further diluted with 50 µL CH3CN containing 
0.01% formic acid and 0.36 µM alprenolol (MS standard) to precipitate potential protein content. 
The samples were centrifuged for 10 min at 4 °C and 3500 rpm and the supernatant quantified 
using a high-performance liquid chromatography-tandem mass spectrometry system (LC-MS/MS). 
MS/MS conditions for compounds were previously optimised using the software QuanOptimize, 
which will optimize the compound ionisation polarity, MSMS transition, cone voltage and collision 
energy. The apparent permeability Papp
 [cm/s] can further be calculated from the MS-results 
(sample peak area ratios normalised to internal MS standard) using eq. 7, which expresses the 
interconnection of Papp with the amount of complex transported during the incubation time, the 
surface area and the different sizes of the A and B chamber: [253] 
Papp=
Ct
R∙VR
Δt
∙
1
C0
D∙A
         eq. 7 
Equation 7: CtR is the compound concentration in the receiver chamber after the incubation period (µM), VR is the volume of the 
solution in the receiver chamber after the incubation period (mL), Δt is the incubation time (120 min); C0D is the compound 
concentration in the donor chamber measured at t = 0 (C0D ~10 µM) and A is the surface area of the transport membrane 
(0.0804 cm2). 
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Originating with the apparent permeability from the apical to the basolateral side and vice versa, an 
efflux ratio can be calculated giving a first indication in the transport mechanisms involved. An 
ER = Papp
 (B-A)/Papp(A-B) ratio of > 3 indicates efflux, > 2 but < 3 might be reflux, values bellow 
that indicate passive or even active transport of the compound through the membrane. 
Taken the Papp(A-B)-values, a theoretical in vivo intestinal absorption (fraction absorbed FA) can be 
calculated using an empirically derived sigmoidal Boltzman function (eq. 8), which was based on 
data comparing the in vivo FA and the Papp(A-B)-values of a test set of 93 compounds.
[257] The 
compounds were then classified according to Table 24. 
%FA=
[min+(max-min)]
[1+(exp(
V50-X
slope
))]
               eq. 8 
Equation 8: X = logPapp(A-B); min = 1; max = 100, slope = 0.39 and V50 = -5.74 with slope and V50 being empirical constants, 
which assumes being in linear range of kinetics.[257] 
 
 
Table 24: Guidance for interpretation of %FA and Papp(A-B)- values and the assessment of a potential permeability risk. 
Papp(A-B) 
[cm/sec] 
estimated %FA permeability 
> 5 x 10-6  > 75% high 
> 1 x 10-6 but < 5 x 10-6 > 35 but < 75% medium 
< 1 x 10-6 < 35% low 
 
5.8.7. Permeability assessment in MDCK cells 
The permeability in MDCK-LE cells was determined by staff of NIBR Cambridge, using an 
evaluated dog kidney epithelial cell-line (MDCK (Madin-Darby canine kidney) cells). The cells 
(37.500 cells/well in 75 µL) were seeded on PET filters in a 96-well format (CORNING) and cultured 
(37 °C, 5% CO2, > 95% RH) for 3-4 days during which optimally differentiated properties 
developed. Medium used in this assay was DMEM containing 10% FBS, 2 mM L-Glu and 
1% penicillin-streptomycin. The complexes were used as 10 mM DMSO stock solution, of which 
600 nL were diluted to a bestatin containing 10 µM solution in transport buffer (Hank's Balanced 
Salt Solution (HBSS) pH 7.4 supplemented with 10 mM HEPES, 0.02% BSA). The cells and 
basolateral chambers were rinsed three times with transport buffer without BSA. The complex 
dilution was added to the apical (A: 75 µL) side of the cells and the basolateral side (B: 250 µL) was 
filled accordingly with transport buffer. Samples for t = 0 were taken from the test solution plate 
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before the assay plate was incubated for 120 min at 37 °C and 40 rpm. At the end of the incubation 
time, samples were taken from the donor (10 µL) and acceptor (50 µL) chamber. To the donor 
samples 50 µL HBSS was added and all samples were further diluted with 50 µL internal MS 
standard solution (glibenclamide in H2O/CH3CN) to precipitate potential protein content. The 
samples were centrifuged for 10 min at 4 °C and 4000 rpm and the supernatant quantified using a 
high-performance liquid chromatography-tandem mass spectrometry system (LC-MS/MS). The 
apparent permeability was calculated as described for Caco-2.  
 
5.8.8. Determination of MDR1 impact on efflux 
The impact of the efflux transporter MDR1 on cell permeability of the complexes was assessed by 
staff of NIBR Cambridge, MA, USA, using an evaluated dog kidney epithelial cell-line (MDCK 
cells), which overexpress MDR1. [262–264] The cells (37.500 cells/well in 75 µL medium) were seeded 
on PET filters in a 96-well format (CORNING) and cultured (37 °C, 5% CO2, > 95% RH) for 
3-4 days during which optimally differentiated properties developed. Medium used in this assay 
was DMEM containing 10% FBS, 2 mM L-Glu and 1% penicillin-streptomycin. The complexes 
were used as 10 mM DMSO stock solution, of which 600 nL were diluted to a bestatin containing 
10 µM solution in transport buffer (Hank's Balanced Salt Solution (HBSS) pH 7.4 supplemented 
with 10 mM HEPES 0.02% BSA). The cells and basolateral chambers were rinsed three times with 
transport buffer without BSA. The complex dilution was added either to the apical (A: 75 µL) or 
basolateral (B: 235 µL) side of the cells and the other side filled accordingly with transport buffer. 
Samples for t = 0 were taken from the test solution plate before the assay plate was incubated for 
120 min at 37 °C and 40 rpm. At the end of the incubation time, samples were taken from the 
donor (10 µL) and acceptor (50 µL) chamber. To the donor samples 50 µL HBSS was added and 
all samples were further diluted with 50 µL internal MS standard solution (glibenclamide in 
H2O/CH3CN) to precipitate potential protein content. The samples were centrifuged for 10 min 
at 4 °C and 4000 rpm and the supernatant quantified using a high-performance liquid 
chromatography-tandem mass spectrometry system (LC-MS/MS). The apparent permeability and 
efflux ratios were calculated as described for Caco-2. An ER > 3 thereby indicates efflux, ER = 2-3 
indicates possible efflux. 
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5.8.9. Determination of ex vivo hepatotoxicity in PCLS 
Precision cut liver slice (PCLS) experiments were performed in Angela Casinis laboratory at the 
Rijksuniversiteit Groningen, the Netherlands. PCLS were prepared from liver tissue obtained from 
male Wistar rats (HsdCpb:WU, HARLAN LABORATORIES) weighing 300-350 g. The rats were 
housed on a 12 h light/dark cycle in a temperature- and humidity-controlled room with food 
(Harlan chow no 2018, HARLAN LABORATORIES) and tap water ad libitum. The animals were allowed 
to acclimatise for at least seven days before experimentation. The experimental protocols were 
approved by the Animal Ethical Committee of the University of Groningen and were performed 
according to strict governmental and international guidelines. The organ was excised under 
5% isoflurane / 95% O2 anaesthesia and placed into ice-cold University of Wisconsin (UW, 
DU-PONT) organ preservation solution until directly following preparation of PCLS as previously 
described.[280] Caretaking of the animals and harvesting of tissue was performed by the technical 
staff at the Rijksuniversiteit Groningen. The viability of rat PCLS after 24 h incubation with the 
compounds and the 0 h, 1 h and 24+1 h control was determined via the ATP content of the PCLS 
which was measured according to a method described in literature.[280] Briefly, liver tissue cores 
were prepared by drilling out cores of the fresh tissue, which are stored in UW until slicing. 
Therefore, the tissue was transferred to a petri dish with a silicone insert and was hold loosely down 
by hand while rapidly drilling symmetrical cylindrical cores at a drill speed setting of 2. The tissue 
must be held covered by UW at all times during that procedure. The tissue was transferred back to 
ice-cold UW solution using a spatula and further kept in ice-cold UW until slicing. 
For slicing a KRUMDIEK slicer was assembled following the supplier’s protocol using a fresh razor 
blade and the system was cooled down by circulating 4 °C cold KHB (KHB1 (Table 25) at 4 °C 
mixed with 500 mL 10 x KHB (filtered through a 0.45 µm filter) upfilled to 5 L with ddH2O at 
4 °C, oxygenated (gas dispersion tube with fritted disc) with 95% O2 / 5% CO2 on ice for 30 min, 
pH adjusted to 7.42 with 5 N NaOHaq.).  
Table 25: Composition of 10 x KHB and KHB1. 
10 x KHB   KHB1   
CaCl2·2H2O 36.7 g  NaHCO3 10.5 g 
KCl 37.3 g  D-glucose·H2O 24.75 g  
NaCl 690 g  HEPES 11.9 g 
MgSO4·7H2O 27.1 g  ddH2O backfill to 2 L 
KH2PO4 16.3 g    
ddH2O backfill to 10 L    
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One liver core is further transferred to the cylindrical core holder of the slicer using a spatula and 
the plunge holder is inserted before the core holder is transferred to the slicer. Slices were prepared 
at a speed of 30-40 and the thickness was adjusted to a value were the gently dried tissue, using 
blotting paper to remove adherent water, would weight ~ 5 mg. After finishing slicing one core, 
the slices were removed from the slicer into a beaker and healthy looking slices (equal thickness, 
uniform colour, smooth edges, no obvious damage) were directly transferred to ice-cold UW using 
a spatula where they were stored until the immediate following use. This step was repeated until 
sufficient healthy slices for the experiment were obtained. Each slice was then placed in one well 
of a 12-well plate containing 1.3 mL of preoxygenated and prewarmed (conditions see below) 
Williams medium E (WME, containing L-glutamine, INVITROGEN) with supplements (1.375 g D-
glucose and 500 µL gentamicin (50 mg/mL) per 500 mL WME), after washing them with the 
prepared preheated WME. The slices were incubated for 1 h at 37 °C under an atmosphere of 95% 
O2 / 5% CO2 and 500 rpm in a shaker with moisture saturated atmosphere. Afterwards the slices 
were transferred to new plates containing fresh prewarmed and -oxygenated medium, and 
compound in DMSO as 10 mM or 1 mM DMSO stock solution was added to the according final 
incubation concentration and mixed in by mild shaking. The plates were thereby stored on heating 
mats and the working steps were performed as fast as possible. The plates were further incubated 
for 24 h at the described conditions.  
After the designated incubation time, the slices were collected individually in 1 mL 70% ethanol 
containing 2 mm EDTA (pH 10.9), quick-frozen in liquid nitrogen and stored at -80 °C. The 
samples were thawed on ice, homogenised for 45 s using a Mini-BeadBeater (BIOSPEC PRODUCTS) 
and centrifuged for 5 min at 13000 rpm and 4 °C. The supernatant was separated from the pellet 
and diluted with Tris/HCl (0.1 M) containing 2 mM EDTA (pH 7.8). The ATP content of this 
dilution was measured in a black 96-well microplate format using the ATP Bioluminescence Assay 
Kit CLS II (ROCHE DIAGNOSTICS GMBH) and a LumiCount microplate luminometer BL10001 
(PACKARD). The ATP content was further calculated by comparing the results to a standard 
calibration curve. The remaining pellet was dried at room temperature for at least 72 h, dissolved 
in 200 µL NaOH (5 M) and incubated at 37 °C in a shaking water bath for 30 min. The solution 
was diluted with 800 µL H2O (final NaOH concentration 1 M) and homogenised again for 40 s 
with a Mini-BeadBeater. The protein content was then determined using the Bio-Rad DC Protein 
Assay (BIO-RAD) in a 96-well microplate assay format compared for a bovine serum albumin (BSA) 
calibration curve. The ATP content of the slice was than normalised to the protein content 
(pmol ATP/µg protein) and expressed as the relative value to the 24 h control tissue. Obtained 
values are the mean of at least two independent experiments. 
Assays for drug-like abilities determination 
230 
 
5.8.10. Determination of metal uptake of PCLS after treatment with 201a and 201b 
For the determination of metal uptake in PCLS, slices were prepared and treated according to the 
protocol for determination of ex vivo hepatotoxicity as described above. After 24 h incubation with 
medium containing the test substance, the tissue slices were removed from the medium and washed 
with fresh KREBS medium. They were individually placed in 1.5 mL Eppendorf tubes, quick frozen 
in liquid nitrogen and stored at -20 °C until further use. In addition to that, medium samples both 
from pure medium as well as the used medium with compound were taken to measure their 
rhodium content to ensure a proper concentration during the experiment.  
All further steps were performed by JAN BAMBERGER from the central mass department of the 
chemistry department of the Philipps-Universität Marburg. The samples were thawed, either slices 
or medium transferred to 50 mL Falcon tubes, and the organic material was digested at 60 °C using 
conc. HNO3, where 2 mL of the acid were added gradually to ensure slow oxidation. In case there 
was still tissue visible, additional acid was added and further oxidised at 60 °C. The resulting 
solution was diluted with water to a final concentration of 5% HNO3.  
For ICP-MS measurement these samples were sucked into the system (Element IITM ICP-MS 
(THERMO FISHER SCIENTIFIC)) using a peristaltic pump at a flow rate of 0.05 mL/scan and the 
rhodium content in ng Rh per g sample was calculated from the obtained results by the supplier’s 
software against a Rh concentration curve. 
 
5.8.11. Preparation of PCLS for morphology studies 
PCLS for morphology studies were prepared and treated with compound according to the 
hepatotoxicity study protocol until the end of the final incubation time. The treated samples were 
compared to untreated 0 h and 24 h control. After the incubation time, three slices each were 
transferred in 500 µL 4% w/v formalin (0 h control at time point 0 respectively) in a 24-well plate, 
sealed with a plastic paraffin film and incubated at 4 °C for 24 h. They were then transferred to an 
according well containing 70% EtOHaq and incubated at 4 °C for at least 24 h. The sections were 
transferred to special dehydration casks and dehydrated using a graded ethanol series, eosin stained 
and paraffinated in the pathology department of the university medical centre Groningen.  
Afterwards the slices were bedded in paraffin and dried at 20 °C over night. The paraffin blocks 
were cut into 4 µm thick stripes, which were incubated in a 50 °C water bath to remove cracks and 
tension from cutting, before they were transferred to a glass slide. The water from the cover slips 
was removed using a soft tissue, the slips were dried for 15-30 min on a 60 °C heating plate and 
further at 37 °C in an oven over night. For deparaffination the slides were incubated two times 
5 min each in fresh ultraclear solution (isoparaffin based clearing reagent) and two times 1 min 
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each in 100% EtOH. They were rehydrated for 1 min in 50% EtOHaq. and stained with 
haematoxylin-solution for 10 min before they were rinsed with tap-water for 1 min. Haematoxylin 
thereby stains the chromatin in the nucleus purple-blue. The slides were incubated in 50% acidic 
EtOHaq (500 mL 50% EtOHaq + 1.25 mL HClaq.), in 70% EtOH and in 80% basic EtOHaq. 
(500 mL 80% EtOH + 7.5 mL 25% NH3aq.) for 1 min each. Afterwards they were incubated for 
2 min in eosin solution to dye the cytoplasm pink, before they were two times incubated in 100% 
EtOH for 1 min and two times in ultraclear for 1 min. The slides were dried at room temperature 
until all drops were evaporated. Afterwards some DPX mounting medium was added to the slides 
and a coverslip was added. The slides were left to dry at room temperature for a couple of hours 
and further stored at room temperature until further examination.  
 
5.9. In vivo studies 
5.9.1. In vivo pharmacokinetics of 201b in mice 
In vivo pharmacokinetic studies of RR97b (201b) were performed by NIBR staff in Cambridge using 
male C57BL/6 mice weighting 28-31 g (HARLAN LABORATORIES). The mice were singly housed 
on a 12 h light/dark cycle in a temperature- and humidity-controlled room (18-22 °C, humidity 
50 + 20%) with tap water ad libitum before and during the experiment. Food (PICOLAB Rodent 
Diet 20) was provided unless otherwise specified. All animal related procedures were conducted 
under a Novartis IACUC (Institutional Animal Care and Use Committee) approved protocol in 
compliance with Animal Welfare Act regulations and the Guide for the Care and Use of Laboratory 
Animals. The compound, formulated as solution in 5% NMP, 20% PEG300, 10% solutol 
backfilled with PBS at pH 7.4 - 7.7, was administered to the mice intravenously via tail vein 
(1 mg/kg, 5 mL/kg, n = 2), intraperitoneally (3 mg/kg, 5 mL/kg, n = 3) or orally via gavage 
(3 mg/kg, 10 mL/kg, n = 3). The animals were placed on wire grate cage bottoms until the end of 
the experiment. Serial blood samples (50 µL, EDTA as anti-coagulant) were taken via tail vein for 
early time points and by cardiac puncture at the last time point, at scheduled times over 7 h after 
dosing. The plasma was separated by centrifugation at 3000 rpm. The concentration of the 
compound was determined by LC-MS/MS. Relevant estimated pharmacokinetic parameters for 
plasma such as clearance, volume of distribution and half-life were derived by non-compartmental 
analysis using the program Watson (Version 7.4.2., THERMO FISHER SCIENTIFIC, INC.). 
Therefore, for the intravenous dose, the concentration of unchanged compound at time zero was 
calculated based on a log-linear regression of the first two data points to back-extrapolate C(0). The 
area under the concentration-time curve from time zero to the last measurable concentration 
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(AUClast) for all administration routes was calculated using the linear trapezoidal rule. Based on the 
AUClast, the area under the plasma concentration-time curve from time zero extrapolated to infinite 
time (AUCinf) was calculated using eq. 9, where z is the terminal elimination rate constant of the 
unchanged compound, which was obtained from the slope of the log linear fit from at least the last 
three data points. 
 
                    AUCinf=AUClast+
Clast
λz
                              eq. 9 
Equation 9: AUCinf = area under the plasma concentration-time curve from time zero extrapolated to infinite time; AUClast = area 
under the plasma concentration-time curve from time zero until the last measurable concentration; clast = last quantifiable 
concentration, z = terminal elimination rate constant. 
Based on z the half-life (t1/2) was further calculated for IV administration. The total body clearance 
from the plasma (CL) and the apparent volume of distribution at steady state (Vss) were also 
calculated from the intravenous data. Clearance thereby relates to the IV dose per AUCinf as shown 
in eq. 10. 
 
      CL=
DoseIV
AUCinf
                                                          eq. 10 
Equation 10: CL = total body clearance from plasma, which is calculated from the ratio of the dose administers IV to AUCinf. 
 
The apparent volume of distribution at steady state was obtained using the IV dose, the AUCinf 
and the area under the first moment concentration-time curve from time zero to infinity (AUMCinf) 
according to eq. 11. 
 
   Vss=
DoseIV∙AUMCinf
(AUCinf)
2                                                     eq. 11 
Equation 11: Vss = apparent volume of distribution at steady state; AUMCinf = area under the first moment concentration-time 
curve from time zero to infinity. 
 
The bioavailability for PO and IP dosing was estimated according to eq. 12 (AUClast 
if %extrapolation is >20%) for PO administration, using either PO or IP data for AUCinf and Dose. 
 %F=
AUCinf PO
AUCinf IV
∙
DoseIV
DosePO
                                                eq. 12 
Equation 12: Determination of bioavailability %F based on the calculated values AUCinf PO/IV and the dose given. 
Experimental part 
 
233 
5.9.2. In vivo pharmacokinetics of 201a in rats 
In vivo pharmacokinetics of RR97a (201a) was determined using pre-cannulated male Sprague 
Dawley rats (Hsd: SD HARLAN LABORATORIES) weighing 310-355 g by NIBR staff in Basel. The 
rats were singly housed on a 12 h light/dark cycle in a temperature- and humidity-controlled room 
(21 °C, humidity 60%) with food and tap water ad libitum before and during the experiment. The 
animals were allowed to acclimatise for at least seven days before experimentation. All in vivo 
research was reviewed and approved by the Novartis Institute of Biomedical Research Institutional 
Animal Care and Use Committee (IACUC) in accordance with all local, state, and federal 
regulations. The compound formulated as solution in 30% NMP, 60% PEG200 and 10% solutol 
HS15 was administered intravenously (3 mg/kg, 6 mg/mL) over 8:45 – 8:52 h into the jugular vein 
via the catheter implanted. Serial blood samples of (EDTA as anti-coagulant) were taken at 
scheduled time points post dose (~150 µL blood samples at 0.08 h, 0.5, 1, 2, 4, 7, 24 h n = 3; 
~600 µL blood samples at 1 h, 4 h, 7 h n = 2) via the catheter implanted after gentle manipulation 
and restraining of the rat. Plasma samples of ~70 µL or 300 µL accordingly were prepared by 
centrifugation (6800 x g, 10 min, 4 °C) from the blood samples. The concentration of RR97a was 
determined by LC-MS/MS, in a way that aliquots of the sample solutions, as well as calibration 
samples, were spiked with an internal standard and separated on a C18 HPLC column (150 mm x 
0.3mm) with a mobile phase gradient at a flow rate of 4.5 µL/min and a column temperature of 40 
°C. The column effluent is directly introduced into the ion source of a quadrupole-orbitrap hybrid 
mass spectrometer (THERMO FISCHER SCIENTIFIC) operating with positive electrospray ionisation. 
Relevant estimated pharmacokinetic parameters for plasma such as clearance, volume of 
distribution and half-life were derived by noncompartmental analysis as described before. The Rh-
content of the samples was determined using ICP-MS as described below. For comparison of the 
two measurement methods, the obtained results from LC-MS/MS were converted from mean nM 
(ng/L) to ng/mL complex (by dividing through 1000 and multiplying with the exact mass of the 
complex (629.03)) and converting from ng/mL complex to ng Rh/mL (multiplying with the exact 
mass of the complex and dividing through the exact mass of the most abundant Rh isotope). The 
results obtained from ICP-MS in ng/g were divided by the literature value of the density of blood 
plasma (1.025 kg/m3)[363] to derive ng Rh/mL. Generally, based on the metabolism data in 
hepatocytes and in vivo, the Rh content is thought to reflect the true content of 201a. 
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5.9.3. Metabolic stability of 201a in vivo 
For the identification of the metabolic stability in vivo, samples of liver, kidney, lung and urine 
(see 5.9.4) 7 h pd were prepared for LC-MS/MS analysis as described under 5.8.4. Tissue samples 
were prepared by treatment of 300 µL homogenised tissue with 300 µL cold CH3CN and 
incubation at 0 °C for 20 min. The procedure was repeated twice and then the mixture was 
centrifuged for 5 min at 10000g. From the supernatant 1 mL was removed and concentrated using 
a cyclone high speed evaporator (PROLAB). The residue was reconstituted with 250 µL 
H2O/CH3CN 9:1 and filtered (0.45 µm) if necessary, to remove precipitate. The urine sample was 
therefore prepared by dilution in 9:1 H2O/CH3CN and filtration (0.45 µm) to remove precipitate 
if necessary. 
5.9.4. In vivo distribution of 201a in rats 
For determination of in vivo distribution of RR97a the same rats as for pharmacokinetic observation 
were used. The rats were therefore deeply anesthetised with isoflurane inhalation 7 h or 24 h pd. 
The organs of interest (spleen, muscle, liver, kidney, lung, heart and brain) were dissected out and 
the animals were euthanised by exsanguination. Blood contaminations on the tissue samples were 
gently removed with a paper tissue. The samples were bisected, frozen and kept -20 °C until further 
use. 
An additional Sprague Dawley rat (Crl: CD (SD) Charles River Laboratories) was dosed accordingly 
and kept in a metabolic cage with free access to food and water for the experimental time span to 
collect urine and faeces quantitatively over 24 h pd. These samples were divided in 0-7 h and 7-
24 h, frozen and kept at -20 °C until further use in metabolism analysis, drug concentration analysis 
via LC-MS/MS and total Rh-content analysis via ICP-MS. All samples were further prepared for 
analysis as described below. 
 
5.9.4.1. Sample preparation for ICP-MS quantification 
The organs and faeces samples were thawed at 20 °C, bisected and transferred to balanced out 
50 mL conical plastic tubes (SARSTEDT). The wet weight of the samples was determined and they 
were dried in a drying oven at 90 °C for 28-48 h until they reached constant weight. Afterwards 
the dry weight was determined and the samples stored at -20 °C until further use. After thawing, 
the organic material was digested with conc. HNO3 at 60 °C (2-8 mL until all organic material was 
digested), where the acid was added gradually to ensure a slow oxidation. The resulting solution 
was further diluted with water to a final concentration of 5% HNO3. In some samples an Y 
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standard was added before backfilling to the final HNO3 concentration as indicated in the 
discussion part. Where applicable, results were normalised to the internal Y standard. 
Plasma samples were weighed into 50 mL conical tubes as liquid and digested with 2 mL conc. 
HNO3. Samples were backfilled to 40 mL with H2O and 100 ppt indium standard was added. 
Samples were measured as described below and results were normalised to the internal In 
concentration. 
 
5.9.4.2. ICP-MS based determination of Rh content 
The samples were measured on an Element IITM ICP-MS system (THERMO FISHER SCIENTIFIC), in 
a way that they were sucked into the system with a peristaltic pump, using e.g. a flow of 
0.05 mL/scan. With high viscosities that volume might be reduced which leads to variations in 
results in comparison to the standards in the calibration curve, which do not contain any organic 
material and therefore have a lower viscosity. The system has an upper measurement range of 
5000ppt (5 µg/L), all values above that value might not be accurate results. For that reason, some 
samples were diluted down with a factor of up to 1:1000 gravimetrically, which might lead to further 
deviations. The upper measurement range was especially problematic in the initial measurement of 
urine and faeces, since some samples contained a content above the calibration curve and are 
therefore expected to have higher results than obtained in the experiment. For urine no repeat 
experiments were possible, due to no more sample available. 
To get more accurate results in some measurements the internal standard Indium was used. 
However, the measurement interferes with isobars containing Sn and Pd so that quite high 
deviations were still in place for samples with a low Rh content which were not diluted down. 
Therefore, later Yttrium was added as internal standard for the latest experiments. If and where 
internal standards are used for the samples is indicated in the according results and discussion or 
experimental section. The Rh content was determined against a measured calibration curve and 
normalised (if applicable) to the standard by the supplier’s program Element (THERMO FISHER 
SCIENTIFIC). 
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6. Appendix 
6.1. List of abbreviations 
6.1.1. Amino Acids 
A Ala alanine 
C Cys cysteine 
D Asp aspartic acid 
E Glu glutamic acid 
F Phe phenylalanine 
G Gly glycine 
H His histidine 
I Ile isoleucine 
K Lys lysine 
L Leu leucine 
M Met methionine 
N Asn asparagine 
P Pro proline 
Q Gln glutamine 
R Arg arginine 
S Ser serine 
T Thr threonine 
V Val valine 
W Trp tryptophane 
Y Tyr tyrosine 
 
6.1.2. Nucleobases 
A adenine 
C cytosine 
G guanine 
T thymine 
U uracil 
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6.1.3. General abbreviations 
(CD3)2CO  deuterated acetone 
(g) gaseous 
(NH4)2S2O8 ammonium persulfate 
13C-NMR nuclear magnetic resonance for carbon atoms (13C isotope) 
1H-NMR  nuclear magnetic resonance for protons (1H isotope) 
2D two dimensional 
2-TMS-EtOH 2-(trimethylsilyl)ethanol 
4EPB2 initiation factor 4E binding protein B2 
A apical 
A 
A 
accessible filter area (PAMPA)  
surface area of transport membrane (cell permeability) 
A2780 human ovarian carcinoma cell line 
A549 human lung carcinoma cell line 
ABC ATP-binding cassette 
abs. absolute/absolutised 
AcOH acetic acid 
ADME(T) absorption distribution metabolism excretion (toxicity) 
ADP adenosine diphosphate 
AGC protein kinases A, G and C-like 
AIBN azobis(isobutyronitrile)  
Akt protein kinase B 
ALK anaplastic lymphoma kinase 
AML acute myeloid leukemia 
APBS adaptive Poisson-Boltzmann solver 
APCI +/- atmospheric pressure chemical ionisation positive/negative mode 
APS  ammonium persulfate 
aq. aqueous 
ASK1 apoptosis signal-regulating kinase 1 
ATP adenosine triphosphate 
ATR attenuated total reflection 
AUC area under the curve  
AUCinf area under the plasma concentration-time curve from time zero 
extrapolated to infinite time 
AUClast area under the plasma concentration-time curve from time zero until the 
last measurable concentration 
B basolateral 
BAD Bcl-2-associated death promoter 
BC before Christ 
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Bcl 2 B-cell lymphoma 2 
BCR-Abl breakpoint cluster region-abelson murine leukemia viral oncogene 
homolog 
bnpy 2-benzylpyridine 
Boc tert-butyloxycarbonyl 
bpy bipyridine 
bpydmb 1,1-dimethylbenzyl)-2,2’-bipyridine 
bpyMe/Et 6-methyl/ethyl-2,2’-bipyridine  
br broad 
B-Raf/BRAF rapidly accelerated fibrosarcoma homolog B 
BSA bovine serum albumin 
BTK bruton's tyrosine kinase 
c/conc. concentration 
C0
D compound concentration in the donor chamber measured at t = 0 
CAC cacodylic acid 
Caco-2 human colon adenocarcinoma cell line 
calcd. calculated 
CAMK Ca2+/calmodulin-dependent protein kinase 
cAMP cyclic adenosine monophosphate 
CBX3 chromobox protein homolog 3  
Cbz carboxybenzyl 
CD3CN  deuterated acetonitrile 
CD3OD deuterated methanol 
Cdc25c/A cell division cycle 25c/A 
CDCl3 deuterated chloroform 
CDK cyclin-dependent kinase 
CDK chemistry development kit 
CH1 human ovarian carcinoma cell line 
CK1 casein kinase 1  
clast last quantifiable concentration 
CLDI crystal-like drug inclusions 
Clh hepatic clearance 
Clint intrinsic clearance 
Clint,s intrinsic clearance scaled to entire liver 
cMET cellular-mesenchymal to epithelial transition factor 
CMGC cyclin-dependant, mitogen-activated, glycogen synthase, and DDK-like 
kinases 
CNS central nervous system 
COSY correlation spectroscopy 
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Cp cyclopentadiene 
Cq quaternary carbon atom 
Crl: CD (SD)  sprague dawley rat strain 
C-TAK1 Cdc25C-associated kinase 1 
CTCL cutaneous T-cell lymphoma  
Ct
R compound concentration in the receiver chamber after the incubation 
period  
CYP cytochrome P450 
cyt c cytochrome c 
d doublet 
D2O deuterated water 
DAPK1 death-associated protein kinase 1 
DBPO dibenzoyl peroxide  
DCM dichloromethane 
DFG amino acid sequence aspartic acid-phenylalanine-glutamine 
dfppy 2-(2,4-difluorophenyl)pyridine  
DIP 4,7-diphenyl-1,10-phenanthroline 
DIPA diisopropylamine 
DIPEA N,N-diisopropylethylamine  
DMAP 4-dimethylaminopyridine 
DMEM  Dulbecco´s modified eagle´s medium 
DMF N,N-dimethylformamide 
DMSO dimethylsulfoxide 
DMSO-δ6 deuterated dimethylsulfoxide 
DNA deoxyribonucleic acid  
DPBS  DULBECCO´s phosphate buffered saline 
DTT dithiothreitol 
DW DOUG WILLIAMS 
DYRK dual specificity tyrosine-phosphorylation-regulated kinase 
e.g. exempli gratia 
E/Z entgegen (opposite)/zusammen (together) configuration of double bonds 
EDCl N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
EDTA ethylenediaminetetraacetic acid 
EGFR epidermal growth factor receptor 
elF4E eukaryotic translation initiation factor 4E 
Em emission 
eq equivalent 
eq. equation 
ER efflux ratio (permeability) 
ER extraction ratio (metabolic stability) 
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ErbB2 avian erythroblastosis oncogene B (equals HER2) 
ERh hepatic extraction ratio  
ESI+/- electron spray ionisation positive/negative mode 
Et2O diethyl ether 
EtOAc ethyl acetate 
EtOH ethanol 
Ex excitation 
F bioavailability 
F254 fluorescence indicator for short wavelength light 
FA fraction absorbed 
FabF β ketoacyl acyl carrier protein synthase II 
FaSSIF fasted state simulated intestinal fluid 
FBS  fetal bovine serum 
FDA US food and drug administration  
FeSSIF fed state simulated intestinal fluids 
Fig. figure 
FL FENG LI 
FLT fms like tyrosine kinase 
FTIR fourier transform infrared spectroscopy 
fub fraction unbound in blood or plasma 
fum fraction unbound in microsomes 
g gram 
G-361 human malignant melanoma cell line 
GADPH glyceraldehyde 3-phosphate dehydrogenase 
GFP green fluorescent protein 
GI gastrointestinal  
GSH glutathione 
GSK3 glycogen synthase kinase 3 
GTP guanosine triphosphate 
h hours 
H3 histone 3 
HAT histone acetyltransferase 
HB HOWARD BREGMAN 
H-bond hydrogen bond 
HBSS Hank's balanced salt solution 
hCA human carbonic anhydrase II  
HCT-116++ human colorectal carcinoma cell line p53 +/+ 
HDA yeast histone deacetylase 
HDAC histone deacetylase 
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HDI histone deacetylase inhibitor 
HDMS hexamethyldisilazane 
HEL human erythroleukemia  
HEL92.1.7 human caucasian erythroleukaemia cell line 
HeLa HENRIETTA LACKS (cervical cancer) cell line 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HER2 human epidermal growth factor receptor 2 
hex hexane 
HIV human immunodeficiency virus 
HMBC heteronuclear multiple bond correlation 
HOAc acetic acid 
HOS human caucasian osteosarcoma cell line 
HOSA hydroxylamine-O-sulfonic acid  
HP1y heterochromatin protein 1y 
hpf hours post fertilisation 
HPLC high pressure liquid chromatography 
HR high resolution 
HRMS high resolution mass spectrometry 
hSA human serum albumin 
Hsd: SD  Sprague Dawley rat strain 
HsdCpb:WU wistar rat strain 
HSP heat shock protein 
HSQC heteronuclear single quantum coherence  
HT high throughput 
HT-29 human colorectal adenocarcinoma cell line  
Hz Hertz 
hν luminous exposure 
IACUC institutional animal care and use committee 
IC50 half maximum inhibition concentration 
ICP-MS inductively coupled plasma mass spectrometry 
IL interleukin 
IP intraperitoneal 
IR infrared spectroscopy 
IV intravenous 
IVIVC in vitro-in vivo correlation 
J coupling constant 
JAHA jay amin hydroxamic acid 
JAK janus kinase 
K-562 myelogenous leukemia cell line 
kD kilo Dalton 
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KHB KREBS-HENSELEIT buffer 
KI kinase inhibitor 
Ki inhibition constant 
KM MICHAELIS-MENTEN constant 
kmic microsomal elimination rate 
kobs apparent inactivation rate constant 
KPi potassium inorganic phosphate buffer 
KW KATHRIN WÄHLER 
L liter 
L ligand 
LC-MS(/MS) liquid chromatography (tandem) mass spectrometry 
LD50 median lethal dose 
LICCS Excel-CDK system 
logD logarithm of distribution coefficient 
logP logarithm of partition coefficient 
logS logarithm of solubility 
m milli 
m meter 
M mega 
m multiplet (NMR) 
m medium (IR) 
M molar 
M metal 
M microsomal protein content 
mAb monoclonal antibody 
mal-p-Bel malonate derivate of belinostat  
malSAHA malonate derivative of SAHA 
MAPK mitogen-activated protein kinase 
MCDB molecular cellular and developmental biology  
MCF7 human breast adenocarcinoma cell line 
MDA-MB-231  human breast adenocarcinoma cell line 
MDCK(-LE) Madin-Darby canine kidney cell line (low efflux) 
MDR1 multidrug resistance protein1 (see Pgp) 
Me3OBF4  trimethyloxonium tetrafluoroborate/ MEERWEIN salt 
MEM modified eagles medium 
MeOH methanol 
MET receptor tyrosine kinase 
min minutes 
MLCK myosin light-chain kinase 
Mops 3-(N-morpholino)propanesulfonic acid 
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mRNA messenger ribonucleic acid 
MS mass spectrometry 
MS Microsoft 
MST-1 mammalian sterile 20–like kinase-1 
MTH1 7,8-dihydro-8-oxoguanosine triphosphatase  
mTOR mammalian target of rapamycin 
MTT  3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MW molecular weight 
MW microwave 
Myc avian myelocytomatosis viral oncogene homolog 
NAD+/NADH nicotinamide adenine dinucleotide  
NADPH nicotinamide adenine dinucleotide phosphate 
NAE NEDD8-activating enzyme  
NBS N-bromosuccinimide 
n-BuLi n-buthyllithium 
NEDD8 neural precursor cell expressed, developmentally down-regulated 8 
NFATC1 nuclear factor of activated T-cells, cytoplasmic 1 
NHS N-hydroxysuccinimide  
NIBR Novartis institutes of biomedical research 
nJ coupling constant over n bonds 
NMP N-methyl-2-pyrrolidone 
NMR nuclear magnetic resonance 
np NICHOLAS PAGANO 
NRAS neuroblastoma RAS viral oncogene homolog 
NuMa nuclear mitotic apparatus protein 
OATP organic anion-transporting polypeptide 
OCT organic cation transport proteins 
OES optical emission spectroscopy 
ORTEP oak ridge thermal-ellipsoid plot program 
p21 protein 21, cyclin-dependent kinase inhibitor 
p27 protein 27, cyclin-dependent kinase inhibitor 
p56 protein 56, phosphoglycerate kinase 
PA buffer A 
Pa apparent permeability (equals Pe) 
PAGE polyacrylamide gel electrophoresis 
PAK1 p21 (RAC1) activated kinase 1 
PAMPA parallel artificial membrane permeability assay 
Papp apparent permeability 
PARSE parameters for solvation energy 
PBS  phosphate buffered saline 
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PCLS precision-cut liver slices 
PCR polymerase chain reaction 
PCT patent cooperation treaty 
PCTE polycarbonate track etch 
PD pharmacodynamic 
pd post dose 
Pd/C palladium on charcoal 
pdb protein database 
Pe effective membrane permeability (equals Pa) 
PEG polyethylene glycol 
PET polyethylene terephthalate 
Pgp permeability glycoprotein 1 (see MDR1) 
phen 1,10-phenanthroline 
PI3K phosphatidylinositol-4,5-bisphosphate 3-kinase 
Pim provirus integration site for Moloney murine leukemia virus 
PK pharmacokinetic 
PKA protein kinase A 
pKa logarithm of acid dissociation constant 
PKC protein kinase C 
P-loop phosphate binding loop 
PMSF phenylmethylsulfonyl fluoride 
PO per oral 
ppm parts per million 
ppy phenylpyridine  
pqr protein (p) atomic partial charge (q) and radius (r)  
PRAS40 proline-rich Akt substrate 
PTCL peripheral T-cell lymphoma  
PVDF polyvinylidene fluoride 
py pyridine 
q quartet 
Qh portal blood flow in liver 
quant. quantitative 
quin. quintet 
r peak area 
RAC1 Ras-related C3 botulinum toxin substrate 1 
RAS rat sarcoma (protein family of small GTPases) 
RelA v-rel avian reticuloendotheliosis viral oncogene homolog A 
RET rearranged during transfection 
Rf retention factor 
RFU relative fluorescence units 
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RGC receptor guanylate cyclase related 
RH relative humidity 
RIPA radioimmunoprecipitation assay 
RLM rat liver microsome 
RLU relative luminescence units 
ROS reactive oxygen species  
RPD3 reduced potassium dependency (yeast HDAC) 
rpm revolutions per minute 
RPMI  Roswell Park Memorial Institute medium 
RR RAJATHEES RAJARATNAM 
s singlet (NMR) 
s strong (NMR) 
S9 liver homogenate fraction 
SAHA suberanilohydroxamic acid 
SAR structure activity relationship 
sat. saturated 
SDS sodium dodecyl sulphate 
SEK SANDRA ELISABETH KLARA (DIECKMANN) 
SEM scanning electron microscopy 
SF scaling factor 
Sirt sirtuin 
SK-OV-3 human ovarian adenocarcinoma cell line 
SLC solute carrier 
SM small molecule 
SM STEFAN MOLLIN 
SMILES simplified molecular input line entry specification 
SMKI small molecule kinase inhibitor 
SOCS suppressor of cytokine signalling 
STAT signal transducers and activators of transcription 
STE homologues of the yeast sterile kinases 
t triplet 
t1/2 elimination half-life 
TBAF tetrabutylammoniumfluoride 
TBS tert-butyldimethylsilyl 
TBST tris buffered saline containing Tween 20 
TDI time-dependant inhibition 
TEER trans epithelial electric resistance 
TEMED  tetramethylethylenediamine 
THF tetrahydrofurane 
thpy 3-(2-pyridinyl)-coumarin, 2-(2-thienyl)pyridine  
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TK tyrosine kinases  
TKI tyrosine kinase inhibitor 
TKL Tyrosine kinase like  
TLC thin layer chromatography 
TMS trimethylsilyl 
TNF-α tumour necrosis factor-α  
Tris  tris(hydroxymethyl)aminomethane 
TrkA neurotrophic tyrosine kinase receptor type 1 
TSA Trichostatin A  
TSC2 tuberous sclerosis complex 2 
UDP uridine diphosphate 
UGT UDP glucuronosyltransferases 
ULS universal linker system 
USA United States of America 
UV ultraviolet 
UW university of wisconsin organ preservation solution 
v very 
V volt 
V incubation volume 
VD volume of the donor compartment  
VEGFR vascular endothelial growth factor receptor 
VPA valproic acid 
VR volume of the receiver compartment  
VR volume of solution in the receiver chamber after the incubation period 
Vss volume of distribution at steady state 
W watt 
w weak 
w/v weight per volume 
WM1366 NRAS mutated (61L) human primary malignant melanoma cell line 
WM983B BRAF mutated (V600E) human metastatic malignant melanoma cell line 
with p53 wt 
WME WILLIAMS medium E 
Wnt wingless-related integration site 
wt wild type 
WWI/II world war 1/2 
Δt incubation time 
λ wavelength 
λz terminal elimination rate constant 
ρ density 
wavenumber 
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6.3. List of newly developed compounds 
6.3.1. List of synthesised compounds from chapter 3.1 
 
 
 
 
 
6.3.2. List of synthesised compounds from chapter 3.4 
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6.4. Crystal structure data 
6.4.1. Crystallographic data of complex 80a 
 
Table 26: Crystallographic data of complex np830 (80a). 
formula C36H36N4O7RuS2 
fw 801.88 
a(Å) 14.3457(9) 
b(Å) 14.4275(8) 
c(Å) 16.6220(11) 
α( °) 90 
β( °) 92.679(2) 
γ( °) 90 
V(Å3) 3436.5(4) 
Z 4 
space group P 1 21/c 1 
dcalcd(Mg/m3) 1.550 
μ(mm-1) 0.634 
Θ range(°) 2.003 to 27.205 
no. of indep. reflections 7652 
no. of parameters 466 
wR2 (all data) b 0.0794 
R1 (I > 2σ(I) ) b 0.0327 
CCDC no.c 968409 
 
aMoKα radiation (λ = 0.71073 Å). bR1 = Σ||Fo| - |Fc||/Σ|Fo|; wR2=[w(Fo
2 – Fc
2)2/Σw(Fo
2)2]1/2. 
cCrystallographic data (excluding structure factors) have been deposited in the Cambridge 
Crystallographic Data Center.  
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6.4.2. Crystallographic data of complex 225a 
 
 
Table 27: Crystallographic data of 5-methoxypyridine derivatised RR97a 
formula C31H29ClN5O6 RhS 
fw 738.01 
a(Å) 7.4160(3) 
b(Å) 14.6172(7) 
c(Å) 27.4671(11) 
α( °) 90 
β( °) 90 
γ( °) 90 
V(Å3) 2977.5(2) 
Z 4 
space group P 21 21 21 
dcalcd(Mg/m3) 1.646 
μ(mm-1) 0.788 
Θ range(°) 2.625 to 27.526 
no. of indep. reflections 6840 
no. of parameters 414 
wR2 (all data) b 0.0595 
R1 (I > 2σ(I) ) b 0.0325 
 
aMoKα radiation (λ = 0.71073 Å). bR1 = Σ||Fo| - |Fc||/Σ|Fo|; wR2=[w(Fo
2 – Fc
2)2/Σw(Fo
2)2]1/2.  
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6.5. NMR-spectra of selected compounds 
6.5.1. 1H- and 13C-NMR-spectra of 119 
 
 
Fig. 74: 1H-NMR-spectrum of 119. 
 
 
 
Fig. 75: 13C-NMR-spectrum of 119. 
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6.5.2. 1H- and 13C-NMR-spectra of 209a 
 
 
Fig. 76: 1H-NMR-spectrum of 209a. 
 
 
 
Fig. 77: 13C-NMR-spectrum of 209a. 
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6.5.3. 1H- and 13C-NMR-spectra of 209b 
 
 
Fig. 78: 1H-NMR-spectrum of 209b. 
 
 
 
Fig. 79: 13C-NMR-spectrum of 209b. 
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6.5.4. 1H- and 13C-NMR-spectra of 210a 
 
 
Fig. 80: 1H-NMR-spectrum of 201a. 
 
 
 
Fig. 81: 13C-NMR-spectrum of 210a. 
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6.5.5. 1H- and 13C-NMR-spectra of 210b 
 
 
Fig. 82: 1H-NMR-spectrum of 210b. 
 
 
 
Fig. 83: 13C-NMR-spectrum of 210b. 
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6.5.6. 1H- and 13C-NMR-spectra of 212a 
 
 
Fig. 84: 1H-NMR-spectrum of 212a. 
 
 
 
Fig. 85: 13C-NMR-spectrum of 212a. 
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6.5.7. 1H- and 13C-NMR-spectra of 212b 
 
 
Fig. 86: 1H-NMR-spectrum of 212b. 
 
 
 
Fig. 87: 13C-NMR-spectrum of 212b. 
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6.5.8. 1H-NMR-spectum of 213a 
 
 
Fig. 88: 1H-NMR-spectrum of 213a. 
 
The 13C-NMR spectrum of 213a was only measured partially due to low solubility and is therefore 
not shown. 
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6.5.9. 1H- and 13C-NMR-spectra of 213b 
 
 
Fig. 89: 1H-NMR-spectrum of 213b. 
 
 
 
Fig. 90: 13C-NMR-spectrum of 213b. 
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6.5.10. 1H- and 13C-NMR-spectra of 223a 
 
 
Fig. 91: 1H-NMR-spectrum of 223a. 
 
 
 
Fig. 92: 13C-NMR-spectrum of 223a. 
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6.5.11. 1H- and 13C-NMR-spectra of 223b 
 
 
Fig. 93: 1H-NMR-spectrum of 223b. 
 
 
 
Fig. 94: 13C-NMR-spectrum of 223b. 
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6.5.12. 1H- and 13C-NMR-spectra of 225a 
 
 
Fig. 95: 1H-NMR-spectrum of 225a. 
 
 
 
Fig. 96: 13C-NMR-spectrum of 225a. 
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6.5.13. 1H- and 13C-NMR-spectra of 225b 
 
 
Fig. 97: 1H-NMR-spectrum of 225b. 
 
 
 
Fig. 98: 13C-NMR-spectrum of 225b. 
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6.5.14. 1H- and 13C-NMR-spectra of 226a 
 
 
Fig. 99: 1H-NMR-spectrum of 226a. 
 
 
 
Fig. 100: 13C-NMR-spectrum of 226a. 
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6.5.15. 1H- and 13C-NMR-spectra of 226b 
 
 
Fig. 101: 1H-NMR-spectrum of 226b. 
 
 
 
Fig. 102: 13C-NMR-spectrum of 226a. 
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6.5.16. 1H-NMR-spectrum of 258a 
 
 
Fig. 103: 1H-NMR-spectrum of 258a. 
 
The 13C-NMR spectrum of 213a was not measured due to a low amount of unclean compound 
available (c.f. 1H-NMR spectrum). 
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6.5.17. 1H- and 13C-NMR-spectra of 258b 
 
 
Fig. 104: 1H-NMR-spectrum of 258b. 
 
 
 
Fig. 105: 13C-NMR-spectrum of 258b. 
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6.6. Content of the electronic supporting information 
 Compound library and further in vitro data (chapter 3.1) 
 Summary of initial  LC-MS measurements (chapter 3.2.1) 
 Stability data (chapter 3.2.2.4.3) 
 Toxicity data (chapter 3.2.3) 
 In vivo data (chapter 3.2.4) 
 In silico data (chapter 3.4.1) 
 Pim1 inhibition data (chapter 3.4.7) 
 Cytotoxicity and HDAC inhibitory data (chapter 3.5) 
 PDF-files of spectra (1H, 13C, IR, HRMS if applicable; chapter 5) 
 Complete crystallographic data (chapter 5.5) 
  
Content of the electronic supporting information 
290 
 
  
Statement 
 
291 
 
7. Statement 
Erklärung 
 
 
gemäß § 10, Abs. 1 der Promotionsordnung der Mathematisch-Naturwissenschaftlichen 
Fachbereiche und des Medizinischen Fachbereichs für seine mathematisch-
naturwissenschaftlichen Fächer der Philipps-Universität Marburg vom 15.07.2009: 
Ich erkläre, dass eine Promotion noch an keiner anderen Hochschule als der Philipps- Universität 
Marburg, Fachbereich Chemie, versucht wurde. Ich versichere, dass ich meine vorgelegte 
Dissertation 
 
Development of a New Generation of Metal-Based Anticancer Drugs 
 
selbst und ohne fremde Hilfe verfasst, nicht andere als die in ihr angegebenen Quellen oder 
Hilfsmittel benutzt, alle vollständig oder sinngemäß übernommene Zitate als solche 
gekennzeichnet sowie die Dissertation in der vorliegenden oder ähnlichen Form noch bei keiner 
anderen in- oder ausländischen Hochschule anlässlich eines Promotionsgesuchs oder zu anderen 
Prüfungszwecken eingereicht habe. 
 
Marburg, den 29.05.2017 
Elisabeth Martin 
Elisabeth Martin 
  
Content of the electronic supporting information 
292 
 
  
Biographical Sketch 
 
293 
8. Biographical Sketch 
 
